#BEGIN_DRUGCARD DB03147

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
146-14-5

# ChEBI_ID:
16238

# Chemical_Formula:
C27H33N9O15P2

# Chemical_IUPAC_Name:
[({[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}(hydroxy)phosphoryl)oxy]({[(2R,3S,4S)-5-{7,8-dimethyl-2,4-dioxo-2H,3H,4H,10H-benzo[g]pteridin-10-yl}-2,3,4-trihydroxypentyl]oxy})phosphinic acid

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
A condensation product of riboflavin and adenosine diphosphate. The coenzyme of various aerobic dehydrogenases, e.g., D-amino acid oxidase and L-amino acid oxidase. (Lehninger, Principles of Biochemistry, 1982, p972)

# Dosage_Forms:
Not Available

# Drug_Category:
Not Available

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Flavin-Adenine Dinucleotide

# HET_ID:
FAD

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C27H33N9O15P2/c1-10-3-12-13(4-11(10)2)35(24-18(32-12)25(42)34-27(43)33-24)5-14(37)19(39)15(38)6-48-52(44,45)51-53(46,47)49-7-16-20(40)21(41)26(50-16)36-9-31-17-22(28)29-8-30-23(17)36/h3-4,8-9,14-16,19-21,26,37-41H,5-7H2,1-2H3,(H,44,45)(H,46,47)(H2,28,29,30)(H,34,42,43)/t14-,15+,16+,19-,20+,21+,26+/m0/s1

# InChI_Key:
InChIKey=VWWQXMAJTJZDQX-UYBVJOGSSA-N

# Indication:
Not Available

# KEGG_Compound_ID:
C00016

# KEGG_Drug_ID:
D00005

# LIMS_Drug_ID:
3147

# Mechanism_Of_Action:
Not Available

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
785.5497

# Molecular_Weight_Mono:
785.157134455

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
1FNB

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
-0.78

# Predicted_LogS:
-2.3

# Predicted_Water_Solubility:
4.25e+00 g/l

# Primary_Accession_No:
DB03147

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
643975

# PubChem_Substance_ID:
46508543

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
EXPT01391

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
CC1=CC2=C(C=C1C)N(C[C@H](O)[C@H](O)[C@H](O)CO[P@](O)(=O)O[P@@](O)(=O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1C=NC3=C1N=CN=C3N)C1=NC(=O)NC(=O)C1=N2

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:21:57 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
Not Available

# Phase_1_Metabolizing_Enzyme_1_Gene_Name:
MAOB

# Phase_1_Metabolizing_Enzyme_1_ID:
3939

# Phase_1_Metabolizing_Enzyme_1_Name:
Amine oxidase [flavin-containing] B

# Phase_1_Metabolizing_Enzyme_1_Protein_Sequence:
>Amine oxidase [flavin-containing] B
MSNKCDVVVVGGGISGMAAAKLLHDSGLNVVVLEARDRVGGRTYTLRNQKVKYVDLGGSY
VGPTQNRILRLAKELGLETYKVNEVERLIHHVKGKSYPFRGPFPPVWNPITYLDHNNFWR
TMDDMGREIPSDAPWKAPLAEEWDNMTMKELLDKLCWTESAKQLATLFVNLCVTAETHEV
SALWFLWYVKQCGGTTRIISTTNGGQERKFVGGSGQVSERIMDLLGDRVKLERPVIYIDQ
TRENVLVETLNHEMYEAKYVISAIPPTLGMKIHFNPPLPMMRNQMITRVPLGSVIKCIVY
YKEPFWRKKDYCGTMIIDGEEAPVAYTLDDTKPEGNYAAIMGFILAHKARKLARLTKEER
LKKLCELYAKVLGSLEALEPVHYEEKNWCEEQYSGGCYTTYFPPGILTQYGRVLRQPVDR
IYFAGTETATHWSGYMEGAVEAGERAAREILHAMGKIPEDEIWQSEPESVDVPAQPITTT
FLERHLPSVPGLLRLIGLTTIFSATALGFLAHKRGLLVRV

# Phase_1_Metabolizing_Enzyme_1_SwissProt_ID:
P27338

# Drug_Target_10_Cellular_Location:
Mitochondrion

# Drug_Target_10_Chromosome_Location:
Not Available

# Drug_Target_10_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_10_Essentiality:
Non-Essential

# Drug_Target_10_GenAtlas_ID:
MAOA

# Drug_Target_10_GenBank_ID_Gene:
M68840

# Drug_Target_10_GenBank_ID_Protein:
187353

# Drug_Target_10_GeneCard_ID:
MAOA

# Drug_Target_10_Gene_Name:
MAOA

# Drug_Target_10_Gene_Sequence:
>1584 bp
ATGGAGAATCAAGAGAAGGCGAGTATCGCGGGCCACATGTTCGACGTAGTCGTGATCGGA
GGTGGCATTTCAGGACTATCTGCTGCCAAACTCTTGACTGAATATGGCGTTAGTGTTTTG
GTTTTAGAAGCTCGGGACAGGGTTGGAGGAAGAACATATACTATAAGGAATGAGCATGTT
GATTACGTAGATGTTGGTGGAGCTTATGTGGGACCAACCCAAAACAGAATCTTACGCTTG
TCTAAGGAGCTGGGCATAGAGACTTACAAAGTGAATGTCAGTGAGCGTCTCGTTCAATAT
GTCAAGGGGAAAACATATCCATTTCGGGGCGCCTTTCCACCAGTATGGAATCCCATTGCA
TATTTGGATTACAATAATCTGTGGAGGACAATAGATAACATGGGGAAGGAGATTCCAACT
GATGCACCCTGGGAGGCTCAACATGCTGACAAATGGGACAAAATGACCATGAAAGAGCTC
ATTGACAAAATCTGCTGGACAAAGACTGCTAGGCGGTTTGCTTATCTTTTTGTGAATATC
AATGTGACCTCTGAGCCTCACGAAGTGTCTGCCCTGTGGTTCTTGTGGTATGTGAAGCAG
TGCGGGGGCACCACTCGGATATTCTCTGTCACCAATGGTGGCCAGGAACGGAAGTTTGTA
GGTGGATCTGGTCAAGTGAGCGAACGGATAATGGACCTCCTCGGAGACCAAGTGAAGCTG
AACCATCCTGTCACTCACGTTGACCAGTCAAGTGACAACATCATCATAGAGACGCTGAAC
CATGAACATTATGAGTGCAAATACGTAATTAATGCGATCCCTCCGACCTTGACTGCCAAG
ATTCACTTCAGACCAGAGCTTCCAGCAGAGAGAAACCAGTTAATTCAGCGGCTTCCAATG
GGAGCTGTCATTAAGTGCATGATGTATTACAAGGAGGCCTTCTGGAAGAAGAAGGATTAC
TGTGGCTGCATGATCATTGAAGATGAAGATGCTCCAATTTCAATAACCTTGGATGACACC
AAGCCTGATGGGTCACTGCCTGCCATCATGGGCTTCATTCTTGCCCGGAAAGCTGATCGA
CTTGCTAAGCTACATAAGGAAATAAGGAAGAAGAAAATCTGTGAGCTCTATGCCAAAGTG
CTGGGATCCCAAGAAGCTTTACATCCAGTGCATTATGAAGAGAAGAACTGGTGTGAGGAG
CAGTACTCTGGGGGCTGCTACACGGCCTACTTCCCTCCTGGGATCATGACTCAATATGGA
AGGGTGATTCGTCAACCCGTGGGCAGGATTTTCTTTGCGGGCACAGAGACTGCCACAAAG
TGGAGCGGCTACATGGAAGGGGCAGTTGAGGCTGGAGAACGAGCAGCTAGGGAGGTCTTA
AATGGTCTCGGGAAGGTGACCGAGAAAGATATCTGGGTACAAGAACCTGAATCAAAGGAC
GTTCCAGCGGTAGAAATCACCCACACCTTCTGGGAAAGGAACCTGCCCTCTGTTTCTGGC
CTGCTGAAGATCATTGGATTTTCCACATCAGTAACTGCCCTGGGGTTTGTGCTGTACAAA
TACAAGCTCCTGCCACGGTCTTGA

# Drug_Target_10_General_Function:
Amino acid transport and metabolism

# Drug_Target_10_General_References:
11812236	Li M, Hubalek F, Newton-Vinson P, Edmondson DE: High-level expression of human liver monoamine oxidase A in Pichia pastoris: comparison with the enzyme expressed in Saccharomyces cerevisiae. Protein Expr Purif. 2002 Feb;24(1):152-62.
1432104	Zhu QS, Grimsby J, Chen K, Shih JC: Promoter organization and activity of human monoamine oxidase (MAO) A and B genes. J Neurosci. 1992 Nov;12(11):4437-46.
2764901	Weyler W: Monoamine oxidase A from human placenta and monoamine oxidase B from bovine liver both have one FAD per subunit. Biochem J. 1989 Jun 15;260(3):725-9.
3178846	Chen SA, Weyler W: Partial amino acid sequence analysis of human placenta monoamine oxidase A and bovine liver monoamine oxidase B. Biochem Biophys Res Commun. 1988 Oct 14;156(1):445-50.
3387449	Bach AW, Lan NC, Johnson DL, Abell CW, Bembenek ME, Kwan SW, Seeburg PH, Shih JC: cDNA cloning of human liver monoamine oxidase A and B: molecular basis of differences in enzymatic properties. Proc Natl Acad Sci U S A. 1988 Jul;85(13):4934-8.
3418353	Hsu YP, Weyler W, Chen S, Sims KB, Rinehart WB, Utterback MC, Powell JF, Breakefield XO: Structural features of human monoamine oxidase A elucidated from cDNA and peptide sequences. J Neurochem. 1988 Oct;51(4):1321-4.
7519662	Denney RM, Sharma A, Dave SK, Waguespack A: A new look at the promoter of the human monoamine oxidase A gene: mapping transcription initiation sites and capacity to drive luciferase expression. J Neurochem. 1994 Sep;63(3):843-56.
8584674	Denney RM: The promoter of the human monoamine oxidase A gene. Prog Brain Res. 1995;106:57-66.

# Drug_Target_10_HGNC_ID:
HGNC:6833

# Drug_Target_10_HPRD_ID:
02400

# Drug_Target_10_ID:
3941

# Drug_Target_10_Locus:
Xp11.3

# Drug_Target_10_Molecular_Weight:
59682

# Drug_Target_10_Name:
Amine oxidase [flavin-containing] A

# Drug_Target_10_Number_of_Residues:
527

# Drug_Target_10_PDB_ID:
1O5W

# Drug_Target_10_Pathway:
Not Available

# Drug_Target_10_Pfam_Domain_Function:
PF01593	Amino_oxidase

# Drug_Target_10_Protein_Sequence:
>Amine oxidase [flavin-containing] A
MENQEKASIAGHMFDVVVIGGGISGLSAAKLLTEYGVSVLVLEARDRVGGRTYTIRNEHV
DYVDVGGAYVGPTQNRILRLSKELGIETYKVNVSERLVQYVKGKTYPFRGAFPPVWNPIA
YLDYNNLWRTIDNMGKEIPTDAPWEAQHADKWDKMTMKELIDKICWTKTARRFAYLFVNI
NVTSEPHEVSALWFLWYVKQCGGTTRIFSVTNGGQERKFVGGSGQVSERIMDLLGDQVKL
NHPVTHVDQSSDNIIIETLNHEHYECKYVINAIPPTLTAKIHFRPELPAERNQLIQRLPM
GAVIKCMMYYKEAFWKKKDYCGCMIIEDEDAPISITLDDTKPDGSLPAIMGFILARKADR
LAKLHKEIRKKKICELYAKVLGSQEALHPVHYEEKNWCEEQYSGGCYTAYFPPGIMTQYG
RVIRQPVGRIFFAGTETATKWSGYMEGAVEAGERAAREVLNGLGKVTEKDIWVQEPESKD
VPAVEITHTFWERNLPSVSGLLKIIGFSTSVTALGFVLYKYKLLPRS

# Drug_Target_10_Reaction:
RCH2NH2 + H2O + O2 = RCHO + NH3 + H2O2

# Drug_Target_10_Signals:
None

# Drug_Target_10_Specific_Function:
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral tissues. MAOA preferentially oxidizes biogenic amines such as 5-hydroxytryptamine (5-HT), norepinephrine and epinephrine

# Drug_Target_10_SwissProt_ID:
P21397

# Drug_Target_10_SwissProt_Name:
AOFA_HUMAN

# Drug_Target_10_Synonyms:
EC 1.4.3.4
MAO-A
Monoamine oxidase type A

# Drug_Target_10_Theoretical_pI:
7.96

# Drug_Target_10_Transmembrane_Regions:
498-518

# Drug_Target_11_Cellular_Location:
Mitochondrion
mitochondrial matrix

# Drug_Target_11_Chromosome_Location:
Not Available

# Drug_Target_11_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_11_Essentiality:
Non-Essential

# Drug_Target_11_GenAtlas_ID:
ACADS

# Drug_Target_11_GenBank_ID_Gene:
M26393

# Drug_Target_11_GenBank_ID_Protein:
337928

# Drug_Target_11_GeneCard_ID:
ACADS

# Drug_Target_11_Gene_Name:
ACADS

# Drug_Target_11_Gene_Sequence:
>1239 bp
ATGGCCGCCGCGCTGCTCGCCCGGGCCTCGGGCCCTGCCCGCAGAGCTCTCTGTCCTAGG
GCCTGGCGGCAGTTACACACCATCTACCAGTCTGTGGAACTGCCCGAGACACACCAGATG
TTGCTCCAGACATGCCGGGACTTTGCCGAGAAGGAGTTGTTTCCCATTGCAGCCCAGGTG
GATAAGGAACATCTCTTCCCAGCGGCTCAGGTGAAGAAGATGGGCGGGCTTGGGCTTCTG
GCCATGGACGTGCCCGAGGAGCTTGGCGGTGCTGGCCTCGATTACCTGGCCTACGCCATC
GCCATGGAGGAGATCAGCCGTGGCTGCGCCTCCACCGGAGTCATCATGAGTGTCAACAAC
TCTCTCTACCTGGGGCCCATCTTGAAGTTTGGCTCCAAGGAGCAGAAGCAGGCGTGGGTC
ACGCCTTTCACCAGTGGTGACAAAATTGGCTGCTTTGCCCTCAGCGAACCAGGGAACGGC
AGTGATGCAGGAGCTGCGTCCACCACCGCCCGGGCCGAGGGCGACTCATGGGTTCTGAAT
GGAACCAAAGCCTGGATCACCAATGCCTGGGAGGCTTCGGCTGCCGTGGTCTTTGCCAGC
ACGGACAGAGCCCTGCAAAACAAGGGCATCAGTGCCTTCCTGGTCCCCATGCCAACGCCT
GGGCTCACGTTGGGGAAGAAAGAAGACAAGCTGGGCATCCGGGGCTCATCCACGGCCAAC
CTCATCTTTGAGGACTGTCGCATCCCCAAGGACAGCATCCTGGGGGAGCCAGGGATGGGC
TTCAAGATAGCCATGCAAACCCTGGACATGGGCCGCATCGGCATCGCCTCCCAGGCCCTG
GGCATTGCCCAGACCGCCCTCGATTGTGCTGTGAACTACGCTGAGAATCGCATGGCCTTC
GGGGCGCCCCTCACCAAGCTCCAGGTCATCCAGTTCAAGTTGGCAGACATGGCCCTGGCC
CTGGAGAGTGCCCGGCTGCTGACCTGGCGCGCTGCCATGCTGAAGGATAACAAGAAGCCT
TTCATCAAGGAGGCAGCCATGGCCAAGCTGGCCGCCTCGGAGGCCGCGACCGCCATCAGC
CACCAGGCCATCCAGATCCTGGGCGGCATGGGCTACGTGACAGAGATGCCGGCAGAGCGG
CACTACCGCGACGCCCGCATCACTGAGATCTACGAGGGCACCAGCGAAATCCAGCGGCTG
GTGATCGCCGGGCATCTGCTCAGGAGCTACCGGAGCTGA

# Drug_Target_11_General_Function:
Lipid transport and metabolism

# Drug_Target_11_General_References:
11134486	Corydon MJ, Vockley J, Rinaldo P, Rhead WJ, Kjeldsen M, Winter V, Riggs C, Babovic-Vuksanovic D, Smeitink J, De Jong J, Levy H, Sewell AC, Roe C, Matern D, Dasouki M, Gregersen N: Role of common gene variations in the molecular pathogenesis of short-chain acyl-CoA dehydrogenase deficiency. Pediatr Res. 2001 Jan;49(1):18-23.
1286669	Hochstrasser DF, Frutiger S, Paquet N, Bairoch A, Ravier F, Pasquali C, Sanchez JC, Tissot JD, Bjellqvist B, Vargas R, et al.: Human liver protein map: a reference database established by microsequencing and gel comparison. Electrophoresis. 1992 Dec;13(12):992-1001.
1692038	Naito E, Indo Y, Tanaka K: Identification of two variant short chain acyl-coenzyme A dehydrogenase alleles, each containing a different point mutation in a patient with short chain acyl-coenzyme A dehydrogenase deficiency. J Clin Invest. 1990 May;85(5):1575-82.
2565344	Naito E, Ozasa H, Ikeda Y, Tanaka K: Molecular cloning and nucleotide sequence of complementary DNAs encoding human short chain acyl-coenzyme A dehydrogenase and the study of the molecular basis of human short chain acyl-coenzyme A dehydrogenase deficiency. J Clin Invest. 1989 May;83(5):1605-13.
9383286	Corydon MJ, Andresen BS, Bross P, Kjeldsen M, Andreasen PH, Eiberg H, Kolvraa S, Gregersen N: Structural organization of the human short-chain acyl-CoA dehydrogenase gene. Mamm Genome. 1997 Dec;8(12):922-6.
9499414	Gregersen N, Winter VS, Corydon MJ, Corydon TJ, Rinaldo P, Ribes A, Martinez G, Bennett MJ, Vianey-Saban C, Bhala A, Hale DE, Lehnert W, Kmoch S, Roig M, Riudor E, Eiberg H, Andresen BS, Bross P, Bolund LA, Kolvraa S: Identification of four new mutations in the short-chain acyl-CoA dehydrogenase (SCAD) gene in two patients: one of the variant alleles, 511C-->T, is present at an unexpectedly high frequency in the general population, as was the case for 625G-->A, together conferring susceptibility to ethylmalonic aciduria. Hum Mol Genet. 1998 Apr;7(4):619-27.

# Drug_Target_11_HGNC_ID:
HGNC:90

# Drug_Target_11_HPRD_ID:
06053

# Drug_Target_11_ID:
839

# Drug_Target_11_Locus:
12q22-qter

# Drug_Target_11_Molecular_Weight:
44298

# Drug_Target_11_Name:
Short-chain specific acyl-CoA dehydrogenase, mitochondrial

# Drug_Target_11_Number_of_Residues:
412

# Drug_Target_11_PDB_ID:
1JQI

# Drug_Target_11_Pathway:
Not Available

# Drug_Target_11_Pfam_Domain_Function:
PF00441	Acyl-CoA_dh_1
PF02770	Acyl-CoA_dh_M
PF02771	Acyl-CoA_dh_N

# Drug_Target_11_Protein_Sequence:
>Short-chain specific acyl-CoA dehydrogenase, mitochondrial precursor
MAAALLARASGPARRALCPRAWRQLHTIYQSVELPETHQMLLQTCRDFAEKELFPIAAQV
DKEHLFPAAQVKKMGGLGLLAMDVPEELGGAGLDYLAYAIAMEEISRGCASTGVIMSVNN
SLYLGPILKFGSKEQKQAWVTPFTSGDKIGCFALSEPGNGSDAGAASTTARAEGDSWVLN
GTKAWITNAWEASAAVVFASTDRALQNKGISAFLVPMPTPGLTLGKKEDKLGIRGSSTAN
LIFEDCRIPKDSILGEPGMGFKIAMQTLDMGRIGIASQALGIAQTALDCAVNYAENRMAF
GAPLTKLQVIQFKLADMALALESARLLTWRAAMLKDNKKPFIKEAAMAKLAASEAATAIS
HQAIQILGGMGYVTEMPAERHYRDARITEIYEGTSEIQRLVIAGHLLRSYRS

# Drug_Target_11_Reaction:
butanoyl-CoA + acceptor = 2-butenoyl-CoA + reduced acceptor

# Drug_Target_11_Signals:
None

# Drug_Target_11_Specific_Function:
Not Available

# Drug_Target_11_SwissProt_ID:
P16219

# Drug_Target_11_SwissProt_Name:
ACADS_HUMAN

# Drug_Target_11_Synonyms:
Butyryl-CoA dehydrogenase
EC 1.3.99.2
SCAD
Short-chain specific acyl-CoA dehydrogenase, mitochondrial precursor

# Drug_Target_11_Theoretical_pI:
8.12

# Drug_Target_11_Transmembrane_Regions:
None

# Drug_Target_12_Cellular_Location:
Not Available

# Drug_Target_12_Chromosome_Location:
Not Available

# Drug_Target_12_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_12_Essentiality:
Non-Essential

# Drug_Target_12_GenAtlas_ID:
Not Available

# Drug_Target_12_GenBank_ID_Gene:
Not Available

# Drug_Target_12_GenBank_ID_Protein:
Not Available

# Drug_Target_12_GeneCard_ID:
Not Available

# Drug_Target_12_Gene_Name:
IL4I1

# Drug_Target_12_Gene_Sequence:
Not Available

# Drug_Target_12_General_Function:
Not Available

# Drug_Target_12_General_References:
Not Available

# Drug_Target_12_HGNC_ID:
Not Available

# Drug_Target_12_HPRD_ID:
Not Available

# Drug_Target_12_ID:
7076

# Drug_Target_12_Locus:
Not Available

# Drug_Target_12_Molecular_Weight:
Not Available

# Drug_Target_12_Name:
L-amino-acid oxidase

# Drug_Target_12_Number_of_Residues:
0

# Drug_Target_12_PDB_ID:
Not Available

# Drug_Target_12_Pathway:
Not Available

# Drug_Target_12_Pfam_Domain_Function:
Not Available

# Drug_Target_12_Protein_Sequence:
Not Available

# Drug_Target_12_Reaction:
Not Available

# Drug_Target_12_Signals:
Not Available

# Drug_Target_12_Specific_Function:
Not Available

# Drug_Target_12_SwissProt_ID:
Q96RQ9

# Drug_Target_12_SwissProt_Name:
OXLA_HUMAN

# Drug_Target_12_Synonyms:
Not Available

# Drug_Target_12_Theoretical_pI:
Not Available

# Drug_Target_12_Transmembrane_Regions:
Not Available

# Drug_Target_13_Cellular_Location:
Not Available

# Drug_Target_13_Chromosome_Location:
Not Available

# Drug_Target_13_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_13_Essentiality:
Non-Essential

# Drug_Target_13_GenAtlas_ID:
Not Available

# Drug_Target_13_GenBank_ID_Gene:
U93405

# Drug_Target_13_GenBank_ID_Protein:
2584857

# Drug_Target_13_GeneCard_ID:
Not Available

# Drug_Target_13_Gene_Name:
fadH

# Drug_Target_13_Gene_Sequence:
>2019 bp
ATGAGCTACCCGTCGCTGTTCGCCCCGCTGGATTTAGGTTTTACCACGTTAAAAAACCGC
GTGTTGATGGGCTCAATGCACACCGGGCTGGAGGAATACCCGGACGGTGCCGAGCGGCTG
GCAGCGTTTTATGCCGAACGCGCCCGTCACGGCGTGGCGCTGATTGTCAGCGGCGGCATT
GCACCAGATTTAACAGGCGTTGGCATGGAAGGTGGCGCAATGCTCAACGACGCCAGCCAG
ATCCCACACCATCGCACCATTACCGAAGCGGTACATCAGGAAGGCGGCAAAATAGCCCTG
CAAATTTTGCATACCGGGCGCTACAGCTACCAACCGCATCTGGTCGCCCCGTCCGCATTG
CAGGCCCCCATCAACCGTTTCGTGCCCCATGAGTTAAGCCATGAAGAGATCCTGCAACTG
ATCGACAATTTCGCCCGCTGCGCGCAACTGGCGCGGGAGGCAGGATACGACGGTGTAGAG
GTGATGGGTTCCGAAGGGTATTTGATCAACGAATTTCTGACGCTGCGCACCAATCAGCGT
AGTGACCAGTGGGGCGGCGATTACCGCAACCGGATGCGATTTGCCGTAGAAGTAGTGCGT
GCGGTGCGCGAACGCGTCGGCAACGACTTCATTATTATCTACCGACTGTCGATGCTCGAC
CTGGTCGAAGACGGCGGGACTTTTGCCGAAACGGTAGAGCTGGCGCAGGCCATTGAAGCG
GCGGGCGCGACCATTATCAACACCGGCATTGGCTGGCATGAAGCACGTATTCCGACCATT
GCCACGCCCGTGCCGCGCGGCGCATTTAGCTGGGTCACGCGCAAACTGAAAGGCCACGTC
TCGCTGCCGCTGGTAACCACCAACCGGATTAACGATCCGCAGGTTGCCGACGATATTCTC
TCGCGCGGCGATGCCGATATGGTATCGATGGCGCGACCGTTTCTTGCTGATGCGGAGCTG
CTGTCAAAAGCGCAATCGGGACGAGCCGATGAGATCAACACTTGTATTGGCTGCAATCAG
GCCTGTCTCGATCAAATCTTCGTTGGCAAAGTCACCTCGTGCCTGGTGAATCCTCGCGCC
TGCCACGAAACCAAAATGCCAATCCTTCCCGCCGTGCAGAAAAAAAATCTGGCGGTGGTC
GGTGCGGGACCTGCTGGGCTGGCGTTTGCCATTAACGCGGCGGCGCGTGGGCATCAGGTA
ACATTGTTTGACGCTCATAGCGAGATTGGCGGGCAGTTTAATATCGCCAAACAGATCCCC
GGCAAAGAGGAGTTTTACGAAACGCTGCGCTATTACCGCCGGATGATCGAAGTGACGGGC
GTGACGCTAAAACTCAATCACACCGTGACGGCGGATCAGTTACAGGCTTTCGATGAAACG
ATCCTCGCCAGTGGGATCGTGCCGCGCACTCCGCCCATCGACGGGATCGATCATCCGAAG
GTATTGAGTTATCTCGATGTACTGCGCGACAAAGCGCCGGTTGGCAACAAAGTTGCCATC
ATCGGTTGTGGCGGGATTGGTTTTGATACGGCGATGTATTTAAGTCAGCCGGGCGAATCC
ACCAGCCAGAATATCGCCGGGTTCTGTAATGAATGGGGGATCGACAGTAGCCTACAACAG
GCTGGTGGCTTAAGCCCGCAGGGAATGCAGATCCCCCGTAGCCCACGGCAGATTGTGATG
CTCCAGCGCAAAGCCAGCAAACCAGGACAGGGGTTAGGCAAAACCACCGGCTGGATCCAT
CGCACCACCCTGCTCTCGCGGGGTGTGAAAATGATCCCAGGCGTAAGTTATCAGAAGATT
GACGATGACGGGCTGCATGTGGTGATCAACGGCGAAACGCAGGTATTAGCAGTGGACAAT
GTGGTGATCTGCGCAGGGCAAGAGCCAAACCGCGCGCTGGCGCAACCGCTGATTGATAGC
GGGAAAACGGTGCATTTAATTGGCGGCTGCGATGTGGCTATGGAGCTGGACGCACGACGG
GCAATTGCCCAGGGAACACGGCTGGCGCTGGAGATTTAA

# Drug_Target_13_General_Function:
Energy production and conversion

# Drug_Target_13_General_References:
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.
9346310	He XY, Yang SY, Schulz H: Cloning and expression of the fadH gene and characterization of the gene product 2,4-dienoyl coenzyme A reductase from Escherichia coli. Eur J Biochem. 1997 Sep 1;248(2):516-20.

# Drug_Target_13_HGNC_ID:
Not Available

# Drug_Target_13_HPRD_ID:
Not Available

# Drug_Target_13_ID:
3573

# Drug_Target_13_Locus:
Not Available

# Drug_Target_13_Molecular_Weight:
72679

# Drug_Target_13_Name:
2,4-dienoyl-CoA reductase [NADPH]

# Drug_Target_13_Number_of_Residues:
672

# Drug_Target_13_PDB_ID:
1PS9

# Drug_Target_13_Pathway:
Not Available

# Drug_Target_13_Pfam_Domain_Function:
PF00070	Pyr_redox
PF00724	Oxidored_FMN
PF07992	Pyr_redox_2

# Drug_Target_13_Protein_Sequence:
>2,4-dienoyl-CoA reductase [NADPH]
MSYPSLFAPLDLGFTTLKNRVLMGSMHTGLEEYPDGAERLAAFYAERARHGVALIVSGGI
APDLTGVGMEGGAMLNDASQIPHHRTITEAVHQEGGKIALQILHTGRYSYQPHLVAPSAL
QAPINRFVPHELSHEEILQLIDNFARCAQLAREAGYDGVEVMGSEGYLINEFLTLRTNQR
SDQWGGDYRNRMRFAVEVVRAVRERVGNDFIIIYRLSMLDLVEDGGTFAETVELAQAIEA
AGATIINTGIGWHEARIPTIATPVPRGAFSWVTRKLKGHVSLPLVTTNRINDPQVADDIL
SRGDADMVSMARPFLADAELLSKAQSGRADEINTCIGCNQACLDQIFVGKVTSCLVNPRA
CHETKMPILPAVQKKNLAVVGAGPAGLAFAINAAARGHQVTLFDAHSEIGGQFNIAKQIP
GKEEFYETLRYYRRMIEVTGVTLKLNHTVTADQLQAFDETILASGIVPRTPPIDGIDHPK
VLSYLDVLRDKAPVGNKVAIIGCGGIGFDTAMYLSQPGESTSQNIAGFCNEWGIDSSLQQ
AGGLSPQGMQIPRSPRQIVMLQRKASKPGQGLGKTTGWIHRTTLLSRGVKMIPGVSYQKI
DDDGLHVVINGETQVLAVDNVVICAGQEPNRALAQPLIDSGKTVHLIGGCDVAMELDARR
AIAQGTRLALEI

# Drug_Target_13_Reaction:
trans-2,3-didehydroacyl-CoA + NADP+ = trans,trans-2,3,4,5-tetradehydroacyl-CoA + NADPH + H+

# Drug_Target_13_Signals:
None

# Drug_Target_13_Specific_Function:
Catalyzes the NADP-dependent reduction of 2,4-dienoyl- CoA to yield trans-2- enoyl-CoA

# Drug_Target_13_SwissProt_ID:
P42593

# Drug_Target_13_SwissProt_Name:
FADH_ECOLI

# Drug_Target_13_Synonyms:
2,4-dienoyl coenzyme A reductase
EC 1.3.1.34

# Drug_Target_13_Theoretical_pI:
6.55

# Drug_Target_13_Transmembrane_Regions:
None

# Drug_Target_14_Cellular_Location:
Not Available

# Drug_Target_14_Chromosome_Location:
Not Available

# Drug_Target_14_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_14_Essentiality:
Non-Essential

# Drug_Target_14_GenAtlas_ID:
Not Available

# Drug_Target_14_GenBank_ID_Gene:
X79863

# Drug_Target_14_GenBank_ID_Protein:
929914

# Drug_Target_14_GeneCard_ID:
Not Available

# Drug_Target_14_Gene_Name:
xecC

# Drug_Target_14_Gene_Sequence:
>1572 bp
GTGAAAGTCTGGAACGCCCGAAACGACCATCTCACCATCAATCAATGGGCCACGCGGATC
GATGAGATCCTCGAGGCGCCCGATGGCGGAGAGGTCATCTACAACGTGGACGAGAACGAT
CCACGCGAATACGACGCCATCTTCATCGGCGGCGGCGCCGCCGGGCGCTTCGGCTCGGCC
TATCTGCGCGCCATGGGCGGCCGGCAGCTCATCGTCGACCGCTGGCCGTTCCTGGGCGGC
TCGTGCCCGCACAATGCGTGCGTGCCGCACCATCTGTTCTCCGACTGCGCGGCCGAGCTG
ATGCTCGCGCGCACCTTCTCGGGCCAGTACTGGTTCCCGGACATGACCGAGAAGGTGGTC
GGCATCAAGGAGGTGGTCGATCTGTTCCGCGCCGGGCGCAACGGCCCGCACGGCATCATG
AACTTCCAGTCCAAGGAACAGCTCAACCTCGAATACATCCTCAACTGCCCGGCCAAGGTG
ATCGATAATCACACCGTCGAGGCGGCCGGCAAGGTGTTCAAGGCCAAGAACCTGATCCTC
GCGGTGGGCGCGGGGCCGGGCACGCTCGACGTGCCGGGCGTCAACGCCAAGGGCGTCTTC
GACCACGCGACGCTGGTGGAGGAGCTCGACTACGAGCCCGGCAGCACCGTGGTCGTGGTG
GGCGGCTCGAAGACCGCGGTCGAATATGGCTGCTTCTTCAACGCCACCGGCCGGCGCACC
GTGATGCTGGTGCGCACCGAGCCGCTCAAGCTCATCAAGGACAACGAGACCCGCGCCTAC
GTGCTCGACCGCATGAAGGAGCAGGGCATGGAGATCATCTCCGGCTCCAACGTCACGCGC
ATCGAGGAGGACGCCAACGGCCGCGTTCAGGCGGTGGTGGCCATGACGCCCAACGGCGAG
ATGCGCATCGAGACCGACTTCGTCTTCCTCGGCCTCGGCGAGCAGCCCCGCTCGGCGGAG
CTGGCGAAGATCCTGGGCCTCGATCTCGGCCCCAAGGGCGAGGTGCTGGTCAACGAATAT
CTTCAGACCAGCGTGCCCAACGTCTACGCGGTGGGCGACCTCATCGGCGGGCCCATGGAG
ATGTTCAAGGCCCGCAAGTCCGGCTGCTATGCCGCGCGCAACGTCATGGGCGAGAAGATC
TCCTACACGCCCAAGAATTATCCCGACTTCCTGCACACCCATTACGAGGTCAGCTTCCTC
GGCATGGGCGAGGAGGAAGCCCGCGCGGCGGGGCACGAGATCGTCACCATCAAGATGCCG
CCGGACACGGAGAACGGCCTCAACGTGGCGCTGCCGGCCTCCGACCGCACCATGCTCTAC
GCCTTCGGCAAGGGCACGGCCCACATGTCGGGCTTCCAGAAGATCGTCATCGACGCCAAG
ACCCGCAAGGTGCTCGGCGCCCATCACGTGGGCTATGGCGCGAAGGACGCGTTCCAATAC
CTGAACGTGCTCATCAAGCAGGGGCTCACCGTCGACGAACTGGGGGACATGGACGAATTG
TTCCTCAATCCGACCCACTTCATCCAGCTCTCGCGCCTGCGCGCGGGCTCGAAGAATCTG
GTGAGCCTGTGA

# Drug_Target_14_General_Function:
Energy production and conversion

# Drug_Target_14_General_References:
12524213	Ensign SA, Allen JR: Aliphatic epoxide carboxylation. Annu Rev Biochem. 2003;72:55-76. Epub 2003 Jan 8.
7704278	Swaving J, Weijers CA, van Ooyen AJ, de Bont JA: Complementation of Xanthobacter Py2 mutants defective in epoxyalkane degradation, and expression and nucleotide sequence of the complementing DNA fragment. Microbiology. 1995 Feb;141 ( Pt 2):477-84.
9150202	Allen JR, Ensign SA: Characterization of three protein components required for functional reconstitution of the epoxide carboxylase multienzyme complex from Xanthobacter strain Py2. J Bacteriol. 1997 May;179(10):3110-5.

# Drug_Target_14_HGNC_ID:
Not Available

# Drug_Target_14_HPRD_ID:
Not Available

# Drug_Target_14_ID:
3247

# Drug_Target_14_Locus:
Not Available

# Drug_Target_14_Molecular_Weight:
57348

# Drug_Target_14_Name:
2-oxopropyl-CoM reductase, carboxylating

# Drug_Target_14_Number_of_Residues:
523

# Drug_Target_14_PDB_ID:
1MOK

# Drug_Target_14_Pathway:
Not Available

# Drug_Target_14_Pfam_Domain_Function:
PF00070	Pyr_redox
PF02852	Pyr_redox_dim
PF07992	Pyr_redox_2

# Drug_Target_14_Protein_Sequence:
>2-oxopropyl-CoM reductase, carboxylating
MKVWNARNDHLTINQWATRIDEILEAPDGGEVIYNVDENDPREYDAIFIGGGAAGRFGSA
YLRAMGGRQLIVDRWPFLGGSCPHNACVPHHLFSDCAAELMLARTFSGQYWFPDMTEKVV
GIKEVVDLFRAGRNGPHGIMNFQSKEQLNLEYILNCPAKVIDNHTVEAAGKVFKAKNLIL
AVGAGPGTLDVPGVNAKGVFDHATLVEELDYEPGSTVVVVGGSKTAVEYGCFFNATGRRT
VMLVRTEPLKLIKDNETRAYVLDRMKEQGMEIISGSNVTRIEEDANGRVQAVVAMTPNGE
MRIETDFVFLGLGEQPRSAELAKILGLDLGPKGEVLVNEYLQTSVPNVYAVGDLIGGPME
MFKARKSGCYAARNVMGEKISYTPKNYPDFLHTHYEVSFLGMGEEEARAAGHEIVTIKMP
PDTENGLNVALPASDRTMLYAFGKGTAHMSGFQKIVIDAKTRKVLGAHHVGYGAKDAFQY
LNVLIKQGLTVDELGDMDELFLNPTHFIQLSRLRAGSKNLVSL

# Drug_Target_14_Reaction:
2-mercaptoethanesulfonate + acetoacetate + NADP+ = 2-(2-oxopropylthio)ethanesulfonate + CO2 + NADPH

# Drug_Target_14_Signals:
None

# Drug_Target_14_Specific_Function:
Catalyzes the reductive cleavage of the thioether linkage of 2-ketopropyl-coenzyme M, and the subsequent carboxylation of the ketopropyl cleavage product, yielding the products acetoacetate and free coenzyme M

# Drug_Target_14_SwissProt_ID:
Q56839

# Drug_Target_14_SwissProt_Name:
XECC_XANP2

# Drug_Target_14_Synonyms:
2-KPCC
Aliphatic epoxide carboxylation component II
EC 1.8.1.5
NADPH:2- ketopropyl-CoM carboxylase/oxidoreductase

# Drug_Target_14_Theoretical_pI:
5.90

# Drug_Target_14_Transmembrane_Regions:
None

# Drug_Target_15_Cellular_Location:
Not Available

# Drug_Target_15_Chromosome_Location:
Not Available

# Drug_Target_15_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_15_Essentiality:
Non-Essential

# Drug_Target_15_GenAtlas_ID:
Not Available

# Drug_Target_15_GenBank_ID_Gene:
M23173

# Drug_Target_15_GenBank_ID_Protein:
151506

# Drug_Target_15_GeneCard_ID:
Not Available

# Drug_Target_15_Gene_Name:
pobA

# Drug_Target_15_Gene_Sequence:
>1185 bp
ATGAAGACTCAAGTCGCCATCATCGGCGCCGGTCCGTCCGGCCTCCTGCTCGGCCAGTTG
CTGCACAAGGCCGGCATCGACAACGTGATCCTCGAACGCCAGACCCCGGACTACGTGCTC
GGCCGCATCCGCGCCGGCGTGCTGGAACAGGGTATGGTCGACCTGCTGCGCGAGGCCGGC
GTCGACCGGCGCATGGCGCGCGACGGGCTGGTCCACGAAGGCGTGGAGATCGCCTTCGCC
GGGCAGCGCCGGCGCATCGACCTGAAGCGCCTGAGCGGCGGCAAGACGGTGACGGTCTAC
GGCCAGACCGAGGTCACCCGCGACCTCATGGAGGCCCGCGAAGCCTGCGGCGCCACTACC
GTCTACCAGGCCGCCGAGGTGCGCCTGCACGACCTGCAAGGTGAGCGCCCCTACGTGACC
TTCGAACGCGACGGCGAACGGCTGCGCCTGGATTGCGACTACATCGCCGGCTGCGATGGC
TTCCACGGCATCTCGCGGCAATCGATCCCGGCGGAGCGGCTGAAGGTCTTCGAGCGGGTC
TATCCGTTCGGCTGGCTCGGCCTGCTCGCCGACACCCCGCCGGTGAGCCACGAACTGATC
TACGCCAACCATCCGCGCGGCTTCGCCCTGTGCAGCCAGCGTTCGGCCACCCGCAGCCGC
TACTACGTGCAGGTGCCATTGTCGGAGAAGGTCGAGGACTGGTCCGACGAGCGCTTCTGG
ACGGAACTGAAGGCGCGACTCCCGTCCGAGGTGGCGGAGAAACTGGTGACCGGACCTTCG
CTGGAGAAGAGCATCGCGCCGCTGCGCAGCTTCGTGGTCGAGCCGATGCAGCATGGCCGG
CTGTTCCTCGCCGGCGACGCCGCGCACATCGTGCCGCCCACCGGCGCCAAGGGACTGAAC
CTGGCCGCCAGCGACGTCAGCACGCTCTACCGGCTGCTGCTGAAGGCCTACCGCGAAGGG
CGCGGCGAACTGCTGGAACGCTACTCGGCAATCTGCCTGCGGCGGATCTGGAAGGCCGAA
CGCTTCTCCTGGTGGATGACTTCGGTGCTGCATCGCTTCCCCGACACCGACGCGTTCAGC
CAGCGCATCCAGCAGACCGAACTGGAGTATTACCTGGGCTCCGAGGCGGGCCTGGCGACC
ATCGCCGAGAACTATGTCGGCCTGCCCTACGAGGAAATCGAGTAG

# Drug_Target_15_General_Function:
Coenzyme transport and metabolism

# Drug_Target_15_General_References:
10984043	Stover CK, Pham XQ, Erwin AL, Mizoguchi SD, Warrener P, Hickey MJ, Brinkman FS, Hufnagle WO, Kowalik DJ, Lagrou M, Garber RL, Goltry L, Tolentino E, Westbrock-Wadman S, Yuan Y, Brody LL, Coulter SN, Folger KR, Kas A, Larbig K, Lim R, Smith K, Spencer D, Wong GK, Wu Z, Paulsen IT, Reizer J, Saier MH, Hancock RE, Lory S, Olson MV: Complete genome sequence of Pseudomonas aeruginosa PA01, an opportunistic pathogen. Nature. 2000 Aug 31;406(6799):959-64.
2465205	Entsch B, Nan Y, Weaich K, Scott KF: Sequence and organization of pobA, the gene coding for p-hydroxybenzoate hydroxylase, an inducible enzyme from Pseudomonas aeruginosa. Gene. 1988 Nov 30;71(2):279-91.
7939628	Gatti DL, Palfey BA, Lah MS, Entsch B, Massey V, Ballou DP, Ludwig ML: The mobile flavin of 4-OH benzoate hydroxylase. Science. 1994 Oct 7;266(5182):110-4.
8312276	Lah MS, Palfey BA, Schreuder HA, Ludwig ML: Crystal structures of mutant Pseudomonas aeruginosa p-hydroxybenzoate hydroxylases: the Tyr201Phe, Tyr385Phe, and Asn300Asp variants. Biochemistry. 1994 Feb 15;33(6):1555-64.
8555229	Gatti DL, Entsch B, Ballou DP, Ludwig ML: pH-dependent structural changes in the active site of p-hydroxybenzoate hydroxylase point to the importance of proton and water movements during catalysis. Biochemistry. 1996 Jan 16;35(2):567-78.

# Drug_Target_15_HGNC_ID:
Not Available

# Drug_Target_15_HPRD_ID:
Not Available

# Drug_Target_15_ID:
2809

# Drug_Target_15_Locus:
Not Available

# Drug_Target_15_Molecular_Weight:
44324

# Drug_Target_15_Name:
P-hydroxybenzoate hydroxylase

# Drug_Target_15_Number_of_Residues:
394

# Drug_Target_15_PDB_ID:
1IUU

# Drug_Target_15_Pathway:
Not Available

# Drug_Target_15_Pfam_Domain_Function:
PF01494	FAD_binding_3

# Drug_Target_15_Protein_Sequence:
>P-hydroxybenzoate hydroxylase
MKTQVAIIGAGPSGLLLGQLLHKAGIDNVILERQTPDYVLGRIRAGVLEQGMVDLLREAG
VDRRMARDGLVHEGVEIAFAGQRRRIDLKRLSGGKTVTVYGQTEVTRDLMEAREACGATT
VYQAAEVRLHDLQGERPYVTFERDGERLRLDCDYIAGCDGFHGISRQSIPAERLKVFERV
YPFGWLGLLADTPPVSHELIYANHPRGFALCSQRSATRSRYYVQVPLSEKVEDWSDERFW
TELKARLPSEVAEKLVTGPSLEKSIAPLRSFVVEPMQHGRLFLAGDAAHIVPPTGAKGLN
LAASDVSTLYRLLLKAYREGRGELLERYSAICLRRIWKAERFSWWMTSVLHRFPDTDAFS
QRIQQTELEYYLGSEAGLATIAENYVGLPYEEIE

# Drug_Target_15_Reaction:
4-hydroxybenzoate + NADPH + H+ + O2 = protocatechuate + NADP+ + H2O

# Drug_Target_15_Signals:
None

# Drug_Target_15_Specific_Function:
4-hydroxybenzoate + NADPH + O(2) = protocatechuate + NADP(+) + H(2)O

# Drug_Target_15_SwissProt_ID:
P20586

# Drug_Target_15_SwissProt_Name:
PHHY_PSEAE

# Drug_Target_15_Synonyms:
4-hydroxybenzoate 3- monooxygenase
EC 1.14.13.2
PHBH

# Drug_Target_15_Theoretical_pI:
6.80

# Drug_Target_15_Transmembrane_Regions:
None

# Drug_Target_16_Cellular_Location:
Sarcolemma
peripheral membrane protein. In skeletal muscle, it is localized b
sarcolemmal membrane

# Drug_Target_16_Chromosome_Location:
Not Available

# Drug_Target_16_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_16_Essentiality:
Non-Essential

# Drug_Target_16_GenAtlas_ID:
NOS1

# Drug_Target_16_GenBank_ID_Gene:
U17327

# Drug_Target_16_GenBank_ID_Protein:
642526

# Drug_Target_16_GeneCard_ID:
NOS1

# Drug_Target_16_Gene_Name:
NOS1

# Drug_Target_16_Gene_Sequence:
>4305 bp
ATGGAGGATCACATGTTCGGTGTTCAGCAAATCCAGCCCAATGTCATTTCTGTTCGTCTC
TTCAAGCGCAAAGTTGGGGGCCTGGGATTTCTGGTGAAGGAGCGGGTCAGTAAGCCGCCC
GTGATCATCTCTGACCTGATTCGTGGGGGCGCCGCAGAGCAGAGTGGCCTCATCCAGGCC
GGAGACATCATTCTTGCGGTCAACGGCCGGCCCTTGGTGGACCTGAGCTATGACAGCGCC
CTGGAGGTACTCAGAGGCATTGCCTCTGAGACCCACGTGGTCCTCATTCTGAGGGGCCCT
GAAGGTTTCACCACGCACCTGGAGACCACCTTTACAGGTGATGGGACCCCCAAGACCATC
CGGGTGACACAGCCCCTGGGTCCCCCCACCAAAGCCGTGGATCTGTCCCACCAGCCACCG
GCCGGCAAAGAACAGCCCCTGGCAGTGGATGGGGCCTCGGGTCCCGGGAATGGGCCTCAG
CATGCCTACGATGATGGGCAGGAGGCTGGCTCACTCCCCCATGCCAACGGCCTGGCCCCC
AGGCCCCCAGGCCAGGACCCCGCGAAGAAAGCAACCAGAGTCAGCCTCCAAGGCAGAGGG
GAGAACAATGAACTGCTCAAGGAGATAGAGCCTGTGCTGAGCCTTCTCACCAGTGGGAGC
AGAGGGGTCAAGGGAGGGGCACCTGCCAAGGCAGAGATGAAAGATATGGGAATCCAGGTG
GACAGAGATTTGGACGGCAAGTCACACAAACCTCTGCCCCTCGGCGTGGAGAACGACCGA
GTCTTCAATGACCTATGGGGGAAGGGCAATGTGCCTGTCGTCCTCAACAACCCATATTCA
GAGAAGGAGCAGCCCCCCACCTCAGGAAAACAGTCCCCCACAAAGAATGGCAGCCCCTCC
AAGTGTCCACGCTTCCTCAAGGTCAAGAACTGGGAGACTGAGGTGGTTCTCACTGACACC
CTCCACCTTAAGAGCACATTGGAAACGGGATGCACTGAGTACATCTGCATGGGCTCCATC
ATGCATCCTTCTCAGCATGCAAGGAGGCCTGAAGACGTCCGCACAAAAGGACAGCTCTTC
CCTCTCGCCAAAGAGTTTATTGATCAATACTATTCATCAATTAAAAGATTTGGCTCCAAA
GCCCACATGGAAAGGCTGGAAGAGGTGAACAAAGAGATCGACACCACTAGCACTTACCAG
CTCAAGGACACAGAGCTCATCTATGGGGCCAAGCACGCCTGGCGGAATGCCTCGCGCTGT
GTGGGCAGGATCCAGTGGTCCAAGCTGCAGGTATTCGATGCCCGTGACTGCACCACGGCC
CACGGGATGTTCAACTACATCTGTAACCATGTCAAGTATGCCACCAACAAAGGGAACCTC
AGGTCTGCCATCACCATATTCCCCCAGAGGACAGACGGCAAGCACGACTTCCGAGTCTGG
AACTCCCAGCTCATCCGCTACGCTGGCTACAAGCAGCCTGACGGCTCCACCCTGGGGGAC
CCAGCCAATGTGCAGTTCACAGAGATATGCATACAGCAGGGCTGGAAACCGCCTAGAGGC
CGCTTCGATGTCCTGCCGCTCCTGCTTCAGGCCAACGGCAATGACCCTGAGCTCTTCCAG
ATTCCTCCAGAGCTGGTGTTGGAAGTTCCCATCAGGCACCCCAAGTTTGAGTGGTTCAAG
GACCTGGGGCTGAAGTGGTACGGCCTCCCCGCCGTGTCCAACATGCTCCTAGAGATTGGC
GGCCTGGAGTTCAGCGCCTGTCCCTTCAGTGGCTGGTACATGGGCACAGAGATTGGTGTC
CGCGACTACTGTGACAACTCCCGCTACAATATCCTGGAGGAAGTGGCCAAGAAGATGAAC
TTAGACATGAGGAAGACGTCCTCCCTGTGGAAGGACCAGGCGCTGGTGGAGATCAATATC
GCGGTTCTCTATAGCTTCCAGAGTGACAAAGTGACCATTGTTGACCATCACTCCGCCACC
GAGTCCTTCATTAAGCACATGGAGAATGAGTACCGCTGCCGGGGGGGCTGCCCTGCCGAC
TGGGTGTGGATCGTGCCCCCCATGTCCGGAAGCATCACCCCTGTGTTCCACCAGGAGATG
CTCAACTACCGGCTCACCCCCTCCTTCGAATACCAGCCTGATCCCTGGAACACGCATGTC
TGGAAAGGCACCAACGGGACCCCCACAAAGCGGCGAGCCATCGGCTTCAAGAAGCTAGCA
GAAGCTGTCAAGTTCTCGGCCAAGCTGATGGGGCAGGCTATGGCCAAGAGGGTGAAAGCG
ACCATCCTCTATGCCACAGAGACAGGCAAATCGCAAGCTTATGCCAAGACCTTGTGTGAG
ATCTTCAAACACGCCTTTGATGCCAAGGTGATGTCCATGGAAGAATATGACATTGTGCAC
CTGGAACATGAAACTCTGGTCCTTGTGGTCACCAGCACCTTTGGCAATGGAGATCCCCCT
GAGAATGGGGAGAAATTCGGCTGTGCTTTGATGGAAATGAGGCACCCCAACTCTGTGCAG
GAAGAAAGGAAGAGCTACAAGGTCCGATTCAACAGCGTCTCCTCCTACTCTGACTCCCAA
AAATCATCAGGCGATGGGCCCGACCTCAGAGACAACTTTGAGAGTGCTGGACCCCTGGCC
AATGTGAGGTTCTCAGTTTTTGGCCTCGGCTCACGAGCATACCCTCACTTTTGCGCCTTC
GGACACGCTGTGGACACCCTCCTGGAAGAACTGGGAGGGGAGAGGATCCTGAAGATGAGG
GAAGGGGATGAGCTCTGTGGGCAGGAAGAGGCTTTCAGGACCTGGGCCAAGAAGGTCTTC
AAGGCAGCCTGTGATGTCTTCTGTGTGGGAGATGATGTCAACATTGAAAAGGCCAACAAT
TCCCTCATCAGCAATGATCGCAGCTGGAAGAGAAACAAGTTCCGCCTCACCTTTGTGGCC
GAAGCTCCAGAACTCACACAAGGTCTATCCAATGTCCACAAAAAGCGAGTCTCAGCTGCC
CGGCTCCTTAGCCGTCAAAACCTCCAGAGCCCTAAATCCAGTCGGTCAACTATCTTCGTG
CGTCTCCACACCAACGGGAGCCAGGAGCTGCAGTACCAGCCTGGGGACCACCTGGGTGTC
TTCCCTGGCAACCACGAGGACCTCGTGAATGCCCTGATCGAGCGGCTGGAGGACGCGCCG
CCTGTCAACCAGATGGTGAAAGTGGAACTGCTGGAGGAGCGGAACACGGCTTTAGGTGTC
ATCAGTAACTGGACAGACGAGCTCCGCCTCCCGCCCTGCACCATCTTCCAGGCCTTCAAG
TACTACCTGGACATCACCACGCCACCAACGCCTCTGCAGCTGCAGCAGTTTGCCTCCCTA
GCTACCAGCGAGAAGGAGAAGCAGCGTCTGCTGGTCCTCAGCAAGGGTTTGCAGGAGTAC
GAGGAATGGAAATGGGGCAAGAACCCCACCATCGTGGAGGTGCTGGAGGAGTTCCCATCT
ATCCAGATGCCGGCCACCCTGCTCCTGACCCAGCTGTCCCTGCTGCAGCCCCGCTACTAT
TCCATCAGCTCCTCCCCAGACATGTACCCTGATGAAGTGCACCTCACTGTGGCCATCGTT
TCCTACCGCACTCGAGATGGAGAAGGACCAATTCACCACGGCGTATGCTCCTCCTGGCTC
AACCGGATACAGGCTGACGAACTGGTCCCCTGTTTCGTGAGAGGAGCACCCAGCTTCCAC
CTGCCCCGGAACCCCCAAGTCCCCTGCATCCTCGTTGGACCAGGCACCGGCATTGCCCCT
TTCCGAAGCTTCTGGCAACAGCGGCAATTTGATATCCAACACAAAGGAATGAACCCCTGC
CCCATGGTCCTGGTCTTCGGGTGCCGGCAATCCAAGATAGATCATATCTACAGGGAAGAG
ACCCTGCAGGCCAAGAACAAGGGGGTCTTCAGAGAGCTGTACACGGCTTACTCCCGGGAG
CCAGACAAACCAAAGAAGTACGTGCAGGACATCCTGCAGGAGCAGCTGGCGGAGTCTGTG
TACCGAGCCCTGAAGGAGCAAGGGGGCCACATATACGTCTGTGGGGACGTCACCATGGCT
GCTGATGTCCTCAAAGCCATCCAGCGCATCATGACCCAGCAGGGGAAGCTCTCGGCAGAG
GACGCCGGCGTATTCATCAGCCGGATGAGGGATGACAACCGATACCATGAGGATATTTTT
GGAGTCACCCTGCGAACGTACGAAGTGACCAACCGCCTTAGATCTGAGTCCATTGCCTTC
ATTGAAGAGAGCAAAAAAGACACCGATGAGGTTTTCAGCTCCTAA

# Drug_Target_16_General_Function:
Inorganic ion transport and metabolism

# Drug_Target_16_General_References:
7515942	Fujisawa H, Ogura T, Kurashima Y, Yokoyama T, Yamashita J, Esumi H: Expression of two types of nitric oxide synthase mRNA in human neuroblastoma cell lines. J Neurochem. 1994 Jul;63(1):140-5.
7528745	Hall AV, Antoniou H, Wang Y, Cheung AH, Arbus AM, Olson SL, Lu WC, Kau CL, Marsden PA: Structural organization of the human neuronal nitric oxide synthase gene (NOS1). J Biol Chem. 1994 Dec 30;269(52):33082-90.
7678401	Nakane M, Schmidt HH, Pollock JS, Forstermann U, Murad F: Cloned human brain nitric oxide synthase is highly expressed in skeletal muscle. FEBS Lett. 1993 Jan 25;316(2):175-80.
8879752	Park CS, Gianotti C, Park R, Krishna G: Neuronal isoform of nitric oxide synthase is expressed at low levels in human retina. Cell Mol Neurobiol. 1996 Aug;16(4):499-515.
9111048	Wang Y, Goligorsky MS, Lin M, Wilcox JN, Marsden PA: A novel, testis-specific mRNA transcript encoding an NH2-terminal truncated nitric-oxide synthase. J Biol Chem. 1997 Apr 25;272(17):11392-401.

# Drug_Target_16_HGNC_ID:
HGNC:7872

# Drug_Target_16_HPRD_ID:
01226

# Drug_Target_16_ID:
76

# Drug_Target_16_Locus:
12q24.2-q24.31

# Drug_Target_16_Molecular_Weight:
160972

# Drug_Target_16_Name:
Nitric-oxide synthase, brain

# Drug_Target_16_Number_of_Residues:
1434

# Drug_Target_16_PDB_ID:
1TLL

# Drug_Target_16_Pathway:
Not Available

# Drug_Target_16_Pfam_Domain_Function:
PF00175	NAD_binding_1
PF00258	Flavodoxin_1
PF00595	PDZ
PF00667	FAD_binding_1
PF02898	NO_synthase

# Drug_Target_16_Protein_Sequence:
>Nitric-oxide synthase, brain
MEDHMFGVQQIQPNVISVRLFKRKVGGLGFLVKERVSKPPVIISDLIRGGAAEQSGLIQA
GDIILAVNGRPLVDLSYDSALEVLRGIASETHVVLILRGPEGFTTHLETTFTGDGTPKTI
RVTQPLGPPTKAVDLSHQPPAGKEQPLAVDGASGPGNGPQHAYDDGQEAGSLPHANGLAP
RPPGQDPAKKATRVSLQGRGENNELLKEIEPVLSLLTSGSRGVKGGAPAKAEMKDMGIQV
DRDLDGKSHKPLPLGVENDRVFNDLWGKGNVPVVLNNPYSEKEQPPTSGKQSPTKNGSPS
KCPRFLKVKNWETEVVLTDTLHLKSTLETGCTEYICMGSIMHPSQHARRPEDVRTKGQLF
PLAKEFIDQYYSSIKRFGSKAHMERLEEVNKEIDTTSTYQLKDTELIYGAKHAWRNASRC
VGRIQWSKLQVFDARDCTTAHGMFNYICNHVKYATNKGNLRSAITIFPQRTDGKHDFRVW
NSQLIRYAGYKQPDGSTLGDPANVQFTEICIQQGWKPPRGRFDVLPLLLQANGNDPELFQ
IPPELVLEVPIRHPKFEWFKDLGLKWYGLPAVSNMLLEIGGLEFSACPFSGWYMGTEIGV
RDYCDNSRYNILEEVAKKMNLDMRKTSSLWKDQALVEINIAVLYSFQSDKVTIVDHHSAT
ESFIKHMENEYRCRGGCPADWVWIVPPMSGSITPVFHQEMLNYRLTPSFEYQPDPWNTHV
WKGTNGTPTKRRAIGFKKLAEAVKFSAKLMGQAMAKRVKATILYATETGKSQAYAKTLCE
IFKHAFDAKVMSMEEYDIVHLEHETLVLVVTSTFGNGDPPENGEKFGCALMEMRHPNSVQ
EERKSYKVRFNSVSSYSDSQKSSGDGPDLRDNFESAGPLANVRFSVFGLGSRAYPHFCAF
GHAVDTLLEELGGERILKMREGDELCGQEEAFRTWAKKVFKAACDVFCVGDDVNIEKANN
SLISNDRSWKRNKFRLTFVAEAPELTQGLSNVHKKRVSAARLLSRQNLQSPKSSRSTIFV
RLHTNGSQELQYQPGDHLGVFPGNHEDLVNALIERLEDAPPVNQMVKVELLEERNTALGV
ISNWTDELRLPPCTIFQAFKYYLDITTPPTPLQLQQFASLATSEKEKQRLLVLSKGLQEY
EEWKWGKNPTIVEVLEEFPSIQMPATLLLTQLSLLQPRYYSISSSPDMYPDEVHLTVAIV
SYRTRDGEGPIHHGVCSSWLNRIQADELVPCFVRGAPSFHLPRNPQVPCILVGPGTGIAP
FRSFWQQRQFDIQHKGMNPCPMVLVFGCRQSKIDHIYREETLQAKNKGVFRELYTAYSRE
PDKPKKYVQDILQEQLAESVYRALKEQGGHIYVCGDVTMAADVLKAIQRIMTQQGKLSAE
DAGVFISRMRDDNRYHEDIFGVTLRTYEVTNRLRSESIAFIEESKKDTDEVFSS

# Drug_Target_16_Reaction:
L-arginine + n NADPH + n H+ + m O2 = citrulline + nitric oxide + n NADP+

# Drug_Target_16_Signals:
None

# Drug_Target_16_Specific_Function:
Produces nitric oxide (NO) which is a messenger molecule with diverse functions throughout the body. In the brain and peripheral nervous system, NO displays many properties of a neurotransmitter

# Drug_Target_16_SwissProt_ID:
P29475

# Drug_Target_16_SwissProt_Name:
NOS1_HUMAN

# Drug_Target_16_Synonyms:
Constitutive NOS
EC 1.14.13.39
N-NOS
NC-NOS
NOS type I
Neuronal NOS
bNOS
nNOS

# Drug_Target_16_Theoretical_pI:
7.44

# Drug_Target_16_Transmembrane_Regions:
None

# Drug_Target_17_Cellular_Location:
Cytoplasm

# Drug_Target_17_Chromosome_Location:
Not Available

# Drug_Target_17_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_17_Essentiality:
Non-Essential

# Drug_Target_17_GenAtlas_ID:
NQO1

# Drug_Target_17_GenBank_ID_Gene:
J03934

# Drug_Target_17_GenBank_ID_Protein:
189246

# Drug_Target_17_GeneCard_ID:
NQO1

# Drug_Target_17_Gene_Name:
NQO1

# Drug_Target_17_Gene_Sequence:
>825 bp
ATGGTCGGCAGAAGAGCACTGATCGTACTGGCTCACTCAGAGAGGACCTCCTTCAACTAT
GCCATGAAGGAGGCTGCTGCAGCGGCTTTGAAGAAGAAAGGATGGGAGGTGGTGGAGTCG
GACCTCTATGCCATGAACTTCAATCCCATCATTTCCAGAAAGGACATCACAGGTAAACTG
AAGGACCCTGCGAACTTTCAGTATCCTGCCGAGTCTGTTCTGGCTTATAAAGAAGGCCAT
CTGAGCCCAGATATTGTGGCTGAACAAAAGAAGCTGGAAGCCGCAGACCTTGTGATATTC
CAGTTCCCCCTGCAGTGGTTTGGAGTCCCTGCCATTCTGAAAGGCTGGTTTGAGCGAGTG
TTCATAGGAGAGTTTGCTTACACTTACGCTGCCATGTATGACAAAGGACCCTTCCGGAGT
AAGAAGGCAGTGCTTTCCATCACCACTGGTGGCAGTGGCTCCATGTACTCTCTGCAAGGG
ATCCACGGGGACATGAATGTCATTCTCTGGCCAATTCAGAGTGGCATTCTGCATTTCTGT
GGCTTCCAAGTCTTAGAACCTCAACTGACATATAGCATTGGGCACACTCCAGCAGACGCC
CGAATTCAAATCCTGGAAGGATGGAAGAAACGCCTGGAGAATATTTGGGATGAGACACCA
CTGTATTTTGCTCCAAGCAGCCTCTTTGACCTAAACTTCCAGGCAGGATTCTTAATGAAA
AAAGAGGTACAGGATGAGGAGAAAAACAAGAAATTTGGCCTTTCTGTGGGCCATCACTTG
GGCAAGTCCATCCCAACTGACAACCAGATCAAAGCTAGAAAATGA

# Drug_Target_17_General_Function:
Involved in oxidoreductase activity

# Drug_Target_17_General_References:
10447260	Kristiansen OP, Larsen ZM, Johannesen J, Nerup J, Mandrup-Poulsen T, Pociot F: No linkage of P187S polymorphism in NAD(P)H: quinone oxidoreductase (NQO1/DIA4) and type 1 diabetes in the Danish population. DIEGG and DSGD. Danish IDDM Epidemiology and Genetics Group and The Danish Study Group of Diabetes in Childhood. Hum Mutat. 1999;14(1):67-70.
10706635	Faig M, Bianchet MA, Talalay P, Chen S, Winski S, Ross D, Amzel LM: Structures of recombinant human and mouse NAD(P)H:quinone oxidoreductases: species comparison and structural changes with substrate binding and release. Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3177-82.
1657151	Jaiswal AK: Human NAD(P)H:quinone oxidoreductase (NQO1) gene structure and induction by dioxin. Biochemistry. 1991 Nov 5;30(44):10647-53.
1737339	Traver RD, Horikoshi T, Danenberg KD, Stadlbauer TH, Danenberg PV, Ross D, Gibson NW: NAD(P)H:quinone oxidoreductase gene expression in human colon carcinoma cells: characterization of a mutation which modulates DT-diaphorase activity and mitomycin sensitivity. Cancer Res. 1992 Feb 15;52(4):797-802.
2843525	Jaiswal AK, McBride OW, Adesnik M, Nebert DW: Human dioxin-inducible cytosolic NAD(P)H:menadione oxidoreductase. cDNA sequence and localization of gene to chromosome 16. J Biol Chem. 1988 Sep 25;263(27):13572-8.

# Drug_Target_17_HGNC_ID:
HGNC:2874

# Drug_Target_17_HPRD_ID:
00518

# Drug_Target_17_ID:
2157

# Drug_Target_17_Locus:
16q22.1

# Drug_Target_17_Molecular_Weight:
30868

# Drug_Target_17_Name:
NAD(P)H dehydrogenase [quinone] 1

# Drug_Target_17_Number_of_Residues:
274

# Drug_Target_17_PDB_ID:
1KBQ

# Drug_Target_17_Pathway:
Not Available

# Drug_Target_17_Pfam_Domain_Function:
PF02525	Flavodoxin_2

# Drug_Target_17_Protein_Sequence:
>NAD(P)H dehydrogenase [quinone] 1
MVGRRALIVLAHSERTSFNYAMKEAAAAALKKKGWEVVESDLYAMNFNPIISRKDITGKL
KDPANFQYPAESVLAYKEGHLSPDIVAEQKKLEAADLVIFQFPLQWFGVPAILKGWFERV
FIGEFAYTYAAMYDKGPFRSKKAVLSITTGGSGSMYSLQGIHGDMNVILWPIQSGILHFC
GFQVLEPQLTYSIGHTPADARIQILEGWKKRLENIWDETPLYFAPSSLFDLNFQAGFLMK
KEVQDEEKNKKFGLSVGHHLGKSIPTDNQIKARK

# Drug_Target_17_Reaction:
NAD(P)H + H+ + a quinone = NAD(P)+ + a hydroquinone

# Drug_Target_17_Signals:
None

# Drug_Target_17_Specific_Function:
The enzyme apparently serves as a quinone reductase in connection with conjugation reactions of hydroquinons involved in detoxification pathways as well as in biosynthetic processes such as the vitamin K-dependent gamma-carboxylation of glutamate residues in prothrombin synthesis

# Drug_Target_17_SwissProt_ID:
P15559

# Drug_Target_17_SwissProt_Name:
NQO1_HUMAN

# Drug_Target_17_Synonyms:
Azoreductase
DT-diaphorase
DTD
EC 1.6.5.2
Menadione reductase
NAD(P)H:quinone oxidoreductase 1
Phylloquinone reductase
QR1
Quinone reductase 1

# Drug_Target_17_Theoretical_pI:
9.34

# Drug_Target_17_Transmembrane_Regions:
None

# Drug_Target_18_Cellular_Location:
Not Available

# Drug_Target_18_Chromosome_Location:
Not Available

# Drug_Target_18_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_18_Essentiality:
Non-Essential

# Drug_Target_18_GenAtlas_ID:
Not Available

# Drug_Target_18_GenBank_ID_Gene:
X68438

# Drug_Target_18_GenBank_ID_Protein:
49145

# Drug_Target_18_GeneCard_ID:
Not Available

# Drug_Target_18_Gene_Name:
pobA

# Drug_Target_18_Gene_Sequence:
>1185 bp
ATGAAGACTCAAGTCGCCATCATCGGCGCCGGTCCGTCCGGCCTCCTGCTCGGCCAGTTG
CTGCACAAGGCCGGCATCGACAACGTGATCCTCGAACGCCAGACCCCGGACTACGTGCTC
GGCCGCATCCGCGCCGGCGTGCTGGAACAGGGTATGGTCGACCTGCTGCGCGAGGCCGGC
GTCGACCGGCGCATGGCGCGCGACGGGCTGGTCCACGAAGGCGTGGAGATCGCCTTCGCC
GGGCAGCGCCGGCGCATCGACCTGAAGCGCCTGAGCGGCGGCAAGACGGTGACGGTCTAC
GGCCAGACCGAGGTCACCCGCGACCTCATGGAAGCCCGCGAAGCCTGCGGCGCCACTACC
GTCTACCAGGCCGCCGAGGTGCGCCTGCACGACCTGCAAGGTGAGCGCCCCTACGTGACC
TTCGAACGCGACGGCGAACGGCTACGCCTGGATTGCGACTACATCGCCGGCTGCGATGGC
TTCCACGGCATCTCGCGGCAATCGATCCCGGCGGAGCGGCTGAAGGTCTTCGAGCGGGTC
TATCCGTTCGGCTGGCTCGGCCTGCTCGCCGACACCCCGCCGGTCAGCCACGAACTGATC
TACGCCAACCATCCGCGCGGCTTCGCCCTGTGCAGCCAGCGTTCGGCGACCCGCAGCCGC
TACTACGTACAGGTGCCATTGACAGAGAAGGTCGAGGACTGGTCCGACGAGCGCTTCTGG
ACGGAACTGAAAGCGCGCCTCCCGGCCGAGGTGGCGGAGAAACTGGTGACCGGTCCTTCG
CTGGAGAAGAGCATCGCGCCGCTGCGCAGCTTCGTGGTCGAGCCGATGCAGCATGGCCGG
CTGTTCCTCGCCGGCGACGCCGCGCACATCGTGCCGCCCACCGGCGCCAAGGGACTGAAC
CTGGCGGCCAGCGACGTCAGCACGCTCTACCGGCTGCTGCTGAAGGCCTACCGCGAAGGG
CGGGGCGAACTGCTGGAACGCTACTCGGCAATCTGCCTGCGGCGGATCTGGAAGGCCGAA
CGCTTCTCCTGGTGGATGACTTCGGTGCTGCATCGCTTCCCCGACACCGACGCGTTCAGC
CAGCGCATCCAGCAGACCGAACTGGAGTACTACCTGGGCTCCGAGGCGGGCCTGGCGACC
ATCGCCGAGAACTATGTCGGCCTGCCCTACGAGGAAATCGAGTAG

# Drug_Target_18_General_Function:
Coenzyme transport and metabolism

# Drug_Target_18_General_References:
10025942	Eppink MH, Bunthol C, Schreuder HA, van Berkel WJ: Phe161 and Arg166 variants of p-hydroxybenzoate hydroxylase. Implications for NADPH recognition and structural stability. FEBS Lett. 1999 Jan 29;443(3):251-5.
1409567	Schreuder HA, van der Laan JM, Swarte MB, Kalk KH, Hol WG, Drenth J: Crystal structure of the reduced form of p-hydroxybenzoate hydroxylase refined at 2.3 A resolution. Proteins. 1992 Oct;14(2):178-90.
1459126	van Berkel W, Westphal A, Eschrich K, Eppink M, de Kok A: Substitution of Arg214 at the substrate-binding site of p-hydroxybenzoate hydroxylase from Pseudomonas fluorescens. Eur J Biochem. 1992 Dec 1;210(2):411-9.
3351945	Schreuder HA, van der Laan JM, Hol WG, Drenth J: Crystal structure of p-hydroxybenzoate hydroxylase complexed with its reaction product 3,4-dihydroxybenzoate. J Mol Biol. 1988 Feb 20;199(4):637-48.
40036	Wierenga RK, de Jong RJ, Kalk KH, Hol WG, Drenth J: Crystal structure of p-hydroxybenzoate hydroxylase. J Mol Biol. 1979 Jun 15;131(1):55-73.
6406227	Weijer WJ, Hofsteenge J, Beintema JJ, Wierenga RK, Drenth J: p-Hydroxybenzoate hydroxylase from Pseudomonas fluorescens. 2. Fitting of the amino-acid sequence to the tertiary structure. Eur J Biochem. 1983 Jun 1;133(1):109-18.
6406229	Hofsteenge J, Weijer WJ, Jekel PA, Beintema JJ: p-Hydroxybenzoate hydroxylase from Pseudomonas fluorescens. 1. Completion of the elucidation of the primary structure. Eur J Biochem. 1983 Jun 1;133(1):91-108.
6780352	Hofsteenge J, Vereijken JM, Weijer WJ, Beintema JJ, Wierenga RK, Drenth J: Primary and tertiary structure studies of p-hydroxybenzoate hydroxylase from Pseudomonas fluorescens. Isolation and alignment of the CNBr peptides; interactions of the protein with flavin adenine dinucleotide. Eur J Biochem. 1980 Dec;113(1):141-50.
6780353	Vereijken JM, Hofsteenge J, Bak HJ, Beintema JJ: The amino-acid sequence of the three smallest CNBr peptides from p-hydroxybenzoate hydroxylase from Pseudomonas fluorescens. Eur J Biochem. 1980 Dec;113(1):151-7.
6809053	Weijer WJ, Hofsteenge J, Vereijken JM, Jekel PA, Beintema JJ: Primary structure of p-hydroxybenzoate hydroxylase from Pseudomonas fluorescens. Biochim Biophys Acta. 1982 Jun 4;704(2):385-8.
7628466	Eppink MH, Schreuder HA, Van Berkel WJ: Structure and function of mutant Arg44Lys of 4-hydroxybenzoate hydroxylase implications for NADPH binding. Eur J Biochem. 1995 Jul 1;231(1):157-65.
9578477	Eppink MH, Schreuder HA, van Berkel WJ: Lys42 and Ser42 variants of p-hydroxybenzoate hydroxylase from Pseudomonas fluorescens reveal that Arg42 is essential for NADPH binding. Eur J Biochem. 1998 Apr 1;253(1):194-201.

# Drug_Target_18_HGNC_ID:
Not Available

# Drug_Target_18_HPRD_ID:
Not Available

# Drug_Target_18_ID:
2769

# Drug_Target_18_Locus:
Not Available

# Drug_Target_18_Molecular_Weight:
44322

# Drug_Target_18_Name:
P-hydroxybenzoate hydroxylase

# Drug_Target_18_Number_of_Residues:
394

# Drug_Target_18_PDB_ID:
2PHH

# Drug_Target_18_Pathway:
Not Available

# Drug_Target_18_Pfam_Domain_Function:
PF01494	FAD_binding_3

# Drug_Target_18_Protein_Sequence:
>P-hydroxybenzoate hydroxylase
MKTQVAIIGAGPSGLLLGQLLHKAGIDNVILERQTPDYVLGRIRAGVLEQGMVDLLREAG
VDRRMARDGLVHEGVEIAFAGQRRRIDLKRLSGGKTVTVYGQTEVTRDLMEAREACGATT
VYQAAEVRLHDLQGERPYVTFERDGERLRLDCDYIAGCDGFHGISRQSIPAERLKVFERV
YPFGWLGLLADTPPVSHELIYANHPRGFALCSQRSATRSRYYVQVPLTEKVEDWSDERFW
TELKARLPAEVAEKLVTGPSLEKSIAPLRSFVVEPMQHGRLFLAGDAAHIVPPTGAKGLN
LAASDVSTLYRLLLKAYREGRGELLERYSAICLRRIWKAERFSWWMTSVLHRFPDTDAFS
QRIQQTELEYYLGSEAGLATIAENYVGLPYEEIE

# Drug_Target_18_Reaction:
4-hydroxybenzoate + NADPH + H+ + O2 = protocatechuate + NADP+ + H2O

# Drug_Target_18_Signals:
None

# Drug_Target_18_Specific_Function:
4-hydroxybenzoate + NADPH + O(2) = protocatechuate + NADP(+) + H(2)O

# Drug_Target_18_SwissProt_ID:
P00438

# Drug_Target_18_SwissProt_Name:
PHHY_PSEFL

# Drug_Target_18_Synonyms:
4-hydroxybenzoate 3- monooxygenase
EC 1.14.13.2

# Drug_Target_18_Theoretical_pI:
6.80

# Drug_Target_18_Transmembrane_Regions:
None

# Drug_Target_19_Cellular_Location:
Periplasm

# Drug_Target_19_Chromosome_Location:
Not Available

# Drug_Target_19_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_19_Essentiality:
Non-Essential

# Drug_Target_19_GenAtlas_ID:
Not Available

# Drug_Target_19_GenBank_ID_Gene:
AE014299

# Drug_Target_19_GenBank_ID_Protein:
24346572

# Drug_Target_19_GeneCard_ID:
Not Available

# Drug_Target_19_Gene_Name:
SO_0970

# Drug_Target_19_Gene_Sequence:
>1791 bp
TTAATTATCTTTAGCGAATTTAGCGGCAGATGCACCCGCGATACGGCCGTAGGTGACGAT
ATCAGAGATAGCGTTACCACCTAAACGGTTAGCACCGTGAACACCACCAGTCACTTCGCC
TGCAGCGTATAAACCAGTGATAGGTTTACCGGTTTTCTCACTCTTCACTTCGGCTTTAGT
ATCAATCACCAGACCACCCATAGTGTGGTGAACCGCTGGTGCAATTTCTAAGGCGTAGAA
AGGAGCTACCACTAATTCACGTGGTAAATCAGGACGTTCAAATTGAGCATCTTTACCTGA
TTTAACGAAACCGTTGTAGGCTGTTACTGTTTTTGCCAATTCAGCTGCAGGTACATCGAT
TTGTTTCGCTAACTCTTCGATGGTTTTACCTTCTTTTACAATGTTCAGGTGAACATAACC
TTCGATGGCCTTCAAGCTCTTACGGATAGAGTCATCGAATACTAGGTAAGCGCTTTCACC
TTTTTGTTGCAGAATCGCCGCAGACGCTTTATCACGGGTGGTGATTTCGTTCATAAAACG
ATTACCTTCACGGTTCACCACGATTGCACCGTTACCACGTACTGCCTCGGTGATCATCAC
GCCACCCGCTGGAGAGTAAGTTGGGTGAGCTTGGATGTATTCTAAGTCACGTGTTGCTGC
GCCCGCTTGTAGAGCTACGTCTAAGCCGTCACCCGTCGCACCTGGGTGGTTGGTCGCTTT
AAAGCCTTTTAACTTAGGATCGTATTTAGAAACACGTTCGTTGTTTTTCGCAAAACCACC
TGCTGCAATGACTACTGCATCGGCTTTGATCACATAGTAACCTGTGTATTCACCTTTCAC
TAAAACGCCGGTCACTTTACCGCTTGCATCTTCAAGGATGCGCACAACGCGGCTGTTTAA
GCGAATATCAGTACCACGCTTAACGGCGTTGTCCCACAGCACTTGTGCTACGTGAGCACC
AACACCTGCACCACCGGTTGGACGGTGACTACGGTTAACGCTCGCGCCACCCATACGACC
CACGTCAGTCATGTCGGCACCCATAGAGGTTAACCAATCGATTGAGTCTGAAGAGTTGTT
AGCCAGTACTTTAACTAATTCAGGATCGTTGATGTTGCGGCCACCTTTCATAGTGTCGTC
GATCATGATTTGTTTCTTATCTTCGATACCTAACTTAGCCTGTGGCTTAGTTTCTGCGGC
GTTCATACCACCGGCAGCCAGTTTAGTGTTACCACCTGGGATAGGTTCTTTTTCTAACAG
AATCACTTTCGCGCCAGCATCACGGGCAGATACGGCAGCGGCAAGACCAGCACCACCAGA
GCCGATAATTACAACGTCTGTGGTTTCTTTCACACCAGCAGCAATGGCTTTATCTTGTGC
TGCTTTGTCTGCATCAACAGGTACAAACTTACGTTCCCACTTGCCACCAAATGGCATATC
GAAGCCGAAGCTATGGCAAGCATCACAATAAGCTACTGATTTTTCGTGGCCTTTGTGGCA
GCTCGTACAAGCGATTTCACCAATTAAGTGAGATTTGTGCGGAGAAACTTTATCTTTAGG
CGCTGCTGCAGCCAGTTCTTTTAAGTCACCGTGGCAGCTAACACATTGGCCATTCTCATG
GGTCAGGTTGTCGTTAGTCACGCCACCTTTGTCTGATACGTGGCAGCTATCGCAGCCACC
CATTTCACCGTGAAAATCGGCTAGTACTTCTGGAGCGGCATAGGCTGTGCCTGCCATTGC
GCCAGAGATCAGCATGGCTAGTGCTGTTTTTTGAATCTTTCTTGTGAACAT

# Drug_Target_19_General_Function:
Energy production and conversion

# Drug_Target_19_General_References:
10581551	Leys D, Tsapin AS, Nealson KH, Meyer TE, Cusanovich MA, Van Beeumen JJ: Structure and mechanism of the flavocytochrome c fumarate reductase of Shewanella putrefaciens MR-1. Nat Struct Biol. 1999 Dec;6(12):1113-7.
11425747	Tsapin AI, Vandenberghe I, Nealson KH, Scott JH, Meyer TE, Cusanovich MA, Harada E, Kaizu T, Akutsu H, Leys D, Van Beeumen JJ: Identification of a small tetraheme cytochrome c and a flavocytochrome c as two of the principal soluble cytochromes c in Shewanella oneidensis strain MR1. Appl Environ Microbiol. 2001 Jul;67(7):3236-44.
12368813	Heidelberg JF, Paulsen IT, Nelson KE, Gaidos EJ, Nelson WC, Read TD, Eisen JA, Seshadri R, Ward N, Methe B, Clayton RA, Meyer T, Tsapin A, Scott J, Beanan M, Brinkac L, Daugherty S, DeBoy RT, Dodson RJ, Durkin AS, Haft DH, Kolonay JF, Madupu R, Peterson JD, Umayam LA, White O, Wolf AM, Vamathevan J, Weidman J, Impraim M, Lee K, Berry K, Lee C, Mueller J, Khouri H, Gill J, Utterback TR, McDonald LA, Feldblyum TV, Smith HO, Venter JC, Nealson KH, Fraser CM: Genome sequence of the dissimilatory metal ion-reducing bacterium Shewanella oneidensis. Nat Biotechnol. 2002 Nov;20(11):1118-23. Epub 2002 Oct 7.

# Drug_Target_19_HGNC_ID:
Not Available

# Drug_Target_19_HPRD_ID:
Not Available

# Drug_Target_19_ID:
2709

# Drug_Target_19_Locus:
Not Available

# Drug_Target_19_Molecular_Weight:
62448

# Drug_Target_19_Name:
Fumarate reductase flavoprotein subunit

# Drug_Target_19_Number_of_Residues:
596

# Drug_Target_19_PDB_ID:
1D4C

# Drug_Target_19_Pathway:
Not Available

# Drug_Target_19_Pfam_Domain_Function:
PF00890	FAD_binding_2

# Drug_Target_19_Protein_Sequence:
>Fumarate reductase flavoprotein subunit precursor
MFTRKIQKTALAMLISGAMAGTAYAAPEVLADFHGEMGGCDSCHVSDKGGVTNDNLTHEN
GQCVSCHGDLKELAAAAPKDKVSPHKSHLIGEIACTSCHKGHEKSVAYCDACHSFGFDMP
FGGKWERKFVPVDADKAAQDKAIAAGVKETTDVVIIGSGGAGLAAAVSARDAGAKVILLE
KEPIPGGNTKLAAGGMNAAETKPQAKLGIEDKKQIMIDDTMKGGRNINDPELVKVLANNS
SDSIDWLTSMGADMTDVGRMGGASVNRSHRPTGGAGVGAHVAQVLWDNAVKRGTDIRLNS
RVVRILEDASGKVTGVLVKGEYTGYYVIKADAVVIAAGGFAKNNERVSKYDPKLKGFKAT
NHPGATGDGLDVALQAGAATRDLEYIQAHPTYSPAGGVMITEAVRGNGAIVVNREGNRFM
NEITTRDKASAAILQQKGESAYLVFDDSIRKSLKAIEGYVHLNIVKEGKTIEELAKQIDV
PAAELAKTVTAYNGFVKSGKDAQFERPDLPRELVVAPFYALEIAPAVHHTMGGLVIDTKA
EVKSEKTGKPITGLYAAGEVTGGVHGANRLGGNAISDIVTYGRIAGASAAKFAKDN

# Drug_Target_19_Reaction:
succinate + acceptor = fumarate + reduced acceptor

# Drug_Target_19_Signals:
1-25

# Drug_Target_19_Specific_Function:
Catalyzes fumarate reduction using artificial electron donors such as methyl viologen. The physiological reductant is unknown, but evidence indicates that flavocytochrome c participates in electron transfer from formate to fumarate and possibly also to trimethylamine oxide (TMAO). This enzyme is essentially unidirectional

# Drug_Target_19_SwissProt_ID:
P83223

# Drug_Target_19_SwissProt_Name:
FRDA_SHEON

# Drug_Target_19_Synonyms:
EC 1.3.99.1
FL cyt
Flavocytochrome c
Fumarate reductase flavoprotein subunit precursor

# Drug_Target_19_Theoretical_pI:
7.64

# Drug_Target_19_Transmembrane_Regions:
None

# Drug_Target_1_Cellular_Location:
Not Available

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
U03041

# Drug_Target_1_GenBank_ID_Protein:
510253

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
glf

# Drug_Target_1_Gene_Sequence:
>1104 bp
ATGTACGATTATATCATTGTTGGTTCTGGTTTGTTTGGTGCCGTTTGTGCGAATGAGTTA
AAAAAGCTAAACAAAAAAGTTTTAGTGATTGAGAAAAGAAATCATATCGGTGGAAATGCG
TACACAGAGGACTGTGAGGGTATCCAGATTCATAAATATGGTGCACATATTTTTCATACC
AATGATAAATATATATGGGATTACGTTAATGATTTAGTAGAATTTAATCGTTTTACTAAT
TCTCCACTGGCGATTTATAAAGACAAATTATTCAACCTTCCTTTTAATATGAATACTTTC
CACCAAATGTGGGGAGTTAAAGATCCTCAAGAAGCTCAAAATATCATTAATGCTCAGAAA
AAAAAGTATGGTGACAAGGTACCTGAAAATTTGGAGGAGCAGGCGATTTCATTAGTTGGG
GAGGACTTATACCAAGCATTGATAAAGGGTTATACGGAGAAGCAGTGGGGAAGAAGTGCA
AAAGAATTGCCTGCATTTATTATTAAGCGAATCCCAGTGAGATTTACGTTTGATAACAAT
TATTTTTCCGATCGCTATCAAGGTATTCCGGTGGGAGGCTACACTAAGCTTATTGAAAAA
ATGCTTGAAGGTGTGGACGTAAAATTAGGCATTGATTTTTTGAAAGACAAAGATTCTCTA
GCGAGTAAAGCCCATAGAATCATCTACACTGGACCCATTGATCAGTACTTCGACTATAGG
TTTGGAGCGTTAGAATATCGCTCTTTAAAATTTGAGACGGAACGCCATGAATTTCCAAAC
TTCCAAGGGAATGCAGTAATAAATTTCACTGATGCTAATGTACCATATACCAGAATAATT
GAGCATAAACATTTTGACTATGTTGAGACAAAGCATACGGTTGTTACAAAAGAATATCCA
TTAGAGTGGAAAGTTGGCGACGAACCCTACTATCCAGTTAATGATAATAAAAACATGGAG
CTTTTTAAGAAATATAGAGAGTTAGCTAGCAGAGAAGACAAGGTTATATTTGGCGGGCGT
TTGGCCGAGTATAAATATTATGATATGCATCAAGTGATATCTGCCGCTCTTTATCAAGTG
AAAAATATAATGAGTACGGATTAA

# Drug_Target_1_General_Function:
Cell wall/membrane/envelope biogenesis

# Drug_Target_1_General_References:
7517390	Yao Z, Valvano MA: Genetic analysis of the O-specific lipopolysaccharide biosynthesis region (rfb) of Escherichia coli K-12 W3110: identification of genes that confer group 6 specificity to Shigella flexneri serotypes Y and 4a. J Bacteriol. 1994 Jul;176(13):4133-43.
7517391	Stevenson G, Neal B, Liu D, Hobbs M, Packer NH, Batley M, Redmond JW, Lindquist L, Reeves P: Structure of the O antigen of Escherichia coli K-12 and the sequence of its rfb gene cluster. J Bacteriol. 1994 Jul;176(13):4144-56.
8576037	Nassau PM, Martin SL, Brown RE, Weston A, Monsey D, McNeil MR, Duncan K: Galactofuranose biosynthesis in Escherichia coli K-12: identification and cloning of UDP-galactopyranose mutase. J Bacteriol. 1996 Feb;178(4):1047-52.
9097040	Itoh T, Aiba H, Baba T, Hayashi K, Inada T, Isono K, Kasai H, Kimura S, Kitakawa M, Kitagawa M, Makino K, Miki T, Mizobuchi K, Mori H, Mori T, Motomura K, Nakade S, Nakamura Y, Nashimoto H, Nishio Y, Oshima T, Saito N, Sampei G, Seki Y, Horiuchi T, et al.: A 460-kb DNA sequence of the Escherichia coli K-12 genome corresponding to the 40.1-50.0 min region on the linkage map. DNA Res. 1996 Dec 31;3(6):379-92.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
3133

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
42966

# Drug_Target_1_Name:
UDP-galactopyranose mutase

# Drug_Target_1_Number_of_Residues:
367

# Drug_Target_1_PDB_ID:
1I8T

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF03275	GLF
PF07992	Pyr_redox_2

# Drug_Target_1_Protein_Sequence:
>UDP-galactopyranose mutase
MYDYIIVGSGLFGAVCANELKKLNKKVLVIEKRNHIGGNAYTEDCEGIQIHKYGAHIFHT
NDKYIWDYVNDLVEFNRFTNSPLAIYKDKLFNLPFNMNTFHQMWGVKDPQEAQNIINAQK
KKYGDKVPENLEEQAISLVGEDLYQALIKGYTEKQWGRSAKELPAFIIKRIPVRFTFDNN
YFSDRYQGIPVGGYTKLIEKMLEGVDVKLGIDFLKDKDSLASKAHRIIYTGPIDQYFDYR
FGALEYRSLKFETERHEFPNFQGNAVINFTDANVPYTRIIEHKHFDYVETKHTVVTKEYP
LEWKVGDEPYYPVNDNKNMELFKKYRELASREDKVIFGGRLAEYKYYDMHQVISAALYQV
KNIMSTD

# Drug_Target_1_Reaction:
UDP-D-galactopyranose = UDP-D-galacto-1,4-furanose

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Involved in the conversion of UDP-GalP into UDP-GalF through a 2-keto intermediate

# Drug_Target_1_SwissProt_ID:
P37747

# Drug_Target_1_SwissProt_Name:
GLF_ECOLI

# Drug_Target_1_Synonyms:
EC 5.4.99.9

# Drug_Target_1_Theoretical_pI:
7.13

# Drug_Target_1_Transmembrane_Regions:
None

# Drug_Target_20_Cellular_Location:
Not Available

# Drug_Target_20_Chromosome_Location:
Not Available

# Drug_Target_20_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_20_Essentiality:
Non-Essential

# Drug_Target_20_GenAtlas_ID:
Not Available

# Drug_Target_20_GenBank_ID_Gene:
Not Available

# Drug_Target_20_GenBank_ID_Protein:
Not Available

# Drug_Target_20_GeneCard_ID:
Not Available

# Drug_Target_20_Gene_Name:
ERO1LB

# Drug_Target_20_Gene_Sequence:
Not Available

# Drug_Target_20_General_Function:
Not Available

# Drug_Target_20_General_References:
Not Available

# Drug_Target_20_HGNC_ID:
Not Available

# Drug_Target_20_HPRD_ID:
Not Available

# Drug_Target_20_ID:
7084

# Drug_Target_20_Locus:
Not Available

# Drug_Target_20_Molecular_Weight:
Not Available

# Drug_Target_20_Name:
ERO1-like protein beta

# Drug_Target_20_Number_of_Residues:
0

# Drug_Target_20_PDB_ID:
Not Available

# Drug_Target_20_Pathway:
Not Available

# Drug_Target_20_Pfam_Domain_Function:
Not Available

# Drug_Target_20_Protein_Sequence:
Not Available

# Drug_Target_20_Reaction:
Not Available

# Drug_Target_20_Signals:
Not Available

# Drug_Target_20_Specific_Function:
Not Available

# Drug_Target_20_SwissProt_ID:
Q86YB8

# Drug_Target_20_SwissProt_Name:
ERO1B_HUMAN

# Drug_Target_20_Synonyms:
Not Available

# Drug_Target_20_Theoretical_pI:
Not Available

# Drug_Target_20_Transmembrane_Regions:
Not Available

# Drug_Target_21_Cellular_Location:
Mitochondrion. Cytoplasm

# Drug_Target_21_Chromosome_Location:
Not Available

# Drug_Target_21_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_21_Essentiality:
Non-Essential

# Drug_Target_21_GenAtlas_ID:
GSR

# Drug_Target_21_GenBank_ID_Gene:
X15722

# Drug_Target_21_GenBank_ID_Protein:
31825

# Drug_Target_21_GeneCard_ID:
GSR

# Drug_Target_21_Gene_Name:
GSR

# Drug_Target_21_Gene_Sequence:
>1569 bp
ATGGCCCTGCTGCCCCGAGCCCTGAGCGCCGGCGCGGGACCGAGCTGGCGGCGGGCGGCG
CGCGCCTTCCGAGGCTTCCTGCTGCTTCTGCCCGAGCCCGCGGCCCTCACGCGCGCCCTC
TCCCGTGCCATGGCCTGCAGGCAGGAGCCGCAGCCGCAGGGCCCGCCGCCCGCTGCTGGC
GCCGTGGCCTCCTATGACTACCTGGTGATCGGGGGCGGCTCGGGCGGGCTGGCCAGCGCG
CGCAGGGCGGCCGAGCTGGGTGCCAGGGCCGCCGTGGTGGAGAGCCACAAGCTGGGTGGC
ACTTGCGTGAATGTTGGATGTGTACCCAAAAAGGTAATGTGGAACACAGCTGTCCACTCT
GAATTCATGCATGATCATGCTGATTATGGCTTTCCAAGTTGTGAGGGTAAATTCAATTGG
CGTGTTATTAAGGAAAAGCGGGATGCCTATGTGAGCCGCCTGAATGCCATCTATCAAAAC
AATCTCACCAAGTCCCATATAGAAATCATCCGTGGCCATGCAGCCTTCACGAGTGATCCC
AAGCCCACAATAGAGGTCAGTGGGAAAAAGTACACCGCCCCACACATCCTGATCGCCACA
GGTGGTATGCCCTCCACCCCTCATGAGAGCCAGATCCCCGGTGCCAGCTTAGGAATAACC
AGCGATGGATTTTTTCAGCTGGAAGAATTGCCCGGCCGCAGCGTCATTGTTGGTGCAGGT
TACATTGCTGTGGAGATGGCAGGGATCCTGTCAGCCCTGGGTTCTAAGACATCACTGATG
ATACGGCATGATAAGGTACTTAGAAGTTTTGATTCAATGATCAGCACCAACTGCACGGAG
GAGCTGGAGAACGCTGGCGTGGAGGTGCTGAAGTTCTCCCAGGTCAAGGAGGTTAAAAAG
ACTTTGTCGGGCTTGGAAGTCAGCATGGTTACTGCAGTTCCCGGTAGGCTACCAGTCATG
ACCATGATTCCAGATGTTGACTGCCTGCTCTGGGCCATTGGGCGGGTCCCGAATACCAAG
GACCTGAGTTTAAACAAACTGGGGATTCAAACCGATGACAAGGGTCATATCATCGTAGAC
GAATTCCAGAATACCAACGTCAAAGGCATCTATGCAGTTGGGGATGTATGTGGAAAAGCT
CTTCTTACTCCAGTTGCAATAGCTGCTGGCCGAAAACTTGCCCATCGACTTTTTGAATAT
AAGGAAGATTCCAAATTAGATTATAACAACATCCCAACTGTGGTCTTCAGCCACCCCCCT
ATTGGGACAGTGGGACTCACGGAAGATGAAGCCATTCATAAATATGGAATAGAAAATGTG
AAGACCTATTCAACGAGCTTTACCCCGATGTATCACGCAGTTACCAAAAGGAAAACAAAA
TGTGTGATGAAAATGGTCTGTGCTAACAAGGAAGAAAAGGTGGTTGGGATCCATATGCAG
GGACTTGGGTGTGATGAAATGCTGCAGGGTTTTGCTGTTGCAGTGAAGATGGGAGCAACG
AAGGCAGACTTTGACAACACAGTCGCCATTCACCCTACCTCTTCAGAAGAGCTGGTCACA
CTTCGTTGA

# Drug_Target_21_General_Function:
RNA processing and modification

# Drug_Target_21_General_References:
10708558	Kelner MJ, Montoya MA: Structural organization of the human glutathione reductase gene: determination of correct cDNA sequence and identification of a mitochondrial leader sequence. Biochem Biophys Res Commun. 2000 Mar 16;269(2):366-8.
2185014	Tutic M, Lu XA, Schirmer RH, Werner D: Cloning and sequencing of mammalian glutathione reductase cDNA. Eur J Biochem. 1990 Mar 30;188(3):523-8.
3656429	Karplus PA, Schulz GE: Refined structure of glutathione reductase at 1.54 A resolution. J Mol Biol. 1987 Jun 5;195(3):701-29.
7060551	Krauth-Siegel RL, Blatterspiel R, Saleh M, Schiltz E, Schirmer RH, Untucht-Grau R: Glutathione reductase from human erythrocytes. The sequences of the NADPH domain and of the interface domain. Eur J Biochem. 1982 Jan;121(2):259-67.
7334521	Thieme R, Pai EF, Schirmer RH, Schulz GE: Three-dimensional structure of glutathione reductase at 2 A resolution. J Mol Biol. 1981 Nov 15;152(4):763-82.
8626496	Savvides SN, Karplus PA: Kinetics and crystallographic analysis of human glutathione reductase in complex with a xanthene inhibitor. J Biol Chem. 1996 Apr 5;271(14):8101-7.
9174360	Stoll VS, Simpson SJ, Krauth-Siegel RL, Walsh CT, Pai EF: Glutathione reductase turned into trypanothione reductase: structural analysis of an engineered change in substrate specificity. Biochemistry. 1997 May 27;36(21):6437-47.
923580	Krohne-Ehrich G, Schirmer RH, Untucht-Grau R: Glutathione reductase from human erythrocytes. Isolation of the enzyme and sequence analysis of the redox-active peptide. Eur J Biochem. 1977 Oct 17;80(1):65-71.
9546215	Becker K, Savvides SN, Keese M, Schirmer RH, Karplus PA: Enzyme inactivation through sulfhydryl oxidation by physiologic NO-carriers. Nat Struct Biol. 1998 Apr;5(4):267-71.

# Drug_Target_21_HGNC_ID:
HGNC:4623

# Drug_Target_21_HPRD_ID:
00704

# Drug_Target_21_ID:
714

# Drug_Target_21_Locus:
8p21.1

# Drug_Target_21_Molecular_Weight:
56258

# Drug_Target_21_Name:
Glutathione reductase, mitochondrial

# Drug_Target_21_Number_of_Residues:
522

# Drug_Target_21_PDB_ID:
1BWC

# Drug_Target_21_Pathway:
Not Available

# Drug_Target_21_Pfam_Domain_Function:
PF00070	Pyr_redox
PF02852	Pyr_redox_dim
PF07992	Pyr_redox_2

# Drug_Target_21_Protein_Sequence:
>Glutathione reductase, mitochondrial precursor
MALLPRALSAGAGPSWRRAARAFRGFLLLLPEPAALTRALSRAMACRQEPQPQGPPPAAG
AVASYDYLVIGGGSGGLASARRAAELGARAAVVESHKLGGTCVNVGCVPKKVMWNTAVHS
EFMHDHADYGFPSCEGKFNWRVIKEKRDAYVSRLNAIYQNNLTKSHIEIIRGHAAFTSDP
KPTIEVSGKKYTAPHILIATGGMPSTPHESQIPGASLGITSDGFFQLEELPGRSVIVGAG
YIAVEMAGILSALGSKTSLMIRHDKVLRSFDSMISTNCTEELENAGVEVLKFSQVKEVKK
TLSGLEVSMVTAVPGRLPVMTMIPDVDCLLWAIGRVPNTKDLSLNKLGIQTDDKGHIIVD
EFQNTNVKGIYAVGDVCGKALLTPVAIAAGRKLAHRLFEYKEDSKLDYNNIPTVVFSHPP
IGTVGLTEDEAIHKYGIENVKTYSTSFTPMYHAVTKRKTKCVMKMVCANKEEKVVGIHMQ
GLGCDEMLQGFAVAVKMGATKADFDNTVAIHPTSSEELVTLR

# Drug_Target_21_Reaction:
2 glutathione + NADP+ = glutathione disulfide + NADPH + H+

# Drug_Target_21_Signals:
None

# Drug_Target_21_Specific_Function:
Maintains high levels of reduced glutathione in the cytosol

# Drug_Target_21_SwissProt_ID:
P00390

# Drug_Target_21_SwissProt_Name:
GSHR_HUMAN

# Drug_Target_21_Synonyms:
EC 1.8.1.7
GR
GRase
Glutathione reductase, mitochondrial precursor

# Drug_Target_21_Theoretical_pI:
8.66

# Drug_Target_21_Transmembrane_Regions:
None

# Drug_Target_22_Cellular_Location:
Not Available

# Drug_Target_22_Chromosome_Location:
Not Available

# Drug_Target_22_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_22_Essentiality:
Non-Essential

# Drug_Target_22_GenAtlas_ID:
Not Available

# Drug_Target_22_GenBank_ID_Gene:
BX842582

# Drug_Target_22_GenBank_ID_Protein:
2076681

# Drug_Target_22_GeneCard_ID:
Not Available

# Drug_Target_22_Gene_Name:
fprA

# Drug_Target_22_Gene_Sequence:
>1371 bp
ATGCGTCCCTATTACATCGCCATCGTGGGCTCCGGGCCGTCGGCGTTCTTCGCCGCGGCA
TCCTTGCTGAAGGCCGCCGACACGACCGAGGACCTCGACATGGCCGTCGACATGCTGGAG
ATGTTGCCGACTCCCTGGGGGCTGGTGCGCTCCGGGGTCGCGCCGGATCACCCCAAGATC
AAGTCGATCAGCAAGCAATTCGAAAAGACGGCCGAGGACCCCCGCTTCCGCTTCTTCGGC
AATGTGGTCGTCGGCGAACACGTCCAGCCCGGCGAGCTCTCCGAGCGCTACGACGCCGTG
ATCTACGCCGTCGGCGCGCAGTCCGATCGCATGTTGAACATCCCCGGTGAGGACCTGCCG
GGCAGTATCGCCGCCGTCGATTTCGTCGGCTGGTACAACGCACATCCACACTTCGAGCAG
GTATCACCCGATCTGTCGGGCGCCCGGGCCGTAGTTATCGGCAATGGAAACGTCGCGCTA
GACGTGGCACGGATTCTGCTCACCGATCCCGACGTGTTGGCACGCACCGATATCGCCGAT
CACGCTTTGGAATCGCTACGCCCACGCGGTATCCAGGAGGTGGTGATCGTCGGGCGCCGA
GGTCCGCTGCAGGCCGCGTTCACCACGTTGGAGTTGCGCGAGCTGGCCGACCTCGACGGG
GTTGACGTGGTGATCGATCCGGCGGAGCTGGACGGCATTACCGACGAGGACGCGGCCGCG
GTGGGCAAGGTCTGCAAGCAGAACATCAAGGTGCTGCGTGGCTATGCGGACCGCGAACCC
CGCCCGGGACACCGCCGCATGGTGTTCCGGTTCTTGACCTCTCCGATCGAGATCAAGGGC
AAGCGCAAAGTGGAGCGGATCGTGCTGGGCCGCAACGAGCTGGTCTCCGACGGCAGCGGG
CGAGTGGCGGCCAAGGACACCGGCGAGCGCGAGGAGCTGCCAGCTCAGCTGGTCGTGCGG
TCGGTCGGCTACCGCGGGGTGCCCACGCCCGGGCTGCCGTTCGACGACCAGAGCGGGACC
ATCCCCAACGTCGGCGGCCGAATCAACGGCAGCCCCAACGAATACGTCGTCGGGTGGATC
AAGCGCGGGCCGACCGGGGTGATCGGGACCAACAAGAAGGACGCCCAAGACACCGTCGAC
ACCTTGATCAAGAATCTTGGCAACGCCAAGGAGGGCGCCGAGTGCAAGAGCTTTCCGGAA
GATCATGCCGACCAGGTGGCCGACTGGCTAGCAGCACGCCAGCCGAAGCTGGTCACGTCG
GCCCACTGGCAGGTGATCGACGCTTTCGAGCGGGCCGCCGGCGAGCCGCACGGGCGTCCC
CGGGTCAAGTTGGCCAGCCTGGCCGAGCTGTTGCGGATTGGGCTCGGCTGA

# Drug_Target_22_General_Function:
Amino acid transport and metabolism

# Drug_Target_22_General_References:
12071965	Fischer F, Raimondi D, Aliverti A, Zanetti G: Mycobacterium tuberculosis FprA, a novel bacterial NADPH-ferredoxin reductase. Eur J Biochem. 2002 Jun;269(12):3005-13.
12102623	Bossi RT, Aliverti A, Raimondi D, Fischer F, Zanetti G, Ferrari D, Tahallah N, Maier CS, Heck AJ, Rizzi M, Mattevi A: A covalent modification of NADP+ revealed by the atomic resolution structure of FprA, a Mycobacterium tuberculosis oxidoreductase. Biochemistry. 2002 Jul 16;41(28):8807-18.
12218036	Fleischmann RD, Alland D, Eisen JA, Carpenter L, White O, Peterson J, DeBoy R, Dodson R, Gwinn M, Haft D, Hickey E, Kolonay JF, Nelson WC, Umayam LA, Ermolaeva M, Salzberg SL, Delcher A, Utterback T, Weidman J, Khouri H, Gill J, Mikula A, Bishai W, Jacobs Jr WR Jr, Venter JC, Fraser CM: Whole-genome comparison of Mycobacterium tuberculosis clinical and laboratory strains. J Bacteriol. 2002 Oct;184(19):5479-90.
12614197	McLean KJ, Scrutton NS, Munro AW: Kinetic, spectroscopic and thermodynamic characterization of the Mycobacterium tuberculosis adrenodoxin reductase homologue FprA. Biochem J. 2003 Jun 1;372(Pt 2):317-27.
9634230	Cole ST, Brosch R, Parkhill J, Garnier T, Churcher C, Harris D, Gordon SV, Eiglmeier K, Gas S, Barry CE 3rd, Tekaia F, Badcock K, Basham D, Brown D, Chillingworth T, Connor R, Davies R, Devlin K, Feltwell T, Gentles S, Hamlin N, Holroyd S, Hornsby T, Jagels K, Krogh A, McLean J, Moule S, Murphy L, Oliver K, Osborne J, Quail MA, Rajandream MA, Rogers J, Rutter S, Seeger K, Skelton J, Squares R, Squares S, Sulston JE, Taylor K, Whitehead S, Barrell BG: Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature. 1998 Jun 11;393(6685):537-44.

# Drug_Target_22_HGNC_ID:
Not Available

# Drug_Target_22_HPRD_ID:
Not Available

# Drug_Target_22_ID:
2526

# Drug_Target_22_Locus:
Not Available

# Drug_Target_22_Molecular_Weight:
49342

# Drug_Target_22_Name:
NADPH-ferredoxin reductase fprA

# Drug_Target_22_Number_of_Residues:
456

# Drug_Target_22_PDB_ID:
1LQU

# Drug_Target_22_Pathway:
Not Available

# Drug_Target_22_Pfam_Domain_Function:
Not Available

# Drug_Target_22_Protein_Sequence:
>NADPH-ferredoxin reductase fprA
MRPYYIAIVGSGPSAFFAAASLLKAADTTEDLDMAVDMLEMLPTPWGLVRSGVAPDHPKI
KSISKQFEKTAEDPRFRFFGNVVVGEHVQPGELSERYDAVIYAVGAQSDRMLNIPGEDLP
GSIAAVDFVGWYNAHPHFEQVSPDLSGARAVVIGNGNVALDVARILLTDPDVLARTDIAD
HALESLRPRGIQEVVIVGRRGPLQAAFTTLELRELADLDGVDVVIDPAELDGITDEDAAA
VGKVCKQNIKVLRGYADREPRPGHRRMVFRFLTSPIEIKGKRKVERIVLGRNELVSDGSG
RVAAKDTGEREELPAQLVVRSVGYRGVPTPGLPFDDQSGTIPNVGGRINGSPNEYVVGWI
KRGPTGVIGTNKKDAQDTVDTLIKNLGNAKEGAECKSFPEDHADQVADWLAARQPKLVTS
AHWQVIDAFERAAGEPHGRPRVKLASLAELLRIGLG

# Drug_Target_22_Reaction:
2 reduced ferredoxin + NADP+ + H+ = 2 oxidized ferredoxin + NADPH

# Drug_Target_22_Signals:
None

# Drug_Target_22_Specific_Function:
May serve as electron transfer protein and supply electrons to P450 systems

# Drug_Target_22_SwissProt_ID:
O05783

# Drug_Target_22_SwissProt_Name:
FPRA_MYCTU

# Drug_Target_22_Synonyms:
EC 1.18.1.2
NFR

# Drug_Target_22_Theoretical_pI:
5.53

# Drug_Target_22_Transmembrane_Regions:
None

# Drug_Target_23_Cellular_Location:
Isoform 1:Endoplasmic reticulum
cytoplasmic side. Mit
endoplasmic reticulum membrane
lipid-anchor

# Drug_Target_23_Chromosome_Location:
Not Available

# Drug_Target_23_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_23_Essentiality:
Non-Essential

# Drug_Target_23_GenAtlas_ID:
CYB5R3

# Drug_Target_23_GenBank_ID_Gene:
M28713

# Drug_Target_23_GenBank_ID_Protein:
553600

# Drug_Target_23_GeneCard_ID:
CYB5R3

# Drug_Target_23_Gene_Name:
CYB5R3

# Drug_Target_23_Gene_Sequence:
>906 bp
ATGGGGGCCCAGCTCAGCACGTTGGGCCATATGGTCCTCTTCCCAGTCTGGTTCCTGTAC
AGTCTGCTCATGAAGCTGTTCCAGGGCTCCACGCCAGCCATCACCCTCGAGAGCCCGGAC
ATCAAGTACCCGCTGCGGCTCATCGACCGGGAGATCATCAGCCATGACACCCGGCGCTTC
CGCTTTGCCCTGCCGCCACCCCAGCACATCCTGGGCCTCCCTGTCGGCCAGCACATCTAC
CTCTCGGCTCGAATTGATGGAAACCTGGTCGTCCGGCCCTATACACCAATCTCCAGCGAT
GATGACAAGGGCTTCGTGGACCTGGTCATCAAGGTTTACTTCAAGGACACCCATCCCAAG
TTTCCCGCTGGAGGGAAGATGTCTCAGTACCTGGAGAGCATGCAGATTGGAGACACCATT
GAGTTCCGGGGCCCCAGTGGGCTGCTGGTCTACCAGGGCAAAGGGAAGTTCGCCATCCGA
CCTGACAAAAAGTCCAACCCTATCATCAGGACAGTGAAGTCTGTGGGCATGATCGCGGGA
GGGACAGGCATCACCCCGATGCTGCAGGTGATCCGCGCCATCATGAAGGACCCTGATGAC
CACACTGTGTGCCACCTGCTCTTTGCCAACCAGACCGAGAAGGACATCCTGCTGCGACCT
GAGCTGGAGGAACTCAGGAACAAACATTCTGCACGCTTCAAGCTCTGGTACACGCTGGAC
AGAGCCCCTGAAGCCTGGGACTACGGCCAGGGCTTCGTGAATGAGGAGATGATCCGGGAC
CACCTTCCACCCCCAGAGGAGGAGCCGCTGGTGCTGATGTGTGGCCCCCCACCCATGATC
CAGTACGCCTGCCTTCCCAACCTGGACCACGTGGGCCACCCCACGGAGCGCTGCTTCGTC
TTCTGA

# Drug_Target_23_General_Function:
Coenzyme transport and metabolism

# Drug_Target_23_General_References:
10591208	Dunham I, Shimizu N, Roe BA, Chissoe S, Hunt AR, Collins JE, Bruskiewich R, Beare DM, Clamp M, Smink LJ, Ainscough R, Almeida JP, Babbage A, Bagguley C, Bailey J, Barlow K, Bates KN, Beasley O, Bird CP, Blakey S, Bridgeman AM, Buck D, Burgess J, Burrill WD, O'Brien KP, et al.: The DNA sequence of human chromosome 22. Nature. 1999 Dec 2;402(6761):489-95.
10807796	Wang Y, Wu YS, Zheng PZ, Yang WX, Fang GA, Tang YC, Xie F, Lan FH, Zhu ZY: A novel mutation in the NADH-cytochrome b5 reductase gene of a Chinese patient with recessive congenital methemoglobinemia. Blood. 2000 May 15;95(10):3250-5.
1400360	Shirabe K, Yubisui T, Borgese N, Tang CY, Hultquist DE, Takeshita M: Enzymatic instability of NADH-cytochrome b5 reductase as a cause of hereditary methemoglobinemia type I (red cell type). J Biol Chem. 1992 Oct 5;267(28):20416-21.
1707593	Katsube T, Sakamoto N, Kobayashi Y, Seki R, Hirano M, Tanishima K, Tomoda A, Takazakura E, Yubisui T, Takeshita M, et al.: Exonic point mutations in NADH-cytochrome B5 reductase genes of homozygotes for hereditary methemoglobinemia, types I and III: putative mechanisms of tissue-dependent enzyme deficiency. Am J Hum Genet. 1991 Apr;48(4):799-808.
1898726	Yubisui T, Shirabe K, Takeshita M, Kobayashi Y, Fukumaki Y, Sakaki Y, Takano T: Structural role of serine 127 in the NADH-binding site of human NADH-cytochrome b5 reductase. J Biol Chem. 1991 Jan 5;266(1):66-70.
2019583	Shirabe K, Yubisui T, Nishino T, Takeshita M: Role of cysteine residues in human NADH-cytochrome b5 reductase studied by site-directed mutagenesis. Cys-273 and Cys-283 are located close to the NADH-binding site but are not catalytically essential. J Biol Chem. 1991 Apr 25;266(12):7531-6.
2479590	Tomatsu S, Kobayashi Y, Fukumaki Y, Yubisui T, Orii T, Sakaki Y: The organization and the complete nucleotide sequence of the human NADH-cytochrome b5 reductase gene. Gene. 1989 Aug 15;80(2):353-61.
3035541	Yubisui T, Naitoh Y, Zenno S, Tamura M, Takeshita M, Sakaki Y: Molecular cloning of cDNAs of human liver and placenta NADH-cytochrome b5 reductase. Proc Natl Acad Sci U S A. 1987 Jun;84(11):3609-13.
3700359	Yubisui T, Miyata T, Iwanaga S, Tamura M, Takeshita M: Complete amino acid sequence of NADH-cytochrome b5 reductase purified from human erythrocytes. J Biochem (Tokyo). 1986 Feb;99(2):407-22.
6389526	Yubisui T, Miyata T, Iwanaga S, Tamura M, Yoshida S, Takeshita M, Nakajima H: Amino acid sequence of NADH-cytochrome b5 reductase of human erythrocytes. J Biochem (Tokyo). 1984 Aug;96(2):579-82.
7718898	Vieira LM, Kaplan JC, Kahn A, Leroux A: Four new mutations in the NADH-cytochrome b5 reductase gene from patients with recessive congenital methemoglobinemia type II. Blood. 1995 Apr 15;85(8):2254-62.
8119939	Shirabe K, Fujimoto Y, Yubisui T, Takeshita M: An in-frame deletion of codon 298 of the NADH-cytochrome b5 reductase gene results in hereditary methemoglobinemia type II (generalized type). A functional implication for the role of the COOH-terminal region of the enzyme. J Biol Chem. 1994 Feb 25;269(8):5952-7.
9048929	Jenkins MM, Prchal JT: A high-frequency polymorphism of NADH-cytochrome b5 reductase in African-Americans. Hum Genet. 1997 Feb;99(2):248-50.
9639531	Bulbarelli A, Valentini A, DeSilvestris M, Cappellini MD, Borgese N: An erythroid-specific transcript generates the soluble form of NADH-cytochrome b5 reductase in humans. Blood. 1998 Jul 1;92(1):310-9.
9695975	Wu YS, Huang CH, Wan Y, Huang QJ, Zhu ZY: Identification of a novel point mutation (Leu72Pro) in the NADH-cytochrome b5 reductase gene of a patient with hereditary methaemoglobinaemia type I. Br J Haematol. 1998 Jul;102(2):575-7.
9886302	Higasa K, Manabe JI, Yubisui T, Sumimoto H, Pung-Amritt P, Tanphaichitr VS, Fukumaki Y: Molecular basis of hereditary methaemoglobinaemia, types I and II: two novel mutations in the NADH-cytochrome b5 reductase gene. Br J Haematol. 1998 Dec;103(4):922-30.

# Drug_Target_23_HGNC_ID:
HGNC:2873

# Drug_Target_23_HPRD_ID:
08942

# Drug_Target_23_ID:
178

# Drug_Target_23_Locus:
22q13.31-qter|22q13.2-q13.31

# Drug_Target_23_Molecular_Weight:
34104

# Drug_Target_23_Name:
NADH-cytochrome b5 reductase 3

# Drug_Target_23_Number_of_Residues:
300

# Drug_Target_23_PDB_ID:
1UMK

# Drug_Target_23_Pathway:
Not Available

# Drug_Target_23_Pfam_Domain_Function:
PF00175	NAD_binding_1
PF00970	FAD_binding_6

# Drug_Target_23_Protein_Sequence:
>NADH-cytochrome b5 reductase
GAQLSTLGHMVLFPVWFLYSLLMKLFQRSTPAITLESPDIKYPLRLIDREIISHDTRRFR
FALPSPQHILGLPVGQHIYLSARIDGNLVVRPYTPISSDDDKGFVDLVIKVYFKDTHPKF
PAGGKMSQYLESMQIGDTIEFRGPSGLLVYQGKGKFAIRPDKKSNPIIRTVKSVGMIAGG
TGITPMLQVIRAIMKDPDDHTVCHLLFANQTEKDILLRPELEELRNKHSARFKLWYTLDR
APEAWDYGQGFVNEEMIRDHLPPPEEEPLVLMCGPPPMIQYACLPNLDHVGHPTERCFVF

# Drug_Target_23_Reaction:
NADH + 2 ferricytochrome b5 = NAD+ + H+ + 2 ferrocytochrome b5

# Drug_Target_23_Signals:
None

# Drug_Target_23_Specific_Function:
Desaturation and elongation of fatty acids, cholesterol biosynthesis, drug metabolism, and, in erythrocyte, methemoglobin reduction

# Drug_Target_23_SwissProt_ID:
P00387

# Drug_Target_23_SwissProt_Name:
NB5R3_HUMAN

# Drug_Target_23_Synonyms:
B5R
Cytochrome b5 reductase
Diaphorase-1
EC 1.6.2.2

# Drug_Target_23_Theoretical_pI:
7.68

# Drug_Target_23_Transmembrane_Regions:
None

# Drug_Target_24_Cellular_Location:
Secreted protein

# Drug_Target_24_Chromosome_Location:
Not Available

# Drug_Target_24_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_24_Essentiality:
Non-Essential

# Drug_Target_24_GenAtlas_ID:
Not Available

# Drug_Target_24_GenBank_ID_Gene:
M31939

# Drug_Target_24_GenBank_ID_Protein:
153212

# Drug_Target_24_GeneCard_ID:
Not Available

# Drug_Target_24_Gene_Name:
choA

# Drug_Target_24_Gene_Sequence:
>1641 bp
GTGACTGCACAACAGCACCTGTCCCGCCGCCGCATGCTCGGCATGGCCGCCTTCGGCGCC
GCCGCCCTCGCCGGGGGCACCACCATCGCCGCCCCCCGTGCGGCCGCCGCCGCCAAGTCC
GCGGCGGACAACGGCGGTTACGTCCCCGCCGTCGTCATCGGCACCGGCTACGGCGCGGCC
GTCTCCGCGCTGCGCCTCGGCGAGGCGGGTGTGCAGACCCTGATGCTGGAGATGGGCCAG
CTGTGGAACCAGCCCGGCCCCGACGGCAACATCTTCTGCGGCATGCTCAACCCGGACAAG
CGGTCCAGCTGGTTCAAGAACCGCACCGAGGCCCCGCTCGGCAGCTTCCTCTGGCTCGAC
GTCGTCAACCGGAACATCGACCCCTACGCGGGTGTCCTGGACCGTGTGAACTACGACCAG
ATGTCGGTCTACGTGGGCCGCGGCGTCGGCGGCGGCTCGCTCGTCAACGGCGGCATGGCC
GTGGAGCCCAAGCGCTCGTACTTCGAGGAGATCCTCCCGCGGGTCGACTCCTCCGAGATG
TACGACCGCTACTTCCCCCGCGCCAACTCCATGCTCCGCGTCAACCACATCGACACCAAG
TGGTTCGAGGACACCGAGTGGTACAAGTTCGCCCGCGTCTCGCGCGAGCAGGCGGGCAAG
GCCGGTCTCGGCACCGTCTTCGTCCCCAACGTCTACGACTTCGGCTACATGCAGCGCGAG
GCCGCGGGCGAGGTGCCCAAGTCCGCCCTGGCGACCGAGGTCATCTACGGCAACAACCAC
GGCAAGCAGAGCCTGGACAAGACCTACCTGGCCGCCGCACTCGGCACCGGCAAGGTCACC
ATCCAGACCCTGCACCAGGTCAAGACGATCCGTCAGACGAAGGACGGCGGCTACGCGCTG
ACCGTCGAGCAGAAGGACACCGACGGCAAGCTCCTGGCCACCAAGGAGATCTCCTGCCGC
TACCTGTTCCTCGGCGCGGGCAGCCTCGGCTCCACCGAACTGCTGGTGCGCGCCCGCGAC
ACCGGCACCCTGCCGAACCTCAACTCCGAGGTGGGCGCGGGCTGGGGCCCCAACGGCAAC
ATCATGACCGCCCGGGCCAACCACATGTGGAACCCCACCGGCGCCCACCAGTCCTCCATC
CCCGCCCTCGGCATCGACGCGTGGGACAACAGCGACTCCTCGGTCTTCGCGGAGATCGCC
CCCATGCCGGCCGGCCTGGAGACGTGGGTCAGCCTCTACCTCGCGATCACCAAGAACCCC
CAGCGCGGCACCTTCGTGTACGACGCCGCGACGGACCGCGCGAAGCTCAACTGGACCCGT
GACCAGAACGCCCCCGCGGTCAACGCAGCCAAGGCGCTGTTCGACCGGATCAACAAGGCG
AACGGCACGATCTACCGGTACGACCTCTTCGGCACCCAGCTGAAGGCCTTCGCCGACGAC
TTCTGCTACCACCCGCTCGGCGGCTGCGTCCTGGGCAAGGCGACGGACGACTACGGCCGC
GTCGCCGGTTACAAGAACCTCTACGTGACCGACGGTTCGCTGATCCCGGGTTCCGTCGGC
GTCAACCCGTTCGTGACCATCACGGCGCTGGCCGAGCGGAACGTCGAGCGCATCATCAAG
CAGGACGTCACGGCGTCGTAA

# Drug_Target_24_General_Function:
Amino acid transport and metabolism

# Drug_Target_24_General_References:
10194345	Yue QK, Kass IJ, Sampson NS, Vrielink A: Crystal structure determination of cholesterol oxidase from Streptomyces and structural characterization of key active site mutants. Biochemistry. 1999 Apr 6;38(14):4277-86.
2914858	Ishizaki T, Hirayama N, Shinkawa H, Nimi O, Murooka Y: Nucleotide sequence of the gene for cholesterol oxidase from a Streptomyces sp. J Bacteriol. 1989 Jan;171(1):596-601.

# Drug_Target_24_HGNC_ID:
Not Available

# Drug_Target_24_HPRD_ID:
Not Available

# Drug_Target_24_ID:
2822

# Drug_Target_24_Locus:
Not Available

# Drug_Target_24_Molecular_Weight:
58994

# Drug_Target_24_Name:
Cholesterol oxidase

# Drug_Target_24_Number_of_Residues:
546

# Drug_Target_24_PDB_ID:
1N4W

# Drug_Target_24_Pathway:
Not Available

# Drug_Target_24_Pfam_Domain_Function:
Not Available

# Drug_Target_24_Protein_Sequence:
>Cholesterol oxidase precursor
MTAQQHLSRRRMLGMAAFGAAALAGGTTIAAPRAAAAAKSAADNGGYVPAVVIGTGYGAA
VSALRLGEAGVQTLMLEMGQLWNQPGPDGNIFCGMLNPDKRSSWFKNRTEAPLGSFLWLD
VVNRNIDPYAGVLDRVNYDQMSVYVGRGVGGGSLVNGGMAVEPKRSYFEEILPRVDSSEM
YDRYFPRANSMLRVNHIDTKWFEDTEWYKFARVSREQAGKAGLGTVFVPNVYDFGYMQRE
AAGEVPKSALATEVIYGNNHGKQSLDKTYLAAALGTGKVTIQTLHQVKTIRQTKDGGYAL
TVEQKDTDGKLLATKEISCRYLFLGAGSLGSTELLVRARDTGTLPNLNSEVGAGWGPNGN
IMTARANHMWNPTGAHQSSIPALGIDAWDNSDSSVFAEIAPMPAGLETWVSLYLAITKNP
QRGTFVYDAATDRAKLNWTRDQNAPAVNAAKALFDRINKANGTIYRYDLFGTQLKAFADD
FCYHPLGGCVLGKATDDYGRVAGYKNLYVTDGSLIPGSVGVNPFVTITALAERNVERIIK
QDVTAS

# Drug_Target_24_Reaction:
cholesterol + O2 = cholest-4-en-3-one + H2O2

# Drug_Target_24_Signals:
1-42

# Drug_Target_24_Specific_Function:
Cholesterol + O(2) = cholest-4-en-3-one + H(2)O(2)

# Drug_Target_24_SwissProt_ID:
P12676

# Drug_Target_24_SwissProt_Name:
CHOD_STRS0

# Drug_Target_24_Synonyms:
CHOD
Cholesterol oxidase precursor
EC 1.1.3.6

# Drug_Target_24_Theoretical_pI:
8.49

# Drug_Target_24_Transmembrane_Regions:
None

# Drug_Target_25_Cellular_Location:
Not Available

# Drug_Target_25_Chromosome_Location:
Not Available

# Drug_Target_25_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_25_Essentiality:
Non-Essential

# Drug_Target_25_GenAtlas_ID:
Not Available

# Drug_Target_25_GenBank_ID_Gene:
AE000512

# Drug_Target_25_GenBank_ID_Protein:
4980954

# Drug_Target_25_GeneCard_ID:
Not Available

# Drug_Target_25_Gene_Name:
thyX

# Drug_Target_25_Gene_Sequence:
>663 bp
TCATACCTGTACCTCCTTCAGGATATCTCCTTTATAAGCATACTTAAGAAATGCCTCAAA
AGTCCAGGGACACTTCTCTTTGAAAATTCTCGCGATTGCCAGAGCGTACTGTTGAATTTC
CCACTGAGCGTGAGAATCTGCCCTCAGGTTCAAAAAGTTCATGAGACTTCTTGCGTTCAC
AGTCCAGAAAAACCTCGTGTACAGATTCAAAGGGAGCACTATCCTTGCCACTTCTCGAGG
AACACCGCTTTCTATCAACTCCAGATACGTTCGATACGCTTTATCGACTATTTCTGAGAT
CTTCTCCGTCACCCGTTCGGGAGGGATGGTCGTTTTGTACCCTTCCAGGCGTTCGGGAGA
GGGAATGTAGAATTCGTAGGAGAGCTTCGAGTATCTGCCGCTCAGTTCGTTGTAAGAAGC
GATCCTGTGTCTGAACCACTGCCTCGCCACGAATATAGGGGCTTTCACGTGGAAAGTGAA
GACAATATGTTCGAAAGGTGTCTCGTGACCGTGTTTCATGAGATATTCGATGAGATGTCT
ATCCCTTTCTTCGTCTTTCAAACCCATATCGAAAGAAACGCGGGCAGCCCGTACAGCGGA
GAGGTCGTTTCCCATCACATCCACAAGTTCAACGAATCCTTTGTCCAAGATATCGATCTT
CAT

# Drug_Target_25_General_Function:
Nucleotide transport and metabolism

# Drug_Target_25_General_References:
10360571	Nelson KE, Clayton RA, Gill SR, Gwinn ML, Dodson RJ, Haft DH, Hickey EK, Peterson JD, Nelson WC, Ketchum KA, McDonald L, Utterback TR, Malek JA, Linher KD, Garrett MM, Stewart AM, Cotton MD, Pratt MS, Phillips CA, Richardson D, Heidelberg J, Sutton GG, Fleischmann RD, Eisen JA, White O, Salzberg SL, Smith HO, Venter JC, Fraser CM: Evidence for lateral gene transfer between Archaea and bacteria from genome sequence of Thermotoga maritima. Nature. 1999 May 27;399(6734):323-9.
12211025	Kuhn P, Lesley SA, Mathews II, Canaves JM, Brinen LS, Dai X, Deacon AM, Elsliger MA, Eshaghi S, Floyd R, Godzik A, Grittini C, Grzechnik SK, Guda C, Hodgson KO, Jaroszewski L, Karlak C, Klock HE, Koesema E, Kovarik JM, Kreusch AT, McMullan D, McPhillips TM, Miller MA, Miller M, Morse A, Moy K, Ouyang J, Robb A, Rodrigues K, Selby TL, Spraggon G, Stevens RC, Taylor SS, van den Bedem H, Velasquez J, Vincent J, Wang X, West B, Wolf G, Wooley J, Wilson IA: Crystal structure of thy1, a thymidylate synthase complementing protein from Thermotoga maritima at 2.25 A resolution. Proteins. 2002 Oct 1;49(1):142-5.

# Drug_Target_25_HGNC_ID:
Not Available

# Drug_Target_25_HPRD_ID:
Not Available

# Drug_Target_25_ID:
2567

# Drug_Target_25_Locus:
Not Available

# Drug_Target_25_Molecular_Weight:
26004

# Drug_Target_25_Name:
Thymidylate synthase thyX

# Drug_Target_25_Number_of_Residues:
220

# Drug_Target_25_PDB_ID:
1O2B

# Drug_Target_25_Pathway:
Not Available

# Drug_Target_25_Pfam_Domain_Function:
PF02511	Thy1

# Drug_Target_25_Protein_Sequence:
>Thymidylate synthase thyX
MKIDILDKGFVELVDVMGNDLSAVRAARVSFDMGLKDEERDRHLIEYLMKHGHETPFEHI
VFTFHVKAPIFVARQWFRHRIASYNELSGRYSKLSYEFYIPSPERLEGYKTTIPPERVTE
KISEIVDKAYRTYLELIESGVPREVARIVLPLNLYTRFFWTVNARSLMNFLNLRADSHAQ
WEIQQYALAIARIFKEKCPWTFEAFLKYAYKGDILKEVQV

# Drug_Target_25_Reaction:
5,10-methylenetetrahydrofolate + dUMP + FADH2 = dTMP + tetrahydrofolate + FAD

# Drug_Target_25_Signals:
None

# Drug_Target_25_Specific_Function:
Catalyzes the formation of dTMP and tetrahydrofolate from dUMP and methylenetetrahydrofolate

# Drug_Target_25_SwissProt_ID:
Q9WYT0

# Drug_Target_25_SwissProt_Name:
THYX_THEMA

# Drug_Target_25_Synonyms:
EC 2.1.1.148
TS
TSase

# Drug_Target_25_Theoretical_pI:
8.38

# Drug_Target_25_Transmembrane_Regions:
None

# Drug_Target_26_Cellular_Location:
Not Available

# Drug_Target_26_Chromosome_Location:
Not Available

# Drug_Target_26_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_26_Essentiality:
Non-Essential

# Drug_Target_26_GenAtlas_ID:
Not Available

# Drug_Target_26_GenBank_ID_Gene:
AL935262

# Drug_Target_26_GenBank_ID_Protein:
28272737

# Drug_Target_26_GeneCard_ID:
Not Available

# Drug_Target_26_Gene_Name:
pox5

# Drug_Target_26_Gene_Sequence:
>1812 bp
TTAAAACCCACCCTGTCCAATTTGATGTTGCAAATCATCTAAGCCAAATTGTTTTAAATA
AGTTGAAAGTGGTTGTAAATCTTGAGCTTCATACCGTTGTTTAAATGCTTCAATATCAGC
TGCCGAACTCGTTGCCGAATCTAAACGAAGCTTTTCAGCAGGCAGTGGCCGATCTCCTGT
AATCACCGCATCAATCAGAACTGGTTCATGCTGAGCGATTGCTTTGGCTTGTTCAAAAAC
ATCAGGTAATTGCTCAATCTTATTAACTCGAAAAGCTTGCATGTGCACGCCATCGGCAAT
CTTACTAAAATCAATATCATTGAATTCAACGCCAATAAAATCATTCTGATTAGTATCTTC
CTGCTCATCTTTGATAAATCCATATTGGCAGTTGGTGAAAACAACATTAATCACTGGTAA
ATGGTATTGAACTTGCGTCGCCAAATCTTGCATGGTCATCGAAGCGCCACCATCACCAGC
CAGATTAAACACCTGCCGCTCAGGATAATTAAGTTTGGCAGCAATTGCTCCCGGAATACC
AACTCCCATCGTAGCAAATAAGTTAGAAGTAATGTGCCGATTGGATGGCGTTAATTTCAA
ATGTCGATTCGCATTCAAATTGATATCACCAACATCAATCGAATAGATTGCATCAGGCTC
CGCAATTTTATTAACCGCACGTAGCACTTGATATGCTTGTAAAGGCCCTTCCTGCTTATC
TTCTAATGAAGCTAGATAAGCCCGCCAATTTTTAACATTGGCTAAATTGGCTTGCCACCA
AGGTGTCGACTCCCGTTCAGATACCTGTGCTAAAATTGCAGCCAGCGTCTTTTGTGCATC
AGCAAGTACCGCAATATCTGTTTTATGTCGTTTACCTAACTTAGCCGGATCAATATCAAT
TTGTAAGAAATAACGCGTATTTTTAAACGCTTTGGAAACTTCTGCAAACGGATAATTATT
ACCAACAAATAAAACAACGTCAGCTTGCGCAAGTGCCTCATTCGCCGGTTTTTGTGCCAC
CCGATTAGCAGAACCCAAATAGGCTGGATAACGATCTGCGACAATCCCCTTAGCTGGATA
CGTACTCATTAATGGAATTTTCAACGTTTTACTCAATTGTTCGAGTTCTTTACCAGCCTT
ACGAGCTCCAATGCCATAGTAAATAAGTGGCCGTTCAGCTGCGAGTAAAGTCTGTGTCAA
TCTCGTCACTGCTTGAACGTCGGGTTCTGGTAATAACGGCGTTTGATAACTATTAGCGGA
AGCATACCAATCTTCAGCTGGAATCTGTTGCCATGGTAAATCGACTGGAATTTGCACAAC
CGCAACACCTTGGTGCGCATAGGCGCGTCGAATTGCTTCGTCAATAACATGTGGCAACGT
GGCAGCATTGACGGCTGTTACATTATAATCTGCAACGTCCGCATAAATCGGATTCTCATT
CATTTCTTGGAACGTATCCATGTTCATCCCAGTAGTGCCAAATTGACCAATAAGCGCTAG
AACAGGGACATGGTCTTCACGCGCATCATATAACCCATTCATAAGATGAGTGCCACCAGG
TCCCGCTGAGCCGAAGCAAACCCCGATTTTACCCGTTAGCTTAGCATCAGCAGCGGCGGC
CATTGCACCAACTTCTTCATGCCGTACTTGAATATAATGGATTCGATCCCTTTCTGCTGA
TAATGCGTCCATAATCGAATTAATTGAACCTCCAGGAATACCATACAAATGATCTACTCC
CCAAGCTTCTAAAACTTTAATAACTGCTGCACCTGCTAGTATGTTAGTTTGTTTTGTTTG
TTTCATAACCAT

# Drug_Target_26_General_Function:
Amino acid transport and metabolism

# Drug_Target_26_General_References:
12566566	Kleerebezem M, Boekhorst J, van Kranenburg R, Molenaar D, Kuipers OP, Leer R, Tarchini R, Peters SA, Sandbrink HM, Fiers MW, Stiekema W, Lankhorst RM, Bron PA, Hoffer SM, Groot MN, Kerkhoven R, de Vries M, Ursing B, de Vos WM, Siezen RJ: Complete genome sequence of Lactobacillus plantarum WCFS1. Proc Natl Acad Sci U S A. 2003 Feb 18;100(4):1990-5. Epub 2003 Feb 3.
8145244	Muller YA, Schumacher G, Rudolph R, Schulz GE: The refined structures of a stabilized mutant and of wild-type pyruvate oxidase from Lactobacillus plantarum. J Mol Biol. 1994 Apr 1;237(3):315-35.
8438155	Muller YA, Schulz GE: Structure of the thiamine- and flavin-dependent enzyme pyruvate oxidase. Science. 1993 Feb 12;259(5097):965-7.

# Drug_Target_26_HGNC_ID:
Not Available

# Drug_Target_26_HPRD_ID:
Not Available

# Drug_Target_26_ID:
2470

# Drug_Target_26_Locus:
Not Available

# Drug_Target_26_Molecular_Weight:
66112

# Drug_Target_26_Name:
Pyruvate oxidase

# Drug_Target_26_Number_of_Residues:
603

# Drug_Target_26_PDB_ID:
1Y9D

# Drug_Target_26_Pathway:
Not Available

# Drug_Target_26_Pfam_Domain_Function:
PF00205	TPP_enzyme_M
PF02775	TPP_enzyme_C
PF02776	TPP_enzyme_N

# Drug_Target_26_Protein_Sequence:
>Pyruvate oxidase
MVMKQTKQTNILAGAAVIKVLEAWGVDHLYGIPGGSINSIMDALSAERDRIHYIQVRHEE
VGAMAAAADAKLTGKIGVCFGSAGPGGTHLMNGLYDAREDHVPVLALIGQFGTTGMNMDT
FQEMNENPIYADVADYNVTAVNAATLPHVIDEAIRRAYAHQGVAVVQIPVDLPWQQIPAE
DWYASANSYQTPLLPEPDVQAVTRLTQTLLAAERPLIYYGIGARKAGKELEQLSKTLKIP
LMSTYPAKGIVADRYPAYLGSANRVAQKPANEALAQADVVLFVGNNYPFAEVSKAFKNTR
YFLQIDIDPAKLGKRHKTDIAVLADAQKTLAAILAQVSERESTPWWQANLANVKNWRAYL
ASLEDKQEGPLQAYQVLRAVNKIAEPDAIYSIDVGDINLNANRHLKLTPSNRHITSNLFA
TMGVGIPGAIAAKLNYPERQVFNLAGDGGASMTMQDLATQVQYHLPVINVVFTNCQYGFI
KDEQEDTNQNDFIGVEFNDIDFSKIADGVHMQAFRVNKIEQLPDVFEQAKAIAQHEPVLI
DAVITGDRPLPAEKLRLDSATSSAADIEAFKQRYEAQDLQPLSTYLKQFGLDDLQHQIGQ
GGF

# Drug_Target_26_Reaction:
pyruvate + phosphate + O2 = acetyl phosphate + CO2 + H2O2

# Drug_Target_26_Signals:
None

# Drug_Target_26_Specific_Function:
Important for the aerobic growth. Decarboxylates pyruvate in four steps. The energy released is partially stored in acetyl phosphate

# Drug_Target_26_SwissProt_ID:
P37063

# Drug_Target_26_SwissProt_Name:
POXB_LACPL

# Drug_Target_26_Synonyms:
EC 1.2.3.3
POX
Pyruvic oxidase

# Drug_Target_26_Theoretical_pI:
5.24

# Drug_Target_26_Transmembrane_Regions:
None

# Drug_Target_27_Cellular_Location:
Cytoplasm

# Drug_Target_27_Chromosome_Location:
Not Available

# Drug_Target_27_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_27_Essentiality:
Non-Essential

# Drug_Target_27_GenAtlas_ID:
Not Available

# Drug_Target_27_GenBank_ID_Gene:
J03762

# Drug_Target_27_GenBank_ID_Protein:
Not Available

# Drug_Target_27_GeneCard_ID:
Not Available

# Drug_Target_27_Gene_Name:
trxB

# Drug_Target_27_Gene_Sequence:
Not Available

# Drug_Target_27_General_Function:
Posttranslational modification, protein turnover, chaperones

# Drug_Target_27_General_References:
10595539	Lennon BW, Williams CH Jr, Ludwig ML: Crystal structure of reduced thioredoxin reductase from Escherichia coli: structural flexibility in the isoalloxazine ring of the flavin adenine dinucleotide cofactor. Protein Sci. 1999 Nov;8(11):2366-79.
10947986	Lennon BW, Williams CH Jr, Ludwig ML: Twists in catalysis: alternating conformations of Escherichia coli thioredoxin reductase. Science. 2000 Aug 18;289(5482):1190-4.
1575737	Ueshima R, Fujita N, Ishihama A: Identification of Escherichia coli proteins cross-reacting with antibodies against region 2.2 peptide of RNA polymerase sigma subunit. Biochem Biophys Res Commun. 1992 Apr 30;184(2):634-9.
2067578	Kuriyan J, Krishna TS, Wong L, Guenther B, Pahler A, Williams CH Jr, Model P: Convergent evolution of similar function in two structurally divergent enzymes. Nature. 1991 Jul 11;352(6331):172-4.
3288628	Russel M, Model P: Sequence of thioredoxin reductase from Escherichia coli. Relationship to other flavoprotein disulfide oxidoreductases. J Biol Chem. 1988 Jun 25;263(18):9015-9.
7934832	Poole RK, Hatch L, Cleeter MW, Gibson F, Cox GB, Wu G: Cytochrome bd biosynthesis in Escherichia coli: the sequences of the cydC and cydD genes suggest that they encode the components of an ABC membrane transporter. Mol Microbiol. 1993 Oct;10(2):421-30.
8114095	Waksman G, Krishna TS, Williams CH Jr, Kuriyan J: Crystal structure of Escherichia coli thioredoxin reductase refined at 2 A resolution. Implications for a large conformational change during catalysis. J Mol Biol. 1994 Feb 25;236(3):800-16.
8380150	Delaney JM, Wall D, Georgopoulos C: Molecular characterization of the Escherichia coli htrD gene: cloning, sequence, regulation, and involvement with cytochrome d oxidase. J Bacteriol. 1993 Jan;175(1):166-75.
8905232	Oshima T, Aiba H, Baba T, Fujita K, Hayashi K, Honjo A, Ikemoto K, Inada T, Itoh T, Kajihara M, Kanai K, Kashimoto K, Kimura S, Kitagawa M, Makino K, Masuda S, Miki T, Mizobuchi K, Mori H, Motomura K, Nakamura Y, Nashimoto H, Nishio Y, Saito N, Horiuchi T, et al.: A 718-kb DNA sequence of the Escherichia coli K-12 genome corresponding to the 12.7-28.0 min region on the linkage map. DNA Res. 1996 Jun 30;3(3):137-55.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.

# Drug_Target_27_HGNC_ID:
Not Available

# Drug_Target_27_HPRD_ID:
Not Available

# Drug_Target_27_ID:
3767

# Drug_Target_27_Locus:
Not Available

# Drug_Target_27_Molecular_Weight:
34623

# Drug_Target_27_Name:
Thioredoxin reductase

# Drug_Target_27_Number_of_Residues:
321

# Drug_Target_27_PDB_ID:
1CL0

# Drug_Target_27_Pathway:
Not Available

# Drug_Target_27_Pfam_Domain_Function:
PF00070	Pyr_redox
PF07992	Pyr_redox_2

# Drug_Target_27_Protein_Sequence:
>Thioredoxin reductase
MGTTKHSKLLILGSGPAGYTAAVYAARANLQPVLITGMEKGGQLTTTTEVENWPGDPNDL
TGPLLMERMHEHATKFETEIIFDHINKVDLQNRPFRLNGDNGEYTCDALIIATGASARYL
GLPSEEAFKGRGVSACATCDGFFYRNQKVAVIGGGNTAVEEALYLSNIASEVHLIHRRDG
FRAEKILIKRLMDKVENGNIILHTNRTLEEVTGDQMGVTGVRLRDTQNSDNIESLDVAGL
FVAIGHSPNTAIFEGQLELENGYIKVQSGIHGNATQTSIPGVFAAGDVMDHIYRQAITSA
GTGCMAALDAERYLDGLADAK

# Drug_Target_27_Reaction:
thioredoxin + NADP+ = thioredoxin disulfide + NADPH + H+

# Drug_Target_27_Signals:
None

# Drug_Target_27_Specific_Function:
Thioredoxin + NADP(+) = thioredoxin disulfide + NADPH

# Drug_Target_27_SwissProt_ID:
P0A9P4

# Drug_Target_27_SwissProt_Name:
TRXB_ECOLI

# Drug_Target_27_Synonyms:
EC 1.8.1.9
TRXR

# Drug_Target_27_Theoretical_pI:
5.20

# Drug_Target_27_Transmembrane_Regions:
None

# Drug_Target_28_Cellular_Location:
Cytoplasm

# Drug_Target_28_Chromosome_Location:
Not Available

# Drug_Target_28_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_28_Essentiality:
Non-Essential

# Drug_Target_28_GenAtlas_ID:
Not Available

# Drug_Target_28_GenBank_ID_Gene:
M13141

# Drug_Target_28_GenBank_ID_Protein:
146248

# Drug_Target_28_GeneCard_ID:
Not Available

# Drug_Target_28_Gene_Name:
gor

# Drug_Target_28_Gene_Sequence:
>1353 bp
ATGACTAAACACTATGATTACATCGCCATCGGCGGCGGCAGCGGCGGTATCGCCTCCATC
AACCGCGCGGCTATGTACGGCCAGAAATGTGCGCTGATTGAAGCCAAAGAGCTGGGCGGC
ACCTGCGTAAATGTTGGCTGTGTGCCGAAAAAAGTGATGTGGCACGCGGCGCAAATCCGT
GAAGCGATCCATATGTACGGCCCGGATTATGGTTTTGATACCACTATCAATAAATTCAAC
TGGGAAACGTTGATCGCCAGCCGTACCGCCTATATCGACCGTATTCATACTTCCTATGAA
AACGTGCTCGGTAAAAATAACGTTGATGTAATCAAAGGCTTTGCCCGCTTCGTTGATGCC
AAAACGCTGGAGGTAAACGGCGAAACCATCACGGCCGATCATATTCTGATCGCCACAGGC
GGTCGTCCGAGCCACCCGGATATTCCGGGCGTGGAATACGGTATTGATTCTGATGGCTTC
TTCGCCCTTCCTGCTTTGCCAGAGCGCGTGGCGGTTGTTGGCGCGGGTTACATCGCCGTT
GAGCTGGCGGGCGTGATTAACGGCCTCGGCGCGAAAACGCATCTGTTTGTGCGTAAACAT
GCGCCGCTGCGCAGCTTCGACCCGATGATTTCCGAAACGCTGGTCGAAGTGATGAACGCC
GAAGGCCCGCAGCTGCACACCAACGCCATCCCGAAAGCGGTAGTGAAAAATACCGATGGT
AGCCTGACGCTGGAGCTGGAAGATGGTCGCAGTGAAACGGTGGATTGCCTGATTTGGGCG
ATTGGTCGCGAGCCTGCCAATGACAACATCAACCTGGAAGCCGCTGGCGTTAAAACTAAC
GAAAAAGGCTATATCGTCGTCGATAAATATCAAAACACCAATATTGAAGGTATTTACGCG
GTGGGCGATAACACGGGTGCAGTGGAGCTGACACCGGTGGCAGTTGCAGCGGGTCGCCGT
CTCTCTGAACGCCTGTTTAATAACAAGCCGGATGAGCATCTGGATTACAGCAACATTCCG
ACCGTGGTCTTCAGCCATCCGCCGATTGGTACTGTTGGTTTAACGGAACCGCAGGCGCGC
GAGCAGTATGGCGACGATCAGGTGAAAGTGTATAAATCCTCTTTCACCGCGATGTATACC
GCCGTCACCACTCACCGCCAGCCGTGCCGCATGAAGCTGGTGTGCGTTGGATCGGAAGAG
AAGATTGTCGGTATTCACGGCATTGGCTTTGGTATGGACGAAATGTTGCAGGGCTTCGCG
GTGGCGCTGAAGATGGGGGCAACCAAAAAAGACTTCGACAATACCGTCGCCATTCACCCA
ACGGCGGCAGAAGAGTTCGTGACAATGCGTTAA

# Drug_Target_28_General_Function:
RNA processing and modification

# Drug_Target_28_General_References:
2006135	Ermler U, Schulz GE: The three-dimensional structure of glutathione reductase from Escherichia coli at 3.0 A resolution. Proteins. 1991;9(3):174-9.
3521741	Greer S, Perham RN: Glutathione reductase from Escherichia coli: cloning and sequence analysis of the gene and relationship to other flavoprotein disulfide oxidoreductases. Biochemistry. 1986 May 6;25(9):2736-42.
8041620	Sofia HJ, Burland V, Daniels DL, Plunkett G 3rd, Blattner FR: Analysis of the Escherichia coli genome. V. DNA sequence of the region from 76.0 to 81.5 minutes. Nucleic Acids Res. 1994 Jul 11;22(13):2576-86.
8061609	Mittl PR, Schulz GE: Structure of glutathione reductase from Escherichia coli at 1.86 A resolution: comparison with the enzyme from human erythrocytes. Protein Sci. 1994 May;3(5):799-809.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.

# Drug_Target_28_HGNC_ID:
Not Available

# Drug_Target_28_HPRD_ID:
Not Available

# Drug_Target_28_ID:
327

# Drug_Target_28_Locus:
Not Available

# Drug_Target_28_Molecular_Weight:
48773

# Drug_Target_28_Name:
Glutathione reductase

# Drug_Target_28_Number_of_Residues:
450

# Drug_Target_28_PDB_ID:
1GET

# Drug_Target_28_Pathway:
Not Available

# Drug_Target_28_Pfam_Domain_Function:
PF00070	Pyr_redox
PF02852	Pyr_redox_dim
PF07992	Pyr_redox_2

# Drug_Target_28_Protein_Sequence:
>Glutathione reductase
MTKHYDYIAIGGGSGGIASINRAAMYGQKCALIEAKELGGTCVNVGCVPKKVMWHAAQIR
EAIHMYGPDYGFDTTINKFNWETLIASRTAYIDRIHTSYENVLGKNNVDVIKGFARFVDA
KTLEVNGETITADHILIATGGRPSHPDIPGVEYGIDSDGFFALPALPERVAVVGAGYIAV
ELAGVINGLGAKTHLFVRKHAPLRSFDPMISETLVEVMNAEGPQLHTNAIPKAVVKNTDG
SLTLELEDGRSETVDCLIWAIGREPANDNINLEAAGVKTNEKGYIVVDKYQNTNIEGIYA
VGDNTGAVELTPVAVAAGRRLSERLFNNKPDEHLDYSNIPTVVFSHPPIGTVGLTEPQAR
EQYGDDQVKVYKSSFTAMYTAVTTHRQPCRMKLVCVGSEEKIVGIHGIGFGMDEMLQGFA
VALKMGATKKDFDNTVAIHPTAAEEFVTMR

# Drug_Target_28_Reaction:
2 glutathione + NADP+ = glutathione disulfide + NADPH + H+

# Drug_Target_28_Signals:
None

# Drug_Target_28_Specific_Function:
Maintains high levels of reduced glutathione in the cytosol

# Drug_Target_28_SwissProt_ID:
P06715

# Drug_Target_28_SwissProt_Name:
GSHR_ECOLI

# Drug_Target_28_Synonyms:
EC 1.8.1.7
GR
GRase

# Drug_Target_28_Theoretical_pI:
5.88

# Drug_Target_28_Transmembrane_Regions:
None

# Drug_Target_29_Cellular_Location:
Not Available

# Drug_Target_29_Chromosome_Location:
Not Available

# Drug_Target_29_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_29_Essentiality:
Non-Essential

# Drug_Target_29_GenAtlas_ID:
Not Available

# Drug_Target_29_GenBank_ID_Gene:
V01502

# Drug_Target_29_GenBank_ID_Protein:
Not Available

# Drug_Target_29_GeneCard_ID:
Not Available

# Drug_Target_29_Gene_Name:
metF

# Drug_Target_29_Gene_Sequence:
Not Available

# Drug_Target_29_General_Function:
Amino acid transport and metabolism

# Drug_Target_29_General_References:
10201405	Guenther BD, Sheppard CA, Tran P, Rozen R, Matthews RG, Ludwig ML: The structure and properties of methylenetetrahydrofolate reductase from Escherichia coli suggest how folate ameliorates human hyperhomocysteinemia. Nat Struct Biol. 1999 Apr;6(4):359-65.
6356036	Saint-Girons I, Duchange N, Zakin MM, Park I, Margarita D, Ferrara P, Cohen GN: Nucleotide sequence of metF, the E. coli structural gene for 5-10 methylene tetrahydrofolate reductase and of its control region. Nucleic Acids Res. 1983 Oct 11;11(19):6723-32.
8346018	Plunkett G 3rd, Burland V, Daniels DL, Blattner FR: Analysis of the Escherichia coli genome. III. DNA sequence of the region from 87.2 to 89.2 minutes. Nucleic Acids Res. 1993 Jul 25;21(15):3391-8.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.

# Drug_Target_29_HGNC_ID:
Not Available

# Drug_Target_29_HPRD_ID:
Not Available

# Drug_Target_29_ID:
3763

# Drug_Target_29_Locus:
Not Available

# Drug_Target_29_Molecular_Weight:
33103

# Drug_Target_29_Name:
5,10-methylenetetrahydrofolate reductase

# Drug_Target_29_Number_of_Residues:
296

# Drug_Target_29_PDB_ID:
1B5T

# Drug_Target_29_Pathway:
Not Available

# Drug_Target_29_Pfam_Domain_Function:
PF02219	MTHFR

# Drug_Target_29_Protein_Sequence:
>5,10-methylenetetrahydrofolate reductase
MSFFHASQRDALNQSLAEVQGQINVSFEFFPPRTSEMEQTLWNSIDRLSSLKPKFVSVTY
GANSGERDRTHSIIKGIKDRTGLEAAPHLTCIDATPDELRTIARDYWNNGIRHIVALRGD
LPPGSGKPEMYASDLVTLLKEVADFDISVAAYPEVHPEAKSAQADLLNLKRKVDAGANRA
ITQFFFDVESYLRFRDRCVSAGIDVEIIPGILPVSNFKQAKKFADMTNVRIPAWMAQMFD
GLDDDAETRKLVGANIAMDMVKILSREGVKDFHFYTLNRAEMSYAICHTLGVRPGL

# Drug_Target_29_Reaction:
5-methyltetrahydrofolate + NADP+ = 5,10-methylenetetrahydrofolate + NADPH + H+

# Drug_Target_29_Signals:
None

# Drug_Target_29_Specific_Function:
5-methyltetrahydrofolate + NAD(P)(+) = 5,10- methylenetetrahydrofolate + NAD(P)H

# Drug_Target_29_SwissProt_ID:
P0AEZ1

# Drug_Target_29_SwissProt_Name:
METF_ECOLI

# Drug_Target_29_Synonyms:
EC 1.5.1.20

# Drug_Target_29_Theoretical_pI:
6.40

# Drug_Target_29_Transmembrane_Regions:
None

# Drug_Target_2_Cellular_Location:
Cytoplasm

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
Not Available

# Drug_Target_2_GenBank_ID_Gene:
X74334

# Drug_Target_2_GenBank_ID_Protein:
460999

# Drug_Target_2_GeneCard_ID:
Not Available

# Drug_Target_2_Gene_Name:
hmp

# Drug_Target_2_Gene_Sequence:
>1212 bp
ATGCTGACCCAGAAAACAAAAGACATCGTAAAGGCCACCGCACCGGTGCTGGCCGAACAC
GGCTACGACATCATCAAGTGCTTCTATCAGCGCATGTTCGAAGCGCATCCCGAACTGAAG
AATGTGTTCAACATGGCCCACCAGGAACAGGGCCAGCAGCAGCAGGCGCTGGCACGGGCG
GTCTATGCCTATGCGGAGAATATCGAGGACCCAAACAGTCTGATGGCCGTCCTGAAGAAC
ATCGCCAACAAGCATGCAAGTCTCGGCGTCAAACCGGAACAGTACCCCATTGTTGGAGAA
CACCTACTGGCCGCCATCAAGGAAGTGTTGGGCAATGCCGCAACCGACGACATCATTTCC
GCTTGGGCGCAAGCCTACGGGAATCTGGCCGATGTCCTGATGGGCATGGAGAGCGAGTTG
TATGAGCGCTCTGCGGAACAACCCGGTGGCTGGAAGGGGTGGCGCACCTTTGTGATTCGT
GAGAAGCGCCCCGAGAGCGATGTGATCACGTCATTCATCCTTGAGCCTGCCGATGGTGGT
CCCGTGGTGAACTTCGAACCCGGACAATACACCAGCGTCGCAATCGATGTGCCCGCGCTC
GGGTTGCAGCAGATTCGCCAATACAGCCTGTCGGATATGCCGAACGGGCGCACGTATCGC
ATCTCGGTGAAGCGCGAGGGCGGCGGGCCGCAGCCTCCGGGCTATGTTTCGAACCTGTTG
CATGATCACGTGAATGTTGGGGATCAGGTCAAGCTGGCTGCGCCCTATGGAAGCTTCCAT
ATCGACGTTGACGCCAAGACACCCATTGTCCTGATCAGCGGTGGCGTTGGGCTGACACCG
ATGGTCAGCATGCTCAAAGTGGCATTGCAGGCCCCACCGAGGCAAGTTGTATTCGTGCAT
GGCGCACGTAACAGCGCAGTACACGCGATGCGCGACAGGCTGCGCGAAGCGGCGAAGACC
TATGAAAACCTTGACCTCTTTGTTTTCTATGACCAACCGCTACCGGAAGATGTCCAGGGA
CGGGACTATGATTATCCGGGCTTAGTCGATGTGAAGCAGATCGAGAAATCGATCCTGCTG
CCAGACGCCGACTACTACATCTGCGGTCCGATTCCGTTCATGCGAATGCAGCATGATGCC
CTGAAGAATCTCGGCATTCATGAGGCACGCATTCATTACGAAGTGTTTGGTCCCGACCTG
TTTGCTGAGTAG

# Drug_Target_2_General_Function:
Energy production and conversion

# Drug_Target_2_General_References:
10336624	Ollesch G, Kaunzinger A, Juchelka D, Schubert-Zsilavecz M, Ermler U: Phospholipid bound to the flavohemoprotein from Alcaligenes eutrophus. Eur J Biochem. 1999 Jun;262(2):396-405.
12948488	Schwartz E, Henne A, Cramm R, Eitinger T, Friedrich B, Gottschalk G: Complete nucleotide sequence of pHG1: a Ralstonia eutropha H16 megaplasmid encoding key enzymes of H(2)-based ithoautotrophy and anaerobiosis. J Mol Biol. 2003 Sep 12;332(2):369-83.
1594608	Zhu H, Riggs AF: Yeast flavohemoglobin is an ancient protein related to globins and a reductase family. Proc Natl Acad Sci U S A. 1992 Jun 1;89(11):5015-9.
8125952	Cramm R, Siddiqui RA, Friedrich B: Primary sequence and evidence for a physiological function of the flavohemoprotein of Alcaligenes eutrophus. J Biol Chem. 1994 Mar 11;269(10):7349-54.
8557026	Ermler U, Siddiqui RA, Cramm R, Friedrich B: Crystal structure of the flavohemoglobin from Alcaligenes eutrophus at 1.75 A resolution. EMBO J. 1995 Dec 15;14(24):6067-77.

# Drug_Target_2_HGNC_ID:
Not Available

# Drug_Target_2_HPRD_ID:
Not Available

# Drug_Target_2_ID:
3102

# Drug_Target_2_Locus:
Not Available

# Drug_Target_2_Molecular_Weight:
44783

# Drug_Target_2_Name:
Flavohemoprotein

# Drug_Target_2_Number_of_Residues:
403

# Drug_Target_2_PDB_ID:
1CQX

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF00042	Globin
PF00175	NAD_binding_1
PF00970	FAD_binding_6

# Drug_Target_2_Protein_Sequence:
>Flavohemoprotein
MLTQKTKDIVKATAPVLAEHGYDIIKCFYQRMFEAHPELKNVFNMAHQEQGQQQQALARA
VYAYAENIEDPNSLMAVLKNIANKHASLGVKPEQYPIVGEHLLAAIKEVLGNAATDDIIS
AWAQAYGNLADVLMGMESELYERSAEQPGGWKGWRTFVIREKRPESDVITSFILEPADGG
PVVNFEPGQYTSVAIDVPALGLQQIRQYSLSDMPNGRSYRISVKREGGGPQPPGYVSNLL
HDHVNVGDQVKLAAPYGSFHIDVDAKTPIVLISGGVGLTPMVSMLKVALQAPPRQVVFVH
GARNSAVHAMRDRLREAAKTYENLDLFVFYDQPLPEDVQGRDYDYPGLVDVKQIEKSILL
PDADYYICGPIPFMRMQHDALKNLGIHEARIHYEVFGPDLFAE

# Drug_Target_2_Reaction:
2 nitric oxide + 2 O2 + NAD(P)H = 2 nitrate + NAD(P)+ + H+

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
In the presence of oxygen and NADH, FHP has NADH oxidase activity, which leads to the generation of superoxide and H(2)O(2), both in vitro and in vivo, and it has been suggested that FHP might act as an amplifier of superoxide stress. Under anaerobic conditions, FHP also exhibits nitric oxide reductase and FAD reductase activities. However, all these reactions are much lower than NOD activity

# Drug_Target_2_SwissProt_ID:
P39662

# Drug_Target_2_SwissProt_Name:
HMP_CUPNH

# Drug_Target_2_Synonyms:
EC 1.14.12.17
FHP
Flavohemoglobin
Hemoglobin-like protein
NO oxygenase
NOD
Nitric oxide dioxygenase

# Drug_Target_2_Theoretical_pI:
5.57

# Drug_Target_2_Transmembrane_Regions:
None

# Drug_Target_30_Cellular_Location:
Cytoplasm

# Drug_Target_30_Chromosome_Location:
Not Available

# Drug_Target_30_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_30_Essentiality:
Non-Essential

# Drug_Target_30_GenAtlas_ID:
Not Available

# Drug_Target_30_GenBank_ID_Gene:
D16521

# Drug_Target_30_GenBank_ID_Protein:
984788

# Drug_Target_30_GeneCard_ID:
Not Available

# Drug_Target_30_Gene_Name:
soxA

# Drug_Target_30_Gene_Sequence:
>1173 bp
ATGAGCACACATTTTGATGTCATCGTTGTTGGAGCTGGATCAATGGGAATGGCGGCAGGT
TATCAATTAGCAAAGCAAGGAGTCAAAACATTATTAGTGGATGCATTTGATCCGCCGCAT
ACAAACGGAAGCCATCACGGTGATACTCGTATCATCCGCCATGCTTACGGTGAGGGAAGA
GAATATGTTCCTCTTGCATTAAGATCACAAGAGTTATGGTATGAACTAGAAAAAGAAACA
CACCATAAAATATTCACGAAAACGGGCGTACTCGTATTTGGTCCTAAAGGTGAATCGGCT
TTCGTTGCAGAAACGATGGAAGCGGCAAAGGAACATTCATTGACTGTTGATTTACTGGAA
GGTGATGAAATAAATAAGCGTTGGCCGGGTATAACGGTTCCGGAAAACTACAATGCTATT
TTCGAACCGAACTCAGGTGTATTATTCAGTGAAAATTGTATTCGTGCCTACCGCGAGTTA
GCTGAAGCGCGAGGTGCTAAAGTTCTAACACATACACGCGTTGAGGACTTTGACATTTCA
CCGGACTCAGTCAAAATCGAAACAGCAAATGGATCATACACAGCTGATAAATTAATTGTT
AGCATGGGAGCTTGGAATAGCAAACTACTTTCAAAACTAAATCTTGACATCCCATTACAG
CCATATCGTCAAGTGGTAGGTTTCTTTGAATCCGATGAATCAAAGTATAGCAATGATATT
GATTTCCCAGGATTCATGGTTGAAGTGCCAAATGGTATTTATTACGGATTCCCAAGCTTC
GGCGGCTGTGGATTGAAACTAGGATATCATACGTTCGGGCAGAAAATTGACCCTGATACA
ATTAATCGCGAATTTGGCGTTTATCCAGAAGATGAAAGTAATCTTCGCGCTTTCTTGGAA
GAATATATGCCAGGAGCAAATGGAGAGTTAAAAAGAGGGGCAGTCTGCATGTACACGAAA
ACATTAGATGAACATTTCATTATAGACTTACATCCTGAACATTCCAACGTAGTCATCGCT
GCCGGCTTCTCTGGCCATGGATTTAAGTTTTCCAGTGGAGTTGGTGAAGTGCTAAGTCAA
TTAGCTTTAACTGGTAAAACAGAGCACGATATTTCAATCTTCTCCATTAACCGTCCTGCT
TTGAAAGAATCGTTACAAAAAACAACTATCTAA

# Drug_Target_30_General_Function:
Amino acid transport and metabolism

# Drug_Target_30_General_References:
10220347	Wagner MA, Khanna P, Jorns MS: Structure of the flavocoenzyme of two homologous amine oxidases: monomeric sarcosine oxidase and N-methyltryptophan oxidase. Biochemistry. 1999 Apr 27;38(17):5588-95.
10368302	Trickey P, Wagner MA, Jorns MS, Mathews FS: Monomeric sarcosine oxidase: structure of a covalently flavinylated amine oxidizing enzyme. Structure. 1999 Mar 15;7(3):331-45.
10913293	Wagner MA, Jorns MS: Monomeric sarcosine oxidase: 2. Kinetic studies with sarcosine, alternate substrates, and a substrate analogue. Biochemistry. 2000 Aug 1;39(30):8825-9.
11087383	Zhao G, Qu J, Davis FA, Jorns MS: Inactivation of monomeric sarcosine oxidase by reaction with N-(cyclopropyl)glycine. Biochemistry. 2000 Nov 21;39(46):14341-7.

# Drug_Target_30_HGNC_ID:
Not Available

# Drug_Target_30_HPRD_ID:
Not Available

# Drug_Target_30_ID:
2380

# Drug_Target_30_Locus:
Not Available

# Drug_Target_30_Molecular_Weight:
43182

# Drug_Target_30_Name:
Monomeric sarcosine oxidase

# Drug_Target_30_Number_of_Residues:
390

# Drug_Target_30_PDB_ID:
1EL5

# Drug_Target_30_Pathway:
Not Available

# Drug_Target_30_Pfam_Domain_Function:
PF01266	DAO

# Drug_Target_30_Protein_Sequence:
>Monomeric sarcosine oxidase
MSTHFDVIVVGAGSMGMAAGYQLAKQGVKTLLVDAFDPPHTNGSHHGDTRIIRHAYGEGR
EYVPLALRSQELWYELEKETHHKIFTKTGVLVFGPKGESAFVAETMEAAKEHSLTVDLLE
GDEINKRWPGITVPENYNAIFEPNSGVLFSENCIRAYRELAEARGAKVLTHTRVEDFDIS
PDSVKIETANGSYTADKLIVSMGAWNSKLLSKLNLDIPLQPYRQVVGFFESDESKYSNDI
DFPGFMVEVPNGIYYGFPSFGGCGLKLGYHTFGQKIDPDTINREFGVYPEDESNLRAFLE
EYMPGANGELKRGAVCMYTKTLDEHFIIDLHPEHSNVVIAAGFSGHGFKFSSGVGEVLSQ
LALTGKTEHDISIFSINRPALKESLQKTTI

# Drug_Target_30_Reaction:
sarcosine + H2O + O2 = glycine + formaldehyde + H2O2

# Drug_Target_30_Signals:
None

# Drug_Target_30_Specific_Function:
Catalyzes the oxidative demethylation of sarcosine. Can also oxidize other secondary amino acids such as N-methyl-L- alanine

# Drug_Target_30_SwissProt_ID:
P40859

# Drug_Target_30_SwissProt_Name:
MSOX_BACB0

# Drug_Target_30_Synonyms:
EC 1.5.3.1
MSOX

# Drug_Target_30_Theoretical_pI:
5.28

# Drug_Target_30_Transmembrane_Regions:
None

# Drug_Target_31_Cellular_Location:
Cytoplasm

# Drug_Target_31_Chromosome_Location:
Not Available

# Drug_Target_31_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_31_Essentiality:
Non-Essential

# Drug_Target_31_GenAtlas_ID:
Not Available

# Drug_Target_31_GenBank_ID_Gene:
M38051

# Drug_Target_31_GenBank_ID_Protein:
162317

# Drug_Target_31_GeneCard_ID:
Not Available

# Drug_Target_31_Gene_Name:
TPR

# Drug_Target_31_Gene_Sequence:
>1479 bp
ATGATGTCAAAAATTTTTGATTTGGTTGTCATTGGCGCCGGCTCGGGCGGACTGGAGGCT
GCTTGGAACGCGGCGACACTCTACAAGAAGCGGGTTGCGGTGATTGATGTTCAGATGGTT
CACGGGCCCCCGTTTTTTTCTGCTCTAGGCGGCACGTGTGTCAATGTTGGCTGCGTTCCG
AAGAAATTGATGGTTACAGGGGCCCAATACATGGAACACCTGCGCGAGTCCGCTGGGTTC
GGGTGGGAGTTTGATCGCACCACTCTCAGGGCGGAATGGAAGAAACTTATTGCTGTCAAG
GACGAGGCGGTGCTGAATATCAACAAGAGTTATGAGGAGATGTTTCGGGACACGGAGGGT
CTGGAGTTTTTTCTGGGCTGGGGATCACTGGAGTCAAAGAATGTCGTCAATGTTCGCGAG
AGTGCCGACCCGGCCAGCGCAGTGAAGGAGCGCCTGGAGACGGAGAACATTCTACTTGCC
AGTGGTTCGTGGCCGCACATGCCAAACATCCCTGGTATTGAGCATTGCATCAGCAGCAAT
GAGGCATTTTACCTGCCGGAGCCACCGCGTCGTGTCCTCACTGTCGGCGGAGGTTTCATT
TCCGTGGAGTTCGCCGGCATTTTTAACGCCTACAAGCCGAAAGACGGACAAGTGACGTTG
TGCTACCGCGGTGAAATGATCCTTCGTGGCTTTGACCACACTCTCCGTGAGGAACTCACA
AAGCAGCTCACCGCCAACGGCATTCAAATCCTTACAAAGGAAAATCCGGCCAAGGTGGAG
TTGAACGCGGATGGCAGCAAAAGTGTTACTTTCGAGAGCGGCAAAAAGATGGACTTTGAT
CTTGTCATGATGGCGATTGGCCGTTCTCCCCGAACAAAGGATTTACAGCTGCAAAACGCC
GGCGTCATGATCAAGAACGGTGGTGTGCAGGTGGACGAGTACTCGCGCACGAATGTTTCC
AACATTTACGCCATCGGTGACGTCACAAATCGTGTCATGTTGACACCCGTTGCCATAAAT
GAAGCCGCTGCCCTTGTGGATACCGTCTTTGGTACCAATCCGCGAAAGACGGACCACACC
CGTGTGGCGAGTGCCGTCTTCTCTATTCCTCCAATTGGTACCTGCGGTCTCATTGAAGAG
GTTGCATCCAAGCGCTACGAGGTGGTGGCGGTATACCTTTCCAGCTTTACCCCGCTCATG
CACAACATCAGCGGATCAAAGTATAAGACTTTTGTTGCAAAGATAATTACCAACCACTCC
GATGGCACTGTGCTTGGTGTACATCTTCTTGGGGACAATGCCCCAGAAATCATCCAAGGT
GTTGGTATCTGTCTCAAGTTAAATGCCAAAATATCCGACTTCTACAACACTATTGGTGTG
CATCCCACAAGTGCGGAGGAGCTGTGCTCCATGCGCACTCCTTCTTACTACTATGTTAAA
GGTGAGAAGATGGAAAAGCCTTCAGAGGCATCTCTGTAA

# Drug_Target_31_General_Function:
Energy production and conversion

# Drug_Target_31_General_References:
2011150	Sullivan FX, Walsh CT: Cloning, sequencing, overproduction and purification of trypanothione reductase from Trypanosoma cruzi. Mol Biochem Parasitol. 1991 Jan;44(1):145-7.
7737173	Borges A, Cunningham ML, Tovar J, Fairlamb AH: Site-directed mutagenesis of the redox-active cysteines of Trypanosoma cruzi trypanothione reductase. Eur J Biochem. 1995 Mar 15;228(3):745-52.
8159665	Lantwin CB, Schlichting I, Kabsch W, Pai EF, Krauth-Siegel RL: The structure of Trypanosoma cruzi trypanothione reductase in the oxidized and NADPH reduced state. Proteins. 1994 Feb;18(2):161-73.
8771196	Zhang Y, Bond CS, Bailey S, Cunningham ML, Fairlamb AH, Hunter WN: The crystal structure of trypanothione reductase from the human pathogen Trypanosoma cruzi at 2.3 A resolution. Protein Sci. 1996 Jan;5(1):52-61.

# Drug_Target_31_HGNC_ID:
Not Available

# Drug_Target_31_HPRD_ID:
Not Available

# Drug_Target_31_ID:
2823

# Drug_Target_31_Locus:
Not Available

# Drug_Target_31_Molecular_Weight:
53868

# Drug_Target_31_Name:
Trypanothione reductase

# Drug_Target_31_Number_of_Residues:
492

# Drug_Target_31_PDB_ID:
1NDA

# Drug_Target_31_Pathway:
Not Available

# Drug_Target_31_Pfam_Domain_Function:
PF00070	Pyr_redox
PF02852	Pyr_redox_dim
PF07992	Pyr_redox_2

# Drug_Target_31_Protein_Sequence:
>Trypanothione reductase
MMSKIFDLVVIGAGSGGLEAAWNAATLYKKRVAVIDVQMVHGPPFFSALGGTCVNVGCVP
KKLMVTGAQYMEHLRESAGFGWEFDRTTLRAEWKKLIAVKDEAVLNINKSYEEMFRDTEG
LEFFLGWGSLESKNVVNVRESADPASAVKERLETENILLASGSWPHMPNIPGIEHCISSN
EAFYLPEPPRRVLTVGGGFISVEFAGIFNAYKPKDGQVTLCYRGEMILRGFDHTLREELT
KQLTANGIQILTKENPAKVELNADGSKSVTFESGKKMDFDLVMMAIGRSPRTKDLQLQNA
GVMIKNGGVQVDEYSRTNVSNIYAIGDVTNRVMLTPVAINEAAALVDTVFGTNPRKTDHT
RVASAVFSIPPIGTCGLIEEVASKRYEVVAVYLSSFTPLMHNISGSKYKTFVAKIITNHS
DGTVLGVHLLGDNAPEIIQGVGICLKLNAKISDFYNTIGVHPTSAEELCSMRTPSYYYVK
GEKMEKPSEASL

# Drug_Target_31_Reaction:
trypanothione + NADP+ = trypanothione disulfide + NADPH + H+

# Drug_Target_31_Signals:
None

# Drug_Target_31_Specific_Function:
Trypanothione is the parasite analog of glutathione; this enzyme is the equivalent of glutathione reductase

# Drug_Target_31_SwissProt_ID:
P28593

# Drug_Target_31_SwissProt_Name:
TYTR_TRYCR

# Drug_Target_31_Synonyms:
EC 1.8.1.12
N(1),N(8)- bis(glutathionyl)spermidine reductase
TR

# Drug_Target_31_Theoretical_pI:
6.68

# Drug_Target_31_Transmembrane_Regions:
None

# Drug_Target_32_Cellular_Location:
Cytoplasm

# Drug_Target_32_Chromosome_Location:
Not Available

# Drug_Target_32_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_32_Essentiality:
Non-Essential

# Drug_Target_32_GenAtlas_ID:
NQO2

# Drug_Target_32_GenBank_ID_Gene:
J02888

# Drug_Target_32_GenBank_ID_Protein:
190818

# Drug_Target_32_GeneCard_ID:
NQO2

# Drug_Target_32_Gene_Name:
NQO2

# Drug_Target_32_Gene_Sequence:
>696 bp
ATGGCAGGTAAGAAAGTACTCATTGTCTATGCACACCAGGAACCCAAGTCTTTCAACGGA
TCCTTGAAGAATGTGGCTGTAGATGAACTGAGCAGGCAGGGCTGCACCGTCACAGTGTCT
GATTTGTATGCCATGAACTTTGAGCCGAGGGCCACAGACAAAGATATCACTGGTACTCTT
TCTAATCCTGAGGTTTTCAATTATGGAGTGGAAACCCACGAAGCCTACAAGCAAAGGTCT
CTGGCTAGCGACATCACTGATGAGCAGAAAAAGGTTCGGGAGGCTGACCTAGTGATATTT
CAGTTCCCGCTGTACTGGTTCAGCGTGCCGGCCATCCTGAAGGGCTGGATGGATAGGGTG
CTGTGCCAGGGCTTTGCCTTTGACATCCCAGGATTCTACGATTCCGGTTTGCTCCAGGGT
AAACTAGCGCTCCTTTCCGTAACCACGGGAGGCACGGCCGAGATGTACACGAAGACAGGA
GTCAATGGAGATTCTCGATACTTCCTGTGGCCACTCCAGCATGGCACATTACACTTCTGT
GGATTTAAAGTCCTTGCCCCTCAGATCAGCTTTGCTCCTGAAATTGCATCCGAAGAAGAA
AGAAAGGGGATGGTGGCTGCGTGGTCCCAGAGGCTGCAGACCATCTGGAAGGAAGAGCCC
ATCCCCTGCACAGCCCACTGGCACTTCGGGCAATAA

# Drug_Target_32_General_Function:
Involved in oxidoreductase activity

# Drug_Target_32_General_References:
10433694	Foster CE, Bianchet MA, Talalay P, Zhao Q, Amzel LM: Crystal structure of human quinone reductase type 2, a metalloflavoprotein. Biochemistry. 1999 Aug 3;38(31):9881-6.
1691923	Jaiswal AK, Burnett P, Adesnik M, McBride OW: Nucleotide and deduced amino acid sequence of a human cDNA (NQO2) corresponding to a second member of the NAD(P)H:quinone oxidoreductase gene family. Extensive polymorphism at the NQO2 gene locus on chromosome 6. Biochemistry. 1990 Feb 20;29(7):1899-906.
8182056	Jaiswal AK: Human NAD(P)H:quinone oxidoreductase2. Gene structure, activity, and tissue-specific expression. J Biol Chem. 1994 May 20;269(20):14502-8.
9050836	Zhao Q, Yang XL, Holtzclaw WD, Talalay P: Unexpected genetic and structural relationships of a long-forgotten flavoenzyme to NAD(P)H:quinone reductase (DT-diaphorase) Proc Natl Acad Sci U S A. 1997 Mar 4;94(5):1669-74.
9367528	Wu K, Knox R, Sun XZ, Joseph P, Jaiswal AK, Zhang D, Deng PS, Chen S: Catalytic properties of NAD(P)H:quinone oxidoreductase-2 (NQO2), a dihydronicotinamide riboside dependent oxidoreductase. Arch Biochem Biophys. 1997 Nov 15;347(2):221-8.

# Drug_Target_32_HGNC_ID:
HGNC:7856

# Drug_Target_32_HPRD_ID:
01190

# Drug_Target_32_ID:
243

# Drug_Target_32_Locus:
6pter-q12

# Drug_Target_32_Molecular_Weight:
25822

# Drug_Target_32_Name:
Ribosyldihydronicotinamide dehydrogenase [quinone]

# Drug_Target_32_Number_of_Residues:
230

# Drug_Target_32_PDB_ID:
1SG0

# Drug_Target_32_Pathway:
Not Available

# Drug_Target_32_Pfam_Domain_Function:
PF02525	Flavodoxin_2

# Drug_Target_32_Protein_Sequence:
>Ribosyldihydronicotinamide dehydrogenase [quinone]
AGKKVLIVYAHQEPKSFNGSLKNVAVDELSRQGCTVTVSDLYAMNFEPRATDKDITGTLS
NPEVFNYGVETHEAYKQRSLASDITDEQKKVREADLVIFQFPLYWFSVPAILKGWMDRVL
CQGFAFDIPGFYDSGLLQGKLALLSVTTGGTAEMYTKTGVNGDSRYFLWPLQHGTLHFCG
FKVLAPQISFAPEIASEEERKGMVAAWSQRLQTIWKEEPIPCTAHWHFGQ

# Drug_Target_32_Reaction:
1-(beta-D-ribofuranosyl)-1,4-dihydronicotinamide + a quinone = 1-(beta-D-ribofuranosyl)nicotinamide + a hydroquinone

# Drug_Target_32_Signals:
None

# Drug_Target_32_Specific_Function:
The enzyme apparently serves as a quinone reductase in connection with conjugation reactions of hydroquinones involved in detoxification pathways as well as in biosynthetic processes such as the vitamin K-dependent gamma-carboxylation of glutamate residues in prothrombin synthesis

# Drug_Target_32_SwissProt_ID:
P16083

# Drug_Target_32_SwissProt_Name:
NQO2_HUMAN

# Drug_Target_32_Synonyms:
EC 1.10.99.2
NRH dehydrogenase [quinone] 2
NRH:quinone oxidoreductase 2
QR2
Quinone reductase 2

# Drug_Target_32_Theoretical_pI:
6.24

# Drug_Target_32_Transmembrane_Regions:
None

# Drug_Target_33_Cellular_Location:
Mitochondrion
mitochondrial matrix

# Drug_Target_33_Chromosome_Location:
Not Available

# Drug_Target_33_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_33_Essentiality:
Non-Essential

# Drug_Target_33_GenAtlas_ID:
IVD

# Drug_Target_33_GenBank_ID_Gene:
M34192

# Drug_Target_33_GenBank_ID_Protein:
306897

# Drug_Target_33_GeneCard_ID:
IVD

# Drug_Target_33_Gene_Name:
IVD

# Drug_Target_33_Gene_Sequence:
>1272 bp
ATGGCGACTGCGACTCGGCTGCTGGGGTGGCGTGTGGCGAGCTGGAGGCTGCGGCCGCCG
CTTGCCGGCTTCGTTTCCCAGCGGGCCCACTCGCTTTTGCCCGTGGACGATGCAATCAAT
GGGCTAAGCGAGGAGCAGAGGCAGCTTCGTCAGACCATGGCTAAGTTCCTTCAGGAGCAC
CTGGCCCCCAAGGCCCAGGAGATCGATCGCAGCAATGAGTTCAAGAACCTGCGAGAATTT
TGGAAGCAGCTGGGGAACCTGGGCGTATTGGGCATCACAGCCCCTGTTCAGTATGGCGGC
TCCGGCCTGGGCTACCTGGAGCATGTGCTGGTGATGGAGGAGATATCCCGAGCTTCCGGA
GCAGTGGGGCTCAGTTACGGTGCCCACTCCAACCTCTGCATCAACCAGCTTGTACGCAAT
GGGAATGAGGCCCAGAAAGAGAAGTATCTCCCGAAGCTGATCAGTGGTGAGTACATCGGA
GCCCTGGCCATGAGTGAGCCCAATGCAGGCTCTGATGTTGTCTCTATGAAGCTCAAAGCG
GAAAAGAAAGGAAATCACTACATCCTGAATGGCAACAAGTTCTGGATCACTAATGGCCCT
GATGCTGACGTCCTGATTGTCTATGCCAAGACAGATCTGGCTGCTGTGCCAGCTTCTCGG
GGCATCACAGCCTTCATTGTGGAGAAGGGTATGCCTGGCTTTAGCACCTCTAAGAAGCTG
GACAAGCTGGGGATGAGGGGCTCTAACACCTGTGAGCTAATCTTTGAAGACTGCAAGATT
CCTGCTGCCAACATCCTGGGCCATGAGAATAAGGGTGTCTACGTGCTGATGAGTGGGCTG
GACCTGGAGCGGCTGGTGCTGGCCGGGGGGCCTCTTGGGCTCATGCAAGCGGTCCTGGAC
CACACCATTCCCTACCTGCACGTGAGGGAAGCCTTTGGCCAGAAGATCGGCCACTTCCAG
TTGATGCAGGGGAAGATGGCTGACATGTACACCCGCCTCATGGCGTGTCGGCAGTATGTC
TACAATGTCGCCAAGGCCTGCGATGAGGGCCATTGCACTGCTAAGGACTGTGCAGGTGTG
ATTCTTTACTCAGCTGAGTGTGCTACACAGGTAGCCCTGGACGGCATTCAGTGTTTTGGT
GGCAATGGCTACATCAATGACTTTCCCATGGGCCGCTTTCTTCGAGATGCCAAGCTGTAT
GAGATAGGGGCTGGGACCAGCGAGGTGAGGCGGCTGGTCATCGGCAGAGCCTTCAATGCA
GACTTTCACTAG

# Drug_Target_33_General_Function:
Lipid transport and metabolism

# Drug_Target_33_General_References:
10677295	Vockley J, Rogan PK, Anderson BD, Willard J, Seelan RS, Smith DI, Liu W: Exon skipping in IVD RNA processing in isovaleric acidemia caused by point mutations in the coding region of the IVD gene. Am J Hum Genet. 2000 Feb;66(2):356-67.
12665801	Gevaert K, Goethals M, Martens L, Van Damme J, Staes A, Thomas GR, Vandekerckhove J: Exploring proteomes and analyzing protein processing by mass spectrometric identification of sorted N-terminal peptides. Nat Biotechnol. 2003 May;21(5):566-9. Epub 2003 Mar 31.
2063866	Vockley J, Parimoo B, Tanaka K: Molecular characterization of four different classes of mutations in the isovaleryl-CoA dehydrogenase gene responsible for isovaleric acidemia. Am J Hum Genet. 1991 Jul;49(1):147-57.
2318964	Matsubara Y, Ito M, Glassberg R, Satyabhama S, Ikeda Y, Tanaka K: Nucleotide sequence of messenger RNA encoding human isovaleryl-coenzyme A dehydrogenase and its expression in isovaleric acidemia fibroblasts. J Clin Invest. 1990 Apr;85(4):1058-64.
7640268	Mohsen AW, Vockley J: Identification of the active site catalytic residue in human isovaleryl-CoA dehydrogenase. Biochemistry. 1995 Aug 15;34(32):10146-52.
8468053	Parimoo B, Tanaka K: Structural organization of the human isovaleryl-CoA dehydrogenase gene. Genomics. 1993 Mar;15(3):582-90.
9214289	Tiffany KA, Roberts DL, Wang M, Paschke R, Mohsen AW, Vockley J, Kim JJ: Structure of human isovaleryl-CoA dehydrogenase at 2.6 A resolution: structural basis for substrate specificity,. Biochemistry. 1997 Jul 15;36(28):8455-64.
9665741	Mohsen AW, Anderson BD, Volchenboum SL, Battaile KP, Tiffany K, Roberts D, Kim JJ, Vockley J: Characterization of molecular defects in isovaleryl-CoA dehydrogenase in patients with isovaleric acidemia. Biochemistry. 1998 Jul 14;37(28):10325-35.

# Drug_Target_33_HGNC_ID:
HGNC:6186

# Drug_Target_33_HPRD_ID:
09516

# Drug_Target_33_ID:
440

# Drug_Target_33_Locus:
15q14-q15

# Drug_Target_33_Molecular_Weight:
46320

# Drug_Target_33_Name:
Isovaleryl-CoA dehydrogenase, mitochondrial

# Drug_Target_33_Number_of_Residues:
423

# Drug_Target_33_PDB_ID:
1IVH

# Drug_Target_33_Pathway:
Not Available

# Drug_Target_33_Pfam_Domain_Function:
PF00441	Acyl-CoA_dh_1
PF02770	Acyl-CoA_dh_M
PF02771	Acyl-CoA_dh_N

# Drug_Target_33_Protein_Sequence:
>Isovaleryl-CoA dehydrogenase, mitochondrial precursor
MATATRLLGWRVASWRLRPPLAGFVSQRAHSLLPVDDAINGLSEEQRQLRQTMAKFLQEH
LAPKAQEIDRSNEFKNLREFWKQLGNLGVLGITAPVQYGGSGLGYLEHVLVMEEISRASG
AVGLSYGAHSNLCINQLVRNGNEAQKEKYLPKLISGEYIGALAMSEPNAGSDVVSMKLKA
EKKGNHYILNGNKFWITNGPDADVLIVYAKTDLAAVPASRGITAFIVEKGMPGFSTSKKL
DKLGMRGSNTCELIFEDCKIPAANILGHENKGVYVLMSGLDLERLVLAGGPLGLMQAVLD
HTIPYLHVREAFGQKIGHFQLMQGKMADMYTRLMACRQYVYNVAKACDEGHCTAKDCAGV
ILYSAECATQVALDGIQCFGGNGYINDFPMGRFLRDAKLYEIGAGTSEVRRLVIGRAFNA
DFH

# Drug_Target_33_Reaction:
3-methylbutanoyl-CoA + acceptor = 3-methylbut-2-enoyl-CoA + reduced acceptor

# Drug_Target_33_Signals:
None

# Drug_Target_33_Specific_Function:
Not Available

# Drug_Target_33_SwissProt_ID:
P26440

# Drug_Target_33_SwissProt_Name:
IVD_HUMAN

# Drug_Target_33_Synonyms:
EC 1.3.99.10
IVD
Isovaleryl-CoA dehydrogenase, mitochondrial precursor

# Drug_Target_33_Theoretical_pI:
8.31

# Drug_Target_33_Transmembrane_Regions:
None

# Drug_Target_34_Cellular_Location:
Peroxisome

# Drug_Target_34_Chromosome_Location:
Not Available

# Drug_Target_34_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_34_Essentiality:
Non-Essential

# Drug_Target_34_GenAtlas_ID:
XDH

# Drug_Target_34_GenBank_ID_Gene:
D11456

# Drug_Target_34_GenBank_ID_Protein:
10336525

# Drug_Target_34_GeneCard_ID:
XDH

# Drug_Target_34_Gene_Name:
XDH

# Drug_Target_34_Gene_Sequence:
>4002 bp
ATGACAGCAGACAAATTGGTTTTCTTTGTGAATGGCAGAAAGGTGGTGGAGAAAAATGCA
GATCCAGAGACAACCCTTTTGGCCTACCTGAGAAGAAAGTTGGGGCTGAGTGGAACCAAG
CTCGGCTGTGGAGAGGGGGGCTGCGGGGCTTGCACAGTGATGCTCTCCAAGTATGATCGT
CTGCAGAACAAGATCGTCCACTTTTCTGCCAATGCCTGCCTGGCCCCCATCTGCTCCTTG
CACCATGTTGCAGTGACAACTGTGGAAGGAATAGGAAGCACCAAGACGAGGCTGCATCCT
GTGCAGGAGAGAATTGCCAAAAGCCACGGCTCCCAGTGCGGGTTCTGCACCCCTGGCATC
GTCATGAGTATGTACACACTGCTCCGGAATCAGCCCGAGCCCACCATGGAGGAGATTGAG
AATGCCTTCCAAGGAAATCTGTGCCGCTGCACAGGCTACAGACCCATCCTCCAGGGCTTC
CGGACCTTTGCCAGGGATGGTGGATGCTGTGGAGGAGATGGGAATAATCCAAATTGCTGC
ATGAACCAGAAGAAAGACCACTCAGTCAGCCTCTCGCCATCTTTATTCAAACCAGAGGAG
TTCACGCCCCTGGATCCAACCCAGGAGCCCATTTTTCCCCCAGAGTTGCTGAGGCTGAAA
GACACTCCTCGGAAGCAGCTGCGATTTGAAGGGGAGCGTGTGACGTGGATACAGGCCTCA
ACCCTCAAGGAGCTGCTGGACCTCAAGGCTCAGCACCCTGACGCCAAGCTGGTCGTGGGG
AACACGGAGATTGGCATTGAGATGAAGTTCAAGAATATGCTGTTTCCTATGATTGTCTGC
CCAGCCTGGATCCCTGAGCTGAATTCGGTAGAACATGGACCCGACGGTATCTCCTTTGGA
GCTGCTTGCCCCCTGAGCATTGTGGAAAAAACCCTGGTGGATGCTGTTGCTAAGCTTCCT
GCCCAAAAGACAGAGGTGTTCAGAGGGGTCCTGGAGCAGCTGCGCTGGTTTGCTGGGAAG
CAAGTCAAGTCTGTGGCGTCCGTTGGAGGGAACATCATCACTGCCAGCCCCATCTCCGAC
CTCAACCCCGTGTTCATGGCCAGTGGGGCCAAGCTGACACTTGTGTCCAGAGGCACCAGG
AGAACTGTCCAGATGGACCACACCTTCTTCCCTGGCTACAGAAAGACCCTGCTGAGCCCG
GAGGAGATACTGCTCTCCATAGAGATCCCCTACAGCAGGGAGGGGGAGTATTTCTCAGCA
TTCAAGCAGGCCTCCCGGAGAGAAGATGACATTGCCAAGGTAACCAGTGGCATGAGAGTT
TTATTCAAGCCAGGAACCACAGAGGTACAGGAGCTGGCCCTTTGCTATGGTGGAATGGCC
AACAGAACCATCTCAGCCCTCAAGACCACTCAGAGGCAGCTTTCCAAGCTCTGGAAGGAG
GAGCTGCTGCAGGACGTGTGTGCAGGACTGGCAGAGGAGCTGCATCTGCCTCCCGATGCC
CCTGGTGGCATGGTGGACTTCCGGTGCACCCTCACCCTCAGCTTCTTCTTCAAGTTCTAC
CTGACAGTCCTTCAGAAGCTGGGCCAAGAGAACCTGGAAGACAAGTGTGGTAAACTGGAC
CCCACTTTCGCCAGTGCAACTTTACTGTTTCAGAAAGACCCCCCAGCCGATGTCCAGCTC
TTCCAAGAGGTGCCCAAGGGTCAGTCTGAGGAGGACATGGTGGGCCGGCCCCTGCCCCAC
CTGGCAGCGGACATGCAGGCCTCTGGTGAGGCCGTGTACTGTGACGACATTCCTCGCTAC
GAGAATGAGCTGTCTCTCCGGCTGGTCACCAGCACCCGGGCCCACGCCAAGATCAAGTCC
ATAGATACATCAGAAGCTAAGAAGGTTCCAGGGTTTGTTTGTTTCATTTCCGCTGATGAT
GTTCCTGGGAGTAACATAACTGGAATTTGTAATGATGAGACAGTCTTTGCGAAGGATAAG
GTTACTTGTGTTGGGCATATCATTGGTGCTGTGGTTGCTGACACCCCGGAACACACACAG
AGAGCTGCCCAAGGGGTGAAAATCACCTATGAAGAACTACCAGCCATTATCACAATTGAG
GATGCTATAAAGAACAACTCCTTTTATGGACCTGAGCTGAAGATCGAGAAAGGGGACCTA
AAGAAGGGGTTTTCCGAAGCAGATAATGTTGTGTCAGGGGAGATATACATCGGTGGCCAA
GAGCACTTCTACCTGGAGACTCACTGCACCATTGCTGTTCCAAAAGGCGAGGCAGGGGAG
ATGGAGCTCTTTGTGTCTACACAGAACACCATGAAGACCCAGAGCTTTGTTGCAAAAATG
TTGGGGGTTCCAGCAAACCGGATTGTGGTTCGAGTGAAGAGAATGGGAGGAGGCTTTGGA
GGCAAGGAGACCCGGAGCACTGTGGTGTCCACGGCAGTGGCCCTGGCTGCATATAAGACC
GGCCGCCCTGTGCGATGCATGCTGGACCGTGATGAGGACATGCTGATAACTGGTGGCAGA
CATCCCTTCCTGGCCAGATACAAGGTTGGCTTCATGAAGACTGGGACAGTTGTGGCTCTT
GAGGTGGACCACTTCAGCAATGTGGGGAACACCCAGGATCTCTCTCAGAGTATTATGGAA
CGAGCTTTATTCCACATGGACAACTGCTATAAAATCCCCAACATCCGGGGCACTGGGCGG
CTGTGCAAAACCAACCTTCCCTCCAACACGGCCTTCCGGGGCTTTGGGGGGCCCCAGGGG
ATGCTCATTGCCGAGTGCTGGATGAGTGAAGTTGCAGTGACCTGTGGGATGCCTGCAGAG
GAGGTGCGGAGAAAAAACCTGTACAAAGAAGGGGACCTGACACACTTCAACCAGAAGCTT
GAGGGTTTCACCTTGCCCAGATGCTGGGAAGAATGCCTAGCAAGCTCTCAGTATCATGCT
CGGAAGAGTGAGGTTGACAAGTTCAACAAGGAGAATTGTTGGAAAAAGAGAGGATTGTGC
ATAATTCCCACCAAGTTTGGAATAAGCTTCACAGTTCCTTTTCTGAATCAGGCAGGAGCC
CTACTTCATGTGTACACAGATGGCTCTGTGCTGCTGACCCACGGGGGGACTGAGATGGGC
CAAGGCCTTCATACCAAAATGGTCCAGGTGGCCAGTAGAGCTCTGAAAATCCCCACCTCT
AAGATTTATATCAGCGAGACAAGCACTAACACTGTGCCCAACACCTCTCCCACGGCTGCC
TCTGTCAGCGCTGACCTCAATGGACAGGCCGTCTATGCGGCTTGTCAGACCATCTTGAAA
AGGCTGGAACCCTACAAGAAGAAGAATCCCAGTGGCTCCTGGGAAGACTGGGTCACAGCT
GCCTACATGGACACAGTGAGCTTGTCTGCCACTGGGTTTTATAGAACACCCAATCTGGGC
TACAGCTTTGAGACTAACTCAGGGAACCCCTTCCACTACTTCAGCTATGGGGTGGCTTGC
TCTGAAGTAGAAATCGACTGCCTAACAGGAGATCATAAGAACCTCCGCACAGATATTGTC
ATGGATGTTGGCTCCAGTCTAAACCCTGCCATTGATATTGGACAGGTGGAAGGGGCATTT
GTCCAGGGCCTTGGCCTCTTCACCCTAGAGGAGCTACACTATTCCCCCGAGGGGAGCCTG
CACACCCGTGGCCCTAGCACCTACAAGATCCCGGCATTTGGCAGCATCCCCATTGAGTTC
AGGGTGTCCCTGCTCCGCGACTGCCCCAACAAGAAGGCCATCTATGCATCGAAGGCTGTT
GGAGAGCCGCCCCTCTTCCTGGCTGCTTCTATCTTCTTTGCCATCAAAGATGCCATCCGT
GCAGCTCGAGCTCAGCACACAGGTAATAACGTGAAGGAACTCTTCCGGCTAGACAGCCCT
GCCACCCCGGAGAAGATCCGCAATGCCTGCGTGGACAAGTTCACCACCCTGTGTGTCACT
GGTGTCCCAGAAAACTGCAAACCCTGGTCTGTGAGGGTCTAA

# Drug_Target_34_General_Function:
Nucleotide transport and metabolism

# Drug_Target_34_General_References:
7575623	Xu P, Huecksteadt TP, Harrison R, Hoidal JR: Molecular cloning, tissue expression of human xanthine dehydrogenase. Biochem Biophys Res Commun. 1995 Oct 4;215(1):429.
8135849	Xu P, Huecksteadt TP, Harrison R, Hoidal JR: Molecular cloning, tissue expression of human xanthine dehydrogenase. Biochem Biophys Res Commun. 1994 Mar 15;199(2):998-1004.
8224915	Ichida K, Amaya Y, Noda K, Minoshima S, Hosoya T, Sakai O, Shimizu N, Nishino T: Cloning of the cDNA encoding human xanthine dehydrogenase (oxidase): structural analysis of the protein and chromosomal location of the gene. Gene. 1993 Nov 15;133(2):279-84.
8670112	Saksela M, Raivio KO: Cloning and expression in vitro of human xanthine dehydrogenase/oxidase. Biochem J. 1996 Apr 1;315 ( Pt 1):235-9.

# Drug_Target_34_HGNC_ID:
HGNC:12805

# Drug_Target_34_HPRD_ID:
06363

# Drug_Target_34_ID:
3947

# Drug_Target_34_Locus:
2p23.1

# Drug_Target_34_Molecular_Weight:
146426

# Drug_Target_34_Name:
Xanthine dehydrogenase/oxidase

# Drug_Target_34_Number_of_Residues:
1333

# Drug_Target_34_PDB_ID:
1V97

# Drug_Target_34_Pathway:
Azathioprine Pathway	SMP00427
Mercaptopurine Pathway	SMP00428
Thioguanine Pathway	SMP00430

# Drug_Target_34_Pfam_Domain_Function:
PF00111	Fer2
PF00941	FAD_binding_5
PF01315	Ald_Xan_dh_C
PF01799	Fer2_2
PF02738	Ald_Xan_dh_C2
PF03450	CO_deh_flav_C

# Drug_Target_34_Protein_Sequence:
>Xanthine dehydrogenase/oxidase [Includes: Xanthine dehydrogenase
MTADKLVFFVNGRKVVEKNADPETTLLAYLRRKLGLSGTKLGCGEGGCGACTVMLSKYDR
LQNKIVHFSANACLAPICSLHHVAVTTVEGIGSTKTRLHPVQERIAKSHGSQCGFCTPGI
VMSMYTLLRNQPEPTMEEIENAFQGNLCRCTGYRPILQGFRTFARDGGCCGGDGNNPNCC
MNQKKDHSVSLSPSLFKPEEFTPLDPTQEPIFPPELLRLKDTPRKQLRFEGERVTWIQAS
TLKELLDLKAQHPDAKLVVGNTEIGIEMKFKNMLFPMIVCPAWIPELNSVEHGPDGISFG
AACPLSIVEKTLVDAVAKLPAQKTEVFRGVLEQLRWFAGKQVKSVASVGGNIITASPISD
LNPVFMASGAKLTLVSRGTRRTVQMDHTFFPGYRKTLLSPEEILLSIEIPYSREGEYFSA
FKQASRREDDIAKVTSGMRVLFKPGTTEVQELALCYGGMANRTISALKTTQRQLSKLWKE
ELLQDVCAGLAEELHLPPDAPGGMVDFRCTLTLSFFFKFYLTVLQKLGQENLEDKCGKLD
PTFASATLLFQKDPPADVQLFQEVPKGQSEEDMVGRPLPHLAADMQASGEAVYCDDIPRY
ENELSLRLVTSTRAHAKIKSIDTSEAKKVPGFVCFISADDVPGSNITGICNDETVFAKDK
VTCVGHIIGAVVADTPEHTQRAAQGVKITYEELPAIITIEDAIKNNSFYGPELKIEKGDL
KKGFSEADNVVSGEIYIGGQEHFYLETHCTIAVPKGEAGEMELFVSTQNTMKTQSFVAKM
LGVPANRIVVRVKRMGGGFGGKETRSTVVSTAVALAAYKTGRPVRCMLDRDEDMLITGGR
HPFLARYKVGFMKTGTVVALEVDHFSNVGNTQDLSQSIMERALFHMDNCYKIPNIRGTGR
LCKTNLPSNTAFRGFGGPQGMLIAECWMSEVAVTCGMPAEEVRRKNLYKEGDLTHFNQKL
EGFTLPRCWEECLASSQYHARKSEVDKFNKENCWKKRGLCIIPTKFGISFTVPFLNQAGA
LLHVYTDGSVLLTHGGTEMGQGLHTKMVQVASRALKIPTSKIYISETSTNTVPNTSPTAA
SVSADLNGQAVYAACQTILKRLEPYKKKNPSGSWEDWVTAAYMDTVSLSATGFYRTPNLG
YSFETNSGNPFHYFSYGVACSEVEIDCLTGDHKNLRTDIVMDVGSSLNPAIDIGQVEGAF
VQGLGLFTLEELHYSPEGSLHTRGPSTYKIPAFGSIPIEFRVSLLRDCPNKKAIYASKAV
GEPPLFLAASIFFAIKDAIRAARAQHTGNNVKELFRLDSPATPEKIRNACVDKFTTLCVT
GVPENCKPWSVRV

# Drug_Target_34_Reaction:
xanthine + NAD+ + H2O = urate + NADH + H+

# Drug_Target_34_Signals:
None

# Drug_Target_34_Specific_Function:
This enzyme can be converted from the dehydrogenase form (D) to the oxidase form (O) irreversibly by proteolysis or reversibly through the oxidation of sulfhydryl groups

# Drug_Target_34_SwissProt_ID:
P47989

# Drug_Target_34_SwissProt_Name:
XDH_HUMAN

# Drug_Target_34_Synonyms:
EC 1.17.1.4
EC 1.17.3.2
XD
XO
Xanthine oxidase

# Drug_Target_34_Theoretical_pI:
7.70

# Drug_Target_34_Transmembrane_Regions:
None

# Drug_Target_35_Cellular_Location:
Secreted protein

# Drug_Target_35_Chromosome_Location:
Not Available

# Drug_Target_35_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_35_Essentiality:
Non-Essential

# Drug_Target_35_GenAtlas_ID:
Not Available

# Drug_Target_35_GenBank_ID_Gene:
D00712

# Drug_Target_35_GenBank_ID_Protein:
216385

# Drug_Target_35_GeneCard_ID:
Not Available

# Drug_Target_35_Gene_Name:
choB

# Drug_Target_35_Gene_Sequence:
>1659 bp
ATGACCGATAGCCGGGCGAACAGAGCCGATGCGACTCGGGGGGTTGCATCCGTCTCACGC
CGTCGATTCCTTGCGGGCGCAGGTCTGACCGCGGGAGCCATCGCGCTCTCGTCGATGTCG
ACCTCCGCCTCCGCAGCCCCCAGCCGCACCCTCGCCGACGGCGACCGCGTCCCTGCCCTC
GTCATCGGCAGTGGATACGGCGGTGCCGTCGCCGCGCTGCGGCTGACGCAGGCCGGTATC
CCCACGCAGATCGTCGAGATGGGCCGCAGCTGGGACACCCCGGGCTCCGACGGCAAGATC
TTCTGCGGGATGCTCAACCCCGACAAGCGCTCGATGTGGTTGGCCGACAAGACCGATCAG
CCGGTCAGCAACTTCATGGGCTTCGGCATCAACAAGAGCATCGACCGGTACGTCGGCGTC
CTCGACTCCGAGCGGTTCTCCGGCATCAAGGTCTACCAGGGCCGCGGCGTCGGCGGCGGC
TCGCTCGTCAACGGCGGTATGGCAGTCACCCCGAAGCGCAACTACTTCGAGGAGATCCTG
CCGTCGGTCGACTCGAACGAGATGTACAACAAGTACTTCCCGCGCGCCAACACCGGTCTG
GGTGTCAACAACATCGACCAGGCGTGGTTCGAGTCCACCGAGTGGTACAAGTTCGCCCGC
ACCGGCCGCAAGACCGCCCAACGTTCGGGTTTCACAACCGCTTTCGTGCCCAACGTGTAC
GACTTCGAGTACATGAAGAAGGAGGCTGCCGGCCAGGTCACCAAGTCGGGCCTCGGCGGT
GAGGTCATCTACGGCAACAACGCCGGCAAGAAGTCGCTCGACAAGACCTACCTCGCGCAG
GCCGCGGCCACCGGGAAGCTGACGATCACGACTTTGCACCGCGTCACCAAGGTCGCGCCG
GCCACCGGCAGCGGCTACAGCGTGACGATGGAACAGATCGACGAGCAGGGCAACGTCGTC
GCCACCAAGGTCGTCACCGCCGATCGGGTGTTCTTCGCGGCCGGCAGCGTCGGCACCAGC
AAGCTCCTGGTCTCGATGAAGGCGCAGGGCCACCTGCCGAACCTGTCGTCGCAGGTCGGC
GAGGGCTGGGGCAACAACGGCAACATCATGGTGGGCCGCGCGAACCACATGTGGGACGCC
ACCGGATCCAAGCAGGCCACCATCCCGACGATGGGAATCGACAACTGGGCCGACCCGACG
GCACCGATCTTCGCGGAGATCGCCCCGCTGCCGGCCGGGCTCGAGACCTACGTCAGCCTG
TACCTGGCCATCACGAAGAACCCCGAACGTGCTCGCTTCCAGTTCAATTCGGGCACCGGC
AAGGTCGATCTCACCTGGGCTCAGTCGCAGAACCAGAAGGGCATCGACATGGCCAAGAAG
GTGTTCGACAAGATCAACCAGAAGGAGGGCACCATCTACCGCACCGATCTGTTCGGTGTC
TACTTCAAGACCTGGGGCGACGACTTCACGTACCACCCGCTGGGCGGCGTGCTGCTGAAC
AAGGCGACCGACAACTTTGGCCGCTTGCCCGAGTACCCCGGCCTGTACGTGGTGGACGGC
TCGCTCGTCCCCGGCAATGTGGGCGTCAACCCGTTCGTCACGATCACCCGGCTCGCCGAG
CGCAACATGGACAAGATCATCTCGTCCGACATCCAGTGA

# Drug_Target_35_General_Function:
Amino acid transport and metabolism

# Drug_Target_35_General_References:
1879703	Ohta T, Fujishiro K, Yamaguchi K, Tamura Y, Aisaka K, Uwajima T, Hasegawa M: Sequence of gene choB encoding cholesterol oxidase of Brevibacterium sterolicum: comparison with choA of streptomyces sp. SA-COO. Gene. 1991 Jul 15;103(1):93-6.
2051487	Vrielink A, Lloyd LF, Blow DM: Crystal structure of cholesterol oxidase from Brevibacterium sterolicum refined at 1.8 A resolution. J Mol Biol. 1991 Jun 5;219(3):533-54.
2271066	Fujishiro K, Ohta T, Hasegawa M, Yamaguchi K, Mizukami T, Uwajima T, Ota T: Isolation and identification of the gene of cholesterol oxidase from Brevibacterium sterolicum ATCC 21387, a widely used enzyme in clinical analysis. Biochem Biophys Res Commun. 1990 Oct 30;172(2):721-7.

# Drug_Target_35_HGNC_ID:
Not Available

# Drug_Target_35_HPRD_ID:
Not Available

# Drug_Target_35_ID:
2268

# Drug_Target_35_Locus:
Not Available

# Drug_Target_35_Molecular_Weight:
59359

# Drug_Target_35_Name:
Cholesterol oxidase

# Drug_Target_35_Number_of_Residues:
552

# Drug_Target_35_PDB_ID:
3COX

# Drug_Target_35_Pathway:
Not Available

# Drug_Target_35_Pfam_Domain_Function:
PF01494	FAD_binding_3

# Drug_Target_35_Protein_Sequence:
>Cholesterol oxidase precursor
MTDSRANRADATRGVASVSRRRFLAGAGLTAGAIALSSMSTSASAAPSRTLADGDRVPAL
VIGSGYGGAVAALRLTQAGIPTQIVEMGRSWDTPGSDGKIFCGMLNPDKRSMWLADKTDQ
PVSNFMGFGINKSIDRYVGVLDSERFSGIKVYQGRGVGGGSLVNGGMAVTPKRNYFEEIL
PSVDSNEMYNKYFPRANTGLGVNNIDQAWFESTEWYKFARTGRKTAQRSGFTTAFVPNVY
DFEYMKKEAAGQVTKSGLGGEVIYGNNAGKKSLDKTYLAQAAATGKLTITTLHRVTKVAP
ATGSGYSVTMEQIDEQGNVVATKVVTADRVFFAAGSVGTSKLLVSMKAQGHLPNLSSQVG
EGWGNNGNIMVGRANHMWDATGSKQATIPTMGIDNWADPTAPIFAEIAPLPAGLETYVSL
YLAITKNPERARFQFNSGTGKVDLTWAQSQNQKGIDMAKKVFDKINQKEGTIYRTDLFGV
YFKTWGDDFTYHPLGGVLLNKATDNFGRLPEYPGLYVVDGSLVPGNVGVNPFVTITRLAE
RNMDKIISSDIQ

# Drug_Target_35_Reaction:
cholesterol + O2 = cholest-4-en-3-one + H2O2

# Drug_Target_35_Signals:
1-45

# Drug_Target_35_Specific_Function:
Cholesterol + O(2) = cholest-4-en-3-one + H(2)O(2)

# Drug_Target_35_SwissProt_ID:
P22637

# Drug_Target_35_SwissProt_Name:
CHOD_BREST

# Drug_Target_35_Synonyms:
CHOD
Cholesterol oxidase precursor
EC 1.1.3.6

# Drug_Target_35_Theoretical_pI:
9.73

# Drug_Target_35_Transmembrane_Regions:
None

# Drug_Target_36_Cellular_Location:
Not Available

# Drug_Target_36_Chromosome_Location:
Not Available

# Drug_Target_36_Drug_References:
Not Available

# Drug_Target_36_Essentiality:
Non-Essential

# Drug_Target_36_GenAtlas_ID:
Not Available

# Drug_Target_36_GenBank_ID_Gene:
AF329477

# Drug_Target_36_GenBank_ID_Protein:
Not Available

# Drug_Target_36_GeneCard_ID:
Not Available

# Drug_Target_36_Gene_Name:
dmg

# Drug_Target_36_Gene_Sequence:
>2493 bp
ATGGCATCGACGCCGCGTATTGTCATTATTGGAGCCGGCATTGTCGGTACGAACCTGGCC
GACGAGCTGGTCACCCGGGGCTGGAATAACATCACTGTCCTGGACCAGGGGCCTTTGAAT
ATGCCCGGCGGGTCCACGTCCCATGCCCCGGGCCTGGTTTTCCAGACCAACCCGTCCAAG
ACCATGGCCTCTTTCGCCAAGTACACGGTGGAGAAGCTGCTGTCGCTGACCGAGGACGGG
GTGAGCTGCTTCAACCAGGTCGGTGGCCTGGAAGTGGCCACCACCGAAACCCGCCTCGCT
GACCTGAAGCGCAAACTCGGCTACGCCGCCGCCTGGGGCATCGAAGGGCGCCTCCTGTCC
CCGGCCGAGTGCCAGGAGCTGTACCCGCTCCTGGACGGGGAAAACATCCTGGGCGGCCTC
CACGTGCCCAGCGATGGCCTGGCCAGCGCCGCCCGTGCGGTGCAGCTGCTGATCAAACGC
ACCGAGTCCGCCGGGGTCACATACCGCGGTTCGACCACCGTGACGGGCATTGAGCAGTCC
GGAGGCCGTGTCACGGGCGTGCAGACCGCCGACGGCGTGATCCCGGCCGATATCGTGGTG
TCCTGCGCCGGGTTCTGGGGCGCGAAGATCGGGGCCATGATCGGCATGGCCGTTCCCCTG
CTCCCGCTGGCCCACCAGTACGTAAAAACCACCCCGGTACCGGCGCAGCAGGGCAGGAAC
GACCAGCCGAACGGGGCCCGGCTGCCGATCCTGCGCCACCAGGACCAGGACCTCTACTAC
CGCGAACACGGGGACCGGTACGGCATCGGCTCCTACGCCCACCGGCCCATGCCCGTGGAC
GTCGACACCCTGGGGGCCTACGCGCCCGAGACCGTCAGCGAACACCACATGCCCTCCCGC
CTCGACTTCACCCTGGAGGACTTCCTGCCGGCGTGGGAGGCCACCAAGCAGCTCCTGCCC
GCGCTGGCGGACAGCGAGATCGAGGACGGCTTCAACGGCATCTTCTCCTTCACCCCCGAC
GGCGGGCCGCTCCTTGGCGAATCCAAGGAACTCGACGGCTTCTACGTCGCCGAAGCCGTC
TGGGTCACGCACTCCGCCGGCGTGGCCAAGGCCATGGCCGAACTGCTGACCACCGGCCGG
TCCGAGACCGACCTGGGCGAGTGCGACATCACCCGCTTCGAGGACGTCCAGCTCACCCCC
GAATACGTCAGCGAAACCTCACAGCAGAACTTCGTGGAAATCTACGACGTCCTGCACCCG
CTCCAGCCCAGACTCTCCCCCCGCAACCTGCGCGTGAGCCCCTTCCACGCCCGGCACAAA
GAACTCGGCGCGTTCTTCCTGGAAGCCGGCGGCTGGGAACGGCCCTACTGGTTCGAAGCC
AACGCCGCACTCCTCAAGGAGATGCCGGCCGAGTGGCTGCCGCCCGCACGCGACGCCTGG
TCCGGAATGTTCAGCTCCCCGATCGCCGCCGCCGAAGCCTGGAAAACCCGCACGGCCGTA
GCCATGTACGACATGACCCCGCTCAAGCGCCTCGAGGTCTCCGGCCCGGGGGCCCTCAAG
CTCCTGCAGGAACTGACGACGGCGGACCTGGCCAAGAAGCCGGGCGCGGTCACCTACACC
CTGCTGCTCGACCACGCCGGCGGCGTGCGAAGCGACATCACGGTGGCCCGCCTGAGCGAG
GACACCTTCCAGCTCGGCGCCAACGGCAACATCGACACCGCCTACTTCGAGCGGGCGGCC
CGGCACCAGACGCAAAGCGGATCCGCCACCGACTGGGTCCAGGTGCGCGACACCACCGGC
GGCACCTGCTGCATCGGCCTCTGGGGCCCGCTCGCCCGGGACCTCGTCAGCAAAGTCAGC
GACGACGACTTCACCAACGACGGCCTGAAGTACTTCCGGGCCAAGAACGTCGTCATCGGC
GGCATTCCCGTTACCGCCATGCGGCTTTCCTACGTCGGTGAACTCGGCTGGGAGCTGTAC
ACCAGCGCCGACAACGGACAGCGGCTGTGGGATGCGCTCTGGCAGGCAGGACAGCCCTTC
GGAGTCATCGCCGCCGGACGCGCGGCATTCAGCTCCCTGCGGCTCGAAAAGGGCTACCGC
TCCTGGGGAACCGACATGACCACGGAGCACGACCCCTTCGAAGCAGGGCTCGGATTCGCC
GTCAAGATGGCCAAGGAGAGCTTCATCGGCAAGGGCGCGCTCGAAGGCCGGACCGAAGAG
GCCTCCGCCCGCCGGCTGCGCTGCCTGACCATCGACGACGGCCGGTCCATCGTCCTCGGC
AAGGAACCCGTCTTCTACAAGGAACAGGCCGTCGGCTACGTCACCAGCGCCGCCTACGGG
TACACCGTGGCCAAACCCATCGCCTACTCCTACCTGCCGGGCACCGTCTCGGTCGGCGAC
TCCGTCGACATCGAATACTTCGGACGGCGCATCACCGCCACCGTCACAGAAGACCCGCTG
TACGACCCGAAAATGACCAGGCTCCGCGGCTAA

# Drug_Target_36_General_Function:
Involved in oxidoreductase activity

# Drug_Target_36_General_References:
11422368	Meskys R, Harris RJ, Casaite V, Basran J, Scrutton NS: Organization of the genes involved in dimethylglycine and sarcosine degradation in Arthrobacter spp.: implications for glycine betaine catabolism. Eur J Biochem. 2001 Jun;268(12):3390-8.
12912903	Leys D, Basran J, Scrutton NS: Channelling and formation of 'active' formaldehyde in dimethylglycine oxidase. EMBO J. 2003 Aug 15;22(16):4038-48.

# Drug_Target_36_HGNC_ID:
Not Available

# Drug_Target_36_HPRD_ID:
Not Available

# Drug_Target_36_ID:
5072

# Drug_Target_36_Locus:
Not Available

# Drug_Target_36_Molecular_Weight:
89986

# Drug_Target_36_Name:
N,N-dimethylglycine oxidase

# Drug_Target_36_Number_of_Residues:
830

# Drug_Target_36_PDB_ID:
1PJ7

# Drug_Target_36_Pathway:
Not Available

# Drug_Target_36_Pfam_Domain_Function:
PF01266	DAO
PF01571	GCV_T

# Drug_Target_36_Protein_Sequence:
>N,N-dimethylglycine oxidase
MASTPRIVIIGAGIVGTNLADELVTRGWNNITVLDQGPLNMPGGSTSHAPGLVFQTNPSK
TMASFAKYTVEKLLSLTEDGVSCFNQVGGLEVATTETRLADLKRKLGYAAAWGIEGRLLS
PAECQELYPLLDGENILGGLHVPSDGLASAARAVQLLIKRTESAGVTYRGSTTVTGIEQS
GGRVTGVQTADGVIPADIVVSCAGFWGAKIGAMIGMAVPLLPLAHQYVKTTPVPAQQGRN
DQPNGARLPILRHQDQDLYYREHGDRYGIGSYAHRPMPVDVDTLGAYAPETVSEHHMPSR
LDFTLEDFLPAWEATKQLLPALADSEIEDGFNGIFSFTPDGGPLLGESKELDGFYVAEAV
WVTHSAGVAKAMAELLTTGRSETDLGECDITRFEDVQLTPEYVSETSQQNFVEIYDVLHP
LQPRLSPRNLRVSPFHARHKELGAFFLEAGGWERPYWFEANAALLKEMPAEWLPPARDAW
SGMFSSPIAAAEAWKTRTAVAMYDMTPLKRLEVSGPGALKLLQELTTADLAKKPGAVTYT
LLLDHAGGVRSDITVARLSEDTFQLGANGNIDTAYFERAARHQTQSGSATDWVQVRDTTG
GTCCIGLWGPLARDLVSKVSDDDFTNDGLKYFRAKNVVIGGIPVTAMRLSYVGELGWELY
TSADNGQRLWDALWQAGQPFGVIAAGRAAFSSLRLEKGYRSWGTDMTTEHDPFEAGLGFA
VKMAKESFIGKGALEGRTEEASARRLRCLTIDDGRSIVLGKEPVFYKEQAVGYVTSAAYG
YTVAKPIAYSYLPGTVSVGDSVDIEYFGRRITATVTEDPLYDPKMTRLRG

# Drug_Target_36_Reaction:
Not Available

# Drug_Target_36_Signals:
None

# Drug_Target_36_Specific_Function:
Not Available

# Drug_Target_36_SwissProt_ID:
Q9AGP8

# Drug_Target_36_SwissProt_Name:
Q9AGP8_ARTGO

# Drug_Target_36_Synonyms:
Not Available

# Drug_Target_36_Theoretical_pI:
5.00

# Drug_Target_36_Transmembrane_Regions:
None

# Drug_Target_37_Cellular_Location:
Not Available

# Drug_Target_37_Chromosome_Location:
Not Available

# Drug_Target_37_Drug_References:
Not Available

# Drug_Target_37_Essentiality:
Non-Essential

# Drug_Target_37_GenAtlas_ID:
Not Available

# Drug_Target_37_GenBank_ID_Gene:
X62755

# Drug_Target_37_GenBank_ID_Protein:
Not Available

# Drug_Target_37_GeneCard_ID:
Not Available

# Drug_Target_37_Gene_Name:
npr

# Drug_Target_37_Gene_Sequence:
>1344 bp
ATGAAAGTTATTGTTTTAGGATCATCACATGGAGGTTATGAAGCGGTAGAGGAATTACTA
AATCTTCATCCTGATGCAGAAATTCAATGGTATGAGAAAGGTGATTTTATCTCATTCTTG
TCTTGTGGCATGCAGTTGTACCTAGAAGGAAAAGTGAAAGATGTTAATTCTGTTCGCTAT
ATGACTGGCGAAAAAATGGAGAGCCGTGGTGTAAATGTCTTTTCTAATACTGAAATTACA
GCGATTCAACCAAAAGAACATCAAGTGACAGTGAAAGATTTAGTGTCAGGTGAAGAACGT
GTTGAAAATTATGATAAATTAATCATCAGTCCCGGAGCTGTCCCATTTGAATTAGATATT
CCAGGTAAAGATTTGGATAATATTTACTTGATGCGTGGTCGTCAATGGGCCATTAAATTA
AAACAAAAAACAGTAGATCCAGAAGTCAATAATGTGGTTGTGATTGGTAGTGGTTATATT
GGGATTGAAGCTGCCGAAGCATTTGCAAAAGCCGGTAAAAAGGTTACCGTTATTGATATT
TTAGATCGTCCATTAGGGGTGTATCTAGATAAAGAATTTACAGATGTTTTAACAGAAGAG
ATGGAAGCCAATAACATTACCATTGCAACTGGTGAAACAGTTGAACGTTACGAAGGCGAC
GGTCGTGTGCAAAAAGTCGTTACAGATAAAAATGCGTACGATGCTGATTTGGTCGTTGTA
GCGGTTGGTGTCCGTCCAAACACTGCTTGGTTAAAAGGTACCTTAGAATTACATCCGAAT
GGCCTAATCAAGACGGATGAATACATGCGGACAAGTGAGCCAGATGTATTTGCAGTAGGG
GATGCTACGTTAATTAAATACAATCCTGCAGACACAGAAGTAAATATTGCCTTAGCAACG
AATGCTCGTAAACAAGGTCGCTTTGCTGTGAAAAACCTAGAGGAACCAGTTAAACCTTTC
CCTGGTGTTCAAGGATCTTCTGGCTTGGCCGTCTTTGATTATAAATTTGCTTCAACAGGG
ATTAACGAAGTCATGGCTCAAAAATTAGGAAAAGAAACAAAAGCGGTGACAGTAGTAGAA
GACTACTTGATGGACTTTAATCCAGACAAACAAAAAGCTTGGTTTAAATTAGTGTATGAT
CCTGAAACAACACAAATTTTAGGCGCTCAATTAATGTCAAAAGCAGATTTAACTGCAAAC
ATTAATGCTATTTCATTAGCGATTCAAGCCAAAATGACAATTGAAGACTTAGCCTATGCG
GATTTCTTCTTCCAACCAGCGTTTGACAAACCTTGGAATATTATTAATACAGCGGCTTTA
GAAGCGGTGAAACAAGAACGTTAA

# Drug_Target_37_General_Function:
Involved in oxidoreductase activity

# Drug_Target_37_General_References:
12663927	Paulsen IT, Banerjei L, Myers GS, Nelson KE, Seshadri R, Read TD, Fouts DE, Eisen JA, Gill SR, Heidelberg JF, Tettelin H, Dodson RJ, Umayam L, Brinkac L, Beanan M, Daugherty S, DeBoy RT, Durkin S, Kolonay J, Madupu R, Nelson W, Vamathevan J, Tran B, Upton J, Hansen T, Shetty J, Khouri H, Utterback T, Radune D, Ketchum KA, Dougherty BA, Fraser CM: Role of mobile DNA in the evolution of vancomycin-resistant Enterococcus faecalis. Science. 2003 Mar 28;299(5615):2071-4.
1719212	Ross RP, Claiborne A: Cloning, sequence and overexpression of NADH peroxidase from Streptococcus faecalis 10C1. Structural relationship with the flavoprotein disulfide reductases. J Mol Biol. 1991 Oct 5;221(3):857-71.
1942054	Stehle T, Ahmed SA, Claiborne A, Schulz GE: Structure of NADH peroxidase from Streptococcus faecalis 10C1 refined at 2.16 A resolution. J Mol Biol. 1991 Oct 20;221(4):1325-44.
2501302	Poole LB, Claiborne A: The non-flavin redox center of the streptococcal NADH peroxidase. I. Thiol reactivity and redox behavior in the presence of urea. J Biol Chem. 1989 Jul 25;264(21):12322-9.
8425532	Stehle T, Claiborne A, Schulz GE: NADH binding site and catalysis of NADH peroxidase. Eur J Biochem. 1993 Jan 15;211(1-2):221-6.
8756456	Yeh JI, Claiborne A, Hol WG: Structure of the native cysteine-sulfenic acid redox center of enterococcal NADH peroxidase refined at 2.8 A resolution. Biochemistry. 1996 Aug 6;35(31):9951-7.
9214307	Crane EJ 3rd, Vervoort J, Claiborne A: 13C NMR analysis of the cysteine-sulfenic acid redox center of enterococcal NADH peroxidase. Biochemistry. 1997 Jul 15;36(28):8611-8.

# Drug_Target_37_HGNC_ID:
Not Available

# Drug_Target_37_HPRD_ID:
Not Available

# Drug_Target_37_ID:
4440

# Drug_Target_37_Locus:
Not Available

# Drug_Target_37_Molecular_Weight:
49566

# Drug_Target_37_Name:
NADH peroxidase

# Drug_Target_37_Number_of_Residues:
447

# Drug_Target_37_PDB_ID:
2NPX

# Drug_Target_37_Pathway:
Not Available

# Drug_Target_37_Pfam_Domain_Function:
PF00070	Pyr_redox
PF02852	Pyr_redox_dim
PF07992	Pyr_redox_2

# Drug_Target_37_Protein_Sequence:
>NADH peroxidase
MKVIVLGSSHGGYEAVEELLNLHPDAEIQWYEKGDFISFLSCGMQLYLEGKVKDVNSVRY
MTGEKMESRGVNVFSNTEITAIQPKEHQVTVKDLVSGEERVENYDKLIISPGAVPFELDI
PGKDLDNIYLMRGRQWAIKLKQKTVDPEVNNVVVIGSGYIGIEAAEAFAKAGKKVTVIDI
LDRPLGVYLDKEFTDVLTEEMEANNITIATGETVERYEGDGRVQKIVTDKNAYDADLVVV
AVGVRPNTAWLKGTLELHPNGLIKTDEYMRTSEPDVFAVGDATLIKYNPADTEVNIALAT
NARKQGRFAVKNLEEPVKPFPGVQGSSGLAVFDYKFASTGINEVMAQKLGKETKAVTVVE
DYLMDFNPDKQKAWFKLVYDPETTQILGAQLMSKADLTANINAISLAIQAKMTIEDLAYA
DFFFQPAFDKPWNIINTAALEAVKQER

# Drug_Target_37_Reaction:
Not Available

# Drug_Target_37_Signals:
None

# Drug_Target_37_Specific_Function:
Peroxidase whose active site is a redox-active cysteine- sulfenic acid

# Drug_Target_37_SwissProt_ID:
P37062

# Drug_Target_37_SwissProt_Name:
NAPE_ENTFA

# Drug_Target_37_Synonyms:
EC 1.11.1.1
NPXase
Npx

# Drug_Target_37_Theoretical_pI:
4.56

# Drug_Target_37_Transmembrane_Regions:
None

# Drug_Target_38_Cellular_Location:
Cytoplasm

# Drug_Target_38_Chromosome_Location:
Not Available

# Drug_Target_38_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_38_Essentiality:
Non-Essential

# Drug_Target_38_GenAtlas_ID:
DPYD

# Drug_Target_38_GenBank_ID_Gene:
U09178

# Drug_Target_38_GenBank_ID_Protein:
558305

# Drug_Target_38_GeneCard_ID:
DPYD

# Drug_Target_38_Gene_Name:
DPYD

# Drug_Target_38_Gene_Sequence:
>3078 bp
ATGGCCCCTGTGCTCAGTAAGGACTCGGCGGACATCGAGAGTATCCTGGCTTTAAATCCT
CGAACACAAACTCATGCAACTCTGTGTTCCACTTCGGCCAAGAAATTAGACAAGAAACAT
TGGAAAAGAAATCCTGATAAGAACTGCTTTAATTGTGAGAAGCTGGAGAATAATTTTGAT
GACATCAAGCACACGACTCTTGGTGAGCGAGGAGCTCTCCGAGAAGCAATGAGATGCCTG
AAATGTGCAGATGCCCCGTGTCAGAAGAGCTGTCCAACTAATCTTGATATTAAATCATTC
ATCACAAGTATTGCAAACAAGAACTATTATGGAGCTGCTAAGATGATATTTTCTGACAAC
CCACTTGGTCTGACTTGTGGAATGGTATGTCCAACCTCTGATCTATGTGTAGGTGGATGC
AATTTATATGCCACTGAAGAGGGACCCATTAATATTGGTGGATTGCAGCAATTTGCTACT
GAGGTATTCAAAGCAATGAGTATCCCACAGATCAGAAATCCTTCGCTGCCTCCCCCAGAA
AAAATGTCTGAAGCCTATTCTGCAAAGATTGCTCTTTTTGGTGCTGGGCCTGCAAGTATA
AGTTGTGCTTCCTTTTTGGCTCGATTGGGGTACTCTGACATCACTATATTTGAAAAACAA
GAATATGTTGGTGGTTTAAGTACTTCTGAAATTCCTCAGTTCCGGCTGCCGTATGATGTA
GTGAATTTTGAGATTGAGCTAATGAAGGACCTTGGTGTAAAGATAATTTGCGGTAAAAGC
CTTTCAGTGAATGAAATGACTCTTAGCACTTTGAAAGAAAAAGGCTACAAAGCTGCTTTC
ATTGGAATAGGTTTGCCAGAACCCAATAAAGATGCCATCTTCCAAGGCCTGACGCAGGAC
CAGGGGTTTTATACATCCAAAGACTTTTTGCCACTTGTAGCCAAAGGCAGTAAAGCAGGA
ATGTGCGCCTGTCACTCTCCATTGCCATCGATACGGGGAGTCGTGATTGTACTTGGAGCT
GGAGACACTGCCTTCGACTGTGCAACATCTGCTCTACGTTGTGGAGCTCGCCGAGTGTTC
ATCGTCTTCAGAAAAGGCTTTGTTAATATAAGAGCTGTCCCTGAGGAGATGGAGCTTGCT
AAGGAAGAAAAGTGTGAATTTCTGCCATTCCTGTCCCCACGGAAGGTTATAGTAAAAGGT
GGGAGAATTGTTGCTATGCAGTTTGTTCGGACAGAGCAAGATGAAACTGGAAAATGGAAT
GAAGATGAAGATCAGATGGTCCATCTGAAAGCCGATGTGGTCATCAGTGCCTTTGGTTCA
GTTCTGAGTGATCCTAAAGTAAAAGAAGCCTTGAGCCCTATAAAATTTAACAGATGGGGT
CTCCCAGAAGTAGATCCAGAAACTATGCAAACTAGTGAAGCATGGGTATTTGCAGGTGGT
GATGTCGTTGGTTTGGCTAACACTACAGTGGAATCGGTGAATGATGGAAAGCAAGCTTCT
TGGTACATTCACAAATACGTACAGTCACAATATGGAGCTTCCGTTTCTGCCAAGCCTGAA
CTACCCCTCTTTTACACTCCTATTGATCTGGTGGACATTAGTGTAGAAATGGCCGGATTG
AAGTTTATAAATCCTTTTGGTCTTGCTAGCGCAACTCCAGCCACCAGCACATCAATGATT
CGAAGAGCTTTTGAAGCTGGATGGGGTTTTGCCCTCACCAAAACTTTCTCTCTTGATAAG
GACATTGTGACAAATGTTTCCCCCAGAATCATCCGGGGAACCACCTCTGGCCCCATGTAT
GGCCCTGGACAAAGCTCCTTTCTGAATATTGAGCTCATCAGTGAGAAAACGGCTGCATAT
TGGTGTCAAAGTGTCACTGAACTAAAGGCTGACTTCCCAGACAACATTGTGATTGCTAGC
ATTATGTGCAGTTACAATAAAAATGACTGGACGGAACTTGCCAAGAAGTCTGAGGATTCT
GGAGCAGATGCCCTGGAGTTAAATTTATCATGTCCACATGGCATGGGAGAAAGAGGAATG
GGCCTGGCCTGTGGGCAGGATCCAGAGCTGGTGCGGAACATCTGCCGCTGGGTTAGGCAA
GCTGTTCAGATTCCTTTTTTTGCCAAGCTGACCCCAAATGTCACTGATATTGTGAGCATC
GCAAGAGCTGCAAAGGAAGGTGGTGCCAATGGCGTTACAGCCACCAACACTGTCTCAGGT
CTGATGGGATTAAAATCTGATGGCACACCTTGGCCAGCAGTGGGGATTGCAAAGCGAACT
ACATATGGAGGAGTGTCTGGGACAGCAATCAGACCTATTGCTTTGAGAGCTGTGACCTCC
ATTGCTCGTGCTCTGCCTGGATTTCCCATTTTGGCTACTGGTGGAATTGACTCTGCTGAA
AGTGGTCTTCAGTTTCTCCATAGTGGTGCTTCCGTCCTCCAGGTATGCAGTGCCATTCAG
AATCAGGATTTCACTGTGATCGAAGACTACTGCACTGGCCTCAAAGCCCTGCTTTATCTG
AAAAGCATTGAAGAACTACAAGACTGGGATGGACAGAGTCCAGCTACTGTGAGTCACCAG
AAAGGGAAACCAGTTCCACGTATAGCTGAACTCATGGACAAGAAACTGCCAAGTTTTGGA
CCTTATCTGGAACAGCGCAAGAAAATCATAGCAGAAAACAAGATTAGACTGAAAGAACAA
AATGTAGCTTTTTCACCACTTAAGAGAAGCTGTTTTATCCCCAAAAGGCCTATTCCTACC
ATCAAGGATGTAATAGGAAAAGCACTGCAGTACCTTGGAACATTTGGTGAATTGAGCAAC
GTAGAGCAAGTTGTGGCTATGATTGATGAAGAAATGTGTATCAACTGTGGTAAATGCTAC
ATGACCTGTAATGATTCTGGCTACCAGGCTATACAGTTTGATCCAGAAACCCACCTGCCC
ACCATAACCGACACTTGTACAGGCTGTACTCTGTGTCTCAGTGTTTGCCCTATTGTCGAC
TGCATCAAAATGGTTTCCAGGACAACACCTTATGAACCAAAGAGAGGCGTACCCTTATCT
GTGAATCCGGTGTGTTAA

# Drug_Target_38_General_Function:
Amino acid transport and metabolism

# Drug_Target_38_General_References:
1512248	Lu ZH, Zhang R, Diasio RB: Purification and characterization of dihydropyrimidine dehydrogenase from human liver. J Biol Chem. 1992 Aug 25;267(24):17102-9.
8083224	Yokota H, Fernandez-Salguero P, Furuya H, Lin K, McBride OW, Podschun B, Schnackerz KD, Gonzalez FJ: cDNA cloning and chromosome mapping of human dihydropyrimidine dehydrogenase, an enzyme associated with 5-fluorouracil toxicity and congenital thymine uraciluria. J Biol Chem. 1994 Sep 16;269(37):23192-6.
8892022	Vreken P, Van Kuilenburg AB, Meinsma R, Smit GP, Bakker HD, De Abreu RA, van Gennip AH: A point mutation in an invariant splice donor site leads to exon skipping in two unrelated Dutch patients with dihydropyrimidine dehydrogenase deficiency. J Inherit Metab Dis. 1996;19(5):645-54.
9135003	Johnson MR, Wang K, Tillmanns S, Albin N, Diasio RB: Structural organization of the human dihydropyrimidine dehydrogenase gene. Cancer Res. 1997 May 1;57(9):1660-3.
9170156	Fernandez-Salguero PM, Sapone A, Wei X, Holt JR, Jones S, Idle JR, Gonzalez FJ: Lack of correlation between phenotype and genotype for the polymorphically expressed dihydropyrimidine dehydrogenase in a family of Pakistani origin. Pharmacogenetics. 1997 Apr;7(2):161-3.
9266349	Vreken P, Van Kuilenburg AB, Meinsma R, van Gennip AH: Identification of novel point mutations in the dihydropyrimidine dehydrogenase gene. J Inherit Metab Dis. 1997 Jul;20(3):335-8.
9439663	Vreken P, Van Kuilenburg AB, Meinsma R, van Gennip AH: Dihydropyrimidine dehydrogenase (DPD) deficiency: identification and expression of missense mutations C29R, R886H and R235W. Hum Genet. 1997 Dec;101(3):333-8.
9464498	Ogura K, Nishiyama T, Takubo H, Kato A, Okuda H, Arakawa K, Fukushima M, Nagayama S, Kawaguchi Y, Watabe T: Suicidal inactivation of human dihydropyrimidine dehydrogenase by (E)-5-(2-bromovinyl)uracil derived from the antiviral, sorivudine. Cancer Lett. 1998 Jan 9;122(1-2):107-13.

# Drug_Target_38_HGNC_ID:
HGNC:3012

# Drug_Target_38_HPRD_ID:
02036

# Drug_Target_38_ID:
1302

# Drug_Target_38_Locus:
1p22

# Drug_Target_38_Molecular_Weight:
111375

# Drug_Target_38_Name:
Dihydropyrimidine dehydrogenase [NADP+]

# Drug_Target_38_Number_of_Residues:
1025

# Drug_Target_38_PDB_ID:
1GTE

# Drug_Target_38_Pathway:
Not Available

# Drug_Target_38_Pfam_Domain_Function:
PF00037	Fer4
PF01180	DHO_dh
PF07992	Pyr_redox_2

# Drug_Target_38_Protein_Sequence:
>Dihydropyrimidine dehydrogenase [NADP+] precursor
MAPVLSKDSADIESILALNPRTQTHATLCSTSAKKLDKKHWKRNPDKNCFNCEKLENNFD
DIKHTTLGERGALREAMRCLKCADAPCQKSCPTNLDIKSFITSIANKNYYGAAKMIFSDN
PLGLTCGMVCPTSDLCVGGCNLYATEEGPINIGGLQQFATEVFKAMSIPQIRNPSLPPPE
KMSEAYSAKIALFGAGPASISCASFLARLGYSDITIFEKQEYVGGLSTSEIPQFRLPYDV
VNFEIELMKDLGVKIICGKSLSVNEMTLSTLKEKGYKAAFIGIGLPEPNKDAIFQGLTQD
QGFYTSKDFLPLVAKGSKAGMCACHSPLPSIRGVVIVLGAGDTAFDCATSALRCGARRVF
IVFRKGFVNIRAVPEEMELAKEEKCEFLPFLSPRKVIVKGGRIVAMQFVRTEQDETGKWN
EDEDQMVHLKADVVISAFGSVLSDPKVKEALSPIKFNRWGLPEVDPETMQTSEAWVFAGG
DVVGLANTTVESVNDGKQASWYIHKYVQSQYGASVSAKPELPLFYTPIDLVDISVEMAGL
KFINPFGLASATPATSTSMIRRAFEAGWGFALTKTFSLDKDIVTNVSPRIIRGTTSGPMY
GPGQSSFLNIELISEKTAAYWCQSVTELKADFPDNIVIASIMCSYNKNDWTELAKKSEDS
GADALELNLSCPHGMGERGMGLACGQDPELVRNICRWVRQAVQIPFFAKLTPNVTDIVSI
ARAAKEGGANGVTATNTVSGLMGLKSDGTPWPAVGIAKRTTYGGVSGTAIRPIALRAVTS
IARALPGFPILATGGIDSAESGLQFLHSGASVLQVCSAIQNQDFTVIEDYCTGLKALLYL
KSIEELQDWDGQSPATVSHQKGKPVPRIAELMDKKLPSFGPYLEQRKKIIAENKIRLKEQ
NVAFSPLKRSCFIPKRPIPTIKDVIGKALQYLGTFGELSNVEQVVAMIDEEMCINCGKCY
MTCNDSGYQAIQFDPETHLPTITDTCTGCTLCLSVCPIVDCIKMVSRTTPYEPKRGVPLS
VNPVC

# Drug_Target_38_Reaction:
5,6-dihydrouracil + NADP+ = uracil + NADPH + H+

# Drug_Target_38_Signals:
None

# Drug_Target_38_Specific_Function:
Involved in pyrimidine base degradation. Catalyzes the reduction of uracil and thymine. Also involved the degradation of the chemotherapeutic drug 5-fluorouracil

# Drug_Target_38_SwissProt_ID:
Q12882

# Drug_Target_38_SwissProt_Name:
DPYD_HUMAN

# Drug_Target_38_Synonyms:
DHPDHase
DPD
Dihydropyrimidine dehydrogenase precursor
Dihydrothymine dehydrogenase
Dihydrouracil dehydrogenase
EC 1.3.1.2

# Drug_Target_38_Theoretical_pI:
7.05

# Drug_Target_38_Transmembrane_Regions:
None

# Drug_Target_39_Cellular_Location:
Cellular thylakoid membrane

# Drug_Target_39_Chromosome_Location:
Not Available

# Drug_Target_39_Drug_References:
Not Available

# Drug_Target_39_Essentiality:
Non-Essential

# Drug_Target_39_GenAtlas_ID:
Not Available

# Drug_Target_39_GenBank_ID_Gene:
X72394

# Drug_Target_39_GenBank_ID_Protein:
Not Available

# Drug_Target_39_GeneCard_ID:
Not Available

# Drug_Target_39_Gene_Name:
petH

# Drug_Target_39_Gene_Sequence:
>1323 bp
ATGTCTAATCAAGGTGCTTTTGATGGTGCTGCCAACGTAGAATCAGGTAGCCGCGTCTTC
GTTTACGAAGTGGTGGGTATGCGTCAGAACGAAGAAACTGATCAAACGAACTACCCAATT
CGTAAAAGTGGCAGTGTGTTCATTAGAGTGCCTTACAACCGCATGAATCAAGAAATGCAG
CGTATCACTCGACTAGGCGGCAAGATTGTTACGATTCAAACAGTAAGCGCACTACAACAA
CTCAATGGTAGAACTACCATTGCAACAGTAACAGATGCGTCTAGTGAGATTGCTAAGTCT
GAGGGGAATGGTAAAGCCACACCTGTAAAAACTGATAGTGGAGCTAAAGCGTTCGCTAAA
CCACCAGCTGAAGAACAGCTTAAGAAAAAAGACAACAAAGGCAACACCATGACTCAAGCG
AAAGCCAAACACGCTGATGTTCCTGTTAATCTTTACCGTCCCAATGCTCCATTTATTGGT
AAGGTAATCTCTAATGAACCACTGGTAAAAGAAGGCGGGATAGGTATTGTTCAGCACATT
AAATTTGATCTAACTGGTGGTAACTTAAAGTACATCGAAGGTCAAAGTATTGGTATCATT
CCACCAGGAGTGGACAAGAACGGCAAGCCGGAAAAATTGAGACTCTACTCCATTGCCTCG
ACCCGTCACGGCGATGATGTGGATGATAAAACCATCTCACTGTGCGTCCGTCAATTAGAG
TACAAACATCCAGAAAGCGGCGAAACAGTTTACGGTGTTTGTTCTACTTACTTGACTCAC
ATTGAACCAGGTTCAGAAGTGAAAATCACTGGGCCTGTGGGTAAAGAAATGCTGTTACCC
GATGATCCTGAAGCTAATGTCATCATGTTGGCAACAGGTACTGGTATTGCGCCTATGCGG
ACTTACCTGTGGCGGATGTTCAAGGATGCAGAAAGAGCTGCTAACCCAGAATATCAATTC
AAAGGATTCTCTTGGTTAGTCTTTGGTGTTCCTACAACTCCTAACATTCTTTATAAAGAA
GAACTGGAAGAAATCCAACAAAAATATCCCGATAACTTCCGCCTAACTTACGCTATCAGC
CGGGAGCAAAAGAATCCCCAAGGTGGCAGAATGTACATCCAAGACCGTGTGGCAGAACAC
GCTGATGAACTGTGGCAATTAATCAAGAATCAAAAAACCCACACCTACATCTGTGGTTTG
CGCGGTATGGAAGAGGGCATTGATGCTGCTTTAAGTGCTGCGGCTGCGAAAGAAGGTGTT
ACCTGGAGTGATTACCAAAAAGACCTCAAGAAAGCTGGTCGCTGGCACGTAGAAACATAC
TAA

# Drug_Target_39_General_Function:
Involved in oxidoreductase activity

# Drug_Target_39_General_References:
10651039	Mayoral T, Medina M, Sanz-Aparicio J, Gomez-Moreno C, Hermoso JA: Structural basis of the catalytic role of Glu301 in Anabaena PCC 7119 ferredoxin-NADP+ reductase revealed by x-ray crystallography. Proteins. 2000 Jan 1;38(1):60-9.
11053838	Morales R, Kachalova G, Vellieux F, Charon MH, Frey M: Crystallographic studies of the interaction between the ferredoxin-NADP+ reductase and ferredoxin from the cyanobacterium Anabaena: looking for the elusive ferredoxin molecule. Acta Crystallogr D Biol Crystallogr. 2000 Nov;56(Pt 11):1408-12.
2124680	Fillat MF, Bakker HA, Weisbeek PJ: Sequence of the ferredoxin-NADP(+)-reductase gene from Anabaena PCC 7119. Nucleic Acids Res. 1990 Dec 11;18(23):7161.
3124746	Sancho J, Peleato ML, Gomez-Moreno C, Edmondson DE: Purification and properties of ferredoxin-NADP+ oxidoreductase from the nitrogen-fixing cyanobacteria Anabaena variabilis. Arch Biochem Biophys. 1988 Jan;260(1):200-7.
8343609	Fillat MF, Flores E, Gomez-Moreno C: Homology of the N-terminal domain of the petH gene product from Anabaena sp. PCC 7119 to the CpcD phycobilisome linker polypeptide. Plant Mol Biol. 1993 Jul;22(4):725-9.
8890910	Serre L, Vellieux FM, Medina M, Gomez-Moreno C, Fontecilla-Camps JC, Frey M: X-ray structure of the ferredoxin:NADP+ reductase from the cyanobacterium Anabaena PCC 7119 at 1.8 A resolution, and crystallographic studies of NADP+ binding at 2.25 A resolution. J Mol Biol. 1996 Oct 18;263(1):20-39.
9922134	Martinez-Julvez M, Hermoso J, Hurley JK, Mayoral T, Sanz-Aparicio J, Tollin G, Gomez-Moreno C, Medina M: Role of Arg100 and Arg264 from Anabaena PCC 7119 ferredoxin-NADP+ reductase for optimal NADP+ binding and electron transfer. Biochemistry. 1998 Dec 22;37(51):17680-91.

# Drug_Target_39_HGNC_ID:
Not Available

# Drug_Target_39_HPRD_ID:
Not Available

# Drug_Target_39_ID:
5073

# Drug_Target_39_Locus:
Not Available

# Drug_Target_39_Molecular_Weight:
48866

# Drug_Target_39_Name:
Ferredoxin--NADP reductase

# Drug_Target_39_Number_of_Residues:
440

# Drug_Target_39_PDB_ID:
1GJR

# Drug_Target_39_Pathway:
Not Available

# Drug_Target_39_Pfam_Domain_Function:
PF00175	NAD_binding_1
PF00667	FAD_binding_1
PF01383	CpcD

# Drug_Target_39_Protein_Sequence:
>Ferredoxin--NADP reductase
MSNQGAFDGAANVESGSRVFVYEVVGMRQNEETDQTNYPIRKSGSVFIRVPYNRMNQEMQ
RITRLGGKIVTIQTVSALQQLNGRTTIATVTDASSEIAKSEGNGKATPVKTDSGAKAFAK
PPAEEQLKKKDNKGNTMTQAKAKHADVPVNLYRPNAPFIGKVISNEPLVKEGGIGIVQHI
KFDLTGGNLKYIEGQSIGIIPPGVDKNGKPEKLRLYSIASTRHGDDVDDKTISLCVRQLE
YKHPESGETVYGVCSTYLTHIEPGSEVKITGPVGKEMLLPDDPEANVIMLATGTGIAPMR
TYLWRMFKDAERAANPEYQFKGFSWLVFGVPTTPNILYKEELEEIQQKYPDNFRLTYAIS
REQKNPQGGRMYIQDRVAEHADELWQLIKNQKTHTYICGLRGMEEGIDAALSAAAAKEGV
TWSDYQKDLKKAGRWHVETY

# Drug_Target_39_Reaction:
Not Available

# Drug_Target_39_Signals:
None

# Drug_Target_39_Specific_Function:
Reduced ferredoxin + NADP(+) = oxidized ferredoxin + NADPH

# Drug_Target_39_SwissProt_ID:
P21890

# Drug_Target_39_SwissProt_Name:
FENR_ANASO

# Drug_Target_39_Synonyms:
EC 1.18.1.2
FNR

# Drug_Target_39_Theoretical_pI:
8.37

# Drug_Target_39_Transmembrane_Regions:
None

# Drug_Target_3_Cellular_Location:
Cytoplasm (Probable)

# Drug_Target_3_Chromosome_Location:
Not Available

# Drug_Target_3_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_3_Essentiality:
Non-Essential

# Drug_Target_3_GenAtlas_ID:
Not Available

# Drug_Target_3_GenBank_ID_Gene:
Z99110

# Drug_Target_3_GenBank_ID_Protein:
2633520

# Drug_Target_3_GeneCard_ID:
Not Available

# Drug_Target_3_Gene_Name:
thiO

# Drug_Target_3_Gene_Sequence:
>1110 bp
ATGAAAAGGCATTATGAAGCAGTGGTGATTGGAGGCGGAATTATCGGTTCCGCAATTGCT
TATTATTTGGCAAAGGAAAACAAAAACACCGCATTGTTTGAAAGCGGAACAATGGGCGGC
AGAACGACAAGTGCCGCTGCCGGAATGCTGGGCGCCCATGCCGAATGCGAGGAACGTGAC
GCGTTTTTTGATTTCGCTATGCACAGTCAGCGTCTGTACAAAGGTCTTGGAGAAGAGCTT
TATGCATTATCCGGTGTGGATATCAGGCAGCATAACGGCGGTATGTTTAAGCTTGCATTT
TCTGAAGAAGATGTGCTGCAGCTGAGACAGATGGACGATTTGGACTCTGTCAGCTGGTAT
TCAAAAGAAGAGGTGTTAGAAAAAGAGCCGTATGCGTCTGGTGACATCTTTGGTGCATCT
TTTATTCAGGATGATGTGCATGTGGAGCCTTATTTTGTTTGCAAGGCATATGTGAAAGCA
GCAAAAATGCTTGGGGCGGAGATTTTTGAGCATACGCCCGTCCTGCATGTCGAACGTGAC
GGTGAAGCCCTGTTCATCAAGACCCCTAGCGGAGACGTATGGGCTAATCATGTTGTCGTT
GCCAGCGGGGTGTGGAGCGGAATGTTTTTTAAACAGCTTGGACTGAACAATGCTTTTCTC
CCTGTAAAAGGGGAGTGCCTGTCCGTTTGGAATGATGATATCCCGCTGACAAAAACGCTT
TACCATGATCACTGCTATATCGTACCGAGAAAAAGCGGAAGACTGGTTGTCGGCGCGACA
ATGAAGCCGGGGGACTGGAGTGAAACACCGGATCTTGGCGGATTGGAATCTGTTATGAAA
AAAGCAAAAACGATGCTGCCGGCTATACAGAATATGAAGGTGGATCGTTTTTGGGCGGGA
CTCCGTCCGGGAACAAAGGATGGAAAACCGTACATCGGCAGACATCCTGAGGACAGCCGT
ATTTTATTTGCGGCTGGCCATTTCAGAAACGGGATCCTGCTTGCTCCCGCAACGGGCGCT
TTGATCAGTGATCTCATCATGAATAAAGAGGTCAACCAAGACTGGCTGCACGCATTCCGA
ATTGATCGCAAGGAGGCGGTTCAGATATGA

# Drug_Target_3_General_Function:
Amino acid transport and metabolism

# Drug_Target_3_General_References:
11744710	Job V, Marcone GL, Pilone MS, Pollegioni L: Glycine oxidase from Bacillus subtilis. Characterization of a new flavoprotein. J Biol Chem. 2002 Mar 1;277(9):6985-93. Epub 2001 Dec 13.
9384377	Kunst F, Ogasawara N, Moszer I, Albertini AM, Alloni G, Azevedo V, Bertero MG, Bessieres P, Bolotin A, Borchert S, Borriss R, Boursier L, Brans A, Braun M, Brignell SC, Bron S, Brouillet S, Bruschi CV, Caldwell B, Capuano V, Carter NM, Choi SK, Codani JJ, Connerton IF, Danchin A, et al.: The complete genome sequence of the gram-positive bacterium Bacillus subtilis. Nature. 1997 Nov 20;390(6657):249-56.
9827558	Nishiya Y, Imanaka T: Purification and characterization of a novel glycine oxidase from Bacillus subtilis. FEBS Lett. 1998 Nov 6;438(3):263-6.

# Drug_Target_3_HGNC_ID:
Not Available

# Drug_Target_3_HPRD_ID:
Not Available

# Drug_Target_3_ID:
2893

# Drug_Target_3_Locus:
Not Available

# Drug_Target_3_Molecular_Weight:
40937

# Drug_Target_3_Name:
Glycine oxidase

# Drug_Target_3_Number_of_Residues:
369

# Drug_Target_3_PDB_ID:
1RYI

# Drug_Target_3_Pathway:
Not Available

# Drug_Target_3_Pfam_Domain_Function:
PF01266	DAO

# Drug_Target_3_Protein_Sequence:
>Glycine oxidase
MKRHYEAVVIGGGIIGSAIAYYLAKENKNTALFESGTMGGRTTSAAAGMLGAHAECEERD
AFFDFAMHSQRLYKGLGEELYALSGVDIRQHNGGMFKLAFSEEDVLQLRQMDDLDSVSWY
SKEEVLEKEPYASGDIFGASFIQDDVHVEPYFVCKAYVKAAKMLGAEIFEHTPVLHVERD
GEALFIKTPSGDVWANHVVVASGVWSGMFFKQLGLNNAFLPVKGECLSVWNDDIPLTKTL
YHDHCYIVPRKSGRLVVGATMKPGDWSETPDLGGLESVMKKAKTMLPAIQNMKVDRFWAG
LRPGTKDGKPYIGRHPEDSRILFAAGHFRNGILLAPATGALISDLIMNKEVNQDWLHAFR
IDRKEAVQI

# Drug_Target_3_Reaction:
(1) glycine + H2O + O2 = glyoxylate + NH3 + H2O2

# Drug_Target_3_Signals:
None

# Drug_Target_3_Specific_Function:
This deaminating oxidase catalyzes the oxidation of sarcosine (N-methylglycine), N-ethylglycine and glycine. Lower activities on D-alanine, D-valine, and D-proline are detected. Does not act on L-amino acids and other D-amino acids

# Drug_Target_3_SwissProt_ID:
O31616

# Drug_Target_3_SwissProt_Name:
GLOX_BACSU

# Drug_Target_3_Synonyms:
EC 1.4.3.19

# Drug_Target_3_Theoretical_pI:
6.32

# Drug_Target_3_Transmembrane_Regions:
None

# Drug_Target_40_Cellular_Location:
Bacterial cell membrane
cytoplasmic side
peripheral membrane protein

# Drug_Target_40_Chromosome_Location:
Not Available

# Drug_Target_40_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_40_Essentiality:
Non-Essential

# Drug_Target_40_GenAtlas_ID:
Not Available

# Drug_Target_40_GenBank_ID_Gene:
M10038

# Drug_Target_40_GenBank_ID_Protein:
145753

# Drug_Target_40_GeneCard_ID:
Not Available

# Drug_Target_40_Gene_Name:
dld

# Drug_Target_40_Gene_Sequence:
>1716 bp
ATGTCTTCCATGACAACAACTGATAATAAAGCCTTTTTGAATGAACTTGCTCGTCTGGTG
GGTTCTTCACACCTGCTCACCGATCCCGCAAAAACGGCCCGCTATCGCAAGGGCTTCCGT
TCTGGTCAGGGCGACGCGCTGGCTGTCGTTTTCCCTGGCTCACTACTAGAATTGTGGCGG
GTGCTGAAAGCCTGCGTCACCGCCGACAAAATTATTCTGATGCAGGCCGCCAATACAGGC
CTGACCGAAGGATCGACGCCAAACGGTAACGATTATGATCGCGATGTCGTTATCATCAGC
ACCCTGCGTCTCGACAAGCTGCACGTTCTTGGCAAGGGCGAACAGGTGCTGGCCTATCCG
GGCACCACGCTCTATTCGCTGGAAAAAGCCCTCAAACCGCTGGGACGCGAACCGCACTCA
GTGATTGGATCATCGTGTATAGGCGCATCGGTCATCGGCGGTATTTGTAACAACTCCGGC
GGCTCGCTGGTGCAACGTGGCCCGGCGTATACCGAAATGTCGTTATTCGCGCGTATAAAT
GAAGACGGCAAACTGACGCTGGTGAACCATCTGGGGATTGATCTGGGCGAAACGCCGGAG
CAGATCCTTAGCAAGCTGGATGATGATCGCATCAAAGATGACGATGTGCGTCACGATGGT
CGTCACGCCCACGATTATGACTATGTCCACCGCGTTCGTGATATTGAAGCCGACACGCCC
GCACGTTATAACGCCGATCCTGATCGGTTATTTGAATCTTCTGGTTGCGCCGGGAAGCTG
GCGGTCTTTGCAGTACGTCTTGATACCTTCGAAGCGGAAAAAAATCAGCAGGTGTTTTAT
ATCGGCACCAACCAGCCGGAAGTGCTGACCGAAATCCGCCGTCATATTCTGGCTAACTTC
GAAAATCTGCCGGTTGCCGGGGAATATATGCACCGGGATATCTACGATATTGCGGAAAAA
TACGGCAAAGACACCTTCCTGATGATTGATAAGTTAGGCACCGACAAGATGCCGTTCTTC
TTTAATCTCAAGGGACGCACCGATGCGATGCTGGAGAAAGTGAAATTCTTCCGTCCGCAT
TTTACTGACCGTGCGATGCAAAAATTCGGTCACCTGTTCCCCAGCCATTTACCGCCGCGC
ATGAAAAACTGGCGCGATAAATACGAGCATCATCTGCTGTTAAAAATGGCGGGCGATGGC
GTGGGCGAAGCCAAATCGTGGCTGGTGGATTATTTCAAACAGGCCGAAGGCGATTTCTTT
GTCTGTACGCCGGAGGAAGGCAGCAAAGCGTTTTTACACCGTTTCGCCGCTGCGGGCGCA
GCAATTCGTTATCAGGCGGTGCATTCCGATGAAGTCGAAGACATTCTGGCGTTGGATATC
GCTCTGCGGCGTAACGACACCGAGTGGTATGAGCATTTACCGCCGGAGATCGACAGCCAG
CTGGTGCACAAGCTCTATTACGGCCATTTTATGTGCTATGTCTTCCATCAGGATTACATA
GTGAAAAAAGGCGTGGATGTGCATGCGTTAAAAGAACAGATGCTGGAACTGCTACAGCAG
CGCGGCGCGCAGTACCCTGCCGAGCATAACGTCGGTCATTTGTATAAAGCACCGGAGACG
TTGCAGAAGTTCTATCGCGAGAACGATCCGACCAACAGCATGAATCCGGGGATCGGTAAA
ACCAGTAAACGGAAAAACTGGCAGGAAGTGGAGTAA

# Drug_Target_40_General_Function:
Energy production and conversion

# Drug_Target_40_General_References:
10944213	Dym O, Pratt EA, Ho C, Eisenberg D: The crystal structure of D-lactate dehydrogenase, a peripheral membrane respiratory enzyme. Proc Natl Acad Sci U S A. 2000 Aug 15;97(17):9413-8.
3882663	Rule GS, Pratt EA, Chin CC, Wold F, Ho C: Overproduction and nucleotide sequence of the respiratory D-lactate dehydrogenase of Escherichia coli. J Bacteriol. 1985 Mar;161(3):1059-68.
6386470	Campbell HD, Rogers BL, Young IG: Nucleotide sequence of the respiratory D-lactate dehydrogenase gene of Escherichia coli. Eur J Biochem. 1984 Oct 15;144(2):367-73.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.

# Drug_Target_40_HGNC_ID:
Not Available

# Drug_Target_40_HPRD_ID:
Not Available

# Drug_Target_40_ID:
126

# Drug_Target_40_Locus:
Not Available

# Drug_Target_40_Molecular_Weight:
64482

# Drug_Target_40_Name:
D-lactate dehydrogenase

# Drug_Target_40_Number_of_Residues:
570

# Drug_Target_40_PDB_ID:
1F0X

# Drug_Target_40_Pathway:
Not Available

# Drug_Target_40_Pfam_Domain_Function:
PF01565	FAD_binding_4

# Drug_Target_40_Protein_Sequence:
>D-lactate dehydrogenase
SSMTTTDNKAFLNELARLVGSSHLLTDPAKTARYRKGFRSGQGDALAVVFPGSLLELWRV
LKACVTADKIILMQAANTGLTEGSTPNGNDYDRDVVIISTLRLDKLHVLGKGEQVLAYPG
TTLYSLEKALKPLGREPHSVIGSSCIGASVIGGICNNSGGSLVQRGPAYTEMSLFARINE
DGKLTLVNHLGIDLGETPEQILSKLDDDRIKDDDVRHDGRHAHDYDYVHRVRDIEADTPA
RYNADPDRLFESSGCAGKLAVFAVRLDTFEAEKNQQVFYIGTNQPEVLTEIRRHILANFE
NLPVAGEYMHRDIYDIAEKYGKDTFLMIDKLGTDKMPFFFNLKGRTDAMLEKVKFFRPHF
TDRAMQKFGHLFPSHLPPRMKNWRDKYEHHLLLKMAGDGVGEAKSWLVDYFKQAEGDFFV
CTPEEGSKAFLHRFAAAGAAIRYQAVHSDEVEDILALDIALRRNDTEWYEHLPPEIDSQL
VHKLYYGHFMCYVFHQDYIVKKGVDVHALKEQMLELLQQRGAQYPAEHNVGHLYKAPETL
QKFYRENDPTNSMNPGIGKTSKRKNWQEVE

# Drug_Target_40_Reaction:
(R)-lactate + NAD+ = pyruvate + NADH + H+

# Drug_Target_40_Signals:
None

# Drug_Target_40_Specific_Function:
First component of the membrane-bound D-lactate oxidase, which is believed to play an important role in the energization of the active transport of a variety of sugars and amino acids

# Drug_Target_40_SwissProt_ID:
P06149

# Drug_Target_40_SwissProt_Name:
DLD_ECOLI

# Drug_Target_40_Synonyms:
EC 1.1.1.28
Respiratory D-lactate dehydrogenase

# Drug_Target_40_Theoretical_pI:
6.65

# Drug_Target_40_Transmembrane_Regions:
None

# Drug_Target_41_Cellular_Location:
Not Available

# Drug_Target_41_Chromosome_Location:
Not Available

# Drug_Target_41_Drug_References:
Not Available

# Drug_Target_41_Essentiality:
Non-Essential

# Drug_Target_41_GenAtlas_ID:
Not Available

# Drug_Target_41_GenBank_ID_Gene:
M23008

# Drug_Target_41_GenBank_ID_Protein:
Not Available

# Drug_Target_41_GeneCard_ID:
Not Available

# Drug_Target_41_Gene_Name:
cysJ

# Drug_Target_41_Gene_Sequence:
>1800 bp
ATGACGACACAGGTCCCACCTTCCGCGTTGCTTCCGTTGAACCCGGAGCAACTGGCACGC
CTTCAGGCGGCCACGACCGATTTAACTCCCACCCAGCTTGCCTGGGTTTCTGGCTATTTC
TGGGGCGTACTCAATCAGCAGCCTGCTGCGCTTGCAGCAACGCCAGCGCCAGCTGCAGAA
ATGCCGGGTATAACTATTATCTCCGCCTCGCAAACCGGCAATGCGCGCCGGGTTGCTGAA
GCATTACGTGATGATTTATTAGCAGCAAAACTGAACGTTAAGCTGGTGAACGCGGGCGAC
TATAAATTCAAACAAATCGCCAGCGAAAAACTGCTCATCGTAGTGACGTCAACGCAAGGG
GAAGGGGAACCGCCGGAAGAAGCCGTCGCGCTGCATAAGTTCCTGTTCTCCAAAAAAGCG
CCAAAGCTGGAAAACACCGCGTTTGCCGTGTTTAGCCTCGGCGATACGTCTTATGAATTT
TTCTGCCAGTCCGGGAAAGATTTCGACAGCAAGCTGGCGGAACTGGGTGGTGAACGCCTG
CTCGACCGTGTCGATGCCGATGTTGAATACCAGGCTGCTGCCAGCGAGTGGCGCGCCCGC
GTGGTTGATGCGCTTAAATCGCGTGCGCCTGTCGCGGCACCTTCGCAATCCGTCGCTACT
GGCGCGGTAAATGAAATCCACACCAGCCCGTACAGCAAAGACGCGCCGCTGGTGGCTAGC
CTCTCTGTTAACCAGAAAATTACCGGGCGTAACTCTGAAAAAGACGTTCGCCATATCGAA
ATTGACTTAGGTGACTCGGGCCTGCGTTACCAGCCGGGTGACGCGCTGGGCGTCTGGTAT
CAGAACGATCCGGCACTGGTGAAAGAACTTGTCGAACTGCTGTGGCTGAAAGGCGATGAA
CCTGTCACCGTCGAGGGCAAAACGTTGCCTCTGAACGAAGCGCTACAGTGGCACTTCGAA
CTGACCGTCAACACCGCCAACATTGTTGAGAATTACGCCACGCTTACCCGCAGTGAAACA
CTGCTGCCGCTGGTGGGCGATAAAGCGAAGTTACAGCATTACGCCGCGACGACGCCGATT
GTTGACATGGTGCGTTTCTCCCCGGCACAGCTTGATGCCGAAGCGCTAATTAATCTGCTG
CGCCCGCTGACGCCGCGTCTCTATTCCATTGCCTCCTCGCAGGCGGAAGTCGAGAACGAA
GTACACGTCACCGTTGGTGTGGTGCGTTACGACGTGGAAGGCCGCGCCCGTGCCGGTGGT
GCCTCCAGCTTCCTCGCTGACCGCGTGGAAGAAGAGGGCGAAGTCCGCGTATTTATCGAA
CATAACGATAACTTCCGCCTGCCAGCCAATCCAGAAACCCCGGTGATTATGATTGGCCCA
GGCACCGGCATCGCGCCGTTCCGCGCCTTTATGCAGCAACGTGCTGCCGATGAAGCGCCG
GGAAAAAACTGGCTGTTCTTTGGCAACCCGCACTTTACGGAAGATTTCCTCTACCAGGTG
GAGTGGCAGCGCTACGTCAAAGAGGGTGTGCTGACGCGGATCGATCTCGCCTGGTCGCGC
GACCAAAAAGAAAAAGTTTACGTACAAGACAAACTGCGCGAACAGGGCGCGGAGCTGTGG
CGCTGGATCAATGACGGTGCCCACATTTATGTCTGCGGTGACGCTAATCGCATGGCGAAA
GACGTTGAGCAGGCACTTCTGGAAGTGATTGCCGAATTTGGTGGCATGGACACCGAAGCG
GCGGATGAATTTTTAAGTGAGCTGCGCGTAGAGCGCCGTTATCAGCGAGATGTCTACTAA

# Drug_Target_41_General_Function:
Involved in sulfite reductase (NADPH) activity

# Drug_Target_41_General_References:
10455035	Coves J, Lebrun C, Gervasi G, Dalbon P, Fontecave M: Overexpression of the FAD-binding domain of the sulphite reductase flavoprotein component from Escherichia coli and its inhibition by iodonium diphenyl chloride. Biochem J. 1999 Sep 1;342 ( Pt 2):465-72.
2550423	Ostrowski J, Barber MJ, Rueger DC, Miller BE, Siegel LM, Kredich NM: Characterization of the flavoprotein moieties of NADPH-sulfite reductase from Salmonella typhimurium and Escherichia coli. Physicochemical and catalytic properties, amino acid sequence deduced from DNA sequence of cysJ, and comparison with NADPH-cytochrome P-450 reductase. J Biol Chem. 1989 Sep 25;264(27):15796-808.
2670946	Ostrowski J, Wu JY, Rueger DC, Miller BE, Siegel LM, Kredich NM: Characterization of the cysJIH regions of Salmonella typhimurium and Escherichia coli B. DNA sequences of cysI and cysH and a model for the siroheme-Fe4S4 active center of sulfite reductase hemoprotein based on amino acid homology with spinach nitrite reductase. J Biol Chem. 1989 Sep 15;264(26):15726-37.
7589518	Eschenbrenner M, Coves J, Fontecave M: NADPH-sulfite reductase flavoprotein from Escherichia coli: contribution to the flavin content and subunit interaction. FEBS Lett. 1995 Oct 23;374(1):82-4.
7657631	Eschenbrenner M, Coves J, Fontecave M: The flavin reductase activity of the flavoprotein component of sulfite reductase from Escherichia coli. A new model for the protein structure. J Biol Chem. 1995 Sep 1;270(35):20550-5.
9153434	Coves J, Zeghouf M, Macherel D, Guigliarelli B, Asso M, Fontecave M: Flavin mononucleotide-binding domain of the flavoprotein component of the sulfite reductase from Escherichia coli. Biochemistry. 1997 May 13;36(19):5921-8.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.
9558350	Zeghouf M, Fontecave M, Macherel D, Coves J: The flavoprotein component of the Escherichia coli sulfite reductase: expression, purification, and spectral and catalytic properties of a monomeric form containing both the flavin adenine dinucleotide and the flavin mononucleotide cofactors. Biochemistry. 1998 Apr 28;37(17):6114-23.
9618257	Zeghouf M, Defaye G, Fontecave M, Coves J: The flavoprotein component of the Escherichia coli sulfite reductase can act as a cytochrome P450c17 reductase. Biochem Biophys Res Commun. 1998 May 29;246(3):602-5.

# Drug_Target_41_HGNC_ID:
Not Available

# Drug_Target_41_HPRD_ID:
Not Available

# Drug_Target_41_ID:
5075

# Drug_Target_41_Locus:
Not Available

# Drug_Target_41_Molecular_Weight:
66270

# Drug_Target_41_Name:
Sulfite reductase [NADPH] flavoprotein alpha-component

# Drug_Target_41_Number_of_Residues:
599

# Drug_Target_41_PDB_ID:
1DDI

# Drug_Target_41_Pathway:
Not Available

# Drug_Target_41_Pfam_Domain_Function:
PF00175	NAD_binding_1
PF00258	Flavodoxin_1
PF00667	FAD_binding_1

# Drug_Target_41_Protein_Sequence:
>Sulfite reductase [NADPH] flavoprotein alpha-component
MTTQVPPSALLPLNPEQLARLQAATTDLTPTQLAWVSGYFWGVLNQQPAALAATPAPAAE
MPGITIISASQTGNARRVAEALRDDLLAAKLNVKLVNAGDYKFKQIASEKLLIVVTSTQG
EGEPPEEAVALHKFLFSKKAPKLENTAFAVFSLGDSSYEFFCQSGKDFDSKLAELGGERL
LDRVDADVEYQAAASEWRARVVDALKSRAPVAAPSQSVATGAVNEIHTSPYSKDAPLVAS
LSVNQKITGRNSEKDVRHIEIDLGDSGMRYQPGDALGVWYQNDPALVKELVELLWLKGDE
PVTVEGKTLPLNEALQWHFELTVNTANIVENYATLTRSETLLPLVGDKAKLQHYAATTPI
VDMVRFSPAQLDAEALINLLRPLTPRLYSIASSQAEVENEVHVTVGVVRYDVEGRARAGG
ASSFLADRVEEEGEVRVFIEHNDNFRLPANPETPVIMIGPGTGIAPFRAFMQQRAADEAP
GKNWLFFGNPHFTEDFLYQVEWQRYVKDGVLTRIDLAWSRDQKEKVYVQDKLREQGAELW
RWINDGAHIYVCGDANRMAKDVEQALLEVIAEFGGMDTEAADEFLSELRVERRYQRDVY

# Drug_Target_41_Reaction:
Not Available

# Drug_Target_41_Signals:
None

# Drug_Target_41_Specific_Function:
Catalyzes the 6-electron reduction of sulfite to sulfide. This is one of several activities required for the biosynthesis of L-cysteine from sulfate. The flavo-protein component catalyzes the electron flow from NADPH -> FAD -> FMN to the hemoprotein component

# Drug_Target_41_SwissProt_ID:
P38038

# Drug_Target_41_SwissProt_Name:
CYSJ_ECOLI

# Drug_Target_41_Synonyms:
EC 1.8.1.2
SIR-FP

# Drug_Target_41_Theoretical_pI:
4.66

# Drug_Target_41_Transmembrane_Regions:
None

# Drug_Target_42_Cellular_Location:
Cytoplasm

# Drug_Target_42_Chromosome_Location:
Not Available

# Drug_Target_42_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_42_Essentiality:
Non-Essential

# Drug_Target_42_GenAtlas_ID:
TXNRD1

# Drug_Target_42_GenBank_ID_Gene:
X91247

# Drug_Target_42_GenBank_ID_Protein:
1237038

# Drug_Target_42_GeneCard_ID:
TXNRD1

# Drug_Target_42_Gene_Name:
TXNRD1

# Drug_Target_42_Gene_Sequence:
>1494 bp
ATGAACGGCCCTGAAGATCTTCCCAAGTCCTATGACTATGACCTTATCATCATTGGAGGT
GGCTCAGGAGGTCTGGCAGCTGCTAAGGAGGCAGCCCAATATGGCAAGAAGGTGATGGTC
CTGGACTTTGTCACTCCCACCCCTCTTGGAACTAGATGGGGTCTTGGAGGAACATGTGTG
AATGTGGGTTGCATACCTAAAAAACTGATGCATCAAGCAGCTTTGTTAGGACAAGCCCTG
CAAGACTCTCGAAATTATGGATGGAAAGTCGAGGAGACAGTTAAGCATGATTGGGACAGA
ATGATAGAAGCTGTACAGAATCACATTGGCTCTTTGAATTGGGGCTACCGAGTAGCTCTG
CGGGAGAAAAAAGTCGTCTATGAGAATGCTTATGGGCAATTTATTGGTCCTCACAGGATT
AAGGCAACAAATAATAAAGGCAAAGAAAAAATTTATTCAGCAGAGAGTTTTCTCATTGCC
ACTGGTGAAAGACCACGTTACTTGGGCATCCCTGGTGACAAAGAATACTGCATCAGCAGT
GATGATCTTTTCTCCTTGCCTTACTGCCCGGGTAAGACCCTGGTTGTTGGAGCATCCTAT
GTCGCTTTGGAGTGCGCTGGATTTCTTGCTGGTATTGGTTTAGGCGTCACTGTTATGGTT
AGGTCCATTCTTCTTAGAGGATTTGACCAGGACATGGCCAACAAAATTGGTGAACACATG
GAAGAACATGGCATCAAGTTTATAAGACAGTTCGTACCAATTAAAGTTGAACAAATTGAA
GCAGGGACACCAGGCCGACTCAGAGTAGTAGCTCAGTCCACCAATAGTGAGGAAATCATT
GAAGGAGAATATAATACGGTGATGCTGGCAATAGGAAGAGATGCTTGCACAAGAAAAATT
GGCTTAGAAACCGTAGGGGTGAAGATAAATGAAAAGACTGGAAAAATACCTGTCACAGAT
GAAGAACAGACCAATGTGCCTTACATCTATGCCATTGGCGATATATTGGAGGATAAGGTG
GAGCTCACCCCAGTTGCAATCCAGGCAGGAAGATTGCTGGCTCAGAGGCTCTATGCAGGT
TCCACTGTCAAGTGTGACTATGAAAATGTTCCAACCACTGTATTTACTCCTTTGGAATAT
GGTGCTTGTGGCCTTTCTGAGGAGAAAGCTGTGGAGAAGTTTGGGGAAGAAAATATTGAG
GTTTACCATAGTTACTTTTGGCCATTGGAATGGACGATTCCGTCAAGAGATAACAACAAA
TGTTATGCAAAAATAATCTGTAATACTAAAGACAATGAACGTGTTGTGGGCTTTCACGTA
CTGGGTCCAAATGCTGGAGAAGTTACACAAGGCTTTGCAGCTGCGCTCAAATGTGGACTG
ACCAAAAAGCAGCTGGACAGCACAATTGGAATCCACCCTGTCTGTGCAGAGGTATTCACA
ACATTGTCTGTGACCAAGCGCTCTGGGGCAAGCATCCTCCAGGCTGGCTGCTGA

# Drug_Target_42_General_Function:
Energy production and conversion

# Drug_Target_42_General_References:
7589432	Gasdaska PY, Gasdaska JR, Cochran S, Powis G: Cloning and sequencing of a human thioredoxin reductase. FEBS Lett. 1995 Oct 2;373(1):5-9.

# Drug_Target_42_HGNC_ID:
HGNC:12437

# Drug_Target_42_HPRD_ID:
03068

# Drug_Target_42_ID:
3610

# Drug_Target_42_Locus:
12q23-q24.1

# Drug_Target_42_Molecular_Weight:
54707

# Drug_Target_42_Name:
Thioredoxin reductase 1, cytoplasmic

# Drug_Target_42_Number_of_Residues:
499

# Drug_Target_42_PDB_ID:
1H6V

# Drug_Target_42_Pathway:
Not Available

# Drug_Target_42_Pfam_Domain_Function:
PF00070	Pyr_redox
PF02852	Pyr_redox_dim
PF07992	Pyr_redox_2

# Drug_Target_42_Protein_Sequence:
>Thioredoxin reductase 1, cytoplasmic precursor
MNGPEDLPKSYDYDLIIIGGGSGGLAAAKEAAQYGKKVMVLDFVTPTPLGTRWGLGGTCV
NVGCIPKKLMHQAALLGQALQDSRNYGWKVEETVKHDWDRMIEAVQNHIGSLNWGYRVAL
REKKVVYENAYGQFIGPHRIKATNNKGKEKIYSAERFLIATGERPRYLGIPGDKEYCISS
DDLFSLPYCPGKTLVVGASYVALECAGFLAGIGLDVTVMVRSILLRGFDQDMANKIGEHM
EEHGIKFIRQFVPIKVEQIEAGTPGRLRVVAQSTNSEEIIEGEYNTVMLAIGRDACTRKI
GLETVGVKINEKTGKIPVTDEEQTNVPYIYAIGDILEDKVELTPVAIQAGRLLAQRLYAG
STVKCDYENVPTTVFTPLEYGACGLSEEKAVEKFGEENIEVYHSYFWPLEWTIPSRDNNK
CYAKIICNTKDNERVVGFHVLGPNAGEVTQGFAAALKCGLTKKQLDSTIGIHPVCAEVFT
TLSVTKRSGASILQAGCCG

# Drug_Target_42_Reaction:
thioredoxin + NADP+ = thioredoxin disulfide + NADPH + H+

# Drug_Target_42_Signals:
None

# Drug_Target_42_Specific_Function:
Thioredoxin + NADP(+) = thioredoxin disulfide + NADPH

# Drug_Target_42_SwissProt_ID:
Q16881

# Drug_Target_42_SwissProt_Name:
TRXR1_HUMAN

# Drug_Target_42_Synonyms:
EC 1.8.1.9
TR
TR1
Thioredoxin reductase 1, cytoplasmic precursor

# Drug_Target_42_Theoretical_pI:
6.43

# Drug_Target_42_Transmembrane_Regions:
None

# Drug_Target_43_Cellular_Location:
Not Available

# Drug_Target_43_Chromosome_Location:
Not Available

# Drug_Target_43_Drug_References:
Not Available

# Drug_Target_43_Essentiality:
Non-Essential

# Drug_Target_43_GenAtlas_ID:
Not Available

# Drug_Target_43_GenBank_ID_Gene:
L36319

# Drug_Target_43_GenBank_ID_Protein:
Not Available

# Drug_Target_43_GeneCard_ID:
Not Available

# Drug_Target_43_Gene_Name:
fpr

# Drug_Target_43_Gene_Sequence:
>777 bp
ATGAGCAATCTGAACGTAGAGCGTGTCCTCAGTGTTCATCACTGGAACGATACCCTGTTC
AGTTTCAAGACCACCCGCAACCCCAGCCTGCGTTTCGAAAACGGCCAATTCGTGATGATC
GGTCTGGAGGTCGATGGACGTCCCCTGATGCGGGCCTACAGCATTGCCAGCCCGAATTAC
GAGGAACATCTGGAGTTCTTCAGCATCAAGGTACAGAACGGTCCGCTCACTTCGCGCCTG
CAACACCTGAAGGAGGGCGACGAACTGATGGTCAGCCGCAAGCCCACCGGCACCCTGGTG
ACCAGCGACCTGCTGCCCGGCAAGCATCTTTACATGCTCAGCACCGGTACCGGACTCGCG
CCTTTCATGAGCCTGATCCAGGACCCGGAGGTCTACGAGCGCTTCGAGAAGGTGGTGCTG
ATCCATGGTGTGCGTCAGGTCAACGAACTGGCCTATCAGCAGTTCATCACCGAGCACCTG
CCGCAGAGCGAGTATTTCGGTGAGGCGGTCAAGGAAAAGCTGATCTACTACCCGACGGTC
ACCCGCGAGTCCTTCCACAACCAGGGACGTCTCACCGACCTGATGCGCAGCGGCAAGCTG
TTCGAGGATATCGGTCTGCCGCCGATCAACCCGCAGGACGATCGCGCGATGATCTGCGGC
AGCCCGAGCATGCTCGACGAGAGTTGCGAAGTGCTGGACGGATTCGGCCTGAAGATCTCT
CCGCGCATGGGCGAGCCGGGCGACTATCTGATCGAGCGCGCCTTCGTCGAAAAATAA

# Drug_Target_43_General_Function:
Involved in oxidoreductase activity

# Drug_Target_43_General_References:
7673160	Isas JM, Yannone SM, Burgess BK: Azotobacter vinelandii NADPH:ferredoxin reductase cloning, sequencing, and overexpression. J Biol Chem. 1995 Sep 8;270(36):21258-63.
8034707	Isas JM, Burgess BK: Purification and characterization of a NADP+/NADPH-specific flavoprotein that is overexpressed in FdI- strains of Azotobacter vinelandii. J Biol Chem. 1994 Jul 29;269(30):19404-9.
9865948	Sridhar Prasad G, Kresge N, Muhlberg AB, Shaw A, Jung YS, Burgess BK, Stout CD: The crystal structure of NADPH:ferredoxin reductase from Azotobacter vinelandii. Protein Sci. 1998 Dec;7(12):2541-9.

# Drug_Target_43_HGNC_ID:
Not Available

# Drug_Target_43_HPRD_ID:
Not Available

# Drug_Target_43_ID:
5076

# Drug_Target_43_Locus:
Not Available

# Drug_Target_43_Molecular_Weight:
29417

# Drug_Target_43_Name:
Ferredoxin--NADP reductase

# Drug_Target_43_Number_of_Residues:
258

# Drug_Target_43_PDB_ID:
1A8P

# Drug_Target_43_Pathway:
Not Available

# Drug_Target_43_Pfam_Domain_Function:
PF00175	NAD_binding_1
PF00970	FAD_binding_6

# Drug_Target_43_Protein_Sequence:
>Ferredoxin--NADP reductase
MSNLNVERVLSVHHWNDTLFSFKTTRNPSLRFENGQFVMIGLEVDGRPLMRAYSIASPNY
EEHLEFFSIKVQNGPLTSRLQHLKEGDELMVSRKPTGTLVTSDLLPGKHLYMLSTGTGLA
PFMSLIQDPEVYERFEKVVLIHGVRQVNELAYQQFITEHLPQSEYFGEAVKEKLIYYPTV
TRESFHNQGRLTDLMRSGKLFEDIGLPPINPQDDRAMICGSPSMLDESCEVLDGFGLKIS
PRMGEPGDYLIERAFVEK

# Drug_Target_43_Reaction:
Not Available

# Drug_Target_43_Signals:
None

# Drug_Target_43_Specific_Function:
Reduced ferredoxin + NADP(+) = oxidized ferredoxin + NADPH

# Drug_Target_43_SwissProt_ID:
Q44532

# Drug_Target_43_SwissProt_Name:
FENR_AZOVI

# Drug_Target_43_Synonyms:
EC 1.18.1.2
FNR
Protein X

# Drug_Target_43_Theoretical_pI:
5.38

# Drug_Target_43_Transmembrane_Regions:
None

# Drug_Target_44_Cellular_Location:
Mitochondrion

# Drug_Target_44_Chromosome_Location:
Not Available

# Drug_Target_44_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_44_Essentiality:
Non-Essential

# Drug_Target_44_GenAtlas_ID:
ACAD8

# Drug_Target_44_GenBank_ID_Gene:
AF126245

# Drug_Target_44_GenBank_ID_Protein:
6465955

# Drug_Target_44_GeneCard_ID:
ACAD8

# Drug_Target_44_Gene_Name:
ACAD8

# Drug_Target_44_Gene_Sequence:
>1248 bp
ATGCTGTGGAGCGGCTGCCGGCGTTTCGGGGCGCGCCTCGGCTGCCTGCCCGGCGGTCTC
CGGGTCCTCGTCCAGACCGGCCACCGGAGCTTGACCTCCTGCATCGACCCTTCCATGGGA
CTTAATGAAGAGCAGAAAGAATTTCAAAAAGTGGCCTTTGACTTTGCTGCCCGAGAGATG
GCTCCAAATATGGCAGAGTGGGACCAGAAGGAGCTGTTCCCAGTGGATGTGATGCGGAAG
GCAGCCCAGCTAGGCTTCGGAGGGGTCTACATACAAACAGATGTGGGCGGGTCTGGGCTG
TCACGTCTTGATACCTCTGTCATTTTTGAAGCCTTGGCTACAGGCTGCACCAGCACCACA
GCCTATATAAGCATCCACAACATGTGTGCCTGGATGATTGATAGCTTCGGAAATGAGGAA
CAGAGGCACAAATTTTGCCCACCGCTCTGTACCATGGAGAAGTTTGCTTCCTACTGCCTC
ACTGAACCAGGAAGTGGGAGTGATGCTGCCTCTCTTCTGACCTCCGCTAAGAAACAGGGA
GATCATTACATCCTCAATGGCTCCAAGGCCTTCATCAGTGGTGCTGGTGAGTCAGACATC
TATGTGGTCATGTGCCGAACAGGAGGACCAGGCCCCAAGGGCATCTCATGCATAGTTGTT
GAGAAGGGGACCCCTGGCCTCAGCTTTGGCAAGAAGGAGAAAAAGGTGGGGTGGAACTCC
CAGCCAACACGAGCTGTGATCTTCGAAGACTGTGCTGTCCCTGTGGCCAACAGAATTGGG
AGCGAGGGGCAGGGCTTCCTCATTGCCGTGAGAGGACTGAACGGAGGGAGGATCAATATT
GCTTCCTGCTCCCTGGGGGCTGCCCACGCCTCTGTCATCCTCACCCGAGACCACCTCAAT
GTCCGGAAGCAGTTTGGAGAGCCTCTGGCCAGTAACCAGTACTTGCAATTCACACTGGCT
GATATGGCAACAAGGCTGGTGGCCGCGCGGCTGATGGTCCGCAATGCAGCAGTGGCTCTG
CAGGAGGAGAGGAAGGATGCAGTGGCCTTGTGCTCCATGGCCAAGCTCTTTGCTACAGAT
GAATGCTTTGCCATCTGCAACCAGGCCTTGCAGATGCACGGGGGCTACGGCTACCTGAAG
GATTACGCTGTTCAGCAGTACGTGCGGGACTCCAGGGTCCACCAGATTCTAGAAGGTAGC
AATGAAGTGATGAGGATACTGATCTCTAGAAGCCTGCTTCAGGAGTAG

# Drug_Target_44_General_Function:
Lipid transport and metabolism

# Drug_Target_44_General_References:
10235267	Naar AM, Beaurang PA, Zhou S, Abraham S, Solomon W, Tjian R: Composite co-activator ARC mediates chromatin-directed transcriptional activation. Nature. 1999 Apr 29;398(6730):828-32.
10524212	Telford EA, Moynihan LM, Markham AF, Lench NJ: Isolation and characterisation of a cDNA encoding the precursor for a novel member of the acyl-CoA dehydrogenase gene family. Biochim Biophys Acta. 1999 Sep 3;1446(3):371-6.
11013134	Andresen BS, Christensen E, Corydon TJ, Bross P, Pilgaard B, Wanders RJ, Ruiter JP, Simonsen H, Winter V, Knudsen I, Schroeder LD, Gregersen N, Skovby F: Isolated 2-methylbutyrylglycinuria caused by short/branched-chain acyl-CoA dehydrogenase deficiency: identification of a new enzyme defect, resolution of its molecular basis, and evidence for distinct acyl-CoA dehydrogenases in isoleucine and valine metabolism. Am J Hum Genet. 2000 Nov;67(5):1095-103. Epub 2000 Sep 29.

# Drug_Target_44_HGNC_ID:
HGNC:87

# Drug_Target_44_HPRD_ID:
11985

# Drug_Target_44_ID:
667

# Drug_Target_44_Locus:
11q25

# Drug_Target_44_Molecular_Weight:
45070

# Drug_Target_44_Name:
Acyl-CoA dehydrogenase family member 8, mitochondrial

# Drug_Target_44_Number_of_Residues:
415

# Drug_Target_44_PDB_ID:
1RX0

# Drug_Target_44_Pathway:
Not Available

# Drug_Target_44_Pfam_Domain_Function:
PF00441	Acyl-CoA_dh_1
PF02770	Acyl-CoA_dh_M
PF02771	Acyl-CoA_dh_N

# Drug_Target_44_Protein_Sequence:
>Acyl-CoA dehydrogenase family member 8, mitochondrial precursor
MLWSGCRRFGARLGCLPGGLRVLVQTGHRSLTSCIDPSMGLNEEQKEFQKVAFDFAAREM
APNMAEWDQKELFPVDVMRKAAQLGFGGVYIQTDVGGSGLSRLDTSVIFEALATGCTSTT
AYISIHNMCAWMIDSFGNEEQRHKFCPPLCTMEKFASYCLTEPGSGSDAASLLTSAKKQG
DHYILNGSKAFISGAGESDIYVVMCRTGGPGPKGISCIVVEKGTPGLSFGKKEKKVGWNS
QPTRAVIFEDCAVPVANRIGSEGQGFLIAVRGLNGGRINIASCSLGAAHASVILTRDHLN
VRKQFGEPLASNQYLQFTLADMATRLVAARLMVRNAAVALQEERKDAVALCSMAKLFATD
ECFAICNQALQMHGGYGYLKDYAVQQYVRDSRVHQILEGSNEVMRILISRSLLQE

# Drug_Target_44_Reaction:
Not Available

# Drug_Target_44_Signals:
None

# Drug_Target_44_Specific_Function:
Has very high activity toward isobutyryl-CoA. Could be an isobutyryl-CoA dehydrogenase that functions in valine catabolism. Plays a role in transcriptional coactivation within the ARC complex

# Drug_Target_44_SwissProt_ID:
Q9UKU7

# Drug_Target_44_SwissProt_Name:
ACAD8_HUMAN

# Drug_Target_44_Synonyms:
ACAD-8
ARC42
Activator- recruited cofactor 42 kDa component
Acyl-CoA dehydrogenase family member 8, mitochondrial precursor
EC 1.3.99.-
Isobutyryl-CoA dehydrogenase

# Drug_Target_44_Theoretical_pI:
7.91

# Drug_Target_44_Transmembrane_Regions:
None

# Drug_Target_45_Cellular_Location:
Not Available

# Drug_Target_45_Chromosome_Location:
Not Available

# Drug_Target_45_Drug_References:
Not Available

# Drug_Target_45_Essentiality:
Non-Essential

# Drug_Target_45_GenAtlas_ID:
Not Available

# Drug_Target_45_GenBank_ID_Gene:
Not Available

# Drug_Target_45_GenBank_ID_Protein:
Not Available

# Drug_Target_45_GeneCard_ID:
Not Available

# Drug_Target_45_Gene_Name:
Not Available

# Drug_Target_45_Gene_Sequence:
Not Available

# Drug_Target_45_General_Function:
Involved in acyl-CoA dehydrogenase activity

# Drug_Target_45_General_References:
7857927	Djordjevic S, Pace CP, Stankovich MT, Kim JJ: Three-dimensional structure of butyryl-CoA dehydrogenase from Megasphaera elsdenii. Biochemistry. 1995 Feb 21;34(7):2163-71.
8399220	Becker DF, Fuchs JA, Banfield DK, Funk WD, MacGillivray RT, Stankovich MT: Characterization of wild-type and an active-site mutant in Escherichia coli of short-chain acyl-CoA dehydrogenase from Megasphaera elsdenii. Biochemistry. 1993 Oct 12;32(40):10736-42.

# Drug_Target_45_HGNC_ID:
Not Available

# Drug_Target_45_HPRD_ID:
Not Available

# Drug_Target_45_ID:
5003

# Drug_Target_45_Locus:
Not Available

# Drug_Target_45_Molecular_Weight:
41409

# Drug_Target_45_Name:
Acyl-CoA dehydrogenase, short-chain specific

# Drug_Target_45_Number_of_Residues:
383

# Drug_Target_45_PDB_ID:
1BUC

# Drug_Target_45_Pathway:
Not Available

# Drug_Target_45_Pfam_Domain_Function:
PF00441	Acyl-CoA_dh_1
PF02770	Acyl-CoA_dh_M
PF02771	Acyl-CoA_dh_N

# Drug_Target_45_Protein_Sequence:
>Acyl-CoA dehydrogenase, short-chain specific
MDFNLTDIQQDFLKLAHDFGEKKLAPTVTERDHKGIYDKELIDELLSLGITGAYFEEKYG
GSGDDGGDVLSYILAVEELAKYDAGVAITLSATVSLCANPIWQFGTEAQKEKFLVPLVEG
TKLGAFGLTEPNAGTDASGQQTIATKNDDGTYTLNGSKIFITNGGAADIYIVFAMTDKSK
GNHGITAFILEDGTPGFTYGKKEDKMGIHTSQTMELVFQDVKVPAENMLGEEGKGFKIAM
MTLDGGRIGVAAQALGIAEAALADAVEYSKQRVQFGKPLCKFQSISFKLADMKMQIEAAR
NLVYKAACKKQEGKPFTVDAAIAKRVASDVAMRVTTEAVQIFGGYGYSEEYPVARHMRDA
KITQIYEGTNEVQLMVTGGALLR

# Drug_Target_45_Reaction:
Not Available

# Drug_Target_45_Signals:
None

# Drug_Target_45_Specific_Function:
Has an optimum specificity for 4-carbon length fatty acyl-CoAs

# Drug_Target_45_SwissProt_ID:
Q06319

# Drug_Target_45_SwissProt_Name:
ACDS_MEGEL

# Drug_Target_45_Synonyms:
BCAD
Butyryl-CoA dehydrogenase
EC 1.3.99.2
SCAD

# Drug_Target_45_Theoretical_pI:
4.82

# Drug_Target_45_Transmembrane_Regions:
None

# Drug_Target_46_Cellular_Location:
Mitochondrion
mitochondrial intermembrane space. Nucleus. Note=Translocated to the nucleus upon ind

# Drug_Target_46_Chromosome_Location:
Not Available

# Drug_Target_46_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_46_Essentiality:
Non-Essential

# Drug_Target_46_GenAtlas_ID:
AIFM1

# Drug_Target_46_GenBank_ID_Gene:
AF100928

# Drug_Target_46_GenBank_ID_Protein:
4323587

# Drug_Target_46_GeneCard_ID:
AIFM1

# Drug_Target_46_Gene_Name:
AIFM1

# Drug_Target_46_Gene_Sequence:
>1842 bp
ATGTTCCGGTGTGGAGGCCTGGCGGCGGGTGCTTTGAAGCAGAAGCTGGTGCCCTTGGTG
CGGACCGTGTGCGTCCGAAGCCCGAGGCAGAGGAACCGGCTCCCAGGCAACTTGTTCCAG
CGATGGCATGTTCCTCTAGAACTCCAGATGACAAGACAAATGGCTAGCTCTGGTGCATCA
GGGGGCAAAATCGATAATTCTGTGTTAGTCCTTATTGTGGGCTTATCAACAGTAGGAGCT
GGTGCCTATGCCTACAAGACTATGAAAGAGGACGAAAAAAGATACAATGAAAGAATTTCA
GGGTTAGGGCTGACACCAGAACAGAAACAGAAAAAGGCCGCGTTATCTGCTTCAGAAGGA
GAGGAAGTTCCTCAAGACAAGGCGCCAAGTCATGTTCCTTTCCTGCTAATTGGTGGAGGC
ACAGCTGCTTTTGCTGCAGCCAGATCCATCCGGGCTCGGGATCCTGGGGCCAGGGTACTG
ATTGTATCTGAAGATCCTGAGCTGCCGTACATGCGACCTCCTCTTTCAAAAGAACTGTGG
TTTTCAGATGACCCAAATGTCACAAAGACACTGCGATTCAAACAGTGGAATGGAAAAGAG
AGAAGCATATATTTCCAGCCACCTTCTTTCTATGTCTCTGCTCAGGACCTGCCTCATATT
GAGAATGGTGGTGTGGCTGTCCTCACTGGGAAGAAGGTAGTACAGCTGGATGTGAGAGAC
AACATGGTGAAACTTAATGATGGCTCTCAAATAACCTATGAAAAGTGCTTGATTGCAACA
GGAGGTACTCCAAGAAGTCTGTCTGCCATTGATAGGGCTGGAGCAGAGGTGAAGAGTAGA
ACAACGCTTTTCAGAAAGATTGGAGACTTTAGAAGCTTGGAGAAGATTTCACGGGAAGTC
AAATCAATTACGATTATCGGTGGGGGCTTCCTTGGTAGCGAACTGGCCTGTGCTCTTGGC
AGAAAGGCTCGAGCCTTGGGCACAGAAGTGATTCAACTCTTCCCCGAGAAAGGAAATATG
GGAAAGATCCTCCCCGAATACCTCAGCAACTGGACCATGGAAAAAGTCAGACGAGAGGGG
GTTAAGGTGATGCCCAATGCTATTGTGCAATCCGTTGGAGTCAGCAGTGGCAAGTTACTT
ATCAAGCTGAAAGACGGCAGGAAGGTAGAAACTGACCACATAGTGGCAGCTGTGGGCCTG
GAGCCCAATGTTGAGTTGGCCAAGACTGGTGGCCTGGAAATAGACTCAGATTTTGGTGGC
TTCCGGGTAAATGCAGAGCTACAAGCACGCTCTAACATCTGGGTGGCAGGAGATGCTGCA
TGCTTCTACGATATAAAGTTGGGAAGGAGGCGGGTAGAGCACCATGATCACGCTGTTGTG
AGTGGAAGATTGGCTGGAGAAAATATGACTGGAGCTGCTAAGCCGTACTGGCATCAGTCA
ATGTTCTGGAGTGATTTGGGCCCCGATGTTGGCTATGAAGCTATTGGTCTTGTGGACAGT
AGTTTGCCCACAGTTGGTGTTTTTGCAAAAGCAACTGCACAAGACAACCCCAAATCTGCC
ACAGAGCAGTCAGGAACTGGTATCCGATCAGAGAGTGAGACAGAGTCCGAGGCCTCAGAA
ATTACTATTCCTCCCAGCACCCCGGCAGTTCCACAGGCTCCCGTCCAGGGGGAGGACTAC
GGCAAAGGTGTCATCTTCTACCTCAGGGACAAAGTGGTCGTGGGGATTGTGCTATGGAAC
ATCTTTAACCGAATGCCAATAGCAAGGAAGATCATTAAGGACGGTGAGCAGCATGAAGAT
CTCAATGAAGTAGCCAAACTATTCAACATTCATGAAGACTGA

# Drug_Target_46_General_Function:
Involved in oxidoreductase activity

# Drug_Target_46_General_References:
10913597	Daugas E, Nochy D, Ravagnan L, Loeffler M, Susin SA, Zamzami N, Kroemer G: Apoptosis-inducing factor (AIF): a ubiquitous mitochondrial oxidoreductase involved in apoptosis. FEBS Lett. 2000 Jul 7;476(3):118-23.
9989411	Susin SA, Lorenzo HK, Zamzami N, Marzo I, Snow BE, Brothers GM, Mangion J, Jacotot E, Costantini P, Loeffler M, Larochette N, Goodlett DR, Aebersold R, Siderovski DP, Penninger JM, Kroemer G: Molecular characterization of mitochondrial apoptosis-inducing factor. Nature. 1999 Feb 4;397(6718):441-6.

# Drug_Target_46_HGNC_ID:
HGNC:8768

# Drug_Target_46_HPRD_ID:
02161

# Drug_Target_46_ID:
1329

# Drug_Target_46_Locus:
Xq25-q26

# Drug_Target_46_Molecular_Weight:
66901

# Drug_Target_46_Name:
Apoptosis-inducing factor 1, mitochondrial

# Drug_Target_46_Number_of_Residues:
613

# Drug_Target_46_PDB_ID:
1M6I

# Drug_Target_46_Pathway:
Not Available

# Drug_Target_46_Pfam_Domain_Function:
PF00070	Pyr_redox
PF07992	Pyr_redox_2

# Drug_Target_46_Protein_Sequence:
>Apoptosis-inducing factor 1, mitochondrial precursor
MFRCGGLAAGALKQKLVPLVRTVCVRSPRQRNRLPGNLFQRWHVPLELQMTRQMASSGAS
GGKIDNSVLVLIVGLSTVGAGAYAYKTMKEDEKRYNERISGLGLTPEQKQKKAALSASEG
EEVPQDKAPSHVPFLLIGGGTAAFAAARSIRARDPGARVLIVSEDPELPYMRPPLSKELW
FSDDPNVTKTLRFKQWNGKERSIYFQPPSFYVSAQDLPHIENGGVAVLTGKKVVQLDVRD
NMVKLNDGSQITYEKCLIATGGTPRSLSAIDRAGAEVKSRTTLFRKIGDFRSLEKISREV
KSITIIGGGFLGSELACALGRKARALGTEVIQLFPEKGNMGKILPEYLSNWTMEKVRREG
VKVMPNAIVQSVGVSSGKLLIKLKDGRKVETDHIVAAVGLEPNVELAKTGGLEIDSDFGG
FRVNAELQARSNIWVAGDAACFYDIKLGRRRVEHHDHAVVSGRLAGENMTGAAKPYWHQS
MFWSDLGPDVGYEAIGLVDSSLPTVGVFAKATAQDNPKSATEQSGTGIRSESETESEASE
ITIPPSTPAVPQAPVQGEDYGKGVIFYLRDKVVVGIVLWNIFNRMPIARKIIKDGEQHED
LNEVAKLFNIHED

# Drug_Target_46_Reaction:
Not Available

# Drug_Target_46_Signals:
None

# Drug_Target_46_Specific_Function:
Probable oxidoreductase that acts as a caspase- independent mitochondrial effector of apoptotic cell death. Extramitochondrial AIF induces nuclear chromatin condensation and large scale DNA fragmentation (in vitro)

# Drug_Target_46_SwissProt_ID:
O95831

# Drug_Target_46_SwissProt_Name:
AIFM1_HUMAN

# Drug_Target_46_Synonyms:
Apoptosis-inducing factor 1, mitochondrial precursor
EC 1.-.-.-
Programmed cell death protein 8

# Drug_Target_46_Theoretical_pI:
9.39

# Drug_Target_46_Transmembrane_Regions:
None

# Drug_Target_47_Cellular_Location:
Not Available

# Drug_Target_47_Chromosome_Location:
Not Available

# Drug_Target_47_Drug_References:
Not Available

# Drug_Target_47_Essentiality:
Non-Essential

# Drug_Target_47_GenAtlas_ID:
Not Available

# Drug_Target_47_GenBank_ID_Gene:
D16831

# Drug_Target_47_GenBank_ID_Protein:
Not Available

# Drug_Target_47_GeneCard_ID:
Not Available

# Drug_Target_47_Gene_Name:
bphA4

# Drug_Target_47_Gene_Sequence:
>1227 bp
ATGTCACAAGAAGCATTGAAAGCCCCCGTTGTAGTTCTCGGTGCAGGCTTGGCCTCCGTC
TCCTTTGTGGCCGAACTGCGCCAGGCGGGCTACCAGGGGCTGATCACCGTAGTCGGCGAT
GAGGCCGAGCGACCTTACGACCGCCCGCCCTTGTCTAAGGACTTCATGGCCCATGGCGAC
GCCGAGAAGATCCGCCTTGACTGCAAGCGCGCGCCTGAGGTCGAATGGCTGCTGGGCGTC
ACGGCGCAGTCGTTCGATCCGCAGGCACACACGGTGGCGCTGTCGGACGGGCGCACCCTT
CCCTATGGCACGCTGGTGCTGGCCACGGGTGCAGCGCCGCGCGCGCTACCGACCTTGCAG
GGCGCCACCATGCCGGTACATACGCTGCGCACGCTGGAAGATGCGCGGCGCATCCAGGCC
GGGCTGCGCCCGCAGTCGCGACTTTTGATCGTAGGCGGCGGTGTGATCGGGCTCGAACTC
GCCGCCACGGCGCGCACTGCTGGTGTCCACGTGAGCCTTGTCGAAACTCAGCCGCGCCTC
ATGAGCCGCGCTGCACCGGCCACGCTGGCCGACTTCGTCGCGCGCTACCACGCGGCGCAA
GGGGTCGATCTGCGCTTTGAGCGCAGCGTCACGGGCTCTGTCGATGGCGTGGTGCTGCTC
GACGATGGCACGCGCATCGCGGCCGACATGGTGGTTGTGGGCATAGGCGTGTTGGCCAAC
GACGCGCTTGCGCGCGCAGCCGGGCTGGCCTGCGACGACGGCATCTTCGTCGATGCCTAT
GGGCGTACCACCTGTCCCGACGTCTATGCTCTTGGCGACGTAACGCGCCAGCGCAACCCT
CTAAGCGGGCGTTTCGAGCGGATCGAAACCTGGTCGAACGCGCAGAACCAGGGCATCGCG
GTGGCGCGCCACTTGGTCGATCCAACCGCGCCTGGATATGCCGAGTTGCCGTGGTATTGG
TCCGACCAGGGTGCGCTGCGCATCCAGGTGGCGGGGCTTGCGAGCGGCGACGAGGAAATC
GTGCGTGGCGAAGTCTCACTCGACGCCCCCAAGTTCACGCTCATCGAGCTGCAAAAGGGC
CGCATTGTGGGCGCGACCTGCGTGAACAACGCGCGCGACTTCGCACCGCTGCGGCGCCTG
CTCGCGGTCGGCGCCAAGCCCGACCGCGCCGCGCTCGCCGACCCGGCCACCGACTTGCGC
AAGCTCGCTGCCGCCGTTGCCGCGTGA

# Drug_Target_47_General_Function:
Involved in oxidoreductase activity

# Drug_Target_47_General_References:
11090282	Senda T, Yamada T, Sakurai N, Kubota M, Nishizaki T, Masai E, Fukuda M, Mitsuidagger Y: Crystal structure of NADH-dependent ferredoxin reductase component in biphenyl dioxygenase. J Mol Biol. 2000 Dec 1;304(3):397-410.
8132464	Kikuchi Y, Nagata Y, Hinata M, Kimbara K, Fukuda M, Yano K, Takagi M: Identification of the bphA4 gene encoding ferredoxin reductase involved in biphenyl and polychlorinated biphenyl degradation in Pseudomonas sp. strain KKS102. J Bacteriol. 1994 Mar;176(6):1689-94.

# Drug_Target_47_HGNC_ID:
Not Available

# Drug_Target_47_HPRD_ID:
Not Available

# Drug_Target_47_ID:
4439

# Drug_Target_47_Locus:
Not Available

# Drug_Target_47_Molecular_Weight:
43174

# Drug_Target_47_Name:
Ferredoxin reductase

# Drug_Target_47_Number_of_Residues:
408

# Drug_Target_47_PDB_ID:
1F3P

# Drug_Target_47_Pathway:
Not Available

# Drug_Target_47_Pfam_Domain_Function:
PF00070	Pyr_redox
PF07992	Pyr_redox_2

# Drug_Target_47_Protein_Sequence:
>Ferredoxin reductase
MSQEALKAPVVVLGAGLASVSFVAELRQAGYQGLITVVGDEAERPYDRPPLSKDFMAHGD
AEKIRLDCKRAPEVEWLLGVTAQSFDPQAHTVALSDGRTLPYGTLVLATGAAPRALPTLQ
GATMPVHTLRTLEDARRIQAGLRPQSRLLIVGGGVIGLELAATARTAGVHVSLVETQPRL
MSRAAPATLADFVARYHAAQGVDLRFERSVTGSVDGVVLLDDGTRIAADMVVVGIGVLAN
DALARAAGLACDDGIFVDAYGRTTCPDVYALGDVTRQRNPLSGRFERIETWSNAQNQGIA
VARHLVDPTAPGYAELPWYWSDQGALRIQVAGLASGDEEIVRGEVSLDAPKFTLIELQKG
RIVGATCVNNARDFAPLRRLLAVGAKPDRAALADPATDLRKLAAAVAA

# Drug_Target_47_Reaction:
Not Available

# Drug_Target_47_Signals:
None

# Drug_Target_47_Specific_Function:
Not Available

# Drug_Target_47_SwissProt_ID:
Q52437

# Drug_Target_47_SwissProt_Name:
Q52437_PSES1

# Drug_Target_47_Synonyms:
Not Available

# Drug_Target_47_Theoretical_pI:
6.27

# Drug_Target_47_Transmembrane_Regions:
None

# Drug_Target_48_Cellular_Location:
Cytoplasm

# Drug_Target_48_Chromosome_Location:
Not Available

# Drug_Target_48_Drug_References:
Not Available

# Drug_Target_48_Essentiality:
Non-Essential

# Drug_Target_48_GenAtlas_ID:
Not Available

# Drug_Target_48_GenBank_ID_Gene:
M37307

# Drug_Target_48_GenBank_ID_Protein:
Not Available

# Drug_Target_48_GeneCard_ID:
Not Available

# Drug_Target_48_Gene_Name:
Not Available

# Drug_Target_48_Gene_Sequence:
>1434 bp
ATGAGCCAGAAGTTCGACGTGATTGTGATTGGTGCAGGCCCCGGCGGCTACGTGGCTGCC
ATCAAGTCTGCCCAGCTTGGCCTCAAGACCGCCCTGATCGAGAAGTACAAGGGCAAGGAA
GGCAAGACCGCGCTTGGCGGTACCTGCCTGAACGTGGGCTGCATTCCCTCCAAGGCGCTG
CTGGACAGCTCCTACAAGTTCCACGAGGCACACGAGAGCTTCAAGCTCCACGGCATCAGC
ACCGGCGAAGTCGCCATCGACGTGCCGACCATGATCGCCCGCAAGGACCAGATCGTCAGA
AACCTCACCGGCGGGGTCGCCTCGCTGATCAAGGCCAATGGCGTCACCCTGTTCGAAGGT
CATGGCAAGCTGCTGGCCGGCAAGAAGGTCGAAGTCACCGCTGCCGACGGCAGCAGCCAG
GTACTCGACACCGAGAACGTCATCCTCGCTTCCGGTTCCAAGCCGGTGGAAATTCCGCCG
GCTCCGGTCGATCAGGATGTCATCGTCGACTCCACCGGCGCCCTGGACTTCCAGAACGTT
CCGGGCAAACTCGGCGTGATCGGCGCCGGCGTGATCGGCCTGGAGCTGGGTTCGGTCTGG
GCTCGCCTGGGTGCCGAGGTCACCGTGCTCGAGGCCATGGACAAGTTCCTGCCGGCCGTC
GATGAACAGGTCGCCAAGGAAGCCCAGAAGATTCTCACCAAGCAAGGCCTGAAGATCCTG
CTGGGTGCCCGCGTCACCGGCACCGAGGTCAAGAACAAGCAGGTCACCGTCAAGTTCGTC
GATGCCGAAGGCGAGAAGTCGCAGGCCTTCGACAAGCTGATCGTCGCGGTCGGCCGCCGC
CCGGTGACTACCGACCTGCTGGCCGCCGACAGCGGCGTGACCCTGGACGAGCGTGGCTTC
ATCTATGTCGACGACTACTGCGCCACCAGCGTGCCGGGCGTCTATGCCATCGGTGACGTG
GTCCGCGGTGCCATGCTGGCCCACAAGGCCTCGGAAGAAGGTGTGGTGGTCGCCGAGCGC
ATCGCCGGTCACAAGGCCCAGATGAACTATGACCTGATCCCGGCCGTCATCTACACCCAC
CCGGAAATCGCCGGCGTGGGCAAGACCGAGCAGGCTCTGAAGGCCGAAGGCGTGGCCATC
AACGTCGGCGTCTTCCCCTTCGCTGCCAGCGGCCGCGCCATGGCCGCCAACGATACCGCA
GGCTTCGTCAAGGTCATCGCCGATGCCAAGACCGACCGCGTGCTGGGCGTCCATGTGATC
GGCCCGAGCGCCGCCGAACTGGTCCAGCAGGGCGCTATCGCCATGGAGTTCGGCACCAGC
GCCGAAGACCTGGGCATGATGGTTTTTGCCCACCCGGCGCTGTCCGAAGCGCTGCACGAG
GCCGCCCTGGCGGTCAGCGGCCACGCGATTCACGTTGCCAACCGCAAGAAGTAA

# Drug_Target_48_General_Function:
Involved in oxidoreductase activity

# Drug_Target_48_General_References:
1880807	Mattevi A, Schierbeek AJ, Hol WG: Refined crystal structure of lipoamide dehydrogenase from Azotobacter vinelandii at 2.2 A resolution. A comparison with the structure of glutathione reductase. J Mol Biol. 1991 Aug 20;220(4):975-94.
2404760	Westphal AH, de Kok A: The 2-oxoglutarate dehydrogenase complex from Azotobacter vinelandii. 2. Molecular cloning and sequence analysis of the gene encoding the succinyltransferase component. Eur J Biochem. 1990 Jan 12;187(1):235-9.
2832161	Westphal AH, de Kok A: Lipoamide dehydrogenase from Azotobacter vinelandii. Molecular cloning, organization and sequence analysis of the gene. Eur J Biochem. 1988 Mar 1;172(2):299-305.

# Drug_Target_48_HGNC_ID:
Not Available

# Drug_Target_48_HPRD_ID:
Not Available

# Drug_Target_48_ID:
5077

# Drug_Target_48_Locus:
Not Available

# Drug_Target_48_Molecular_Weight:
49568

# Drug_Target_48_Name:
Dihydrolipoyl dehydrogenase

# Drug_Target_48_Number_of_Residues:
477

# Drug_Target_48_PDB_ID:
3LAD

# Drug_Target_48_Pathway:
Not Available

# Drug_Target_48_Pfam_Domain_Function:
PF00070	Pyr_redox
PF02852	Pyr_redox_dim
PF07992	Pyr_redox_2

# Drug_Target_48_Protein_Sequence:
>Dihydrolipoyl dehydrogenase
MSQKFDVIVIGAGPGGYVAAIKSAQLGLKTALIEKYKGKEGKTALGGTCLNVGCIPSKAL
LDSSYKFHEAHESFKLHGISTGEVAIDVPTMIARKDQIVRNLTGGVASLIKANGVTLFEG
HGKLLAGKKVEVTAADGSSQVLDTENVILASGSKPVEIPPAPVDQDVIVDSTGALDFQNV
PGKLGVIGAGVIGLELGSVWARLGAEVTVLEAMDKFLPAVDEQVAKEAQKILTKQGLKIL
LGARVTGTEVKNKQVTVKFVDAEGEKSQAFDKLIVAVGRRPVTTDLLAADSGVTLDERGF
IYVDDYCATSVPGVYAIGDVVRGAMLAHKASEEGVVVAERIAGHKAQMNYDLIPAVIYTH
PEIAGVGKTEQALKAEGVAINVGVFPFAASGRAMAANDTAGFVKVIADAKTDRVLGVHVI
GPSAAELVQQGAIAMEFGTSAEDLGMMVFAHPALSEALHEAALAVSGHAIHVANRKK

# Drug_Target_48_Reaction:
Not Available

# Drug_Target_48_Signals:
None

# Drug_Target_48_Specific_Function:
The pyruvate dehydrogenase complex catalyzes the overall conversion of pyruvate to acetyl-CoA and CO(2). It contains multiple copies of three enzymatic components:pyruvate dehydrogenase (E1), dihydrolipoamide acetyltransferase (E2) and lipoamide dehydrogenase (E3)

# Drug_Target_48_SwissProt_ID:
P18925

# Drug_Target_48_SwissProt_Name:
DLDH_AZOVI

# Drug_Target_48_Synonyms:
Dihydrolipoamide dehydrogenase
E3 component of pyruvate complex
EC 1.8.1.4

# Drug_Target_48_Theoretical_pI:
6.38

# Drug_Target_48_Transmembrane_Regions:
None

# Drug_Target_49_Cellular_Location:
Not Available

# Drug_Target_49_Chromosome_Location:
Not Available

# Drug_Target_49_Drug_References:
Not Available

# Drug_Target_49_Essentiality:
Non-Essential

# Drug_Target_49_GenAtlas_ID:
Not Available

# Drug_Target_49_GenBank_ID_Gene:
AE016853

# Drug_Target_49_GenBank_ID_Protein:
Not Available

# Drug_Target_49_GeneCard_ID:
Not Available

# Drug_Target_49_Gene_Name:
PSPTO1126

# Drug_Target_49_Gene_Sequence:
>987 bp
TCATTGAAGGTGTTCCAGCAGCCGACGTGCCGCTTCCTGGCCGCTCAGCCATGCGCCTTC
CACACGCCCCGACAGGCACCAGTCGCCGCACACGTAAATACCCAGATCGGCATCCGACAG
CGCGCCCCATTCATGAGCGCCGGCAGGCCGCGCGTACAACCAGCGATGCGCCAGGCTGAA
CACCGGGGCGGGCATGGTGCAGTCGATCAGCTCTGCAAAAGCACCGTGCAAGTGCTCGAT
GACCTGTTCACGGGATGCATCAAGGTTTTGCCTGCTCCATTGACTGGTGGCGTGCAGAAT
CCAGGTATCGAGCGTGTCGTCGCGTTCCGGCTTGCTGCGGTTGCGGGCCAGCCAGTCGAG
CGGACTGTCCTGCACGAAGCAACCCTGCATGGGGGTTTGCAACGGGGTCTCGAAGGCCAG
TGCAACCGCCCAGGTCGGGTCCATCTTGACGCCCGCCACCACGCTGGCCAGCTTGGGTGC
GGCAGCCAGCAGTGTGCTGGCCTGCGGGGCAGGGGTGGCGATGATGACATGGCTGAACGG
GCCGTGATTTTGGCCCTCGGCGTCCAGCAGGTTCCAGTGCTCTTCGCCGCGAAACACCTC
GGTGATGCGGCACGAGAATGACACCGGCATGTCGCCGCGCATGGCACGGGTAATCGCGCT
CATGCCGGGCTTGCCGACCCAGCGCACCTGTTCATCCGGCGACGGGCTGAGCCTGCCAGC
GTGGAAGTTGTAAAGCAGGGGTGTCCACTCGGCAACGTGCCCCTGGGCTTGCCACTGCTT
GACCGCAGTGGCGAAGCGTCGGTCACGAGCGGTGAAATACTGCGCACCCATGTCCAGCGC
ACCTGCGTCGCTGCGCTTGCTGGACATCCGACCGCCGCTGCCGCGGCTCTTGTCGAAAAG
GTGCACCTGATGCCCGGCCGCTGTGAGCGCCTGAGCTGCTGAAAGTCCGGCGATACCGGT
ACCGATGATTGCGATAGGGACAGTCAT

# Drug_Target_49_General_Function:
Involved in oxidoreductase activity

# Drug_Target_49_General_References:
12928499	Buell CR, Joardar V, Lindeberg M, Selengut J, Paulsen IT, Gwinn ML, Dodson RJ, Deboy RT, Durkin AS, Kolonay JF, Madupu R, Daugherty S, Brinkac L, Beanan MJ, Haft DH, Nelson WC, Davidsen T, Zafar N, Zhou L, Liu J, Yuan Q, Khouri H, Fedorova N, Tran B, Russell D, Berry K, Utterback T, Van Aken SE, Feldblyum TV, D'Ascenzo M, Deng WL, Ramos AR, Alfano JR, Cartinhour S, Chatterjee AK, Delaney TP, Lazarowitz SG, Martin GB, Schneider DJ, Tang X, Bender CL, White O, Fraser CM, Collmer A: The complete genome sequence of the Arabidopsis and tomato pathogen Pseudomonas syringae pv. tomato DC3000. Proc Natl Acad Sci U S A. 2003 Sep 2;100(18):10181-6. Epub 2003 Aug 19.

# Drug_Target_49_HGNC_ID:
Not Available

# Drug_Target_49_HPRD_ID:
Not Available

# Drug_Target_49_ID:
5078

# Drug_Target_49_Locus:
Not Available

# Drug_Target_49_Molecular_Weight:
35840

# Drug_Target_49_Name:
Amine oxidase, flavin-containing

# Drug_Target_49_Number_of_Residues:
328

# Drug_Target_49_PDB_ID:
1YVV

# Drug_Target_49_Pathway:
Not Available

# Drug_Target_49_Pfam_Domain_Function:
PF01593	Amino_oxidase

# Drug_Target_49_Protein_Sequence:
>Amine oxidase, flavin-containing
MTVPIAIIGTGIAGLSAAQALTAAGHQVHLFDKSRGSGGRMSSKRSDAGALDMGAQYFTA
RDRRFATAVKQWQAQGHVAEWTPLLYNFHAGRLSPSPDEQVRWVGKPGMSAITRAMRGDM
PVSFSCRITEVFRGEEHWNLLDAEGQNHGPFSHVIIATPAPQASTLLAAAPKLASVVAGV
KMDPTWAVALAFETPLQTPMQGCFVQDSPLDWLARNRSKPERDDTLDTWILHATSQWSRQ
NLDASREQVIEHLHGAFAELIDCTMPAPVFSLAHRWLYARPAGAHEWGALSDADLGIYVC
GDWCLSGRVEGAWLSGQEAARRLLEHLQ

# Drug_Target_49_Reaction:
Not Available

# Drug_Target_49_Signals:
None

# Drug_Target_49_Specific_Function:
Not Available

# Drug_Target_49_SwissProt_ID:
Q888A4

# Drug_Target_49_SwissProt_Name:
Q888A4_PSESM

# Drug_Target_49_Synonyms:
Not Available

# Drug_Target_49_Theoretical_pI:
6.84

# Drug_Target_49_Transmembrane_Regions:
None

# Drug_Target_4_Cellular_Location:
Endoplasmic reticulum

# Drug_Target_4_Chromosome_Location:
Not Available

# Drug_Target_4_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_4_Essentiality:
Non-Essential

# Drug_Target_4_GenAtlas_ID:
POR

# Drug_Target_4_GenBank_ID_Gene:
S90469

# Drug_Target_4_GenBank_ID_Protein:
247307

# Drug_Target_4_GeneCard_ID:
POR

# Drug_Target_4_Gene_Name:
POR

# Drug_Target_4_Gene_Sequence:
>2031 bp
GGAGACTCCCACGTGGACACCAGCTCCACCGTGTCCGAGGCGGTGGCCGAAGAAGTATCT
CTTTTCAGCATGACGGACATGATTCTGTTTTCGCTCATCGTGGGTCTCCTAACCTACTGG
TTCCTCTTCAGAAAGAAAAAAGAAGAAGTCCCCGAGTTCACCAAAATTCAGACATTGACC
TCCTCTGTCAGAGAGAGCAGCTTTGTGGAAAAGATGAAGAAAACGGGGAGGAACATCATC
GTGTTCTACGGCTCCCAGACGGGGACTGCAGAGGAGTTTGCCAACCGCCTGTCCAAGGAC
GCCCACCGCTACGGGATGCGAGGCATGTCAGCGGACCCTGAGGAGTATGACCTGGCCGAC
CTGAGCAGCCTGCCAGAGATCGACAACGCCCTGGTGGTTTTCTGCATGGCCACCTACGGT
GAGGGAGACCCCACCGACAATGCCCAGGACTTCTACGACTGGCTGCAGGAGACAGACGTG
GATCTCTCTGGGGTCAAGTTCGCGGTGTTTGGTCTTGGGAACAAGACCTACGAGCACTTC
AATGCCATGGGCAAGTACGTGGACAAGCGGCTGGAGCAGCTCGGCGCCCAGCGCATCTTT
GAGCTGGGGTTGGGCGACGACGATGGGAACTTGGAGGAGGACTTCATCACCTGGCGAGAG
CAGTTCTGGCCGGCCGTGTGTGAACACTTTGGGGTGGAAGCCACTGGCGAGGAGTCCAGC
ATTCGCCAGTACGAGCTTGTGGTCCACACCGACATAGATGCGGCCAAGGTGTACATGGGG
GAGATGGGCCGGCTGAAGAGCTACGAGAACCAGAAGCCCCCCTTTGATGCCAAGAATCCG
TTCCTGGCTGCAGTCACCACCAACCGGAAGCTGAACCAGGGAACCGAGCGCCACCTCATG
CACCTGGAATTGGACATCTCGGACTCCAAAATCAGGTATGAATCTGGGGACCACGTGGCT
GTGTACCCAGCCAACGACTCTGCTCTCGTCAACCAGCTGGGCAAAATCCTGGGTGCCGAC
CTGGACGTCGTCATGTCCCTGAACAACCTGGATGAGGAGTCCAACAAGAAGCACCCATTC
CCGTGCCCTACGTCCTACCGCACGGCCCTCACCTACTACCTGGACATCACCAACCCGCCG
CGTACCAACGTGCTGTACGAGCTGGCGCAGTACGCCTCGGAGCCCTCGGAGCAGGAGCTG
CTGCGCAAGATGGCCTCCTCCTCCGGCGAGGGCAAGGAGCTGTACCTGAGCTGGGTGGTG
GAGGCCCGGAGGCACATCCTGGCCATCCTGCAGGACTGCCCGTCCCTGCGGCCCCCCATC
GACCACCTGTGTGAGCTGCTGCCGCGCCTGCAGGCCCGCTACTACTCCATCGCCTCATCC
TCCAAGGTCCACCCCAACTCTGTGCACATCTGTGCGGTGGTTGTGGAGTACGAGACCAAG
GCCGGCCGCATCAACAAGGGCGTGGCCACCAACTGGCTGCGGGCCAAGGAGCCTGTCGGG
GAGAACGGCGGCCGTGCGCTGGTGCCCATGTTCGTGCGCAAGTCCCAGTTACGCCTGCCC
TTCAAGGCCACCACGCCTGTCATCATGGTGGGCCCCGGCACCGGGTGGCACCCTTTCATA
GGCTTCATCCAGGAGCGGGCCTGGCTGCGACAGCAGGGCAAGGAGGTGGGGGAGACGCTG
CTGTACTACGGCTGCCGCCGCTCGGATGAGGACTACCTGTACCGGGAGGAGCTGGCGCAG
TTCCACAGGGACGGTGCGCTCACCCAGCTCAACGTGGCCTTCTCCCGGGAGCAGTCCCAC
AAGGTCTACGTCCAGCACCTGCTAAAGCAAGACCGAGAGCACCTGTGGAAGTTGATCGAA
GGCGGTGCCCACATCTACGTCTGTGGGGATGCACGGAACATGGCCAGGGATGTGCAGAAC
ACCTTCTACGACATCGTGGCTGAGCTCGGGGCCATGGAGCACGCGCAGGCGGTGGACTAC
ATCAAGAAACTGATGACCAAGGGCCGCTACTCCCTGGACGTGTGGAGCTAG

# Drug_Target_4_General_Function:
Inorganic ion transport and metabolism

# Drug_Target_4_General_References:
10048323	Zhao Q, Modi S, Smith G, Paine M, McDonagh PD, Wolf CR, Tew D, Lian LY, Roberts GC, Driessen HP: Crystal structure of the FMN-binding domain of human cytochrome P450 reductase at 1.93 A resolution. Protein Sci. 1999 Feb;8(2):298-306.
1550342	Shephard EA, Palmer CN, Segall HJ, Phillips IR: Quantification of cytochrome P450 reductase gene expression in human tissues. Arch Biochem Biophys. 1992 Apr;294(1):168-72.
2513880	Haniu M, McManus ME, Birkett DJ, Lee TD, Shively JE: Structural and functional analysis of NADPH-cytochrome P-450 reductase from human liver: complete sequence of human enzyme and NADPH-binding sites. Biochemistry. 1989 Oct 17;28(21):8639-45.

# Drug_Target_4_HGNC_ID:
HGNC:9208

# Drug_Target_4_HPRD_ID:
00485

# Drug_Target_4_ID:
4120

# Drug_Target_4_Locus:
7q11.2

# Drug_Target_4_Molecular_Weight:
76691

# Drug_Target_4_Name:
NADPH--cytochrome P450 reductase

# Drug_Target_4_Number_of_Residues:
677

# Drug_Target_4_PDB_ID:
1AMO

# Drug_Target_4_Pathway:
Not Available

# Drug_Target_4_Pfam_Domain_Function:
PF00175	NAD_binding_1
PF00258	Flavodoxin_1
PF00667	FAD_binding_1

# Drug_Target_4_Protein_Sequence:
>NADPH--cytochrome P450 reductase
MGDSHVDTSSTVSEAVAEEVSLFSMTDMILFSLIVGLLTYWFLFRKKKEEVPEFTKIQTL
TSSVRESSFVEKMKKTGRNIIVFYGSQTGTAEEFANRLSKDAHRYGMRGMSADPEEYDLA
DLSSLPEIDNALVVFCMATYGEGDPTDNAQDFYDWLQETDVDLSGVKFAVFGLGNKTYEH
FNAMGKYVDKRLEQLGAQRIFELGLGDDDGNLEEDFITWREQFWPAVCEHFGVEATGEES
SIRQYELVVHTDIDAAKVYMGEMGRLKSYENQKPPFDAKNPFLAAVTTNRKLNQGTERHL
MHLELDISDSKIRYESGDHVAVYPANDSALVNQLGKILGADLDVVMSLNNLDEESNKKHP
FPCPTSYRTALTYYLDITNPPRTNVLYELAQYASEPSEQELLRKMASSSGEGKELYLSWV
VEARRHILAILQDCPSLRPPIDHLCELLPRLQARYYSIASSSKVHPNSVHICAVVVEYET
KAGRINKGVATNWLRAKEPAGENGGRALVPMFVRKSQFRLPFKATTPVIMVGPGTGVAPF
IGFIQERAWLRQQGKEVGETLLYYGCRRSDEDYLYREELAQFHRDGALTQLNVAFSREQS
HKVYVQHLLKQDREHLWKLIEGGAHIYVCGDARNMARDVQNTFYDIVAELGAMEHAQAVD
YIKKLMTKGRYSLDVWS

# Drug_Target_4_Reaction:
NADPH + H+ + n oxidized hemoprotein = NADP+ + n reduced hemoprotein ALL_REAC (other) R00106

# Drug_Target_4_Signals:
None

# Drug_Target_4_Specific_Function:
This enzyme is required for electron transfer from NADP to cytochrome P450 in microsomes. It can also provide electron transfer to heme oxygenase and cytochrome B5

# Drug_Target_4_SwissProt_ID:
P16435

# Drug_Target_4_SwissProt_Name:
NCPR_HUMAN

# Drug_Target_4_Synonyms:
CPR
EC 1.6.2.4
P450R

# Drug_Target_4_Theoretical_pI:
5.28

# Drug_Target_4_Transmembrane_Regions:
None

# Drug_Target_50_Cellular_Location:
Not Available

# Drug_Target_50_Chromosome_Location:
Not Available

# Drug_Target_50_Drug_References:
Not Available

# Drug_Target_50_Essentiality:
Non-Essential

# Drug_Target_50_GenAtlas_ID:
Not Available

# Drug_Target_50_GenBank_ID_Gene:
K01299

# Drug_Target_50_GenBank_ID_Protein:
Not Available

# Drug_Target_50_GeneCard_ID:
Not Available

# Drug_Target_50_Gene_Name:
phrB

# Drug_Target_50_Gene_Sequence:
>1419 bp
ATGACTACCCATCTGGTCTGGTTTCGCCAGGATTTACGTCTGCACGATAATCTCGCACTG
GCTGCCGCCTGCCGCAATTCGTCTGCACGCGTGCTGGCGTTGTATATCGCTACACCACGC
CAGTGGGCGACGCATAACATGTCGCCGCGTCAGGCTGAACTTATCAATGCTCAACTGAAT
GGGCTACAAATAGCGCTTGCGGAAAAAGGTATTCCTTTATTGTTCCGTGAAGTGGATGAC
TTTGTCGCCAGTGTCGAAATAGTTAAACAGGTGTGCGCGGAAAACAGCGTTACCCACCTG
TTTTATAACTATCAGTATGAAGTGAATGAGCGGGCGCGGGATGTGGAAGTTGAAAGAGCG
CTGCGTAACGTGGTGTGTGAAGGATTTGATGACAGCGTGATCCTGCCGCCTGGCGCGGTG
ATGACCGGTAATCACGAGATGTACAAAGTCTTTACGCCTTTTAAGAATGCCTGGCTGAAA
CGGCTGCGGGAAGGGATGCCGGAGTGCGTCGCTGCGCCAAAAGTTCGTAGTAGCGGATCG
ATAGAGCCCTCGCCATCCATTACGCTGAATTATCCTCGTCAGTCTTTCGATACTGCGCAT
TTTCCGGTGGAAGAAAAAGCGGCGATTGCGCAATTACGCCAGTTTTGCCAGAACGGTGCC
GGAGAATATGAGCAACAACGAGATTTTCCGGCAGTGGAAGGCACCAGCCGTTTGTCGGCC
AGCCTGGCAACGGGCGGGTTATCGCCTCGCCAGTGCTTGCATCGCTTGTTGGCTGAACAG
CCGCAGGCGCTGGACGGTGGGGCCGGTAGTGTCTGGCTTAATGAGCTGATCTGGCGCGAG
TTTTACCGTCACCTGATAACGTATCACCCCTCGTTGTGTAAACATCGTCCATTTATTGCC
TGGACGGATCGTGTACAGTGGCAGAGCAATCCCGCACATTTACAGGCCTGGCAGGAAGGC
AAAACGGGATACCCGATTGTTGATGCCGCTATGCGTCAGCTTAACAGCACTGGCTGGATG
CATAACAGGCTACGGATGATTACAGCCAGTTTTCTGGTGAAAGATTTATTGATCGACTGG
CGCGAAGGCGAGCGATATTTCATGTCGCAGCTGATTGATGGTGATTTGGCAGCCAATAAC
GGTGGCTGGCAGTGGGCCGCTTCAACCGGAACCGATGCAGCGCCGTATTTTCGTATTTTC
AACCCGACAACCCAGGGCGAGAAATTTGATCATGAGGGCGAGTTTATCCGCCAGTGGCTA
CCGGAACTGCGCGATGTGCCAGGGAAAGTGGTGCATGAGCCGTGGAAGTGGGCGCAGAAA
GCAGGTGTGACGCTGGATTATCCGCAACCGATAGTCGAGCACAAAGAAGCGAGAGTACAA
ACGTTGGCAGCGTATGAGGCGGCGCGGAAGGGGAAATAA

# Drug_Target_50_General_Function:
Involved in DNA photolyase activity

# Drug_Target_50_General_References:
2200511	Li YF, Sancar A: Active site of Escherichia coli DNA photolyase: mutations at Trp277 alter the selectivity of the enzyme without affecting the quantum yield of photorepair. Biochemistry. 1990 Jun 19;29(24):5698-706.
6325460	Sancar GB, Smith FW, Lorence MC, Rupert CS, Sancar A: Sequences of the Escherichia coli photolyase gene and protein. J Biol Chem. 1984 May 10;259(9):6033-8.
7604260	Park HW, Kim ST, Sancar A, Deisenhofer J: Crystal structure of DNA photolyase from Escherichia coli. Science. 1995 Jun 30;268(5219):1866-72.
8905232	Oshima T, Aiba H, Baba T, Fujita K, Hayashi K, Honjo A, Ikemoto K, Inada T, Itoh T, Kajihara M, Kanai K, Kashimoto K, Kimura S, Kitagawa M, Makino K, Masuda S, Miki T, Mizobuchi K, Mori H, Motomura K, Nakamura Y, Nashimoto H, Nishio Y, Saito N, Horiuchi T, et al.: A 718-kb DNA sequence of the Escherichia coli K-12 genome corresponding to the 12.7-28.0 min region on the linkage map. DNA Res. 1996 Jun 30;3(3):137-55.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.

# Drug_Target_50_HGNC_ID:
Not Available

# Drug_Target_50_HPRD_ID:
Not Available

# Drug_Target_50_ID:
5079

# Drug_Target_50_Locus:
Not Available

# Drug_Target_50_Molecular_Weight:
53667

# Drug_Target_50_Name:
Deoxyribodipyrimidine photo-lyase

# Drug_Target_50_Number_of_Residues:
472

# Drug_Target_50_PDB_ID:
1DNP

# Drug_Target_50_Pathway:
Not Available

# Drug_Target_50_Pfam_Domain_Function:
PF00875	DNA_photolyase
PF03441	FAD_binding_7

# Drug_Target_50_Protein_Sequence:
>Deoxyribodipyrimidine photo-lyase
MTTHLVWFRQDLRLHDNLALAAACRNSSARVLALYIATPRQWATHNMSPRQAELINAQLN
GLQIALAEKGIPLLFREVDDFVASVEIVKQVCAENSVTHLFYNYQYEVNERARDVEVERA
LRNVVCEGFDDSVILPPGAVMTGNHEMYKVFTPFKNAWLKRLREGMPECVAAPKVRSSGS
IEPSPSITLNYPRQSFDTAHFPVEEKAAIAQLRQFCQNGAGEYEQQRDFPAVEGTSRLSA
SLATGGLSPRQCLHRLLAEQPQALDGGAGSVWLNELIWREFYRHLITYHPSLCKHRPFIA
WTDRVQWQSNPAHLQAWQEGKTGYPIVDAAMRQLNSTGWMHNRLRMITASFLVKDLLIDW
REGERYFMSQLIDGDLAANNGGWQWAASTGTDAAPYFRIFNPTTQGEKFDHEGEFIRQWL
PELRDVPGKVVHEPWKWAQKAGVTLDYPQPIVEHKEARVQTLAAYEAARKGK

# Drug_Target_50_Reaction:
Not Available

# Drug_Target_50_Signals:
None

# Drug_Target_50_Specific_Function:
Involved in repair of UV radiation-induced DNA damage. Catalyzes the light-dependent monomerization (300-600 nm) of cyclobutyl pyrimidine dimers (in cis-syn configuration), which are formed between adjacent bases on the same DNA strand upon exposure to ultraviolet radiation

# Drug_Target_50_SwissProt_ID:
P00914

# Drug_Target_50_SwissProt_Name:
PHR_ECOLI

# Drug_Target_50_Synonyms:
DNA photolyase
EC 4.1.99.3
Photoreactivating enzyme

# Drug_Target_50_Theoretical_pI:
7.22

# Drug_Target_50_Transmembrane_Regions:
None

# Drug_Target_51_Cellular_Location:
Not Available

# Drug_Target_51_Chromosome_Location:
Not Available

# Drug_Target_51_Drug_References:
Not Available

# Drug_Target_51_Essentiality:
Non-Essential

# Drug_Target_51_GenAtlas_ID:
Not Available

# Drug_Target_51_GenBank_ID_Gene:
X07230

# Drug_Target_51_GenBank_ID_Protein:
Not Available

# Drug_Target_51_GeneCard_ID:
Not Available

# Drug_Target_51_Gene_Name:
phr

# Drug_Target_51_Gene_Sequence:
>1455 bp
GTGGCGGCTCCGATTCTGTTTTGGCACCGGCGTGACCTGCGCCTCAGCGACAACATTGGT
CTGGCGGCGGCGCGGGCACAATCAGCGCAGCTGATCGGTCTGTTTTGCCTCGACCCTCAG
ATTCTCCAGAGTGCTGACATGGCGCCAGCACGGGTTGCCTACCTGCAGGGCTGCCTACAG
GAACTCCAGCAGCGTTATCAACAGGCGGGCAGTCGGCTGCTATTGCTCCAAGGGGATCCA
CAACACCTGATCCCGCAACTGGCGCAGCAGCTTCAGGCGGAAGCAGTTTATTGGAACCAA
GACATTGAACCCTACGGCCGCGATCGCGATGGGCAGGTCGCAGCCGCTCTGAAAACGGCA
GGCATTCGGGCTGTTCAACTCTGGGATCAACTGCTCCATAGCCCCGATCAAATCCTCAGC
GGCAGCGGTAATCCCTACAGCGTCTACGGGCCGTTTTGGAAAAATTGGCAGGCTCAGCCC
AAGCCCACGCCGGTTGCCACACCGACAGAACTGGTCGATCTCTCACCAGAGCAACTAACT
GCGATCGCACCTCTGCTGTTGTCGGAACTACCGACCCTGAAGCAGCTTGGCTTTGACTGG
GACGGGGGTTTTCCAGTGGAGCCGGGGGAAACAGCGGCGATCGCCCGTCTTCAAGAATTT
TGCGATCGCGCGATCGCCGACTACGATCCCCAGCGCAATTTTCCGGCGGAAGCAGGAACC
TCGGGCTTGAGTCCCGCTTTGAAATTCGGGGCGATCGGTATTCGTCAGGCTTGGCAGGCT
GCCAGTGCAGCCCATGCCCTCAGCCGCAGCGACGAAGCCCGCAACAGCATTCGCGTTTGG
CAGCAGGAACTCGCTTGGCGGGAGTTCTATCAGCATGCGCTCTACCATTTCCCGAGCCTG
GCCGATGGTCCCTATCGCTCGCTCTGGCAGCAATTCCCTTGGGAAAATCGCGAGGCTCTG
TTCACGGCTTGGACCCAGGCGCAAACGGGCTATCCGATTGTTGATGCAGCGATGCGCCAA
CTGACTGAAACCGGCTGGATGCACAACCGTTGCCGGATGATTGTTGCCAGCTTTTTGACC
AAGGATTTGATCATCGACTGGCGGCGTGGGGAGCAGTTCTTTATGCAGCACTTGGTCGAT
GGCGATCTGGCTGCAAATAACGGCGGTTGGCAGTGGAGCGCTTCCAGTGGCATGGATCCC
AAACCGCTGCGGATTTTCAATCCTGCTAGTCAGGCCAAGAAGTTTGATGCCACGGCGACC
TACATCAAACGTTGGCTGCCAGAACTGCGCCATGTCCATCCCAAGGACTTGATCAGTGGG
GAGATCACGCCGATTGAACGCCGAGGCTATCCTGCCCCGATCGTGAATCACAACCTGCGC
CAGAAACAGTTCAAGGCGCTCTACAACCAGCTCAAAGCGGCTATCGCTGAACCTGAGGCT
GAGCCCGATTCATAG

# Drug_Target_51_General_Function:
Involved in DNA photolyase activity

# Drug_Target_51_General_References:
2110564	Eker AP, Kooiman P, Hessels JK, Yasui A: DNA photoreactivating enzyme from the cyanobacterium Anacystis nidulans. J Biol Chem. 1990 May 15;265(14):8009-15.
2837735	Yasui A, Takao M, Oikawa A, Kiener A, Walsh CT, Eker AP: Cloning and characterization of a photolyase gene from the cyanobacterium Anacystis nidulans. Nucleic Acids Res. 1988 May 25;16(10):4447-63.
9360600	Tamada T, Kitadokoro K, Higuchi Y, Inaka K, Yasui A, de Ruiter PE, Eker AP, Miki K: Crystal structure of DNA photolyase from Anacystis nidulans. Nat Struct Biol. 1997 Nov;4(11):887-91.

# Drug_Target_51_HGNC_ID:
Not Available

# Drug_Target_51_HPRD_ID:
Not Available

# Drug_Target_51_ID:
5080

# Drug_Target_51_Locus:
Not Available

# Drug_Target_51_Molecular_Weight:
54462

# Drug_Target_51_Name:
Deoxyribodipyrimidine photo-lyase

# Drug_Target_51_Number_of_Residues:
484

# Drug_Target_51_PDB_ID:
1OWP

# Drug_Target_51_Pathway:
Not Available

# Drug_Target_51_Pfam_Domain_Function:
PF00875	DNA_photolyase
PF03441	FAD_binding_7

# Drug_Target_51_Protein_Sequence:
>Deoxyribodipyrimidine photo-lyase
MAAPILFWHRRDLRLSDNIGLAAARAQSAQLIGLFCLDPQILQSADMAPARVAYLQGCLQ
ELQQRYQQAGSRLLLLQGDPQHLIPQLAQQLQAEAVYWNQDIEPYGRDRDGQVAAALKTA
GIRAVQLWDQLLHSPDQILSGSGNPYSVYGPFWKNWQAQPKPTPVATPTELVDLSPEQLT
AIAPLLLSELPTLKQLGFDWDGGFPVEPGETAAIARLQEFCDRAIADYDPQRNFPAEAGT
SGLSPALKFGAIGIRQAWRAASAAHALSRSDEARNSIRVWQQELAWREFYQHALYHFPSL
ADGPYRSLWQQFPWENREALFTAWTQAQTGYPIVDAAMRQLTETGWMHNRCWMIVASFLT
KDLIIDWRRGEQFFMQHLVDGDLAANNGGWQWSASSGMDPKPLRIFNPASQAKKFDATAT
YIKRWLPELRHVHPKDLISGEITPIGRRGYPAPIVNHNLRQKQFKALYNQLKAAIAEPEA
EPDS

# Drug_Target_51_Reaction:
Not Available

# Drug_Target_51_Signals:
None

# Drug_Target_51_Specific_Function:
Involved in repair of UV radiation-induced DNA damage. Catalyzes the light-dependent monomerization (300-600 nm) of cyclobutyl pyrimidine dimers (in cis-syn configuration), which are formed between adjacent bases on the same DNA strand upon exposure to ultraviolet radiation

# Drug_Target_51_SwissProt_ID:
P05327

# Drug_Target_51_SwissProt_Name:
PHR_SYNP6

# Drug_Target_51_Synonyms:
DNA photolyase
EC 4.1.99.3
Photoreactivating enzyme

# Drug_Target_51_Theoretical_pI:
6.74

# Drug_Target_51_Transmembrane_Regions:
None

# Drug_Target_52_Cellular_Location:
Cytoplasm

# Drug_Target_52_Chromosome_Location:
Not Available

# Drug_Target_52_Drug_References:
Not Available

# Drug_Target_52_Essentiality:
Non-Essential

# Drug_Target_52_GenAtlas_ID:
Not Available

# Drug_Target_52_GenBank_ID_Gene:
X12714

# Drug_Target_52_GenBank_ID_Protein:
Not Available

# Drug_Target_52_GeneCard_ID:
Not Available

# Drug_Target_52_Gene_Name:
nadB

# Drug_Target_52_Gene_Sequence:
>1623 bp
ATGAATACTCTCCCTGAACATTCATGTGACGTGTTGATTATCGGTAGCGGCGCAGCCGGA
CTTTCACTGGCGCTACGCCTGGCTGACCAGCATCAGGTCATCGTTCTAAGTAAAGGCCCG
GTAACGGAAGGTTCAACATTTTATGCCCAGGGCGGTATTGCCGCCGTGTTTGATGAAACT
GACAGCATTGACTCGCATGTGGAAGACACATTGATTGCCGGGGCTGGTATTTGCGATCGC
CATGCAGTTGAATTTGTCGCCAGCAATGCACGATCCTGTGTGCAATGGCTAATCGACCAG
GGGGTGTTGTTTGATACCCACATTCAACCGAATGGCGAAGAAAGTTACCATCTGACCCGT
GAAGGTGGACATAGTCACCGTCGTATTCTTCATGCCGCCGACGCCACCGGTAGAGAAGTA
GAAACCACGCTGGTGAGCAAGGCGCTGAACCATCCGAATATTCGCGTGCTGGAGCGCACG
AACGCGGTTGATCTGATTGTTTCTGACAAAATTGGCCTGCCGGGCACGCGACGGGTTGTT
GGCGCGTGGGTATGGAACCGTAATAAAGAAACGGTGGAAACCTGCCACGCAAAAGCGGTG
GTGCTGGCAACCGGCGGTGCGTCGAAGGTTTATCAGTACACCACCAATCCGGATATTTCT
TCTGGCGATGGCATTGCTATGGCGTGGCGCGCAGGCTGCCGGGTTGCCAATCTCGAATTT
AATCAGTTCCACCCTACCGCGCTATATCACCCACAGGCACGCAATTTCCTGTTAACAGAA
GCACTGCGCGGCGAAGGCGCTTATCTCAAGCGCCCGGATGGTACGCGTTTTATGCCCGAT
TTTGATGAGCGCGGCGAACTGGCCCCGCGCGATATTGTCGCCCGCGCCATTGACCATGAA
ATGAAACGCCTCGGCGCAGATTGTATGTTCCTTGATATCAGCCATAAGCCCGCCGATTTT
ATTCGCCAGCATTTCCCGATGATTTATGAAAAGCTGCTCGGGCTGGGGATTGATCTCACA
CAAGAACCGGTACCGATTGTGCCTGCTGCACATTATACCTGCGGTGGTGTAATGGTTGAT
GATCATGGGCGTACGGACGTCGAGGGCTTGTATGCCATTGGCGAGGTGAGTTATACCGGC
TTACACGGCGCTAACCGCATGGCCTCGAATTCATTGCTGGAGTGTCTGGTCTATGGCTGG
TCGGCGGCGGAAGATATCACCAGACGTATGCCTTATGCCCACGACATCAGTACGTTACCG
CCGTGGGATGAAAGCCGCGTTGAGAACCCTGACGAACGGGTAGTAATTCAGCATAACTGG
CACGAGCTACGTCTGTTTATGTGGGATTACGTTGGCATTGTGCGCACAACGAAGCGCCTG
GAACGCGCCCTGCGGCGGATAACCATGCTCCAACAAGAAATAGACGAATATTACGCCCAT
TTCCGCGTCTCAGATAATTTGCTGGAGCTGCGTAATCTGGTACAGGTTGCCGAGTTGATT
GTTCGCTGTGCAATGATGCGTAAAGAGAGTCGGGGGTTGCATTTCACGCTGGATTATCCG
GAACTGCTCACCCATTCCGGTCCGTCGATCCTTTCCCCCGGCAATCATTACATAAACAGA
TAA

# Drug_Target_52_General_Function:
Involved in oxidoreductase activity

# Drug_Target_52_General_References:
10425677	Mattevi A, Tedeschi G, Bacchella L, Coda A, Negri A, Ronchi S: Structure of L-aspartate oxidase: implications for the succinate dehydrogenase/fumarate reductase oxidoreductase family. Structure. 1999 Jul 15;7(7):745-56.
2187483	Seifert J, Kunz N, Flachmann R, Laufer A, Jany KD, Gassen HG: Expression of the E. coli nadB gene and characterization of the gene product L-aspartate oxidase. Biol Chem Hoppe Seyler. 1990 Mar;371(3):239-48.
2841129	Flachmann R, Kunz N, Seifert J, Gutlich M, Wientjes FJ, Laufer A, Gassen HG: Molecular biology of pyridine nucleotide biosynthesis in Escherichia coli. Cloning and characterization of quinolinate synthesis genes nadA and nadB. Eur J Biochem. 1988 Aug 1;175(2):221-8.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.

# Drug_Target_52_HGNC_ID:
Not Available

# Drug_Target_52_HPRD_ID:
Not Available

# Drug_Target_52_ID:
5081

# Drug_Target_52_Locus:
Not Available

# Drug_Target_52_Molecular_Weight:
60338

# Drug_Target_52_Name:
L-aspartate oxidase

# Drug_Target_52_Number_of_Residues:
540

# Drug_Target_52_PDB_ID:
1CHU

# Drug_Target_52_Pathway:
Not Available

# Drug_Target_52_Pfam_Domain_Function:
PF00890	FAD_binding_2
PF02910	Succ_DH_flav_C

# Drug_Target_52_Protein_Sequence:
>L-aspartate oxidase
MNTLPEHSCDVLIIGSGAAGLSLALRLADQHQVIVLSKGPVTEGSTFYAQGGIAAVFDET
DSIDSHVEDTLIAGAGICDRHAVEFVASNARSCVQWLIDQGVLFDTHIQPNGEESYHLTR
EGGHSHRRILHAADATGREVETTLVSKALNHPNIRVLERSNAVDLIVSDKIGLPGTRRVV
GAWVWNRNKETVETCHAKAVVLATGGASKVYQYTTNPDISSGDGIAMAWRAGCRVANLEF
NQFHPTALYHPQARNFLLTEALRGEGAYLKRPDGTRFMPDFDERGELAPRDIVARAIDHE
MKRLGADCMFLDISHKPADFIRQHFPMIYEKLLGLGIDLTQEPVPIVPAAHYTCGGVMVD
DHGRTDVEGLYAIGEVSYTGLHGANRMASNSLLECLVYGWSAAEDITRRMPYAHDISTLP
PWDESRVENPDERVVIQHNWHELRLFMWDYVGIVRTTKRLERALRRITMLQQEIDEYYAH
FRVSNNLLELRNLVQVAELIVRCAMMRKESRGLHFTLDYPELLTHSGPSILSPGNHYINR

# Drug_Target_52_Reaction:
Not Available

# Drug_Target_52_Signals:
None

# Drug_Target_52_Specific_Function:
Catalyzes the oxidation of L-aspartate to iminoaspartate

# Drug_Target_52_SwissProt_ID:
P10902

# Drug_Target_52_SwissProt_Name:
NADB_ECOLI

# Drug_Target_52_Synonyms:
EC 1.4.3.16
LASPO
Quinolinate synthetase B

# Drug_Target_52_Theoretical_pI:
6.32

# Drug_Target_52_Transmembrane_Regions:
None

# Drug_Target_53_Cellular_Location:
Not Available

# Drug_Target_53_Chromosome_Location:
Not Available

# Drug_Target_53_Drug_References:
Not Available

# Drug_Target_53_Essentiality:
Non-Essential

# Drug_Target_53_GenAtlas_ID:
Not Available

# Drug_Target_53_GenBank_ID_Gene:
Not Available

# Drug_Target_53_GenBank_ID_Protein:
Not Available

# Drug_Target_53_GeneCard_ID:
Not Available

# Drug_Target_53_Gene_Name:
cry

# Drug_Target_53_Gene_Sequence:
Not Available

# Drug_Target_53_General_Function:
Involved in DNA photolyase activity

# Drug_Target_53_General_References:
10871367	Hitomi K, Okamoto K, Daiyasu H, Miyashita H, Iwai S, Toh H, Ishiura M, Todo T: Bacterial cryptochrome and photolyase: characterization of two photolyase-like genes of Synechocystis sp. PCC6803. Nucleic Acids Res. 2000 Jun 15;28(12):2353-62.
12535521	Brudler R, Hitomi K, Daiyasu H, Toh H, Kucho K, Ishiura M, Kanehisa M, Roberts VA, Todo T, Tainer JA, Getzoff ED: Identification of a new cryptochrome class. Structure, function, and evolution. Mol Cell. 2003 Jan;11(1):59-67.
8905231	Kaneko T, Sato S, Kotani H, Tanaka A, Asamizu E, Nakamura Y, Miyajima N, Hirosawa M, Sugiura M, Sasamoto S, Kimura T, Hosouchi T, Matsuno A, Muraki A, Nakazaki N, Naruo K, Okumura S, Shimpo S, Takeuchi C, Wada T, Watanabe A, Yamada M, Yasuda M, Tabata S: Sequence analysis of the genome of the unicellular cyanobacterium Synechocystis sp. strain PCC6803. II. Sequence determination of the entire genome and assignment of potential protein-coding regions. DNA Res. 1996 Jun 30;3(3):109-36.

# Drug_Target_53_HGNC_ID:
Not Available

# Drug_Target_53_HPRD_ID:
Not Available

# Drug_Target_53_ID:
5083

# Drug_Target_53_Locus:
Not Available

# Drug_Target_53_Molecular_Weight:
57040

# Drug_Target_53_Name:
Cryptochrome DASH

# Drug_Target_53_Number_of_Residues:
489

# Drug_Target_53_PDB_ID:
1NP7

# Drug_Target_53_Pathway:
Not Available

# Drug_Target_53_Pfam_Domain_Function:
PF00875	DNA_photolyase
PF03441	FAD_binding_7

# Drug_Target_53_Protein_Sequence:
>Cryptochrome DASH
MKHVPPTVLVWFRNDLRLHDHEPLHRALKSGLAITAVYCYDPRQFAQTHQGFAKTGPWRS
NFLQQSVQNLAESLQKVGNKLLVTTGLPEQVIPQIAKQINAKTIYYHREVTQEELDVERN
LVKQLTILGIEAKGYWGSTLCHPEDLPFSIQDLPDLFTKFRKDIEKKKISIRPCFFAPSQ
LLPSPNIKLELTAPPPEFFPQINFDHRSVLAFQGGETAGLARLQDYFWHGDRLKDYKETR
NGMVGADYSSKFSPWLALGCLSPRFIYQEVKRYEQERVSNDSTHWLIFELLWRDFFRFVA
QKYGNKLFNRGGLLNKNFPWQEDQVRFELWRSGQTGYPLVDANMRELNLTGFMSNRGRQN
VASFLCKNLGIDWRWGAEWFESCLIDYDVCSNWGNWNYTAGIGNDARDFRYFNIPKQSQQ
YDPQGTYLRHWLPELKNLPGDKIHQPWLLSATEQKQWGVQLGVDYPRPCVNFHQSVEARR
KIEQMGVIA

# Drug_Target_53_Reaction:
Not Available

# Drug_Target_53_Signals:
None

# Drug_Target_53_Specific_Function:
May have a photoreceptor function. Binds DNA; represses transcription of at least 8 genes, including slr0364 and slr1866. Does not encode a DNA photolyase function. Its disruption does not affect circadian rhythm

# Drug_Target_53_SwissProt_ID:
P77967

# Drug_Target_53_SwissProt_Name:
CRYD_SYNY3

# Drug_Target_53_Synonyms:
Not Available

# Drug_Target_53_Theoretical_pI:
8.80

# Drug_Target_53_Transmembrane_Regions:
None

# Drug_Target_54_Cellular_Location:
Mitochondrion
mitochondrial matrix

# Drug_Target_54_Chromosome_Location:
Not Available

# Drug_Target_54_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.

# Drug_Target_54_Essentiality:
Non-Essential

# Drug_Target_54_GenAtlas_ID:
DLD

# Drug_Target_54_GenBank_ID_Gene:
J03490

# Drug_Target_54_GenBank_ID_Protein:
307137

# Drug_Target_54_GeneCard_ID:
DLD

# Drug_Target_54_Gene_Name:
DLD

# Drug_Target_54_Gene_Sequence:
>1530 bp
ATGCAGAGCTGGAGTCGTGTGTACTGCTCCTTGGCCAAGAGAGGCCATTTCAATCGAATA
TCTCATGGCCTACAGGGACTTTCTGCAGTGCCTCTGAGAACTTACGCAGATCAGCCGATT
GATGCTGATGTAACAGTTATAGGTTCTGGTCCTGGAGGATATGTTGCTGCTATTAAAGCT
GCCCAGTTAGGCTTCAAGACAGTCTGCATTGAGAAAAATGAAACACTTGGTGGAACATGC
TTGAATGTTGGTTGTATTCCTTCTAAGGCTTTATTGAACAACTCTCATTATTACCATATG
GCCCATGGAACAGATTTTGCATCTAGAGGAATTGAAATGTCCGAAGTTCGCTTGAATTTA
GACAAGATGATGGAGCAGAAGAGTACTGCAGTAAAAGCTTTAACAGGTGGAATTGCCCAC
TTATTCAAACAGAATAAGGTTGTTCATGTCAATGGATATGGAAAGATAACTGGCAAAAAT
CAAGTCACTGCTACGAAAGCTGATGGCGGCACTCAGGTTATTGATACAAAGAACATTCTT
ATAGCCACGGGTTCAGAAGTTACTCCTTTTCCTGGAATCACGATAGATGAAGATACAATA
GTGTCATCTACAGGTGCTTTATCTTTAAAAAAAGTTCCAGAAAAGATGGTTGTTATTGGT
GCAGGAGTAATAGGTGTAGAATTGGGTTCAGTTTGGCAAAGACTTGGTGCAGATGTGACA
GCAGTTGAATTTTTAGGTCATGTAGGTGGAGTTGGAATTGATATGGAGATATCTAAAAAC
TTTCAACGCATCCTTCAAAAACAGGGGTTTAAATTTAAATTGAATACAAAGGTTACTGGT
GCTACCAAGAAGTCAGATGGAAAAATTGATGTTTCTATTGAAGCTGCTTCTGGTGGTAAA
GCTGAAGTTATCACTTGTGATGTACTCTTGGTTTGCATTGGCCGACGACCCTTTACTAAG
AATTTGGGACTAGAAGAGCTGGGAATTGAACTAGATCCTAGAGGTAGAATTCCAGTCAAT
ACCAGATTTCAAACTAAAATTCCAAATATCTATGCCATTGGTGATGTAGTTGCTGGTCCA
ATGCTGGCTCACAAAGCAGAGGATGAAGGCATTATCTGTGTTGAAGGAATGGCTGGTGGT
GCTGTGCACATTGACTACAATTGTGTGCCATCAGTGATTTACACACACCCTGAAGTTGCT
TGGGTTGGCAAATCAGAAGAGCAGTTGAAAGAAGAGGGTATTGAGTACAAAGTTGGGAAA
TTCCCATTTGCTGCTAACAGCAGAGCTAAGACAAATGCTGACACAGATGGCATGGTGAAG
ATCCTTGGGCAGAAATCGACAGACAGAGTACTGGGAGCACATATTCTTGGACCAGGTGCT
GGAGAAATGGTAAATGAAGCTGCTCTTGCTTTGGAATATGGAGCATCCTGTGAAGATATA
GCTAGAGTCTGTCATGCACATCCGACCTTATCAGAAGCTTTTAGAGAAGCAAATCTTGCT
GCGTCATTTGGCAAATCAATCAACTTTTGA

# Drug_Target_54_General_Function:
Energy production and conversion

# Drug_Target_54_General_References:
1332063	Johanning GL, Morris JI, Madhusudhan KT, Samols D, Patel MS: Characterization of the transcriptional regulatory region of the human dihydrolipoamide dehydrogenase gene. Proc Natl Acad Sci U S A. 1992 Nov 15;89(22):10964-8.
3278312	Pons G, Raefsky-Estrin C, Carothers DJ, Pepin RA, Javed AA, Jesse BW, Ganapathi MK, Samols D, Patel MS: Cloning and cDNA sequence of the dihydrolipoamide dehydrogenase component human alpha-ketoacid dehydrogenase complexes. Proc Natl Acad Sci U S A. 1988 Mar;85(5):1422-6.
3693355	Otulakowski G, Robinson BH: Isolation and sequence determination of cDNA clones for porcine and human lipoamide dehydrogenase. Homology to other disulfide oxidoreductases. J Biol Chem. 1987 Dec 25;262(36):17313-8.
8406489	Feigenbaum AS, Robinson BH: The structure of the human dihydrolipoamide dehydrogenase gene (DLD) and its upstream elements. Genomics. 1993 Aug;17(2):376-81.
8506365	Liu TC, Kim H, Arizmendi C, Kitano A, Patel MS: Identification of two missense mutations in a dihydrolipoamide dehydrogenase-deficient patient. Proc Natl Acad Sci U S A. 1993 Jun 1;90(11):5186-90.
8968745	Hong YS, Kerr DS, Craigen WJ, Tan J, Pan Y, Lusk M, Patel MS: Identification of two mutations in a compound heterozygous child with dihydrolipoamide dehydrogenase deficiency. Hum Mol Genet. 1996 Dec;5(12):1925-30.
9934985	Shaag A, Saada A, Berger I, Mandel H, Joseph A, Feigenbaum A, Elpeleg ON: Molecular basis of lipoamide dehydrogenase deficiency in Ashkenazi Jews. Am J Med Genet. 1999 Jan 15;82(2):177-82.

# Drug_Target_54_HGNC_ID:
HGNC:2898

# Drug_Target_54_HPRD_ID:
02006

# Drug_Target_54_ID:
812

# Drug_Target_54_Locus:
7q31-q32

# Drug_Target_54_Molecular_Weight:
54151

# Drug_Target_54_Name:
Dihydrolipoyl dehydrogenase, mitochondrial

# Drug_Target_54_Number_of_Residues:
509

# Drug_Target_54_PDB_ID:
Not Available

# Drug_Target_54_Pathway:
Not Available

# Drug_Target_54_Pfam_Domain_Function:
PF00070	Pyr_redox
PF02852	Pyr_redox_dim
PF07992	Pyr_redox_2

# Drug_Target_54_Protein_Sequence:
>Dihydrolipoyl dehydrogenase, mitochondrial precursor
MQSWSRVYCSLAKRGHFNRISHGLQGLSAVPLRTYADQPIDADVTVIGSGPGGYVAAIKA
AQLGFKTVCIEKNETLGGTCLNVGCIPSKALLNNSHYYHMAHGTDFASRGIEMSEVRLNL
DKMMEQKSTAVKALTGGIAHLFKQNKVVHVNGYGKITGKNQVTATKADGGTQVIDTKNIL
IATGSEVTPFPGITIDEDTIVSSTGALSLKKVPEKMVVIGAGVIGVELGSVWQRLGADVT
AVEFLGHVGGVGIDMEISKNFQRILQKQGFKFKLNTKVTGATKKSDGKIDVSIEAASGGK
AEVITCDVLLVCIGRRPFTKNLGLEELGIELDPRGRIPVNTRFQTKIPNIYAIGDVVAGP
MLAHKAEDEGIICVEGMAGGAVHIDYNCVPSVIYTHPEVAWVGKSEEQLKEEGIEYKVGK
FPFAANSRAKTNADTDGMVKILGQKSTDRVLGAHILGPGAGEMVNEAALALEYGASCEDI
ARVCHAHPTLSEAFREANLAASFGKSINF

# Drug_Target_54_Reaction:
protein N6-(dihydrolipoyl)lysine + NAD+ = protein N6-(lipoyl)lysine + NADH + H+ ALL_REAC (other) R00209 R01698 R03815 R07618

# Drug_Target_54_Signals:
None

# Drug_Target_54_Specific_Function:
Lipoamide dehydrogenase is a component of the glycine cleavage system as well as of the alpha-ketoacid dehydrogenase complexes

# Drug_Target_54_SwissProt_ID:
P09622

# Drug_Target_54_SwissProt_Name:
DLDH_HUMAN

# Drug_Target_54_Synonyms:
Dihydrolipoamide dehydrogenase
Dihydrolipoyl dehydrogenase, mitochondrial precursor
EC 1.8.1.4
Glycine cleavage system L protein

# Drug_Target_54_Theoretical_pI:
7.76

# Drug_Target_54_Transmembrane_Regions:
None

# Drug_Target_55_Cellular_Location:
Periplasm

# Drug_Target_55_Chromosome_Location:
Not Available

# Drug_Target_55_Drug_References:
Not Available

# Drug_Target_55_Essentiality:
Non-Essential

# Drug_Target_55_GenAtlas_ID:
Not Available

# Drug_Target_55_GenBank_ID_Gene:
AJ236923

# Drug_Target_55_GenBank_ID_Protein:
Not Available

# Drug_Target_55_GeneCard_ID:
Not Available

# Drug_Target_55_Gene_Name:
ifcA

# Drug_Target_55_Gene_Sequence:
>1767 bp
ATGAAACTAAAATATCTGGTATCAGCGATGGCATTGGTTGTGCTTTCCTCTGGTACTGCA
ATGGCTAAAACCCCCGATATGGGGTCATTCCATGCTGACATGGGCAGTTGTCAATCTTGT
CACGCCAAACCTATCAAGGTTACTGATAGCGAAACTCATGAAAATGCTCAGTGTAAATCA
TGCCACGGAGAGTACGCTGAACTGGCTAATGACAAATTACAGTTTGACCCACACAATTCA
CATTTAGGTGACATTAACTGTACTAGTTGCCATAAAGGCCATGAAGAACCAAAATTTTAC
TGTAATGAGTGTCATTCATTTGATATCAAGCCGATGCCATTTTCTGATGCCAAGAAGAAA
AAATCTTGGGACGACGGATGGGATCAAGACAAAATTCAAAAAGCGATTGCTGCAGGCCCA
AGTGAAACAACGCAAGTATTAGTAGTCGGTGCGGGTAGTGCAGGTTTTAACGCATCATTA
GCCGCTAAAAAAGCCGGTGCTAATGTTATTTTGGTGGATAAAGCACCGTTCAGTGGTGGT
AATTCTATGATTTCAGCTGGTGGTATGAATGCTGTTGGAACTAAGCAGCAAACAGCTCAT
GGTGTTGAAGATAAAGTTGAATGGTTTATCGAAGATGCCATGAAAGGCGGCCGTCAACAG
AATGATATAAAACTGGTGACTATTCTTGCTGAACAGTCTGCTGATGGTGTGCAATGGTTA
GAGTCTTTAGGTGCAAACTTAGATGACTTAAAACGCTCAGGTGGTGCTCGTGTCGACCGT
ACTCATCGTCCACATGGAGGTAAAAGCTCTGGGCCAGAAATTATTGATACTTTACGCAAA
GCGGCCAAAGAACAGGGTATTGATACACGACTAAACTCTCGTGTAGTTAAGTTAGTGGTT
AATGACGATCATAGTGTTGTCGGCGCCGTGGTTCATGGTAAACATACTGGCTATTACATG
ATTGGTGCTAAATCTGTTGTGCTAGCAACGGGTGGTTATGGCATGAATAAAGAAATGATT
GCTTATTACCGTCCAACAATGAAAGACATGACCAGTTCGAACAACATTACCGCCACTGGT
GATGGTGTATTGATGGCAAAAGAAATTGGTGCCAGCATGACCGATATCGACTGGGTTCAA
GCTCACCCAACAGTGGGTAAAGACAGCCGTATTCTGATTTCAGAAACCGTCCGTGGTGTG
GGCGCTGTGATGGTAAACAAAGACGGTAATCGCTTTATTAGCGAGTTAACAACTCGTGAC
AAAGCATCTGATGCTATCTTAAAACAACCTGGCCAGTTTGCTTGGATTATTTTTGATAAC
CAGTTATACAAAAAAGCCAAAATGGTACGCGGTTATGACCATTTAGAAATGCTTTACAAA
GGCGATACTGTTGAACAGTTAGCGAAGAGCACCGGTATGAAAGTCGCTGATTTAGCTAAA
ACAGTCTCTGACTACAATGGTTATGTAGCATCTGGTAAAGACACTGCGTTTGGTCGTGCT
GATATGCCATTGAACATGACCCAAAGTCCTTACTATGCCGTTAAAGTTGCTCCTGGTATT
CATCACACTATGGGTGGTGTCGCGATTAACACAACAGCGTCTGTACTTGACCTTCAAAGT
AAGCCAATTGACGGTTTGTTTGCCGCAGGTGAAGTGACTGGTGGTGTTCATGGTTACAAC
CGTTTGGGCGGTAATGCAATAGCAGATACCGTGGTCTTCGGTCGAATTGCAGGAGATAAC
GCAGCCAAGCATGCTCTAGATAAATAG

# Drug_Target_55_General_Function:
Involved in oxidoreductase activity

# Drug_Target_55_General_References:
10455032	Dobbin PS, Butt JN, Powell AK, Reid GA, Richardson DJ: Characterization of a flavocytochrome that is induced during the anaerobic respiration of Fe3+ by Shewanella frigidimarina NCIMB400. Biochem J. 1999 Sep 1;342 ( Pt 2):439-48.
10581549	Bamford V, Dobbin PS, Richardson DJ, Hemmings AM: Open conformation of a flavocytochrome c3 fumarate reductase. Nat Struct Biol. 1999 Dec;6(12):1104-7.

# Drug_Target_55_HGNC_ID:
Not Available

# Drug_Target_55_HPRD_ID:
Not Available

# Drug_Target_55_ID:
4912

# Drug_Target_55_Locus:
Not Available

# Drug_Target_55_Molecular_Weight:
62947

# Drug_Target_55_Name:
Fumarate reductase flavoprotein subunit

# Drug_Target_55_Number_of_Residues:
588

# Drug_Target_55_PDB_ID:
1QO8

# Drug_Target_55_Pathway:
Not Available

# Drug_Target_55_Pfam_Domain_Function:
PF00890	FAD_binding_2

# Drug_Target_55_Protein_Sequence:
>Fumarate reductase flavoprotein subunit
MKLKYLVSAMALVVLSSGTAMAKTPDMGSFHADMGSCQSCHAKPIKVTDSETHENAQCKS
CHGEYAELANDKLQFDPHNSHLGDINCTSCHKGHEEPKFYCNECHSFDIKPMPFSDAKKK
KSWDDGWDQDKIQKAIAAGPSETTQVLVVGAGSAGFNASLAAKKAGANVILVDKAPFSGG
NSMISAGGMNAVGTKQQTAHGVEDKVEWFIEDAMKGGRQQNDIKLVTILAEQSADGVQWL
ESLGANLDDLKRSGGARVDRTHRPHGGKSSGPEIIDTLRKAAKEQGIDTRLNSRVVKLVV
NDDHSVVGAVVHGKHTGYYMIGAKSVVLATGGYGMNKEMIAYYRPTMKDMTSSNNITATG
DGVLMAKEIGASMTDIDWVQAHPTVGKDSRILISETVRGVGAVMVNKDGNRFISELTTRD
KASDAILKQPGQFAWIIFDNQLYKKAKMVRGYDHLEMLYKGDTVEQLAKSTGMKVADLAK
TVSDYNGYVASGKDTAFGRADMPLNMTQSPYYAVKVAPGIHHTMGGVAINTTASVLDLQS
KPIDGLFAAGEVTGGVHGYNRLGGNAIADTVVFGRIAGDNAAKHALDK

# Drug_Target_55_Reaction:
Not Available

# Drug_Target_55_Signals:
1-22

# Drug_Target_55_Specific_Function:
Catalyzes unidirectional fumarate reduction using artificial electron donors such as methyl viologen. The physiological reductant is unknown

# Drug_Target_55_SwissProt_ID:
Q9Z4P0

# Drug_Target_55_SwissProt_Name:
FRD2_SHEFN

# Drug_Target_55_Synonyms:
EC 1.3.99.1
Fumarate reductase flavoprotein subunit precursor
Ifc3
Iron(III)-induced flavocytochrome C3

# Drug_Target_55_Theoretical_pI:
7.69

# Drug_Target_55_Transmembrane_Regions:
None

# Drug_Target_56_Cellular_Location:
Not Available

# Drug_Target_56_Chromosome_Location:
Not Available

# Drug_Target_56_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.

# Drug_Target_56_Essentiality:
Non-Essential

# Drug_Target_56_GenAtlas_ID:
Not Available

# Drug_Target_56_GenBank_ID_Gene:
Not Available

# Drug_Target_56_GenBank_ID_Protein:
Not Available

# Drug_Target_56_GeneCard_ID:
Not Available

# Drug_Target_56_Gene_Name:
CYB5R1

# Drug_Target_56_Gene_Sequence:
Not Available

# Drug_Target_56_General_Function:
Not Available

# Drug_Target_56_General_References:
Not Available

# Drug_Target_56_HGNC_ID:
Not Available

# Drug_Target_56_HPRD_ID:
Not Available

# Drug_Target_56_ID:
7017

# Drug_Target_56_Locus:
Not Available

# Drug_Target_56_Molecular_Weight:
Not Available

# Drug_Target_56_Name:
NADH-cytochrome b5 reductase 1

# Drug_Target_56_Number_of_Residues:
0

# Drug_Target_56_PDB_ID:
Not Available

# Drug_Target_56_Pathway:
Not Available

# Drug_Target_56_Pfam_Domain_Function:
Not Available

# Drug_Target_56_Protein_Sequence:
Not Available

# Drug_Target_56_Reaction:
Not Available

# Drug_Target_56_Signals:
Not Available

# Drug_Target_56_Specific_Function:
Not Available

# Drug_Target_56_SwissProt_ID:
Q9UHQ9

# Drug_Target_56_SwissProt_Name:
NB5R1_HUMAN

# Drug_Target_56_Synonyms:
Not Available

# Drug_Target_56_Theoretical_pI:
Not Available

# Drug_Target_56_Transmembrane_Regions:
Not Available

# Drug_Target_57_Cellular_Location:
Not Available

# Drug_Target_57_Chromosome_Location:
Not Available

# Drug_Target_57_Drug_References:
Not Available

# Drug_Target_57_Essentiality:
Non-Essential

# Drug_Target_57_GenAtlas_ID:
Not Available

# Drug_Target_57_GenBank_ID_Gene:
Not Available

# Drug_Target_57_GenBank_ID_Protein:
Not Available

# Drug_Target_57_GeneCard_ID:
Not Available

# Drug_Target_57_Gene_Name:
Not Available

# Drug_Target_57_Gene_Sequence:
Not Available

# Drug_Target_57_General_Function:
Involved in oxidoreductase activity

# Drug_Target_57_General_References:
11397813	Coulombe R, Yue KQ, Ghisla S, Vrielink A: Oxygen access to the active site of cholesterol oxidase through a narrow channel is gated by an Arg-Glu pair. J Biol Chem. 2001 Aug 10;276(32):30435-41. Epub 2001 Jun 7.

# Drug_Target_57_HGNC_ID:
Not Available

# Drug_Target_57_HPRD_ID:
Not Available

# Drug_Target_57_ID:
4725

# Drug_Target_57_Locus:
Not Available

# Drug_Target_57_Molecular_Weight:
61520

# Drug_Target_57_Name:
Oxidoreductase

# Drug_Target_57_Number_of_Residues:
561

# Drug_Target_57_PDB_ID:
1I19

# Drug_Target_57_Pathway:
Not Available

# Drug_Target_57_Pfam_Domain_Function:
PF01565	FAD_binding_4

# Drug_Target_57_Protein_Sequence:
>Oxidoreductase
STGPVAPLPTPPNFPNDIALFQQAYQNWSKEIMLDATWVCSPKTPQDVVRLANWAHEHDY
KIRPRGAMHGWTPLTVEKGANVEKVILADTMTHLNGITVNTGGPVATVTAGAGASIEAIV
TELQKHDLGWANLPAPGVLSIGGALAVNAHGAALPAVGQTTLPGHTYGSLSNLVTELTAV
VWNGTTYALETYQRNDPRITPLLTNLGRCFLTSVTMQAGPNFRQRCQSYTDIPWRELFAP
KGADGRTFEKFVAESGGAEAIWYPFTEKPWMKVWTVSPTKPDSSNEVGSLGSAGSLVGKP
PQAREVSGPYNYIFSDNLPEPITDMIGAINAGNPGIAPLFGPAMYEITKLGLAATNANDI
WGWSKDVQFYIKATTLRLTEGGGAVVTSRANIATVINDFTEWFHERIEFYRAKGEFPLNG
PVEIRCCGLDQAADVKVPSVGPPTISATRPRPDHPDWDVAIWLNVLGVPGTPGMFEFYRE
MEQWMRSHYNNDDATFRPEWSKGWAFGPDPYTDNDIVTNKMRATYIEGVPTTENWDTARA
RYNQIDPHRVFTNGFMDKLLP

# Drug_Target_57_Reaction:
Not Available

# Drug_Target_57_Signals:
None

# Drug_Target_57_Specific_Function:
Not Available

# Drug_Target_57_SwissProt_ID:
Q7SID9

# Drug_Target_57_SwissProt_Name:
Q7SID9_BREST

# Drug_Target_57_Synonyms:
Not Available

# Drug_Target_57_Theoretical_pI:
5.47

# Drug_Target_57_Transmembrane_Regions:
None

# Drug_Target_58_Cellular_Location:
Mitochondrion

# Drug_Target_58_Chromosome_Location:
Not Available

# Drug_Target_58_Drug_References:
Not Available

# Drug_Target_58_Essentiality:
Non-Essential

# Drug_Target_58_GenAtlas_ID:
MAOB

# Drug_Target_58_GenBank_ID_Gene:
S62734

# Drug_Target_58_GenBank_ID_Protein:
398415

# Drug_Target_58_GeneCard_ID:
MAOB

# Drug_Target_58_Gene_Name:
MAOB

# Drug_Target_58_Gene_Sequence:
>1560 bp
ATGAGCAACAAATGCGACGTGGTCGTGGTGGGGGGCGGCATCTCAGGTATGGCAGCAGCC
AAACTTCTGCATGACTCTGGACTGAATGTGGTTGTTCTGGAAGCCCGGGACCGTGTGGGA
GGCAGGACTTACACTCTTAGGAACCAAAAGGTTAAATATGTGGACCTTGGAGGATCCTAT
GTTGGACCAACCCAGAATCGTATCTTGAGATTAGCCAAGGAGCTAGGATTGGAGACCTAC
AAAGTGAATGAGGTTGAGCGTCTGATCCACCATGTAAAGGGCAAATCATACCCCTTCAGG
GGGCCATTCCCACCTGTATGGAATCCAATTACCTACTTAGATCATAACAACTTTTGGAGG
ACAATGGATGACATGGGGCGAGAGATTCCGAGTGATGCCCCATGGAAGGCTCCCCTTGCA
GAAGAGTGGGACAACATGACAATGAAGGAGCTACTGGACAAGCTCTGCTGGACTGAATCT
GCAAAGCAGCTTGCCACTCTCTTTGTGAACCTGTGTGTCACTGCAGAGACCCATGAGGTC
TCTGCTCTCTGGTTCCTGTGGTATGTGAAGCAGTGTGGAGGCACAACAAGAATCATCTCG
ACAACAAATGGAGGACAGGAGAGGAAATTTGTGGGCGGATCTGGTCAAGTGAGTGAGCGG
ATAATGGACCTCCTTGGAGACCGAGTGAAGCTGGAGAGGCCTGTGATCTACATTGACCAG
ACAAGAGAAAATGTCCTTGTGGAGACCCTAAACCATGAGATGTATGAGGCTAAATATGTG
ATTAGTGCTATTCCTCCTACTCTGGGCATGAAGATTCACTTCAATCCCCCTCTGCCAATG
ATGAGAAACCAGATGATCACTCGTGTGCCTTTGGGTTCAGTCATCAAGTGTATAGTTTAT
TATAAAGAGCCTTTCTGGAGGAAAAAGGATTACTGTGGAACCATGATTATTGATGGAGAA
GAAGCTCCAGTTGCCTACACGTTGGATGATACCAAACCTGAAGGCAACTATGCTGCCATA
ATGGGATTTATCCTGGCCCACAAAGCCAGAAAACTGGCACGTCTTACCAAAGAGGAAAGG
TTGAAGAAACTTTGTGAACTCTATGCCAAGGTTCTGGGTTCCCTAGAAGCTCTGGAGCCA
GTGCATTATGAAGAAAAGAACTGGTGTGAGGAGCAGTACTCTGGGGGCTGCTACACAACT
TATTTCCCCCCTGGGATCCTGACTCAATATGGAAGGGTTCTACGCCAGCCAGTGGACAGG
ATTTACTTTGCAGGCACCGAGACTGCCACACACTGGAGCGGCTACATGGAGGGGGCTGTA
GAGGCCGGGGAGAGAGCAGCCCGAGAGATCCTGCATGCCATGGGGAAGATTCCAGAGGAT
GAAATCTGGCAGTCAGAACCAGAGTCTGTGGATGTCCCTGCACAGCCCATCACCACCACC
TTTTTGGAGAGACATTTGCCCTCCGTGCCAGGCCTGCTCAGGCTGATTGGATTGACCACC
ATCTTTTCAGCAACGGCTCTTGGCTTCCTGGCCCACAAAAGGGGGCTACTTGTGAGAGTC

# Drug_Target_58_General_Function:
Amino acid transport and metabolism

# Drug_Target_58_General_References:
11049757	Newton-Vinson P, Hubalek F, Edmondson DE: High-level expression of human liver monoamine oxidase B in Pichia pastoris. Protein Expr Purif. 2000 Nov;20(2):334-45.
11753429	Binda C, Newton-Vinson P, Hubalek F, Edmondson DE, Mattevi A: Structure of human monoamine oxidase B, a drug target for the treatment of neurological disorders. Nat Struct Biol. 2002 Jan;9(1):22-6.
1432104	Zhu QS, Grimsby J, Chen K, Shih JC: Promoter organization and activity of human monoamine oxidase (MAO) A and B genes. J Neurosci. 1992 Nov;12(11):4437-46.
2023912	Grimsby J, Chen K, Wang LJ, Lan NC, Shih JC: Human monoamine oxidase A and B genes exhibit identical exon-intron organization. Proc Natl Acad Sci U S A. 1991 May 1;88(9):3637-41.
3387449	Bach AW, Lan NC, Johnson DL, Abell CW, Bembenek ME, Kwan SW, Seeburg PH, Shih JC: cDNA cloning of human liver monoamine oxidase A and B: molecular basis of differences in enzymatic properties. Proc Natl Acad Sci U S A. 1988 Jul;85(13):4934-8.
8515265	Chen K, Wu HF, Shih JC: The deduced amino acid sequences of human platelet and frontal cortex monoamine oxidase B are identical. J Neurochem. 1993 Jul;61(1):187-90.

# Drug_Target_58_HGNC_ID:
HGNC:6834

# Drug_Target_58_HPRD_ID:
02401

# Drug_Target_58_ID:
3939

# Drug_Target_58_Locus:
Xp11.23

# Drug_Target_58_Molecular_Weight:
58764

# Drug_Target_58_Name:
Amine oxidase [flavin-containing] B

# Drug_Target_58_Number_of_Residues:
520

# Drug_Target_58_PDB_ID:
2BK3

# Drug_Target_58_Pathway:
Not Available

# Drug_Target_58_Pfam_Domain_Function:
PF01593	Amino_oxidase

# Drug_Target_58_Protein_Sequence:
>Amine oxidase [flavin-containing] B
MSNKCDVVVVGGGISGMAAAKLLHDSGLNVVVLEARDRVGGRTYTLRNQKVKYVDLGGSY
VGPTQNRILRLAKELGLETYKVNEVERLIHHVKGKSYPFRGPFPPVWNPITYLDHNNFWR
TMDDMGREIPSDAPWKAPLAEEWDNMTMKELLDKLCWTESAKQLATLFVNLCVTAETHEV
SALWFLWYVKQCGGTTRIISTTNGGQERKFVGGSGQVSERIMDLLGDRVKLERPVIYIDQ
TRENVLVETLNHEMYEAKYVISAIPPTLGMKIHFNPPLPMMRNQMITRVPLGSVIKCIVY
YKEPFWRKKDYCGTMIIDGEEAPVAYTLDDTKPEGNYAAIMGFILAHKARKLARLTKEER
LKKLCELYAKVLGSLEALEPVHYEEKNWCEEQYSGGCYTTYFPPGILTQYGRVLRQPVDR
IYFAGTETATHWSGYMEGAVEAGERAAREILHAMGKIPEDEIWQSEPESVDVPAQPITTT
FLERHLPSVPGLLRLIGLTTIFSATALGFLAHKRGLLVRV

# Drug_Target_58_Reaction:
RCH2NH2 + H2O + O2 = RCHO + NH3 + H2O2

# Drug_Target_58_Signals:
None

# Drug_Target_58_Specific_Function:
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral tissues. MAOB preferentially degrades benzylamine and phenylethylamine

# Drug_Target_58_SwissProt_ID:
P27338

# Drug_Target_58_SwissProt_Name:
AOFB_HUMAN

# Drug_Target_58_Synonyms:
EC 1.4.3.4
MAO-B
Monoamine oxidase type B

# Drug_Target_58_Theoretical_pI:
7.55

# Drug_Target_58_Transmembrane_Regions:
490-516

# Drug_Target_59_Cellular_Location:
Not Available

# Drug_Target_59_Chromosome_Location:
Not Available

# Drug_Target_59_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.

# Drug_Target_59_Essentiality:
Non-Essential

# Drug_Target_59_GenAtlas_ID:
Not Available

# Drug_Target_59_GenBank_ID_Gene:
Not Available

# Drug_Target_59_GenBank_ID_Protein:
Not Available

# Drug_Target_59_GeneCard_ID:
Not Available

# Drug_Target_59_Gene_Name:
FDXR

# Drug_Target_59_Gene_Sequence:
Not Available

# Drug_Target_59_General_Function:
Not Available

# Drug_Target_59_General_References:
Not Available

# Drug_Target_59_HGNC_ID:
Not Available

# Drug_Target_59_HPRD_ID:
Not Available

# Drug_Target_59_ID:
6990

# Drug_Target_59_Locus:
Not Available

# Drug_Target_59_Molecular_Weight:
Not Available

# Drug_Target_59_Name:
NADPH:adrenodoxin oxidoreductase, mitochondrial

# Drug_Target_59_Number_of_Residues:
0

# Drug_Target_59_PDB_ID:
Not Available

# Drug_Target_59_Pathway:
Not Available

# Drug_Target_59_Pfam_Domain_Function:
Not Available

# Drug_Target_59_Protein_Sequence:
Not Available

# Drug_Target_59_Reaction:
Not Available

# Drug_Target_59_Signals:
Not Available

# Drug_Target_59_Specific_Function:
Not Available

# Drug_Target_59_SwissProt_ID:
P22570

# Drug_Target_59_SwissProt_Name:
ADRO_HUMAN

# Drug_Target_59_Synonyms:
Not Available

# Drug_Target_59_Theoretical_pI:
Not Available

# Drug_Target_59_Transmembrane_Regions:
Not Available

# Drug_Target_5_Cellular_Location:
Mitochondrion
mitochondrial matrix

# Drug_Target_5_Chromosome_Location:
Not Available

# Drug_Target_5_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_5_Essentiality:
Non-Essential

# Drug_Target_5_GenAtlas_ID:
GCDH

# Drug_Target_5_GenBank_ID_Gene:
U69141

# Drug_Target_5_GenBank_ID_Protein:
1549327

# Drug_Target_5_GeneCard_ID:
GCDH

# Drug_Target_5_Gene_Name:
GCDH

# Drug_Target_5_Gene_Sequence:
>1317 bp
ATGGCCCTGAGAGGCGTCTCCGTGCGGCTGCTGAGCCGCGGACCCGGCCTGCACGTCCTT
CGCACGTGGGTCTCGTCGGCGGCGCAGACCGAGAAAGGCGGGAGAACACAGAGCCAACTG
GCTAAGTCCTCGCGTCCCGAGTTTGACTGGCAGGACCCGCTGGTGCTGGAGGAGCAGCTG
ACCACAGATGAGATCCTCATCAGGGACACCTTCCGCACCTACTGCCAGGAGAGACTCATG
CCTCGCATCCTGTTGGCCAATCGCAACGAAGTTTTTCATCGGGAGATCATTTCGGAGATG
GGGGAGTTGGGTGTGCTGGGCCCCACCATCAAAGGATATGGCTGTGCTGGGGTTTCGTCT
GTGGCCTATGGGCTCCTGGCCCGAGAGCTGGAGCGGGTGGACAGTGGCTACAGGTCGGCG
ATGAGTGTCCAGTCCTCCCTCGTCATGCACCCTATCTATGCCTATGGCAGCGAGGAACAG
CGGCAGAAGTACCTGCCCCAGCTGGCCAAGGGGGAGCTCCTGGGCTGCTTCGGGCTCACA
GAGCCCAACAGCGGAAGTGACCCCAGCAGCATGGAGACCAGAGCCCACTACAACTCATCC
AACAAGAGCTACACCCTCAATGGGACCAAGACCTGGATCACGAACTCGCCTATGGCCGAT
CTGTTTGTAGTGTGGGCTCGGTGTGAAGATGGCTGCATTCGGGGCTTCCTGCTGGAGAAG
GGGATGCGGGGTCTCTCGGCCCCCAGGATCCAGGGCAAGTTCTCGCTGCGGGCCTCAGCC
ACAGGCATGATCATCATGGACGGTGTGGAGGTGCCAGAGGAGAATGTGCTCCCTGGTGCA
TCCAGCCTGGGGGGTCCCTTCGGCTGCCTGAACAACGCCCGGTACGGCATCGCGTGGGGC
GTGCTTGGAGCTTCGGAGTTCTGCTTGCACACAGCCCGGCAGTACGCCCTCGACAGGATG
CAGTTTGGTGTCCCACTGGCCAGGAACCAGCTGATTCAGAAGAAGCTGGCAGACATGCTC
ACTGAGATTACCCTGGGCCTTCACGCCTGCCTGCAGCTCGGCCGCTTGAAGGACCAGGAC
AAGGCTGCCCCCGAGATGGTTTCTCTGCTGAAGAGGAATAACTGTGGGAAAGCCCTGGAC
ATCGCCCGCCAGGCCCGAGACATGCTGGGGGGGAATGGGATTTCTGACGAGTATCACGTG
ATCCGGCACGCCATGAACCTGGAGGCCGTGAACACCTACGAAGGTACACATGACATTCAC
GCCCTGATCCTTGGGAGAGCTATCACGGGAATCCAGGCGTTCACGGCCAGCAAGTGA

# Drug_Target_5_General_Function:
Lipid transport and metabolism

# Drug_Target_5_General_References:
1438360	Goodman SI, Kratz LE, Frerman FE: Pork and human cDNAs encoding glutaryl-CoA dehydrogenase. Prog Clin Biol Res. 1992;375:169-73.
8541831	Goodman SI, Kratz LE, DiGiulio KA, Biery BJ, Goodman KE, Isaya G, Frerman FE: Cloning of glutaryl-CoA dehydrogenase cDNA, and expression of wild type and mutant enzymes in Escherichia coli. Hum Mol Genet. 1995 Sep;4(9):1493-8.
8900227	Biery BJ, Stein DE, Morton DH, Goodman SI: Gene structure and mutations of glutaryl-coenzyme A dehydrogenase: impaired association of enzyme subunits that is due to an A421V substitution causes glutaric acidemia type I in the Amish. Am J Hum Genet. 1996 Nov;59(5):1006-11.
8900228	Anikster Y, Shaag A, Joseph A, Mandel H, Ben-Zeev B, Christensen E, Elpeleg ON: Glutaric aciduria type I in the Arab and Jewish communities in Israel. Am J Hum Genet. 1996 Nov;59(5):1012-8.
9600243	Schwartz M, Christensen E, Superti-Furga A, Brandt NJ: The human glutaryl-CoA dehydrogenase gene: report of intronic sequences and of 13 novel mutations causing glutaric aciduria type I. Hum Genet. 1998 Apr;102(4):452-8.
9711871	Goodman SI, Stein DE, Schlesinger S, Christensen E, Schwartz M, Greenberg CR, Elpeleg ON: Glutaryl-CoA dehydrogenase mutations in glutaric acidemia (type I): review and report of thirty novel mutations. Hum Mutat. 1998;12(3):141-4.

# Drug_Target_5_HGNC_ID:
HGNC:4189

# Drug_Target_5_HPRD_ID:
01977

# Drug_Target_5_ID:
3506

# Drug_Target_5_Locus:
19p13.2

# Drug_Target_5_Molecular_Weight:
48128

# Drug_Target_5_Name:
Glutaryl-CoA dehydrogenase, mitochondrial

# Drug_Target_5_Number_of_Residues:
438

# Drug_Target_5_PDB_ID:
1SIR

# Drug_Target_5_Pathway:
Not Available

# Drug_Target_5_Pfam_Domain_Function:
PF00441	Acyl-CoA_dh_1
PF02770	Acyl-CoA_dh_M
PF02771	Acyl-CoA_dh_N

# Drug_Target_5_Protein_Sequence:
>Glutaryl-CoA dehydrogenase, mitochondrial precursor
MALRGVSVRLLSRGPGLHVLRTWVSSAAQTEKGGRTQSQLAKSSRPEFDWQDPLVLEEQL
TTDEILIRDTFRTYCQERLMPRILLANRNEVFHREIISEMGELGVLGPTIKGYGCAGVSS
VAYGLLARELERVDSGYRSAMSVQSSLVMHPIYAYGSEEQRQKYLPQLAKGELLGCFGLT
EPNSGSDPSSMETRAHYNSSNKSYTLNGTKTWITNSPMADLFVVWARCEDGCIRGFLLEK
GMRGLSAPRIQGKFSLRASATGMIIMDGVEVPEENVLPGASSLGGPFGCLNNARYGIAWG
VLGASEFCLHTARQYALDRMQFGVPLARNQLIQKKLADMLTEITLGLHACLQLGRLKDQD
KAAPEMVSLLKRNNCGKALDIARQARDMLGGNGISDEYHVIRHAMNLEAVNTYEGTHDIH
ALILGRAITGIQAFTASK

# Drug_Target_5_Reaction:
glutaryl-CoA + acceptor = crotonoyl-CoA + CO2 + reduced acceptor

# Drug_Target_5_Signals:
None

# Drug_Target_5_Specific_Function:
Catalyzes the oxidative decarboxylation of glutaryl-CoA to crotonyl-CoA and CO(2) in the degradative pathway of L-lysine, L-hydroxylysine, and L-tryptophan metabolism. It uses electron transfer flavoprotein as its electron acceptor. The short isoform is inactive

# Drug_Target_5_SwissProt_ID:
Q92947

# Drug_Target_5_SwissProt_Name:
GCDH_HUMAN

# Drug_Target_5_Synonyms:
EC 1.3.99.7
GCD
Glutaryl-CoA dehydrogenase, mitochondrial precursor

# Drug_Target_5_Theoretical_pI:
8.15

# Drug_Target_5_Transmembrane_Regions:
None

# Drug_Target_60_Cellular_Location:
Peroxisome

# Drug_Target_60_Chromosome_Location:
1

# Drug_Target_60_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.

# Drug_Target_60_Essentiality:
Non-Essential

# Drug_Target_60_GenAtlas_ID:
Not Available

# Drug_Target_60_GenBank_ID_Gene:
U07866

# Drug_Target_60_GenBank_ID_Protein:
495475

# Drug_Target_60_GeneCard_ID:
ACOX1

# Drug_Target_60_Gene_Name:
ACOX1

# Drug_Target_60_Gene_Sequence:
Not Available

# Drug_Target_60_General_Function:
Lipid transport and metabolism

# Drug_Target_60_General_References:
11815777	Suzuki Y, Iai M, Kamei A, Tanabe Y, Chida S, Yamaguchi S, Zhang Z, Takemoto Y, Shimozawa N, Kondo N: Peroxisomal acyl CoA oxidase deficiency. J Pediatr. 2002 Jan;140(1):128-30.
15489334	Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7.
17081983	Olsen JV, Blagoev B, Gnad F, Macek B, Kumar C, Mortensen P, Mann M: Global, in vivo, and site-specific phosphorylation dynamics in signaling networks. Cell. 2006 Nov 3;127(3):635-48.
18669648	Dephoure N, Zhou C, Villen J, Beausoleil SA, Bakalarski CE, Elledge SJ, Gygi SP: A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci U S A. 2008 Aug 5;105(31):10762-7. Epub 2008 Jul 31.
7876265	Chu R, Varanasi U, Chu S, Lin Y, Usuda N, Rao MS, Reddy JK: Overexpression and characterization of the human peroxisomal acyl-CoA oxidase in insect cells. J Biol Chem. 1995 Mar 3;270(9):4908-15.
8040306	Fournier B, Saudubray JM, Benichou B, Lyonnet S, Munnich A, Clevers H, Poll-The BT: Large deletion of the peroxisomal acyl-CoA oxidase gene in pseudoneonatal adrenoleukodystrophy. J Clin Invest. 1994 Aug;94(2):526-31.
8117268	Aoyama T, Tsushima K, Souri M, Kamijo T, Suzuki Y, Shimozawa N, Orii T, Hashimoto T: Molecular cloning and functional expression of a human peroxisomal acyl-coenzyme A oxidase. Biochem Biophys Res Commun. 1994 Feb 15;198(3):1113-8.
8159712	Varanasi U, Chu R, Chu S, Espinosa R, LeBeau MM, Reddy JK: Isolation of the human peroxisomal acyl-CoA oxidase gene: organization, promoter analysis, and chromosomal localization. Proc Natl Acad Sci U S A. 1994 Apr 12;91(8):3107-11.

# Drug_Target_60_HGNC_ID:
GNC:119

# Drug_Target_60_HPRD_ID:
Not Available

# Drug_Target_60_ID:
6639

# Drug_Target_60_Locus:
17q24-q25|17q25.1

# Drug_Target_60_Molecular_Weight:
74423.0

# Drug_Target_60_Name:
Peroxisomal acyl-coenzyme A oxidase 1

# Drug_Target_60_Number_of_Residues:
660

# Drug_Target_60_PDB_ID:
Not Available

# Drug_Target_60_Pathway:
Not Available

# Drug_Target_60_Pfam_Domain_Function:
PF01756	ACOX
PF02770	Acyl-CoA_dh_M

# Drug_Target_60_Protein_Sequence:
>Peroxisomal acyl-coenzyme A oxidase 1
MNPDLRRERDSASFNPELLTHILDGSPEKTRRRREIENMILNDPDFQHEDLNFLTRSQRY
EVAVRKSAIMVKKMREFGIADPDEIMWFKKLHLVNFVEPVGLNYSMFIPTLLNQGTTAQK
EKWLLSSKGLQIIGTYAQTEMGHGTHLRGLETTATYDPETQEFILNSPTVTSIKWWPGGL
GKTSNHAIVLAQLITKGKCYGLHAFIVPIREIGTHKPLPGITVGDIGPKFGYDEIDNGYL
KMDNHRIPRENMLMKYAQVKPDGTYVKPLSNKLTYGTMVFVRSFLVGEAARALSKACTIA
IRYSAVRHQSEIKPGEPEPQILDFQTQQYKLFPLLATAYAFQFVGAYMKETYHRINEGIG
QGDLSELPELHALTAGLKAFTSWTANTGIEACRMACGGHGYSHCSGLPNIYVNFTPSCTF
EGENTVMMLQTARFLMKSYDQVHSGKLVCGMVSYLNDLPSQRIQPQQVAVWPTMVDINSP
ESLTEAYKLRAARLVEIAAKNLQKEVIHRKSKEVAWNLTSVDLVRASEAHCHYVVVKLFS
EKLLKIQDKAIQAVLRSLCLLYSLYGISQNAGDFLQGSIMTEPQITQVNQRVKELLTLIR
SDAVALVDAFDFQDVTLGSVLGRYDGNVYENLFEWAKNSPLNKAEVHESYKHLKSLQSKL

# Drug_Target_60_Reaction:
Not Available

# Drug_Target_60_Signals:
None

# Drug_Target_60_Specific_Function:
Catalyzes the desaturation of very long chain acyl-CoAs to 2-trans-enoyl-CoAs

# Drug_Target_60_SwissProt_ID:
Q15067

# Drug_Target_60_SwissProt_Name:
ACOX1_HUMAN

# Drug_Target_60_Synonyms:
AOX
Palmitoyl-CoA oxidase
SCOX
Straight-chain acyl-CoA oxidase

# Drug_Target_60_Theoretical_pI:
8.29

# Drug_Target_60_Transmembrane_Regions:
None

# Drug_Target_61_Cellular_Location:
Cytoplasm (Probable)

# Drug_Target_61_Chromosome_Location:
Not Available

# Drug_Target_61_Drug_References:
Not Available

# Drug_Target_61_Essentiality:
Non-Essential

# Drug_Target_61_GenAtlas_ID:
Not Available

# Drug_Target_61_GenBank_ID_Gene:
M10123

# Drug_Target_61_GenBank_ID_Protein:
Not Available

# Drug_Target_61_GeneCard_ID:
Not Available

# Drug_Target_61_Gene_Name:
murB

# Drug_Target_61_Gene_Sequence:
>1029 bp
ATGAACCACTCCTTAAAACCCTGGAACACATTTGGCATTGATCATAATGCTCAGCACATT
GTATGTGCCGAAGACGAACAACAATTACTCAATGCCTGGCAGTATGCAACCGCAGAAGGA
CAACCCGTTCTTATTCTGGGTGAAGGAAGTAATGTACTTTTTCTGGAGGACTATCGCGGC
ACGGTGATCATCAACCGGATCAAAGGTATCGAAATTCATGATGAACCTGATGCGTGGTAT
TTACATGTAGGAGCCGGAGAAAACTGGCATCGTCTGGTAAAATACACTTTGCAGGAAGGT
ATGCCTGGTCTGGAAAATCTGGCATTAATTCCTGGTTGTGTCGGCTCATCACCTATCCAG
AATATTGGTGCTTATGGCGTAGAATTACAGCGAGTTTGCGCTTATGTTGATTCTGTTGAA
CTGGCGACAGGCAAGCAAGTGCGCTTAACTGCCAAAGAGTGCCGTTTTGGCTATCGCGAC
AGTATTTTTAAACATGAATACCAGGACCGCTTCGCTATTGTAGCCGTAGGTCTGCGTCTG
CCAAAAGAGTGGCAACCTGTACTAACGTATGGTGACTTAACTCGTCTGGATCCTACAACA
GTAACGCCACAGCAAGTATTTAATGCGGTGTGTCATATGCGCACCACCAAACTCCCTGAT
CCAAAAGTGAATGGCAATGCCGGTAGTTTCTTCAAAAACCCTGTTGTATCTGCCGAAACG
GCTAAAGCATTACTGTCACAATTTCCAACAGCACCAAATTACCCCCAGGCGGATGGTTCA
GTAAAACTGGCAGCAGGTTGGCTTATCGATCAGTGCCAGCTAAAAGGGATGCAAATAGGT
GGGGCTGCGGTGCACCGTCAACAGGCGTTAGTTCTCATTAATGAAGACAATGCAAAAAGC
GAAGATGTTGTACAGCTGGCGCATCATGTAAGACAGAAAGTTGGTGAAAAATTTAATGTC
TGGCTTGAGCCTGAAGTCCGCTTTATTGGTGCATCAGGTGAAGTGAGCGCAGTGGAGACA
ATTTCATGA

# Drug_Target_61_General_Function:
Involved in UDP-N-acetylmuramate dehydrogenase activity

# Drug_Target_61_General_References:
1311302	Pucci MJ, Discotto LF, Dougherty TJ: Cloning and identification of the Escherichia coli murB DNA sequence, which encodes UDP-N-acetylenolpyruvoylglucosamine reductase. J Bacteriol. 1992 Mar;174(5):1690-3.
3899863	Howard PK, Shaw J, Otsuka AJ: Nucleotide sequence of the birA gene encoding the biotin operon repressor and biotin holoenzyme synthetase functions of Escherichia coli. Gene. 1985;35(3):321-31.
7028991	Brosius J, Dull TJ, Sleeter DD, Noller HF: Gene organization and primary structure of a ribosomal RNA operon from Escherichia coli. J Mol Biol. 1981 May 15;148(2):107-27.
8265357	Blattner FR, Burland V, Plunkett G 3rd, Sofia HJ, Daniels DL: Analysis of the Escherichia coli genome. IV. DNA sequence of the region from 89.2 to 92.8 minutes. Nucleic Acids Res. 1993 Nov 25;21(23):5408-17.
8448160	Benson TE, Marquardt JL, Marquardt AC, Etzkorn FA, Walsh CT: Overexpression, purification, and mechanistic study of UDP-N-acetylenolpyruvylglucosamine reductase. Biochemistry. 1993 Mar 2;32(8):2024-30.
8805513	Benson TE, Walsh CT, Hogle JM: The structure of the substrate-free form of MurB, an essential enzyme for the synthesis of bacterial cell walls. Structure. 1996 Jan 15;4(1):47-54.
9020778	Benson TE, Walsh CT, Hogle JM: X-ray crystal structures of the S229A mutant and wild-type MurB in the presence of the substrate enolpyruvyl-UDP-N-acetylglucosamine at 1.8-A resolution. Biochemistry. 1997 Jan 28;36(4):806-11.
9150408	Constantine KL, Mueller L, Goldfarb V, Wittekind M, Metzler WJ, Yanchunas J Jr, Robertson JG, Malley MF, Friedrichs MS, Farmer BT 2nd: Characterization of NADP+ binding to perdeuterated MurB: backbone atom NMR assignments and chemical-shift changes. J Mol Biol. 1997 Apr 18;267(5):1223-46.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.

# Drug_Target_61_HGNC_ID:
Not Available

# Drug_Target_61_HPRD_ID:
Not Available

# Drug_Target_61_ID:
5091

# Drug_Target_61_Locus:
Not Available

# Drug_Target_61_Molecular_Weight:
37851

# Drug_Target_61_Name:
UDP-N-acetylenolpyruvoylglucosamine reductase

# Drug_Target_61_Number_of_Residues:
342

# Drug_Target_61_PDB_ID:
1MBT

# Drug_Target_61_Pathway:
Not Available

# Drug_Target_61_Pfam_Domain_Function:
PF01565	FAD_binding_4
PF02873	MurB_C

# Drug_Target_61_Protein_Sequence:
>UDP-N-acetylenolpyruvoylglucosamine reductase
MNHSLKPWNTFGIDHNAQHIVCAEDEQQLLNAWQYATAEGQPVLILGEGSNVLFLEDYRG
TVIINRIKGIEIHDEPDAWYLHVGAGENWHRLVKYTLQEGMPGLENLALIPGCVGSSPIQ
NIGAYGVELQRVCAYVDSVELATGKQVRLTAKECRFGYRDSIFKHEYQDRFAIVAVGLRL
PKEWQPVLTYGDLTRLDPTTVTPQQVFNAVCHMRTTKLPDPKVNGNAGSFFKNPVVSAET
AKALLSQFPTAPNYPQADGSVKLAAGWLIDQCQLKGMQIGGAAVHRQQALVLINEDNAKS
EDVVQLAHHVRQKVGEKFNVWLEPEVRFIGASGEVSAVETIS

# Drug_Target_61_Reaction:
Not Available

# Drug_Target_61_Signals:
None

# Drug_Target_61_Specific_Function:
Cell wall formation

# Drug_Target_61_SwissProt_ID:
P08373

# Drug_Target_61_SwissProt_Name:
MURB_ECOLI

# Drug_Target_61_Synonyms:
EC 1.1.1.158
UDP-N- acetylmuramate dehydrogenase

# Drug_Target_61_Theoretical_pI:
6.13

# Drug_Target_61_Transmembrane_Regions:
None

# Drug_Target_62_Cellular_Location:
Not Available

# Drug_Target_62_Chromosome_Location:
Not Available

# Drug_Target_62_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.

# Drug_Target_62_Essentiality:
Non-Essential

# Drug_Target_62_GenAtlas_ID:
Not Available

# Drug_Target_62_GenBank_ID_Gene:
Not Available

# Drug_Target_62_GenBank_ID_Protein:
Not Available

# Drug_Target_62_GeneCard_ID:
Not Available

# Drug_Target_62_Gene_Name:
GFER

# Drug_Target_62_Gene_Sequence:
Not Available

# Drug_Target_62_General_Function:
Not Available

# Drug_Target_62_General_References:
Not Available

# Drug_Target_62_HGNC_ID:
Not Available

# Drug_Target_62_HPRD_ID:
Not Available

# Drug_Target_62_ID:
7090

# Drug_Target_62_Locus:
Not Available

# Drug_Target_62_Molecular_Weight:
Not Available

# Drug_Target_62_Name:
FAD-linked sulfhydryl oxidase ALR

# Drug_Target_62_Number_of_Residues:
0

# Drug_Target_62_PDB_ID:
Not Available

# Drug_Target_62_Pathway:
Not Available

# Drug_Target_62_Pfam_Domain_Function:
Not Available

# Drug_Target_62_Protein_Sequence:
Not Available

# Drug_Target_62_Reaction:
Not Available

# Drug_Target_62_Signals:
Not Available

# Drug_Target_62_Specific_Function:
Not Available

# Drug_Target_62_SwissProt_ID:
P55789

# Drug_Target_62_SwissProt_Name:
ALR_HUMAN

# Drug_Target_62_Synonyms:
Not Available

# Drug_Target_62_Theoretical_pI:
Not Available

# Drug_Target_62_Transmembrane_Regions:
Not Available

# Drug_Target_63_Cellular_Location:
Cytoplasm (Probable)

# Drug_Target_63_Chromosome_Location:
Not Available

# Drug_Target_63_Drug_References:
Not Available

# Drug_Target_63_Essentiality:
Non-Essential

# Drug_Target_63_GenAtlas_ID:
Not Available

# Drug_Target_63_GenBank_ID_Gene:
BA000033

# Drug_Target_63_GenBank_ID_Protein:
Not Available

# Drug_Target_63_GeneCard_ID:
Not Available

# Drug_Target_63_Gene_Name:
murB

# Drug_Target_63_Gene_Sequence:
>924 bp
TTACGATTCCTTTGGATGTTCACCAATAATGCGAACTTCACGATTTAATTCAATGCCAAA
TTTTTCTTTGACGGTCTTTTGTACATAATGAATAAGGTTTTCATAATCTGTAGCAGTTCC
ATTGTCTACATTTACCATAAAACCAGCGTGTTTAGTTGAAACTTCAACGCCGCCAATACG
GTGACCTTGCAAATTAGAATCTTGTATCAATTTACCTGCAAAATGACCAGGCGGTCTTTG
GAATACACTACCACATGAAGGATACTCTAAAGGTTGTTTAGATTCTCTACGTTCTGTTAA
ATCATCCATTTTAGCTTGTATTTCAGTCATTTTACCAGGAGCTAAAGTAAATGCAGCTTC
TAATACAACTAAGTGTTCTTTTTGAATAATGCTATTACGATAATCTAACTCTAATTCTTT
TGTTGTAAGTTTAATTAACGAGCCTTGTTCGTTTACGCAAAGCGCATAGTCTATACAATC
TTTAACTTCGCCACCATAAGCGCCAGCATTCATATACACTGCACCACCGATTGAACCTGG
AATACCACATGCAAATTCAAGGCCAGTAAGTGCGTAATCACGAGCAACACGTGAGACATC
AATAATTGCAGCGCCGCTACCGGCTATTATCGCATCATCAGATACTTCGATATGATCTAG
TGATAATAAACTAATTACAATGCCACGAATACCACCTTCACGGATAATAATATTTGAGCC
ATTTCCTAAATATGTAACAGGAATCTCATTTTGATAGGCATATTTAACAACTGCTTGTAC
TTCTTCATTTTTAGTAGGGGTAATATAAAAGTCGGCATTACCACCTGTTTTAGTATAAGT
GTATCGTTTTAAAGGTTCATCAACTTTAATTTTTTCATTTGGGATAAGTTGTTGTAAAGC
TTGATAGATGTCTTTATTTATCAC

# Drug_Target_63_General_Function:
Involved in UDP-N-acetylmuramate dehydrogenase activity

# Drug_Target_63_General_References:
12044378	Baba T, Takeuchi F, Kuroda M, Yuzawa H, Aoki K, Oguchi A, Nagai Y, Iwama N, Asano K, Naimi T, Kuroda H, Cui L, Yamamoto K, Hiramatsu K: Genome and virulence determinants of high virulence community-acquired MRSA. Lancet. 2002 May 25;359(9320):1819-27.

# Drug_Target_63_HGNC_ID:
Not Available

# Drug_Target_63_HPRD_ID:
Not Available

# Drug_Target_63_ID:
5093

# Drug_Target_63_Locus:
Not Available

# Drug_Target_63_Molecular_Weight:
33798

# Drug_Target_63_Name:
UDP-N-acetylenolpyruvoylglucosamine reductase

# Drug_Target_63_Number_of_Residues:
307

# Drug_Target_63_PDB_ID:
1HSK

# Drug_Target_63_Pathway:
Not Available

# Drug_Target_63_Pfam_Domain_Function:
PF01565	FAD_binding_4
PF02873	MurB_C

# Drug_Target_63_Protein_Sequence:
>UDP-N-acetylenolpyruvoylglucosamine reductase
MINKDIYQALQQLIPNEKIKVDEPLKRYTYTKTGGNADFYITPTKNEEVQAVVKYAYQNE
IPVTYLGNGSNIIIREGGIRGIVISLLSLDHIEVSDDAIIAGSGAAIIDVSRVARDYALT
GLEFACGIPGSIGGAVYMNAGAYGGEVKDCIDYALCVNEQGSLIKLTTKELELDYRNSII
QKEHLVVLEAAFTLAPGKMTEIQAKMDDLTERRESKQPLEYPSCGSVFQRPPGHFAGKLI
QDSNLQGHRIGGVEVSTKHAGFMVNVDNGTATDYENLIHYVQKTVKEKFGIELNREVRII
GEHPKES

# Drug_Target_63_Reaction:
Not Available

# Drug_Target_63_Signals:
None

# Drug_Target_63_Specific_Function:
Cell wall formation (By similarity)

# Drug_Target_63_SwissProt_ID:
P61432

# Drug_Target_63_SwissProt_Name:
MURB_STAAW

# Drug_Target_63_Synonyms:
EC 1.1.1.158
UDP-N- acetylmuramate dehydrogenase

# Drug_Target_63_Theoretical_pI:
5.25

# Drug_Target_63_Transmembrane_Regions:
None

# Drug_Target_64_Cellular_Location:
Cytoplasm

# Drug_Target_64_Chromosome_Location:
Not Available

# Drug_Target_64_Drug_References:
Not Available

# Drug_Target_64_Essentiality:
Non-Essential

# Drug_Target_64_GenAtlas_ID:
Not Available

# Drug_Target_64_GenBank_ID_Gene:
X58872

# Drug_Target_64_GenBank_ID_Protein:
Not Available

# Drug_Target_64_GeneCard_ID:
Not Available

# Drug_Target_64_Gene_Name:
hmp

# Drug_Target_64_Gene_Sequence:
>1191 bp
ATGCTTGACGCTCAAACCATCGCTACAGTAAAAGCCACCATCCCTTTACTGGTGGAAACG
GGGCCAAAGTTAACCGCCCATTTCTACGACCGTATGTTTACTCATAACCCAGAACTCAAA
GAAATTTTTAACATGAGTAACCAGCGTAATGGCGATCAACGTGAAGCCCTGTTTAACGCT
ATTGCCGCCTACGCCAGTAATATTGAAAACCTGCCTGCGCTGCTGCCAGCGGTAGAAAAA
ATCGCGCAGAAGCACACCAGCTTCCAGATCAAACCGGAACAGTACAACATCGTCGGTGAA
CACCTGTTGGCAACGCTGGACGAAATGTTCAGCCCGGGGCAGGAAGTGCTGGACGCGTGG
GGTAAAGCCTATGGTGTACTGGCTAATGTATTTATCAATCGCGAGGCGGAAATCTATAAC
GAAAACGCCAGCAAAGCCGGTGGTTGGGAAGGTACTCGCGATTTCCGCATTGTGGCTAAA
ACACCGCGCAGCGCGCTTATCACCAGCTTCGAACTGGAGCCGGTCGACGGTGGCGCAGTG
GCAGAATACCGTCCGGGGCAATATCTCGGCGTCTGGCTGAAGCCGGAAGGTTTCCCACAT
CAGGAAATTCGTCAGTACTCTTTGACTCGCAAACCGGATGGCAAAGGCTATCGTATTGCG
GTGAAACGCGAAGAGGGTGGGCAGGTATCCAACTGGTTGCACAATCACGCCAATGTTGGC
GATGTCGTGAAACTGGTCGCTCCGGCAGGTGATTTCTTTATGGCTGTCGCAGATGACACA
CCAGTGACGTTAATCTCTGCCGGTGTTGGTCAAACGCCAATGCTGGCAATGCTCGACACG
CTGGCAAAAGCAGGCCACACAGCACAAGTGAACTGGTTCCATGCGGCAGAAAATGGCGAT
GTTCACGCCTTTGCCGATGAAGTTAAGGAACTGGGGCAGTCACTGCCGCGCTTTACCGCG
CACACCTGGTATCGTCAGCCGAGCGAAGCCGATCGCGCTAAAGGTCAGTTTGATAGCGAA
GGTCTGATGGATTTGAGCAAACTGGAAGGTGCGTTCAGCGATCCGACAATGCAGTTCTAT
CTCTGCGGCCCGGTTGGCTTCATGCAGTTTACCGCGAAACAGTTAGTGGATCTGGGCGTG
AAGCAGGAAAACATTCATTACGAATGCTTTGGCCCGCATAAGGTGCTGTAA

# Drug_Target_64_General_Function:
Involved in oxidoreductase activity

# Drug_Target_64_General_References:
1325799	Orii Y, Ioannidis N, Poole RK: The oxygenated flavohaemoglobin from Escherichia coli: evidence from photodissociation and rapid-scan studies for two kinetic and spectral forms. Biochem Biophys Res Commun. 1992 Aug 31;187(1):94-100.
1601132	Andrews SC, Shipley D, Keen JN, Findlay JB, Harrison PM, Guest JR: The haemoglobin-like protein (HMP) of Escherichia coli has ferrisiderophore reductase activity and its C-terminal domain shares homology with ferredoxin NADP+ reductases. FEBS Lett. 1992 May 18;302(3):247-52.
2034230	Vasudevan SG, Armarego WL, Shaw DC, Lilley PE, Dixon NE, Poole RK: Isolation and nucleotide sequence of the hmp gene that encodes a haemoglobin-like protein in Escherichia coli K-12. Mol Gen Genet. 1991 Apr;226(1-2):49-58.
6190704	Plamann MD, Stauffer GV: Characterization of the Escherichia coli gene for serine hydroxymethyltransferase. Gene. 1983 Apr;22(1):9-18.
8292013	Eschenbrenner M, Coves J, Fontecave M: Ferric reductases in Escherichia coli: the contribution of the haemoglobin-like protein. Biochem Biophys Res Commun. 1994 Jan 14;198(1):127-31.
9205837	Yamamoto Y, Aiba H, Baba T, Hayashi K, Inada T, Isono K, Itoh T, Kimura S, Kitagawa M, Makino K, Miki T, Mitsuhashi N, Mizobuchi K, Mori H, Nakade S, Nakamura Y, Nashimoto H, Oshima T, Oyama S, Saito N, Sampei G, Satoh Y, Sivasundaram S, Tagami H, Horiuchi T, et al.: Construction of a contiguous 874-kb sequence of the Escherichia coli -K12 genome corresponding to 50.0-68.8 min on the linkage map and analysis of its sequence features. DNA Res. 1997 Apr 28;4(2):91-113.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.
9298646	Link AJ, Robison K, Church GM: Comparing the predicted and observed properties of proteins encoded in the genome of Escherichia coli K-12. Electrophoresis. 1997 Aug;18(8):1259-313.
9724711	Gardner PR, Gardner AM, Martin LA, Salzman AL: Nitric oxide dioxygenase: an enzymic function for flavohemoglobin. Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10378-83.

# Drug_Target_64_HGNC_ID:
Not Available

# Drug_Target_64_HPRD_ID:
Not Available

# Drug_Target_64_ID:
4969

# Drug_Target_64_Locus:
Not Available

# Drug_Target_64_Molecular_Weight:
43868

# Drug_Target_64_Name:
Flavohemoprotein

# Drug_Target_64_Number_of_Residues:
396

# Drug_Target_64_PDB_ID:
1GVH

# Drug_Target_64_Pathway:
Not Available

# Drug_Target_64_Pfam_Domain_Function:
PF00042	Globin
PF00175	NAD_binding_1
PF00970	FAD_binding_6

# Drug_Target_64_Protein_Sequence:
>Flavohemoprotein
MLDAQTIATVKATIPLLVETGPKLTAHFYDRMFTHNPELKEIFNMSNQRNGDQREALFNA
IAAYASNIENLPALLPAVEKIAQKHTSFQIKPEQYNIVGEHLLATLDEMFSPGQEVLDAW
GKAYGVLANVFINREAEIYNENASKAGGWEGTRDFRIVAKTPRSALITSFELEPVDGGAV
AEYRPGQYLGVWLKPEGFPHQEIRQYSLTRKPDGKGYRIAVKREEGGQVSNWLHNHANVG
DVVKLVAPAGDFFMAVADDTPVTLISAGVGQTPMLAMLDTLAKAGHTAQVNWFHAAENGD
VHAFADEVKELGQSLPRFTAHTWYRQPSEADRAKGQFDSEGLMDLSKLEGAFSDPTMQFY
LCGPVGFMQFTAKQLVDLGVKQENIHYECFGPHKVL

# Drug_Target_64_Reaction:
Not Available

# Drug_Target_64_Signals:
None

# Drug_Target_64_Specific_Function:
Various electron acceptors are also reduced by HMP in vitro, including dihydropterine, ferrisiderophores, ferric citrate, cytochrome c, nitrite, S-nitrosoglutathione, and alkylhydroperoxides. However, it is unknown if these reactions are of any biological significance in vivo

# Drug_Target_64_SwissProt_ID:
P24232

# Drug_Target_64_SwissProt_Name:
HMP_ECOLI

# Drug_Target_64_Synonyms:
EC 1.14.12.17
Flavohemoglobin
HMP
Hemoglobin-like protein
NO oxygenase
NOD
Nitric oxide dioxygenase

# Drug_Target_64_Theoretical_pI:
5.57

# Drug_Target_64_Transmembrane_Regions:
None

# Drug_Target_65_Cellular_Location:
Not Available

# Drug_Target_65_Chromosome_Location:
Not Available

# Drug_Target_65_Drug_References:
Not Available

# Drug_Target_65_Essentiality:
Non-Essential

# Drug_Target_65_GenAtlas_ID:
Not Available

# Drug_Target_65_GenBank_ID_Gene:
AF140605

# Drug_Target_65_GenBank_ID_Protein:
Not Available

# Drug_Target_65_GeneCard_ID:
Not Available

# Drug_Target_65_Gene_Name:
pheA2

# Drug_Target_65_Gene_Sequence:
>486 bp
ATGGACGATCGCTTATTTCGCAATGCAATGGGGAAATTTGCTACAGGGGTTACGGTAATT
ACGACGGAGCTTAACGGGGCTGTCCATGGAATGACGGCAAACGCCTTTATGTCTGTTTCC
TTAAATCCGAAACTTGTGTTGGTTTCCATTGGAGAAAAAGCGAAAATGCTGGAAAAAATT
CAACAATCGAAAAAATATGCAGTTAACATTTTGTCACAGGATCAAAAAGTGCTTTCGATG
AATTTTGCCGGACAGCTGGAAAAACCAGTAGATGTGCAATTCGAAGAGCTGGGGGGACTG
CCGGTCATTAAAGATGCTCTTGCACAAATTTCCTGCCAAGTTGTTAACGAAGTTCAAGCA
GGCGATCATACCCTTTTCATTGGGGAAGTGACAGATATAAAAATTACAGAGCAAGATCCG
CTTCTGTTTTTTAGCGGAAAATATCATCAGCTTGCCCAAAACGAAAAAGTGGAGACGTCG
AGCTAA

# Drug_Target_65_General_Function:
Involved in oxidoreductase activity

# Drug_Target_65_General_References:
11054550	Duffner FM, Kirchner U, Bauer MP, Muller R: Phenol/cresol degradation by the thermophilic Bacillus thermoglucosidasius A7: cloning and sequence analysis of five genes involved in the pathway. Gene. 2000 Oct 3;256(1-2):215-21.

# Drug_Target_65_HGNC_ID:
Not Available

# Drug_Target_65_HPRD_ID:
Not Available

# Drug_Target_65_ID:
4486

# Drug_Target_65_Locus:
Not Available

# Drug_Target_65_Molecular_Weight:
17659

# Drug_Target_65_Name:
Phenol 2-hydroxylase component B

# Drug_Target_65_Number_of_Residues:
161

# Drug_Target_65_PDB_ID:
1RZ1

# Drug_Target_65_Pathway:
Not Available

# Drug_Target_65_Pfam_Domain_Function:
PF01613	Flavin_Reduct

# Drug_Target_65_Protein_Sequence:
>Phenol 2-hydroxylase component B
MDDRLFRNAMGKFATGVTVITTELNGAVHGMTANAFMSVSLNPKLVLVSIGEKAKMLEKI
QQSKKYAVNILSQDQKVLSMNFAGQLEKPVDVQFEELGGLPVIKDALAQISCQVVNEVQA
GDHTLFIGEVTDIKITEQDPLLFFSGKYHQLAQNEKVETSS

# Drug_Target_65_Reaction:
Not Available

# Drug_Target_65_Signals:
None

# Drug_Target_65_Specific_Function:
Not Available

# Drug_Target_65_SwissProt_ID:
Q9LAG2

# Drug_Target_65_SwissProt_Name:
Q9LAG2_BACTR

# Drug_Target_65_Synonyms:
Not Available

# Drug_Target_65_Theoretical_pI:
5.22

# Drug_Target_65_Transmembrane_Regions:
None

# Drug_Target_66_Cellular_Location:
Not Available

# Drug_Target_66_Chromosome_Location:
Not Available

# Drug_Target_66_Drug_References:
Not Available

# Drug_Target_66_Essentiality:
Non-Essential

# Drug_Target_66_GenAtlas_ID:
Not Available

# Drug_Target_66_GenBank_ID_Gene:
AB029373

# Drug_Target_66_GenBank_ID_Protein:
Not Available

# Drug_Target_66_GeneCard_ID:
Not Available

# Drug_Target_66_Gene_Name:
metF

# Drug_Target_66_Gene_Sequence:
>687 bp
ATGAAAATACGGGACCTCCTCAAGGCGCGGCGGGGCCCGCTTTTCTCCTTTGAGTTCTTC
CCCCCGAAGGACCCGGAGGGGGAGGAGGCCCTCTTCCGCACCCTGGAGGAGCTCAAGGCC
TTCCGCCCCGCCTTCGTCTCCATCACCTACGGGGCCATGGGGAGCACCCGGGAGAGGAGC
GTGGCCTGGGCCCAGAGGATCCAGAGCCTCGGCCTCAACCCCCTCGCCCACCTCACCGTG
GCGGGCCAGAGCCGGAAGGAGGTGGCCGAGGTCCTCCACCGCTTCGTGGAAAGCGGTGTG
GAAAACCTCCTCGCCCTCCGGGGCGACCCCCCAAGAGGGGAAAGGGTCTTCCGCCCCCAC
CCGGAGGGTTTCCGCTACGCGGCGGAGCTCGTGGCCCTCATCCGGGAGCGGTACGGGGAC
CGGGTCTCCGTGGGCGGGGCGGCTTACCCCGAGGGGCACCCGGAAAGCGAGAGCCTCGAG
GCCGACCTCCGCCACTTCAAGGCCAAGGTGGAGGCGGGGCTGGACTTCGCCATCACCCAG
CTCTTCTTCAACAACGCCCACTACTTCGGCTTCCTGGAGCGGGCGAGGCGGGCGGGCATC
GGGATCCCCATCCTCCCCGGGATCATGCCCGTCACCAGCTACCGCCAGTCCGCCGCTTCA
CCGAGGTCTGCGGGGCGAGCATCCCCG

# Drug_Target_66_General_Function:
Involved in methylenetetrahydrofolate reductase (NADPH) activity

# Drug_Target_66_General_References:
Not Available

# Drug_Target_66_HGNC_ID:
Not Available

# Drug_Target_66_HPRD_ID:
Not Available

# Drug_Target_66_ID:
5094

# Drug_Target_66_Locus:
Not Available

# Drug_Target_66_Molecular_Weight:
25476

# Drug_Target_66_Name:
5,10-methylenetetrahydrofolate reductase

# Drug_Target_66_Number_of_Residues:
229

# Drug_Target_66_PDB_ID:
1V93

# Drug_Target_66_Pathway:
Not Available

# Drug_Target_66_Pfam_Domain_Function:
PF02219	MTHFR

# Drug_Target_66_Protein_Sequence:
>5,10-methylenetetrahydrofolate reductase
MKIRDLLKARRGPLFSFEFFPPKDPEGEEALFRTLEELKAFRPAFVSITYGAMGSTRERS
VAWAQRIQSLGLNPLAHLTVAGQSRKEVAEVLHRFVESGVENLLALRGDPPRGERVFRPH
PEGFRYAAELVALIRERYGDRVSVGGAAYPEGHPESESLEADLRHFKAKVEAGLDFAITQ
LFFNNAHYFGFLERARRAGIGIPILPGIMPVTSYRQSAASPRSAGRASP

# Drug_Target_66_Reaction:
Not Available

# Drug_Target_66_Signals:
None

# Drug_Target_66_Specific_Function:
Not Available

# Drug_Target_66_SwissProt_ID:
Q9RA47

# Drug_Target_66_SwissProt_Name:
Q9RA47_THETH

# Drug_Target_66_Synonyms:
Not Available

# Drug_Target_66_Theoretical_pI:
10.06

# Drug_Target_66_Transmembrane_Regions:
None

# Drug_Target_67_Cellular_Location:
Not Available

# Drug_Target_67_Chromosome_Location:
Not Available

# Drug_Target_67_Drug_References:
Not Available

# Drug_Target_67_Essentiality:
Non-Essential

# Drug_Target_67_GenAtlas_ID:
Not Available

# Drug_Target_67_GenBank_ID_Gene:
J05406

# Drug_Target_67_GenBank_ID_Protein:
Not Available

# Drug_Target_67_GeneCard_ID:
Not Available

# Drug_Target_67_Gene_Name:
camA

# Drug_Target_67_Gene_Sequence:
>1269 bp
GTGAACGCAAACGACAACGTGGTCATCGTCGGTACCGGACTGGCTGGCGTTGAGGTCGCC
TTCGGCCTGCGCGCCAGCGGCTGGGAAGGCAATATCCGGTTGGTGGGGGATGCGACGGTA
ATTCCCCATCACCTACCACCGCTATCCAAAGCTTACTTGGCCGGCAAAGCCACAGCGGAA
AGCCTGTACCTGAGAACCCCAGATGCCTATGCAGCGCAGAACATCCAACTACTCGGAGGC
ACACAGGTAACGGCTATCAACCGCGACCGACAGCAAGTAATCCTATCGGATGGCCGGGCA
CTGGATTACGACCGGCTGGTATTGGCTACCGGAGGGCGTCCAAGACCCCTACCGGTGGCC
AGTGGCGCAGTTGGAAAGGCGAACAACTTTCGATACCTGCGCACACTCGAGGACGCCGAG
TGCATTCGCCGGCAGCTGATTGCGGATAACCGTCTGGTGGTGATTGGTGGCGGCTACATT
GGCCTTGAAGTGGCTGCCACCGCCATCAAGGCGAACATGCACGTCACCCTGCTTGATACG
GCAGCCCGGGTTCTGGAGCGGGTTACCGCCCCGCCGGTATCGGCCTTTTACGAGCACCTA
CACCGCGAAGCCGGCGTTGACATACGAACCGGCACGCAGGTGTGCGGGTTCGAGATGTCG
ACCGACCAACAGAAGGTTACTGCCGTCCTCTGCGAGGACGGCACAAGGCTGCCAGCGGAT
CTGGTAATCGCCGGGATTGGCCTGATACCAAACTGCGAGTTGGCCAGTGCGGCCGGCCTG
CAGGTTGATAACGGCATCGTGATCAACGAACACATGCAGACCTCTGATCCCTTGATCATG
GCCGTCGGCGACTGTGCCCGATTTCACAGTCAGCTCTATGACCGCTGGGTGCGTATCGAA
TCGGTGCCCAATGCCTTGGAGCAGGCACGAAAGATCGCCGCCATCCTCTGTGGCAAGGTG
CCACGCGATGAGGCGGCGCCCTGGTTCTGGTCCGATCAGTATGAGATCGGATTGAAGATG
GTCGGACTGTCCGAAGGGTACGACCGGATCATTGTCCGCGGCTCTTTGGCGCAACCCGAC
TTCAGCGTTTTCTACCTGCAGGGAGACCGGGTATTGGCGGTCGATACAGTGAACCGTCCA
GTGGAGTTCAACCAGTCAAAACAAATAATCACGGATCGTTTGCCGGTTGAACCAAACCTA
CTCGGTGACGAAAGCGTGCCGTTAAAGGAAATCATCGCCGCCGCCAAAGCTGAACTGAGT
AGTGCCTGA

# Drug_Target_67_General_Function:
Involved in oxidoreductase activity

# Drug_Target_67_General_References:
11524002	Sevrioukova IF, Hazzard JT, Tollin G, Poulos TL: Laser flash induced electron transfer in P450cam monooxygenase: putidaredoxin reductase-putidaredoxin interaction. Biochemistry. 2001 Sep 4;40(35):10592-600.
12011076	Sevrioukova IF, Poulos TL: Putidaredoxin reductase, a new function for an old protein. J Biol Chem. 2002 Jul 12;277(28):25831-9. Epub 2002 May 13.
2180940	Peterson JA, Lorence MC, Amarneh B: Putidaredoxin reductase and putidaredoxin. Cloning, sequence determination, and heterologous expression of the proteins. J Biol Chem. 1990 Apr 15;265(11):6066-73.
2613690	Koga H, Yamaguchi E, Matsunaga K, Aramaki H, Horiuchi T: Cloning and nucleotide sequences of NADH-putidaredoxin reductase gene (camA) and putidaredoxin gene (camB) involved in cytochrome P-450cam hydroxylase of Pseudomonas putida. J Biochem (Tokyo). 1989 Nov;106(5):831-6.
3003058	Unger BP, Gunsalus IC, Sligar SG: Nucleotide sequence of the Pseudomonas putida cytochrome P-450cam gene and its expression in Escherichia coli. J Biol Chem. 1986 Jan 25;261(3):1158-63.

# Drug_Target_67_HGNC_ID:
Not Available

# Drug_Target_67_HPRD_ID:
Not Available

# Drug_Target_67_ID:
5095

# Drug_Target_67_Locus:
Not Available

# Drug_Target_67_Molecular_Weight:
45580

# Drug_Target_67_Name:
Putidaredoxin reductase

# Drug_Target_67_Number_of_Residues:
422

# Drug_Target_67_PDB_ID:
1Q1W

# Drug_Target_67_Pathway:
Not Available

# Drug_Target_67_Pfam_Domain_Function:
PF00070	Pyr_redox
PF07992	Pyr_redox_2

# Drug_Target_67_Protein_Sequence:
>Putidaredoxin reductase
MNANDNVVIVGTGLAGVEVAFGLRASGWEGNIRLVGDATVIPHHLPPLSKAYLAGKATAE
SLYLRTPDAYAAQNIQLLGGTQVTAINRDRQQVILSDGRALDYDRLVLATGGRPRPLPVA
SGAVGKANNFRYLRTLEDAECIRRQLIADNRLVVIGGGYIGLEVAATAIKANMHVTLLDT
AARVLERVTAPPVSAFYEHLHREAGVDIRTGTQVCGFEMSTDQQKVTAVLCEDGTRLPAD
LVIAGIGLIPNCELASAAGLQVDNGIVINEHMQTSDPLIMAVGDCARFHSQLYDRWVRIE
SVPNALEQARKIAAILCGKVPRDEAAPWFWSDQYEIGLKMVGLSEGYDRIIVRGSLAQPD
FSVFYLQGDRVLAVDTVNRPVEFNQSKQIITDRLPVEPNLLGDESVPLKEIIAAAKAELS
SA

# Drug_Target_67_Reaction:
Not Available

# Drug_Target_67_Signals:
None

# Drug_Target_67_Specific_Function:
The oxidation of camphor by cytochrome P450-CAM requires the participation of a flavoprotein, putidaredoxin reductase, and an iron-sulfur protein, putidaredoxin, to mediate the transfer of electrons from NADH to P450 for oxygen activation

# Drug_Target_67_SwissProt_ID:
P16640

# Drug_Target_67_SwissProt_Name:
CAMA_PSEPU

# Drug_Target_67_Synonyms:
EC 1.18.1.-

# Drug_Target_67_Theoretical_pI:
5.29

# Drug_Target_67_Transmembrane_Regions:
None

# Drug_Target_68_Cellular_Location:
Not Available

# Drug_Target_68_Chromosome_Location:
Not Available

# Drug_Target_68_Drug_References:
Not Available

# Drug_Target_68_Essentiality:
Non-Essential

# Drug_Target_68_GenAtlas_ID:
Not Available

# Drug_Target_68_GenBank_ID_Gene:
BX842582

# Drug_Target_68_GenBank_ID_Protein:
Not Available

# Drug_Target_68_GeneCard_ID:
Not Available

# Drug_Target_68_Gene_Name:
lpdA

# Drug_Target_68_Gene_Sequence:
>1482 bp
TCAGTTACTCGTCGGTAGGTGGTGTGGCACCAAGGCTAGTTGTTCAGCCGCGTCTTGAGC
TGCCGTGCAGTCCAGATCGTCGTGCGCCATCAGCCGGCGGGCCGCCTCGGTTATCGAACC
CGACAACGATGGGTAAACGGCCAGTGTCTGGGCCAGCTCGTTGACGGTGATGCGGTTCTG
AACGGCTACGGCGATGGGCAGGATCAGCTCCGATGCGATCGGCGCCACCACCACGCCGCC
GATCACAACGCCGGTGGACCGCCGGCAGAAGATCTTGACGAACCCGTGACGCATCTCCGA
CATCTTGGCGCGCGCGTTGGTTCGTAACGGCAGCATGATGGTCCGGGCGGCCACCGAACC
GGCGTCGATGACCGATTGCGGCACCCCGACCGCGGCGATCTCGGGCCTGGTGAAAACCGT
CGCGGCCACCGTGCGTAACCGGATCGGGCTGACGCCCTCCCCCAGCGCGTGGTACATCGC
GATGCGGCCCTGCATTGCGGCGACCGACGCCAGGGGCAGCAAACCCGTGCAGTCGCCCGC
GGCGTAGATGCCGGTCGCCAACGTCCGCGACACCCGGTCCACGGTCAGGTAATTGCCCCG
GCCAAGCTGGATGCCGACCCGTTCCAGGCCCAGGCCGCTGGTGTTGGGCACCGACCCGAT
GGTCATCAGGGCGTGGCTGCCCTCGACGGTGCGACCGTCGGTCATCGTGACGAGCACCCC
GGCCCCGGTGCGGGTGACCGATGCTGCCCGGGCATTTTTGAACAGCCGGACTCCCCGTTC
GGCGAACGACTCTTCCAGGACCAGCGCAGCGTCAGCGTCCTCATACGGCAGCACGTGGTC
CTGGCTGGCCACCACCGTGACCGGCACCCCCAATTCGGTATAGGCGTCCACGAACTCAGC
ACCGGTAACCCCGGAGCCCACCACGATGAGGTGGTCGGGCAACGCGTCCAAGTCGTAGAG
CTGCCGCCAGGTCAGAATGCGCTCACCGTCCGGCTGGGCCGACGGCAGGATCCGCGGGCT
GGCGCCGGTGGCGACCAGCACGACGTCGGCCTCATGCTCACTGGTGGAGCCGTCGGCGGC
GGTCGCCTTAATGCGATGGCGCGCCAGACCCGGTGTGGAGTCGATCAACTCGCCCCGGCC
GGCGATCACCTGAACCCCCATGCTGAGCAGCTGGGCGGTGATGTCGGCCGACTGTGCGGC
GGCCAGCGTCTTGACCCGGGCATGGATTTGCGGCAACGAGATCTTGGCGTCGTCGAAGTC
GATATGAAAGCCCAGGTGCGGCGCTCGGCGCAGTTCGGTACGCAGCCCGGTGGAGGCGAT
GAACGTCTTCGACGGCACACAGTCGTCCAGTACGGCAGCCCCGCCGATGCCGTCGCAGTC
AATCACGGTAACTTGGGTTGTTTCCGGGTGTGAGGTGGCGGCCACCAGTGCGGCCTCGTA
ACCGGCCGGGCCGCCACCGAGGATCACGATGCGGGTCACCAC

# Drug_Target_68_General_Function:
Involved in oxidoreductase activity

# Drug_Target_68_General_References:
9634230	Cole ST, Brosch R, Parkhill J, Garnier T, Churcher C, Harris D, Gordon SV, Eiglmeier K, Gas S, Barry CE 3rd, Tekaia F, Badcock K, Basham D, Brown D, Chillingworth T, Connor R, Davies R, Devlin K, Feltwell T, Gentles S, Hamlin N, Holroyd S, Hornsby T, Jagels K, Krogh A, McLean J, Moule S, Murphy L, Oliver K, Osborne J, Quail MA, Rajandream MA, Rogers J, Rutter S, Seeger K, Skelton J, Squares R, Squares S, Sulston JE, Taylor K, Whitehead S, Barrell BG: Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature. 1998 Jun 11;393(6685):537-44.

# Drug_Target_68_HGNC_ID:
Not Available

# Drug_Target_68_HPRD_ID:
Not Available

# Drug_Target_68_ID:
5097

# Drug_Target_68_Locus:
Not Available

# Drug_Target_68_Molecular_Weight:
51490

# Drug_Target_68_Name:
PROBABLE DIHYDROLIPOAMIDE DEHYDROGENASE LPDA

# Drug_Target_68_Number_of_Residues:
493

# Drug_Target_68_PDB_ID:
1XDI

# Drug_Target_68_Pathway:
Not Available

# Drug_Target_68_Pfam_Domain_Function:
PF00070	Pyr_redox
PF02852	Pyr_redox_dim
PF07992	Pyr_redox_2

# Drug_Target_68_Protein_Sequence:
>PROBABLE DIHYDROLIPOAMIDE DEHYDROGENASE LPDA
MVTRIVILGGGPAGYEAALVAATSHPETTQVTVIDCDGIGGAAVLDDCVPSKTFIASTGL
RTELRRAPHLGFHIDFDDAKISLPQIHARVKTLAAAQSADITAQLLSMGVQVIAGRGELI
DSTPGLARHRIKATAADGSTSEHEADVVLVATGASPRILPSAQPDGERILTWRQLYDLDA
LPDHLIVVGSGVTGAEFVDAYTELGVPVTVVASQDHVLPYEDADAALVLEESFAERGVRL
FKNARAASVTRTGAGVLVTMTDGRTVEGSHALMTIGSVPNTSGLGLERVGIQLGRGNYLT
VDRVSRTLATGIYAAGDCTGLLPLASVAAMQGRIAMYHALGEGVSPIRLRTVAATVFTRP
EIAAVGVPQSVIDAGSVAARTIMLPLRTNARAKMSEMRHGFVKIFCRRSTGVVIGGVVVA
PIASELILPIAVAVQNRITVNELAQTLAVYPSLSGSITEAARRLMAHDDLDCTAAQDAAE
QLALVPHHLPTSN

# Drug_Target_68_Reaction:
Not Available

# Drug_Target_68_Signals:
None

# Drug_Target_68_Specific_Function:
Not Available

# Drug_Target_68_SwissProt_ID:
O53355

# Drug_Target_68_SwissProt_Name:
LPDA_MYCTU

# Drug_Target_68_Synonyms:
DIAPHORASE
DIHYDROLIPOYL DEHYDROGENASE
EC 1.8.1.4
LIPOAMIDE REDUCTASE
LIPOYL DEHYDROGENASE
NADH)

# Drug_Target_68_Theoretical_pI:
6.27

# Drug_Target_68_Transmembrane_Regions:
None

# Drug_Target_69_Cellular_Location:
Not Available

# Drug_Target_69_Chromosome_Location:
Not Available

# Drug_Target_69_Drug_References:
Not Available

# Drug_Target_69_Essentiality:
Non-Essential

# Drug_Target_69_GenAtlas_ID:
Not Available

# Drug_Target_69_GenBank_ID_Gene:
U96128

# Drug_Target_69_GenBank_ID_Protein:
Not Available

# Drug_Target_69_GeneCard_ID:
Not Available

# Drug_Target_69_Gene_Name:
glf

# Drug_Target_69_Gene_Sequence:
>1200 bp
ATGCAACCGATGACCGCTCGTTTTGACCTTTTCGTCGTCGGCTCAGGATTCTTCGGCCTG
ACGATTGCCGAGCGCGTGGCCACCCAACTCGACAAGCGCGTGCTCGTCCTCGAGCGGCGC
CCGCACATCGGGGGCAATGCCTATTCCGAAGCCGAGCCACAGACCGGCATCGAGGTCCAC
AAGTACGGTGCGCACCTGTTTCACACCTCTAATAAGAGAGTGTGGGACTACGTGCGGCAG
TTCACCGACTTCACCGACTACCGGCACCGGGTCTTCGCGATGCACAACGGGCAGGCATAT
CAGTTTCCGATGGGGCTCGGCCTGGTATCGCAGTTCTTCGGCAAGTACTTCACGCCCGAG
CAAGCCCGCCAGCTGATCGCCGAGCAGGCCGCCGAGATCGACACCGCCGACGCGCAGAAC
CTCGAGGAGAAGGCCATCTCGCTGATCGGCCGGCCGCTCTACGAAGCGTTCGTCAAGGGG
TACACGGCCAAGCAATGGCAGACTGACCCCAAAGAACTTCCGGCCGCCAACATCACGCGG
CTTCCCGTGCGCTACACCTTCGACAACCGGTATTTCAGCGATACTTACGAGGGTTTGCCG
ACCGACGGGTACACGGCGTGGTTGCAAAACATGGCCGCTGACCACCGCATCGAGGTCAGG
CTGAACACCGACTGGTTCGACGTGCGCGGCCAGCTGCGCCCCGGCAGCCCGGCGGCCCCG
GTCGTTTACACCGGCCCGCTGGACCGCTACTTCGACTACGCCGAAGGCCGATTGGGCTGG
CGCACCTTGGACTTCGAGGTGGAAGTGCTACCGATCGGGGACTTTCAGGGCACCGCGGTG
ATGAACTACAACGATCTCGACGTCCCCTACACGCGCATCCACGAGTTCCGCCACTTCCAC
CCCGAGCGTGACTACCCAACGGACAAAACGGTGATCATGCGGGAATACTCCCGGTTCGCC
GAGGACGACGACGAGCCATACTATCCGATCAACACCGAGGCTGACCGCGCCCTGTTGGCC
ACCTATCGGGCCAGGGCGAAGTCCGAGACCGCGTCATCGAAGGTACTGTTCGGCGGCCGG
TTGGGCACCTACCAATATCTGGATATGCATATGGCCATTGCCAGCGCCTTGAACATGTAC
GACAACGTCCTCGCGCCGCATCTGCGCGACGGCGTCCCACTGCTTCAGGACGGCGCATGA

# Drug_Target_69_General_Function:
Involved in oxidoreductase activity

# Drug_Target_69_General_References:
12218036	Fleischmann RD, Alland D, Eisen JA, Carpenter L, White O, Peterson J, DeBoy R, Dodson R, Gwinn M, Haft D, Hickey E, Kolonay JF, Nelson WC, Umayam LA, Ermolaeva M, Salzberg SL, Delcher A, Utterback T, Weidman J, Khouri H, Gill J, Mikula A, Bishai W, Jacobs Jr WR Jr, Venter JC, Fraser CM: Whole-genome comparison of Mycobacterium tuberculosis clinical and laboratory strains. J Bacteriol. 2002 Oct;184(19):5479-90.
9634230	Cole ST, Brosch R, Parkhill J, Garnier T, Churcher C, Harris D, Gordon SV, Eiglmeier K, Gas S, Barry CE 3rd, Tekaia F, Badcock K, Basham D, Brown D, Chillingworth T, Connor R, Davies R, Devlin K, Feltwell T, Gentles S, Hamlin N, Holroyd S, Hornsby T, Jagels K, Krogh A, McLean J, Moule S, Murphy L, Oliver K, Osborne J, Quail MA, Rajandream MA, Rogers J, Rutter S, Seeger K, Skelton J, Squares R, Squares S, Sulston JE, Taylor K, Whitehead S, Barrell BG: Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature. 1998 Jun 11;393(6685):537-44.
9692181	Weston A, Stern RJ, Lee RE, Nassau PM, Monsey D, Martin SL, Scherman MS, Besra GS, Duncan K, McNeil MR: Biosynthetic origin of mycobacterial cell wall galactofuranosyl residues. Tuber Lung Dis. 1997;78(2):123-31.
9784509	Chen P, Bishai WR: Novel selection for isoniazid (INH) resistance genes supports a role for NAD+-binding proteins in mycobacterial INH resistance. Infect Immun. 1998 Nov;66(11):5099-106.

# Drug_Target_69_HGNC_ID:
Not Available

# Drug_Target_69_HPRD_ID:
Not Available

# Drug_Target_69_ID:
5099

# Drug_Target_69_Locus:
Not Available

# Drug_Target_69_Molecular_Weight:
45815

# Drug_Target_69_Name:
UDP-galactopyranose mutase

# Drug_Target_69_Number_of_Residues:
399

# Drug_Target_69_PDB_ID:
1V0J

# Drug_Target_69_Pathway:
Not Available

# Drug_Target_69_Pfam_Domain_Function:
PF01266	DAO
PF03275	GLF

# Drug_Target_69_Protein_Sequence:
>UDP-galactopyranose mutase
MQPMTARFDLFVVGSGFFGLTIAERVATQLDKRVLVLERRPHIGGNAYSEAEPQTGIEVH
KYGAHLFHTSNKRVWDYVRQFTDFTDYRHRVFAMHNGQAYQFPMGLGLVSQFFGKYFTPE
QARQLIAEQAAEIDTADAQNLEEKAISLIGRPLYEAFVKGYTAKQWQTDPKELPAANITR
LPVRYTFDNRYFSDTYEGLPTDGYTAWLQNMAADHRIEVRLNTDWFDVRGQLRPGSPAAP
VVYTGPLDRYFDYAEGRLGWRTLDFEVEVLPIGDFQGTAVMNYNDLDVPYTRIHEFRHFH
PERDYPTDKTVIMREYSRFAEDDDEPYYPINTEADRALLATYRARAKSETASSKVLFGGR
LGTYQYLDMHMAIASALNMYDNVLAPHLRDGVPLLQDGA

# Drug_Target_69_Reaction:
Not Available

# Drug_Target_69_Signals:
None

# Drug_Target_69_Specific_Function:
Not Available

# Drug_Target_69_SwissProt_ID:
O06934

# Drug_Target_69_SwissProt_Name:
O06934_MYCTU

# Drug_Target_69_Synonyms:
EC 5.4.99.9
NAD+-FLAVIN ADENINE DINUCLEOTIDE-REQUIRING ENZYME
UDP-GALACTOPYRANOSE MUTASE GLF
UDP-GALP MUTASE

# Drug_Target_69_Theoretical_pI:
5.60

# Drug_Target_69_Transmembrane_Regions:
None

# Drug_Target_6_Cellular_Location:
Mitochondrion
mitochondrial matrix

# Drug_Target_6_Chromosome_Location:
Not Available

# Drug_Target_6_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_6_Essentiality:
Non-Essential

# Drug_Target_6_GenAtlas_ID:
ACADM

# Drug_Target_6_GenBank_ID_Gene:
M91432

# Drug_Target_6_GenBank_ID_Protein:
187433

# Drug_Target_6_GeneCard_ID:
ACADM

# Drug_Target_6_Gene_Name:
ACADM

# Drug_Target_6_Gene_Sequence:
>1266 bp
ATGGCAGCGGGGTTCGGGCGATGCTGCAGGGTCCTGAGAAGTATTTCTCGTTTTCATTGG
AGATCACAGCATACAAAAGCCAATCGACAACGTGAACCAGGATTAGGATTTAGTTTTGAG
TTCACCGAACAGCAGAAAGAATTTCAAGCTACTGCTCGTAAATTTGCCAGAGAGGAAATC
ATCCCAGTGGCTGCAGAATATGATAAAACTGGTGAATATCCAGTCCCCCTAATTAGAAGA
GCCTGGGAACTTGGTTTAATGAACACACACATTCCAGAGAACTGTGGAGGTCTTGGACTT
GGAACTTTTGATGCTTGTTTAATTAGTGAAGAATTGGCTTATGGATGTACAGGGGTTCAG
ACTGCTATTGAAGGAAATTCTTTGGGGCAAATGCCTATTATTATTGCTGGAAATGATCAA
CAAAAGAAGAAGTATTTGGGGAGAATGACTGAGGAGCCATTGATGTGTGCTTATTGTGTA
ACAGAACCTGGAGCAGGCTCTGATGTAGCTGGTATAAAGACCAAAGCAGAAAAGAAAGGA
GATGAGTATATTATTAATGGTCAGAAGATGTGGATAACCAACGGAGGAAAAGCTAATTGG
TATTTTTTATTGGCACGTTCTGATCCAGATCCTAAAGCTCCTGCTAATAAAGCCTTTACT
GGATTCATTGTGGAAGCAGATACCCCAGGAATTCAGATTGGGAGAAAGGAATTAAACATG
GGCCAGCGATGTTCAGATACTAGAGGAATTGTCTTCGAAGATGTGAAAGTGCCTAAAGAA
AATGTTTTAATTGGTGACGGAGCTGGTTTCAAAGTTGCAATGGGAGCTTTTGATAAAACC
AGACCTGTAGTAGCTGCTGGTGCTGTTGGATTAGCACAAAGAGCTTTGGATGAAGCTACC
AAGTATGCCCTGGAAAGGAAAACTTTCGGAAAGCTACTTGTAGAGCACCAAGCAATATCA
TTTATGCTGGCTGAAATGGCAATGAAAGTTGAACTAGCTAGAATGAGTTACCAGAGAGCA
GCTTGGGAGGTTGATTCTGGTCGTCGAAATACCTATTATGCTTCTATTGCAAAGGCATTT
GCTGGAGATATTGCAAATCAGTTAGCTACTGATGCTGTGCAGATACTTGGAGGCAATGGA
TTTAATACAGAATATCCTGTAGAAAAACTAATGAGGGATGCCAAAATCTATCAGATTTAT
GAAGGTACTTCACAAATTCAAAGACTTATTGTAGCCCGTGAACACATTGACAAGTACAAA
AATTAA

# Drug_Target_6_General_Function:
Lipid transport and metabolism

# Drug_Target_6_General_References:
10767181	Yang BZ, Ding JH, Zhou C, Dimachkie MM, Sweetman L, Dasouki MJ, Wilkinson J, Roe CR: Identification of a novel mutation in patients with medium-chain acyl-CoA dehydrogenase deficiency. Mol Genet Metab. 2000 Mar;69(3):259-62.
11349232	Andresen BS, Dobrowolski SF, O'Reilly L, Muenzer J, McCandless SE, Frazier DM, Udvari S, Bross P, Knudsen I, Banas R, Chace DH, Engel P, Naylor EW, Gregersen N: Medium-chain acyl-CoA dehydrogenase (MCAD) mutations identified by MS/MS-based prospective screening of newborns differ from those observed in patients with clinical symptoms: identification and characterization of a new, prevalent mutation that results in mild MCAD deficiency. Am J Hum Genet. 2001 Jun;68(6):1408-18. Epub 2001 May 8.
11409868	Zschocke J, Schulze A, Lindner M, Fiesel S, Olgemoller K, Hoffmann GF, Penzien J, Ruiter JP, Wanders RJ, Mayatepek E: Molecular and functional characterisation of mild MCAD deficiency. Hum Genet. 2001 May;108(5):404-8.
11486912	Albers S, Levy HL, Irons M, Strauss AW, Marsden D: Compound heterozygosity in four asymptomatic siblings with medium-chain acyl-CoA dehydrogenase deficiency. J Inherit Metab Dis. 2001 Jun;24(3):417-8.
1363805	Tanaka K, Yokota I, Coates PM, Strauss AW, Kelly DP, Zhang Z, Gregersen N, Andresen BS, Matsubara Y, Curtis D, et al.: Mutations in the medium chain acyl-CoA dehydrogenase (MCAD) gene. Hum Mutat. 1992;1(4):271-9.
1671131	Blakemore AI, Singleton H, Pollitt RJ, Engel PC, Kolvraa S, Gregersen N, Curtis D: Frequency of the G985 MCAD mutation in the general population. Lancet. 1991 Feb 2;337(8736):298-9.
1684086	Yokota I, Coates PM, Hale DE, Rinaldo P, Tanaka K: Molecular survey of a prevalent mutation, 985A-to-G transition, and identification of five infrequent mutations in the medium-chain Acyl-CoA dehydrogenase (MCAD) gene in 55 patients with MCAD deficiency. Am J Hum Genet. 1991 Dec;49(6):1280-91.
1902818	Gregersen N, Andresen BS, Bross P, Winter V, Rudiger N, Engst S, Christensen E, Kelly D, Strauss AW, Kolvraa S, et al.: Molecular characterization of medium-chain acyl-CoA dehydrogenase (MCAD) deficiency: identification of a lys329 to glu mutation in the MCAD gene, and expression of inactive mutant enzyme protein in E. coli. Hum Genet. 1991 Apr;86(6):545-51.
2251268	Kelly DP, Whelan AJ, Ogden ML, Alpers R, Zhang ZF, Bellus G, Gregersen N, Dorland L, Strauss AW: Molecular characterization of inherited medium-chain acyl-CoA dehydrogenase deficiency. Proc Natl Acad Sci U S A. 1990 Dec;87(23):9236-40.
2393404	Matsubara Y, Narisawa K, Miyabayashi S, Tada K, Coates PM, Bachmann C, Elsas LJ 2nd, Pollitt RJ, Rhead WJ, Roe CR: Identification of a common mutation in patients with medium-chain acyl-CoA dehydrogenase deficiency. Biochem Biophys Res Commun. 1990 Aug 31;171(1):498-505.
2394825	Yokota I, Indo Y, Coates PM, Tanaka K: Molecular basis of medium chain acyl-coenzyme A dehydrogenase deficiency. An A to G transition at position 985 that causes a lysine-304 to glutamate substitution in the mature protein is the single prevalent mutation. J Clin Invest. 1990 Sep;86(3):1000-3.
3035565	Kelly DP, Kim JJ, Billadello JJ, Hainline BE, Chu TW, Strauss AW: Nucleotide sequence of medium-chain acyl-CoA dehydrogenase mRNA and its expression in enzyme-deficient human tissue. Proc Natl Acad Sci U S A. 1987 Jun;84(12):4068-72.
7603790	Ziadeh R, Hoffman EP, Finegold DN, Hoop RC, Brackett JC, Strauss AW, Naylor EW: Medium chain acyl-CoA dehydrogenase deficiency in Pennsylvania: neonatal screening shows high incidence and unexpected mutation frequencies. Pediatr Res. 1995 May;37(5):675-8.
7929823	Brackett JC, Sims HF, Steiner RD, Nunge M, Zimmerman EM, deMartinville B, Rinaldo P, Slaugh R, Strauss AW: A novel mutation in medium chain acyl-CoA dehydrogenase causes sudden neonatal death. J Clin Invest. 1994 Oct;94(4):1477-83.
8198141	Andresen BS, Jensen TG, Bross P, Knudsen I, Winter V, Kolvraa S, Bolund L, Ding JH, Chen YT, Van Hove JL, et al.: Disease-causing mutations in exon 11 of the medium-chain acyl-CoA dehydrogenase gene. Am J Hum Genet. 1994 Jun;54(6):975-88.
8823176	Lee HJ, Wang M, Paschke R, Nandy A, Ghisla S, Kim JJ: Crystal structures of the wild type and the Glu376Gly/Thr255Glu mutant of human medium-chain acyl-CoA dehydrogenase: influence of the location of the catalytic base on substrate specificity. Biochemistry. 1996 Sep 24;35(38):12412-20.
9158144	Andresen BS, Bross P, Udvari S, Kirk J, Gray G, Kmoch S, Chamoles N, Knudsen I, Winter V, Wilcken B, Yokota I, Hart K, Packman S, Harpey JP, Saudubray JM, Hale DE, Bolund L, Kolvraa S, Gregersen N: The molecular basis of medium-chain acyl-CoA dehydrogenase (MCAD) deficiency in compound heterozygous patients: is there correlation between genotype and phenotype? Hum Mol Genet. 1997 May;6(5):695-707.
9882619	Kuchler B, Abdel-Ghany AG, Bross P, Nandy A, Rasched I, Ghisla S: Biochemical characterization of a variant human medium-chain acyl-CoA dehydrogenase with a disease-associated mutation localized in the active site. Biochem J. 1999 Jan 15;337 ( Pt 2):225-30.

# Drug_Target_6_HGNC_ID:
HGNC:89

# Drug_Target_6_HPRD_ID:
08447

# Drug_Target_6_ID:
3185

# Drug_Target_6_Locus:
1p31

# Drug_Target_6_Molecular_Weight:
46589

# Drug_Target_6_Name:
Medium-chain specific acyl-CoA dehydrogenase, mitochondrial

# Drug_Target_6_Number_of_Residues:
421

# Drug_Target_6_PDB_ID:
1T9G

# Drug_Target_6_Pathway:
Not Available

# Drug_Target_6_Pfam_Domain_Function:
PF00441	Acyl-CoA_dh_1
PF02770	Acyl-CoA_dh_M
PF02771	Acyl-CoA_dh_N

# Drug_Target_6_Protein_Sequence:
>Medium-chain specific acyl-CoA dehydrogenase, mitochondrial precursor
MAAGFGRCCRVLRSISRFHWRSQHTKANRQREPGLGFSFEFTEQQKEFQATARKFAREEI
IPVAAEYDKTGEYPVPLIRRAWELGLMNTHIPENCGGLGLGTFDACLISEELAYGCTGVQ
TAIEGNSLGQMPIIIAGNDQQKKKYLGRMTEEPLMCAYCVTEPGAGSDVAGIKTKAEKKG
DEYIINGQKMWITNGGKANWYFLLARSDPDPKAPANKAFTGFIVEADTPGIQIGRKELNM
GQRCSDTRGIVFEDVKVPKENVLIGDGAGFKVAMGAFDKTRPVVAAGAVGLAQRALDEAT
KYALERKTFGKLLVEHQAISFMLAEMAMKVELARMSYQRAAWEVDSGRRNTYYASIAKAF
AGDIANQLATDAVQILGGNGFNTEYPVEKLMRDAKIYQIYEGTSQIQRLIVAREHIDKYK
N

# Drug_Target_6_Reaction:
acyl-CoA + acceptor = 2,3-dehydroacyl-CoA + reduced acceptor

# Drug_Target_6_Signals:
None

# Drug_Target_6_Specific_Function:
This enzyme is specific for acyl chain lengths of 4 to 16

# Drug_Target_6_SwissProt_ID:
P11310

# Drug_Target_6_SwissProt_Name:
ACADM_HUMAN

# Drug_Target_6_Synonyms:
EC 1.3.99.3
MCAD
Medium-chain specific acyl-CoA dehydrogenase, mitochondrial precursor

# Drug_Target_6_Theoretical_pI:
8.51

# Drug_Target_6_Transmembrane_Regions:
None

# Drug_Target_70_Cellular_Location:
Not Available

# Drug_Target_70_Chromosome_Location:
Not Available

# Drug_Target_70_Drug_References:
Not Available

# Drug_Target_70_Essentiality:
Non-Essential

# Drug_Target_70_GenAtlas_ID:
Not Available

# Drug_Target_70_GenBank_ID_Gene:
AJ250267

# Drug_Target_70_GenBank_ID_Protein:
Not Available

# Drug_Target_70_GeneCard_ID:
Not Available

# Drug_Target_70_Gene_Name:
abfD

# Drug_Target_70_Gene_Sequence:
>1473 bp
ATGTTAATGACAGCAGAACAGTACATTGAGAGTCTAAGAAAGCTAAACACAAGAGTTTAT
ATGTTTGGTGAAAAAATCGAGAATTGGGTGGATCATCCAATGATCAGACCTTCCATCAAC
TGCGTAGCAATGACTTATGAATTAGCTCAGGATCCTCAGTACGCTGACTTAATGACTACA
AAGTCAAACTTAATAGGTAAAACTATCAACAGATTTGCAAATCTACACCAGAGCACAGAT
GACCTTAGAAAAAAGGTTAAGATGCAGAGACTTCTTGGACAGAAGACCGCATCATGCTTC
CAGAGATGTGTAGGTATGGACGCTTTCAATGCAGTTTTCTCAACTACATATGAAATCGAC
CAGAAATATGGAACAAACTATCACAAGAACTTTACTGAATACTTAAAGTATATACAGGAA
AATGACCTTATTGTTGACGGTGCAATGACTGACCCTAAGGGTGACAGAGGACTTGCTCCA
TCCGCACAGAAGGATCCAGATCTTTTCTTGAGAATCGTTGAAAAAAGAGAAGATGGTATC
GTTGTAAGAGGAGCTAAGGCTCACCAGACTGGTTCCATCAACTCCCACGAACACATCATC
ATGCCTACAATCGCTATGACAGAAGCTGATAAGGATTATGCAGTATCATTTGCTTGTCCT
TCCGATGCTGATGGTCTATTCATGATCTACGGCAGACAGTCATGTGACACAAGAAAGATG
GAAGAAGGCGCTGACATTGACCTTGGTAACAAGCAGTTCGGCGGACAGGAAGCTTTAGTC
GTATTCGATAACGTATTTATTCCAAATGACAGAATCTTCCTTTGCCAAGAATATGATTTC
GCTGGCATGATGGTAGAAAGATTTGCTGGATACCACAGACAGTCATACGGCGGATGTAAG
GTTGGAGTAGGCGACGTTGTAATCGGTGCTGCTGCTTTAGCTGCTGACTACAATGGAGCT
CAGAAGGCTTCTCACGTTAAAGATAAGCTTATCGAAATGACTCACTTAAATGAAACTTTA
TATTGCTGCGGTATTGCTTGTTCAGCAGAAGGTTATCCAACTGCTGCTGGTAACTATCAG
ATTGACCTTCTTCTTGCAAATGTATGTAAGCAGAACATCACTAGATTCCCTTACGAAATC
GTAAGACTAGCTGAAGATATCGCTGGTGGATTAATGGTTACTATGCCTTCAGAAGCTGAC
TTTAAGTCAGAAACAGTTGTTGGTAGAGATGGCGAAACTATTGGAGATTTCTGCAATAAG
TTCTTCGCTGCTGCTCCTACTTGCACAACAGAAGAAAGAATGAGAGTTCTTAGATTCTTA
GAAAACATCTGCTTAGGTGCATCCGCTGTAGGTTACAGAACTGAATCCATGCATGGTGCA
GGTTCCCCTCAGGCTCAGAGAATCATGATCGCTCGTCAGGGCAACATCAACGCTAAGAAA
GAATTAGCTAAGGCAATCGCTGGAATTAAATAA

# Drug_Target_70_General_Function:
Involved in acyl-CoA dehydrogenase activity

# Drug_Target_70_General_References:
11041350	Gerhardt A, Cinkaya I, Linder D, Huisman G, Buckel W: Fermentation of 4-aminobutyrate by Clostridium aminobutyricum: cloning of two genes involved in the formation and dehydration of 4-hydroxybutyryl-CoA. Arch Microbiol. 2000 Sep;174(3):189-99.
8344309	Scherf U, Buckel W: Purification and properties of an iron-sulfur and FAD-containing 4-hydroxybutyryl-CoA dehydratase/vinylacetyl-CoA delta 3-delta 2-isomerase from Clostridium aminobutyricum. Eur J Biochem. 1993 Jul 15;215(2):421-9.

# Drug_Target_70_HGNC_ID:
Not Available

# Drug_Target_70_HPRD_ID:
Not Available

# Drug_Target_70_ID:
5100

# Drug_Target_70_Locus:
Not Available

# Drug_Target_70_Molecular_Weight:
54423

# Drug_Target_70_Name:
Gamma-aminobutyrate metabolism dehydratase/isomerase

# Drug_Target_70_Number_of_Residues:
490

# Drug_Target_70_PDB_ID:
1U8V

# Drug_Target_70_Pathway:
Not Available

# Drug_Target_70_Pfam_Domain_Function:
PF03241	HpaB

# Drug_Target_70_Protein_Sequence:
>Gamma-aminobutyrate metabolism dehydratase/isomerase
MLMTAEQYIESLRKLNTRVYMFGEKIENWVDHPMIRPSINCVAMTYELAQDPQYADLMTT
KSNLIGKTINRFANLHQSTDDLRKKVKMQRLLGQKTASCFQRCVGMDAFNAVFSTTYEID
QKYGTNYHKNFTEYLKYIQENDLIVDGAMTDPKGDRGLAPSAQKDPDLFLRIVEKREDGI
VVRGAKAHQTGSINSHEHIIMPTIAMTEADKDYAVSFACPSDADGLFMIYGRQSCDTRKM
EEGADIDLGNKQFGGQEALVVFDNVFIPNDRIFLCQEYDFAGMMVERFAGYHRQSYGGCK
VGVGDVVIGAAALAADYNGAQKASHVKDKLIEMTHLNETLYCCGIACSAEGYPTAAGNYQ
IDLLLANVCKQNITRFPYEIVRLAEDIAGGLMVTMPSEADFKSETVVGRDGETIGDFCNK
FFAAAPTCTTEERMRVLRFLENICLGASAVGYRTESMHGAGSPQAQRIMIARQGNINAKK
ELAKAIAGIK

# Drug_Target_70_Reaction:
Not Available

# Drug_Target_70_Signals:
None

# Drug_Target_70_Specific_Function:
Catalyzes the reversible conversion of 4-hydroxybutyryl- CoA to crotonyl-CoA. The mechanism of the reaction seems to go through three steps:(1) the FAD-dependent oxidation of 4- hydroxybutyryl-CoA to 4-hydroxycrotonyl-CoA; (2) the hydroxyl group is substituted by a hydride derived from the now reduced FAD in an SN2' reaction leading to vinylacetyl-CoA; (3) isomerization to yield crotonyl-CoA

# Drug_Target_70_SwissProt_ID:
P55792

# Drug_Target_70_SwissProt_Name:
HDVD_CLOAM

# Drug_Target_70_Synonyms:
Not Available

# Drug_Target_70_Theoretical_pI:
6.03

# Drug_Target_70_Transmembrane_Regions:
None

# Drug_Target_71_Cellular_Location:
Not Available

# Drug_Target_71_Chromosome_Location:
Not Available

# Drug_Target_71_Drug_References:
Not Available

# Drug_Target_71_Essentiality:
Non-Essential

# Drug_Target_71_GenAtlas_ID:
Not Available

# Drug_Target_71_GenBank_ID_Gene:
U96338

# Drug_Target_71_GenBank_ID_Protein:
Not Available

# Drug_Target_71_GeneCard_ID:
Not Available

# Drug_Target_71_Gene_Name:
pchF

# Drug_Target_71_Gene_Sequence:
>1566 bp
ATGTCCGAGCAAAACAATGCTGTGTTGCCCAAAGGGGTAACGCAGGGCGAGTTCAACAAG
GCGGTGCAGAAATTCCGCGCCTTGCTGGGTGACGATAATGTATTGGTCGAATCCGACCAG
TTGGTGCCTTACAACAAGATCATGATGCCGGTCGAGAATGCGGCTCATGCCCCCTCGGCC
GCCGTCACCGCGACCACCGTCGAGCAGGTGCAGGGTGTAGTCAAGATCTGTAACGAACAC
AAAATTCCGATCTGGACCATCTCCACTGGGCGCAACTTCGGTTACGGGTCCGCCGCGCCG
GTGCAGCGCGGTCAGGTAATCCTTGACCTGAAGAAGATGAACAAGATCATCAAGATCGAC
CCGGAAATGTGCTATGCGCTGGTCGAGCCGGGGGTTACCTTCGGTCAGATGTATGACTAC
ATCCAGGAAAACAACCTGCCGGTGATGCTGTCGTTCTCGGCACCCTCGGCGATTGCCGGC
CCGGTCGGCAATACCATGGACCGAGGCGTGGGCTACACCCCCTACGGCGAACACTTCATG
ATGCAGTGCGGCATGGAAGTGGTGCTGGCCAACGGTGACGTTTACCGCACCGGCATGGGT
GGCGTGCCTGGCAGCAACACCTGGCAGATTTTCAAATGGGGCTATGGTCCGACCCTGGAT
GGCATGTTCACTCAGGCCAACTATGGCATTTGCACCAAGATGGGCTTCTGGCTGATGCCC
AAGCCGCCCGTGTTCAAGCCGTTCGAAGTGATCTTCGAGGACGAGGCGGACATCGTCGAG
ATCGTCGATGCACTGCGCCCGCTGCGCATGAGCAACACCATCCCCAACTCGGTGGTAATC
GCCAGCACCTTGTGGGAAGCCGGCAGTGCGCACCTGACCCGCGCCCAGTACACCACCGAG
CCGGGCCACACGCCGGATAGCGTGATCAAGCAGATGCAGAAAGACACCGGCATGGGTGCC
TGGAACCTCTACGCTGCGCTGTACGGTACCCAGGAACAGGTCGACGTAAACTGGAAGATC
GTAACTGACGTCTTCAAGAAACTTGGCAAGGGCCGTATCGTCACCCAGGAAGAGGCGGGT
GACACCCAGCCGTTCAAATACCGTGCCCAGCTGATGTCCGGCGTGCCCAACCTGCAGGAA
TTCGGCCTGTACAACTGGCGTGGGGGCGGTGGCTCCATGTGGTTCGCGCCGGTCAGCGAG
GCGCGTGGCAGCGAGTGCAAGAAGCAGGCGGCCATGGCCAAGCGCGTTCTGCACAAGTAC
GGCCTGGATTATGTGGCCGAGTTCATCGTGGCGCCGCGCGACATGCACCACGTCATCGAC
GTGCTCTACGACCGCACCAATCCTGAGGAAACCAAGCGCGCCGACGCCTGCTTCAATGAG
CTGCTGGATGAGTTCGAGAAGGAAGGCTATGCGGTGTATCGGGTGAACACCCGCTTCCAG
GATCGCGTGGCGCAGAGCTATGGCCCGGTCAAGCGCAAGCTGGAGCATGCCATCAAGCGT
GCGGTGGACCCGAACAACATCCTCGCTCCGGGCCGCTCGGGCATCGACCTCAATAACGAT
TTCTGA

# Drug_Target_71_General_Function:
Involved in catalytic activity

# Drug_Target_71_General_References:
10565539	Cronin CN, Kim J, Fuller JH, Zhang X, McIntire WS: Organization and sequences of p-hydroxybenzaldehyde dehydrogenase and other plasmid-encoded genes for early enzymes of the p-cresol degradative pathway in Pseudomonas putida NCIMB 9866 and 9869. DNA Seq. 1999;10(1):7-17.
10623531	Cunane LM, Chen ZW, Shamala N, Mathews FS, Cronin CN, McIntire WS: Structures of the flavocytochrome p-cresol methylhydroxylase and its enzyme-substrate complex: gated substrate entry and proton relays support the proposed catalytic mechanism. J Mol Biol. 2000 Jan 14;295(2):357-74.
1846290	Mathews FS, Chen ZW, Bellamy HD, McIntire WS: Three-dimensional structure of p-cresol methylhydroxylase (flavocytochrome c) from Pseudomonas putida at 3.0-A resolution. Biochemistry. 1991 Jan 8;30(1):238-47.
3790500	McIntire W, Singer TP, Smith AJ, Mathews FS: Amino acid and sequence analysis of the cytochrome and flavoprotein subunits of p-cresol methylhydroxylase. Biochemistry. 1986 Oct 7;25(20):5975-81.
7929007	Kim J, Fuller JH, Cecchini G, McIntire WS: Cloning, sequencing, and expression of the structural genes for the cytochrome and flavoprotein subunits of p-cresol methylhydroxylase from two strains of Pseudomonas putida. J Bacteriol. 1994 Oct;176(20):6349-61.

# Drug_Target_71_HGNC_ID:
Not Available

# Drug_Target_71_HPRD_ID:
Not Available

# Drug_Target_71_ID:
5102

# Drug_Target_71_Locus:
Not Available

# Drug_Target_71_Molecular_Weight:
57946

# Drug_Target_71_Name:
4-cresol dehydrogenase [hydroxylating] flavoprotein subunit

# Drug_Target_71_Number_of_Residues:
521

# Drug_Target_71_PDB_ID:
1DIQ

# Drug_Target_71_Pathway:
Not Available

# Drug_Target_71_Pfam_Domain_Function:
PF01565	FAD_binding_4
PF02913	FAD-oxidase_C

# Drug_Target_71_Protein_Sequence:
>4-cresol dehydrogenase [hydroxylating] flavoprotein subunit
MSEQNNAVLPKGVTQGEFNKAVQKFRALLGDDNVLVESDQLVPYNKIMMPVENAAHAPSA
AVTATTVEQVQGVVKICNEHKIPIWTISTGRNFGYGSAAPVQRGQVILDLKKMNKIIKID
PEMCYALVEPGVTFGQMYDYIQENNLPVMLSFSAPSAIAGPVGNTMDRGVGYTPYGEHFM
MQCGMEVVLANGDVYRTGMGGVPGSNTWQIFKWGYGPTLDGMFTQANYGICTKMGFWLMP
KPPVFKPFEVIFEDEADIVEIVDALRPLRMSNTIPNSVVIASTLWEAGSAHLTRAQYTTE
PGHTPDSVIKQMQKDTGMGAWNLYAALYGTQEQVDVNWKIVTDVFKKLGKGRIVTQEEAG
DTQPFKYRAQLMSGVPNLQEFGLYNWRGGGGSMWFAPVSEARGSECKKQAAMAKRVLHKY
GLDYVAEFIVAPRDMHHVIDVLYDRTNPEETKRADACFNELLDEFEKEGYAVYRVNTRFQ
DRVAQSYGPVKRKLEHAIKRAVDPNNILAPGRSGIDLNNDF

# Drug_Target_71_Reaction:
Not Available

# Drug_Target_71_Signals:
None

# Drug_Target_71_Specific_Function:
4-cresol + acceptor + H(2)O = 4- hydroxybenzaldehyde + reduced acceptor

# Drug_Target_71_SwissProt_ID:
P09788

# Drug_Target_71_SwissProt_Name:
DH4C_PSEPU

# Drug_Target_71_Synonyms:
EC 1.17.99.1
P-cresol methylhydroxylase
PCMH

# Drug_Target_71_Theoretical_pI:
6.26

# Drug_Target_71_Transmembrane_Regions:
None

# Drug_Target_72_Cellular_Location:
Not Available

# Drug_Target_72_Chromosome_Location:
Not Available

# Drug_Target_72_Drug_References:
Not Available

# Drug_Target_72_Essentiality:
Non-Essential

# Drug_Target_72_GenAtlas_ID:
Not Available

# Drug_Target_72_GenBank_ID_Gene:
AE008724

# Drug_Target_72_GenBank_ID_Protein:
Not Available

# Drug_Target_72_GeneCard_ID:
Not Available

# Drug_Target_72_Gene_Name:
ahpF

# Drug_Target_72_Gene_Sequence:
>1566 bp
ATGCTCGACACAAATATGAAAACCCAGCTCAGGGCTTACCTTGAGAAACTGACCAAACCT
GTTGAGCTGATTGCCACGCTGGATGACAGCGCTAAATCGGCGGAAATCAAGGAACTGCTG
GCTGAAATCGCCGAGCTGTCCGACAAAGTCACGTTTAAAGAAGACAATACTCTGCCGGTG
CGCAAGCCGTCTTTCCTGATTACGAATCCAGGTTCTCAGCAAGGGCCGCGCTTTGCCGGT
TCTCCGCTGGGCCACGAATTTACCTCGCTGGTTTTGGCGCTGCTGTGGACCGGCGGTCAT
CCGTCAAAAGAAGCGCAGTCGCTGCTGGAGCAGATTCGCGATATTGACGGCGATTTTGAA
TTCGAAACTTATTATTCACTCTCCTGCCATAACTGCCCGGACGTAGTGCAGGCGCTGAAC
CTGATGGCGGTGCTGAACCCGCGTATTAAACATACGGCAATTGATGGCGGCACCTTCCAG
AACGAAATCACCGAACGTAACGTGATGGGCGTTCCGGCGGTATTTGTTAACGGTAAAGAG
TTCGGCCAGGGACGTATGACTCTGACCGAGATTGTCGCTAAAGTGGATACTGGCGCAGAA
AAACGCGCGGCGGAAGCGCTGAACAAACGCGATGCGTATGACGTACTGATTGTCGGCTCC
GGCCCGGCGGGCGCGGCGGCGGCGGTCTACTCGGCGCGCAAAGGCATCCGTACCGGTCTG
ATGGGCGAGCGCTTCGGCGGTCAGGTGCTGGATACCGTGGATATCGAAAACTATATCTCG
GTGCCGAAAACCGAAGGCCAGAAACTGGCGGGCGCGCTGAAAGCGCATGTCAGCGATTAC
GACGTTGACGTTATCGACAGCCAGAGCGCAAGTAAACTGGTTCCGGCCGCAACAGAAGGC
GGCTTGCATCAGATTGAAACGGCGTCCGGCGCAGTATTGAAAGCGCGTAGTATCATCATC
GCCACCGGCGCGAAATGGCGCAATATGAATGTGCCGGGCGAGGATCAGTATCGCACCAAA
GGCGTCACCTATTGTCCGCACTGCGACGGTCCGTTATTTAAAGGGAAGCGTGTGGCGGTC
ATCGGCGGCGGCAACTCTGGCGTTGAAGCGGCTATCGATCTGGCAGGTATTGTAGAACAT
GTTACGTTGCTGGAGTTCGCGCCGGAGATGAAGGCGGATCAGGTGCTACAGGACAAAGTG
CGTAGTCTGAAAAATGTCGATATCATTTTGAATGCGCAAACGACAGAAGTGAAGGGCGAC
GGTTCGAAAGTGGTGGGACTGGAGTATCGTGACCGTGTCAGCGGCGATATTCATAGCGTC
GCGCTGGCAGGGATTTTTGTGCAGATTGGTCTGTTGCCGAATACCCACTGGCTGGAAGGC
GCGCTTGAGCGTAACCGCATGGGCGAGATCATTATTGACGCCAAATGTGAAACCAGCGTT
AAGGGCGTCTTCGCCGCAGGCGATTGCACCACCGTTCCTTACAAACAGATTATCATCGCC
ACGGGCGAAGGGGCGAAAGCCTCGTTGAGCGCCTTTGATTATCTGATTCGCACCAAAATC
GCATAA

# Drug_Target_72_General_Function:
Involved in oxidoreductase activity, acting on NADH or NADPH

# Drug_Target_72_General_References:
11677609	McClelland M, Sanderson KE, Spieth J, Clifton SW, Latreille P, Courtney L, Porwollik S, Ali J, Dante M, Du F, Hou S, Layman D, Leonard S, Nguyen C, Scott K, Holmes A, Grewal N, Mulvaney E, Ryan E, Sun H, Florea L, Miller W, Stoneking T, Nhan M, Waterston R, Wilson RK: Complete genome sequence of Salmonella enterica serovar Typhimurium LT2. Nature. 2001 Oct 25;413(6858):852-6.
2191951	Tartaglia LA, Storz G, Brodsky MH, Lai A, Ames BN: Alkyl hydroperoxide reductase from Salmonella typhimurium. Sequence and homology to thioredoxin reductase and other flavoprotein disulfide oxidoreductases. J Biol Chem. 1990 Jun 25;265(18):10535-40.
2643600	Jacobson FS, Morgan RW, Christman MF, Ames BN: An alkyl hydroperoxide reductase from Salmonella typhimurium involved in the defense of DNA against oxidative damage. Purification and properties. J Biol Chem. 1989 Jan 25;264(3):1488-96.

# Drug_Target_72_HGNC_ID:
Not Available

# Drug_Target_72_HPRD_ID:
Not Available

# Drug_Target_72_ID:
5107

# Drug_Target_72_Locus:
Not Available

# Drug_Target_72_Molecular_Weight:
55951

# Drug_Target_72_Name:
Alkyl hydroperoxide reductase subunit F

# Drug_Target_72_Number_of_Residues:
521

# Drug_Target_72_PDB_ID:
1HYU

# Drug_Target_72_Pathway:
Not Available

# Drug_Target_72_Pfam_Domain_Function:
PF00070	Pyr_redox
PF00462	Glutaredoxin
PF07992	Pyr_redox_2

# Drug_Target_72_Protein_Sequence:
>Alkyl hydroperoxide reductase subunit F
MLDTNMKTQLRAYLEKLTKPVELIATLDDSAKSAEIKELLAEIAELSDKVTFKEDNTLPV
RKPSFLITNPGSQQGPRFAGSPLGHEFTSLVLALLWTGGHPSKEAQSLLEQIRDIDGDFE
FETYYSLSCHNCPDVVQALNLMAVLNPRIKHTAIDGGTFQNEITERNVMGVPAVFVNGKE
FGQGRMTLTEIVAKVDTGAEKRAAEALNKRDAYDVLIVGSGPAGAAAAVYSARKGIRTGL
MGERFGGQVLDTVDIENYISVPKTEGQKLAGALKAHVSDYDVDVIDSQSASKLVPAATEG
GLHQIETASGAVLKARSIIIATGAKWRNMNVPGEDQYRTKGVTYCPHCDGPLFKGKRVAV
IGGGNSGVEAAIDLAGIVEHVTLLEFAPEMKADQVLQDKVRSLKNVDIILNAQTTEVKGD
GSKVVGLEYRDRVSGDIHSVALAGIFVQIGLLPNTHWLEGALERNRMGEIIIDAKCETSV
KGVFAAGDCTTVPYKQIIIATGEGAKASLSAFDYLIRTKIA

# Drug_Target_72_Reaction:
Not Available

# Drug_Target_72_Signals:
None

# Drug_Target_72_Specific_Function:
Serves to protect the cell against DNA damage by alkyl hydroperoxides. It can use either NADH or NADPH as electron donor for direct reduction of redox dyes or of alkyl hydroperoxides when combined with the ahpC protein

# Drug_Target_72_SwissProt_ID:
P19480

# Drug_Target_72_SwissProt_Name:
AHPF_SALTY

# Drug_Target_72_Synonyms:
Alkyl hydroperoxide reductase F52A protein
EC 1.6.4.-

# Drug_Target_72_Theoretical_pI:
5.69

# Drug_Target_72_Transmembrane_Regions:
None

# Drug_Target_73_Cellular_Location:
Not Available

# Drug_Target_73_Chromosome_Location:
Not Available

# Drug_Target_73_Drug_References:
Not Available

# Drug_Target_73_Essentiality:
Non-Essential

# Drug_Target_73_GenAtlas_ID:
Not Available

# Drug_Target_73_GenBank_ID_Gene:
X77920

# Drug_Target_73_GenBank_ID_Protein:
Not Available

# Drug_Target_73_GeneCard_ID:
Not Available

# Drug_Target_73_Gene_Name:
m-6

# Drug_Target_73_Gene_Sequence:
>1785 bp
ATGGCTTTAGTTGAATTGAAAGTGCCCGACATTGGCGGACACGAAAATGTAGATATTATC
GCGGTTGAAGTAAACGTGGGCGACACTATTGCTGTGGACGATACCCTGATTACTTTGGAA
ACCGATAAAGCGACTATGGACGTACCTGCTGAAGTTGCAGGCGTAGTCAAAGAAGTTAAA
GTTAAAGTCGGCGACAAAATCTCTGAAGGTGGTTTGATTGTCGTCGTTGAAGCTGAAGGC
ACGGCAGCCGCTCCTAAAGCCGAAGCGGCTGCCGCCCCGGCGCAAGAAGCCCCTAAAGCT
GCCGCTCCTGCTCCGCAAGCCGCGCAATTCGGCGGTTCTGCCGATGCCGAGTACGACGTG
GTCGTATTGGGTGGCGGTCCCGGCGGTTACTCCGCTGCATTTGCCGCTGCCGATGAAGGC
TTGAAAGTCGCCATCGTCGAACGTTACAAAACTTTGGGCGGCGTTTGCCTGAACGTCGGC
TGTATCCCTTCCAAAGCCTTGTTGCACAATGCCGCCGTTATCGACGAAGTGCGCCACTTG
GCTGCCAACGGTATCAAATACCCCGAGCCGGAACTCGACATCGATATGCTTCGCGCCTAC
AAAGACGGCGTAGTTTCCCGCCTCACGGGCGGTTTGGCAGGTATGGCGAAAAGCCGTAAA
GTGGACGTTATCCAAGGCGACGGGCAATTCTTAGATCCGCACCACTTGGAAGTGTCGCTG
ACTGCCGGCGACGCGTACGAACAGGCAGCCCCTACCGGCGAGAAAAAAATCGTTGCCTTC
AAAAACTGTATCATTGCAGCAGGCAGCCGCGTAACCAAACTGCCTTTCATTCCTGAAGAT
CCGCGCATCATCGATTCCAGCGGCGCATTGGCTCTGAAAGAAGTACCGGGCAAACTGCTG
ATTATCGGCGGCGGCATTATCGGCCTCGAGATGGGTACGGTTTACAGCACGCTGGGTTCG
CGTTTGGATGTGGTTGAAATGATGGACGGCCTGATGCAAGGCGCAGACCGCGATTTGGTA
AAAGTATGGCAAAAACAAAACGAATACCGTTTTGACAACATTATGGTCAACACCAAAACC
GTTGCAGTTGAGCCGAAAGAAGACGGCGTTTACGTTACCTTTGAAGGCGCGAACGCGCCT
AAAGAGCCGCAACGCTACGATGCCGTATTGGTTGCCGCCGGCCGCGCGCCCAACGGCAAA
CTCATCAGCGCGGAAAAAGCAGGCGTTGCCGTAACCGATCGCGGCTTCATCGAAGTGGAC
AAACAAATGCGTACCAATGTGCCGCACATCTACGCCATCGGCGACATCGTCGGTCAGCCG
ATGTTGGCGCACAAAGCCGTTCACGAAGGCCACGTTGCCGCCGAAAACTGCGCCGGCCAC
AAAGCCTACTTCGACGCACGCGTGATTCCGGGCGTTGCCTACACTTCCCCCGAAGTGGCG
TGGGTGGGCGAAACCGAACTGTCCGCCAAAGCCTCCGGCCGCAAAATCACCAAAGCCAAC
TTCCCGTGGGCGGCTTCCGGCCGTGCGATTGCCAACGGTTGCGACAAGCCGTTTACCAAG
CTGATTTTTGATGCCGAAACCGGCCGCATCATCGGCGGCGGCATTGTCGGTCCGAACGGT
GGCGATATGATCGGCGAAGTCTGCCTTGCCATCGAAATGGGCTGCGACGCGGCAGACATC
GGCAAAACCATCCACCCGCACCCGACCTTGGGCGAATCCATCGGTATGGCGGCGGAAGTG
GCATTGGGTACTTGTACCGACCTGCCTCCGCAAAAGAAAAAATAA

# Drug_Target_73_General_Function:
Involved in oxidoreductase activity

# Drug_Target_73_General_References:
10234839	Silva R, Menendez T, Alonso LM, Iglesias E, Musacchio A, Leal MJ, Alvarez A, Coizeau E, Martin A, Herrera L, Guillen G: Characterisation of the lpdA gene from Neisseria meningitidis by polymerase chain reaction, restriction fragment length polymorphism and sequencing. FEMS Microbiol Lett. 1999 May 1;174(1):191-9.
9193005	Li de la Sierra I, Pernot L, Prange T, Saludjian P, Schiltz M, Fourme R, Padron G: Molecular structure of the lipoamide dehydrogenase domain of a surface antigen from Neisseria meningitidis. J Mol Biol. 1997 May 30;269(1):129-41.

# Drug_Target_73_HGNC_ID:
Not Available

# Drug_Target_73_HPRD_ID:
Not Available

# Drug_Target_73_ID:
5109

# Drug_Target_73_Locus:
Not Available

# Drug_Target_73_Molecular_Weight:
61883

# Drug_Target_73_Name:
Outer membrane protein p64k or PM-6

# Drug_Target_73_Number_of_Residues:
594

# Drug_Target_73_PDB_ID:
1OJT

# Drug_Target_73_Pathway:
Not Available

# Drug_Target_73_Pfam_Domain_Function:
PF00070	Pyr_redox
PF00364	Biotin_lipoyl
PF02852	Pyr_redox_dim
PF07992	Pyr_redox_2

# Drug_Target_73_Protein_Sequence:
>Outer membrane protein p64k or PM-6
MALVELKVPDIGGHENVDIIAVEVNVGDTIAVDDTLITLETDKATMDVPAEVAGVVKEVK
VKVGDKISEGGLIVVVEAEGTAAAPKAEAAAAPAQEAPKAAAPAPQAAQFGGSADAEYDV
VVLGGGPGGYSAAFAAADEGLKVAIVERYKTLGGVCLNVGCIPSKALLHNAAVIDEVRHL
AANGIKYPEPELDIDMLRAYKDGVVSRLTGGLAGMAKSRKVDVIQGDGQFLDPHHLEVSL
TAGDAYEQAAPTGEKKIVAFKNCIIAAGSRVTKLPFIPEDPRIIDSSGALALKEVPGKLL
IIGGGIIGLEMGTVYSTLGSRLDVVEMMDGLMQGADRDLVKVWQKQNEYRFDNIMVNTKT
VAVEPKEDGVYVTFEGANAPKEPQRYDAVLVAAGRAPNGKLISAEKAGVAVTDRGFIEVD
KQMRTNVPHIYAIGDIVGQPMLAHKAVHEGHVAAENCAGHKAYFDARVIPGVAYTSPEVA
WVGETELSAKASGRKITKANFPWAASGRAIANGCDKPFTKLIFDAETGRIIGGGIVGPNG
GDMIGEVCLAIEMGCDAADIGKTIHPHPTLGESIGMAAEVALGTCTDLPPQKKK

# Drug_Target_73_Reaction:
Not Available

# Drug_Target_73_Signals:
None

# Drug_Target_73_Specific_Function:
Not Available

# Drug_Target_73_SwissProt_ID:
Q51225

# Drug_Target_73_SwissProt_Name:
Q51225_NEIME

# Drug_Target_73_Synonyms:
Not Available

# Drug_Target_73_Theoretical_pI:
4.89

# Drug_Target_73_Transmembrane_Regions:
None

# Drug_Target_74_Cellular_Location:
Cytoplasm

# Drug_Target_74_Chromosome_Location:
Not Available

# Drug_Target_74_Drug_References:
Not Available

# Drug_Target_74_Essentiality:
Non-Essential

# Drug_Target_74_GenAtlas_ID:
Not Available

# Drug_Target_74_GenBank_ID_Gene:
X93462

# Drug_Target_74_GenBank_ID_Protein:
Not Available

# Drug_Target_74_GeneCard_ID:
Not Available

# Drug_Target_74_Gene_Name:
GR2

# Drug_Target_74_Gene_Sequence:
>1503 bp
ATGGTTTACGATTTAATTGTAATTGGTGGTGGAAGTGGAGGAATGGCTGCAGCTAGGAGG
GCAGCAAGGCATAACGCAAAAGTTGCTCTTGTCGAAAAATCCCGTTTAGGTGGAACGTGT
GTCAACGTTGGATGTGTTCCTAAAAAAATTATGTTCAATGCTGCCTCAGTTCATGATATT
TTGGAAAATTCCAGGCATTACGGATTTGACACCAAATTTTCGTTCAACTTACCTCTGTTG
GTAGAGAGAAGGGATAAGTACATTCAAAGGTTGAATAATATTTATAGACAGAATTTAAGT
AAGGATAAGGTAGATTTGTACGAAGGAACAGCTAGCTTTTTAAGCGAAAATAGGATATTA
ATAAAAGGCACAAAAGATAATAATAATAAGGATAATGGGCCTTTGAATGAAGAAATCCTT
GAAGGAAGAAATATTCTTATAGCTGTTGGAAATAAACCAGTATTTCCACCGGTTAAAGGT
ATAGAAAATACAATATCAAGTGATGAATTTTTTAATATTAAAGAATCTAAAAAAATTGGT
ATTGTTGGAAGTGGATATATAGCTGTTGAATTAATAAATGTTATAAAAAGATTAGGTATT
GATTCTTATATATTTGCAAGAGGAAATAGAATATTAAGGAAATTTGATGAGTCTGTTATT
AATGTATTAGAAAATGATATGAAAAAGAATAATATAAATATTGTAACATTTGCAGATGTT
GTTGAAATAAAAAAAGTTAGTGATAAAAATTTGTCCATACATTTATCTGATGGAAGAATA
TATGAACATTTTGATCATGTCATTTATTGTGTTGGTAGATCACCAGATACCGAAAATTTA
AAGTTAGAAAAATTAAATGTGGAAACAAATAATAATTATATAGTAGTAGATGAAAATCAA
CGAACTAGTGTAAACAATATTTATGCTGTTGGTGATTGTTGTATGGTAAAAAAATCAAAA
GAAATTGAAGATTTAAATTTATTGAAATTATATAATGAAGAAAGATATCTAAATAAAAAA
GAAAATGTTACAGAAGATATTTTTTATAATGTACAATTAACACCGGTAGCTATTAATGCA
GGAAGATTATTAGCTGATAGATTATTTTTAAAAAAAACACGAAAAACAAATTATAAACTT
ATACCAACTGTTATATTTTCTCATCCACCTATAGGTACTATTGGTCTTTCTGAAGAAGCA
GCAATTCAAATATATGGAAAGGAAAATGTTAAAATATATGAATCCAAATTTACTAATTTA
TTCTTTTCAGTTTATGATATAGAACCAGAACTAAAAGAAAAAACATATCTTAAATTAGTA
TGTGTTGGAAAAGATGAATTAATTAAAGGATTACATATAATAGGATTAAATGCAGATGAA
ATTGTTCAAGGTTTTGCAGTGGCCTTAAAAATGAATGCTACCAAAAAGGATTTCGATGAA
ACCATACCTATACATCCTACAGCAGCAGAAGAATTTCTAACCTTACAGCCATGGATGAAA
TGA

# Drug_Target_74_General_Function:
Involved in oxidoreductase activity

# Drug_Target_74_General_References:
8631352	Krauth-Siegel RL, Muller JG, Lottspeich F, Schirmer RH: Glutathione reductase and glutamate dehydrogenase of Plasmodium falciparum, the causative agent of tropical malaria. Eur J Biochem. 1996 Jan 15;235(1-2):345-50.
8774709	Farber PM, Becker K, Muller S, Schirmer RH, Franklin RM: Molecular cloning and characterization of a putative glutathione reductase gene, the PfGR2 gene, from Plasmodium falciparum. Eur J Biochem. 1996 Aug 1;239(3):655-61.

# Drug_Target_74_HGNC_ID:
Not Available

# Drug_Target_74_HPRD_ID:
Not Available

# Drug_Target_74_ID:
5110

# Drug_Target_74_Locus:
Not Available

# Drug_Target_74_Molecular_Weight:
56562

# Drug_Target_74_Name:
Glutathione reductase

# Drug_Target_74_Number_of_Residues:
500

# Drug_Target_74_PDB_ID:
1ONF

# Drug_Target_74_Pathway:
Not Available

# Drug_Target_74_Pfam_Domain_Function:
PF00070	Pyr_redox
PF02852	Pyr_redox_dim
PF07992	Pyr_redox_2

# Drug_Target_74_Protein_Sequence:
>Glutathione reductase
MVYDLIVIGGGSGGMAAARRAARHNAKVALVEKSRLGGTCVNVGCVPKKIMFNAASVHDI
LENSRHYGFDTKFSFNLPLLVERRDKYIQRLNNIYRQNLSKDKVDLYEGTASFLSENRIL
IKGTKDNNNKDNGPLNEEILEGRNILIAVGNKPVFPPVKGIENTISSDEFFNIKESKKIG
IVGSGYIAVELINVIKRLGIDSYIFARGNRILRKFDESVINVLENDMKKNNINIVTFADV
VEIKKVSDKNLSIHLSDGRIYEHFDHVIYCVGRSPDTENLKLEKLNVETNNNYIVVDENQ
RTSVNNIYAVGDCCMVKKSKEIEDLNLLKLYNEERYLNKKENVTEDIFYNVQLTPVAINA
GRLLADRLFLKKTRKTNYKLIPTVIFSHPPIGTIGLSEEAAIQIYGKENVKIYESKFTNL
FFSVYDIEPELKEKTYLKLVCVGKDELIKGLHIIGLNADEIVQGFAVALKMNATKKDFDE
TIPIHPTAAEEFLTLQPWMK

# Drug_Target_74_Reaction:
Not Available

# Drug_Target_74_Signals:
None

# Drug_Target_74_Specific_Function:
Maintains high levels of reduced glutathione in the cytosol (By similarity)

# Drug_Target_74_SwissProt_ID:
Q94655

# Drug_Target_74_SwissProt_Name:
GSHR_PLAFK

# Drug_Target_74_Synonyms:
EC 1.8.1.7
GR
GRase

# Drug_Target_74_Theoretical_pI:
8.49

# Drug_Target_74_Transmembrane_Regions:
None

# Drug_Target_75_Cellular_Location:
Not Available

# Drug_Target_75_Chromosome_Location:
Not Available

# Drug_Target_75_Drug_References:
Not Available

# Drug_Target_75_Essentiality:
Non-Essential

# Drug_Target_75_GenAtlas_ID:
Not Available

# Drug_Target_75_GenBank_ID_Gene:
CP000088

# Drug_Target_75_GenBank_ID_Protein:
Not Available

# Drug_Target_75_GeneCard_ID:
Not Available

# Drug_Target_75_Gene_Name:
pamO

# Drug_Target_75_Gene_Sequence:
>1629 bp
CTAGGTGAGGACGAAACCTTCGTAGCCCTTGGCAGCCACCTCGTCGCAGATCTGCCGGTA
GCGGTGGAAGCCGCCGACGTAGAGCATGAACACCCGGGGTTTACCGGGGACGTTGGCGCC
CGTGTACCACGAGGCGGTCATGGGGTAGAGGGTTTCGTCGGCGATCTCGTTGACGTGCTC
CACCCACTCGTCTTCTTTCTCCAGGACTGCCTCGGATCGGGTGAGGCCGTTCTTGAACAT
GTAGGCGATGTGGTCGGTCACCCATTCCACGTGCTGTTCGATAGAGACCAGCATGTTGCT
GAGCGCAGACGGGCTGCCCGGGCCTGCGATGAAGAACAGGTTGGGGAACCCGGCGGTGGA
CAGTCCCAGGTAGGTGCGTGGCCCTGCGGCCCACTTCTCCTTCAAAGCGACGTTGCCCAC
ACCGCGGATGTCGATCTTGAACAGCGCCCCGGTCAGCGCGTCGAACCCGGTCGCCAGCAC
CAGGGAGTCGAGTTCGTACTCCCGTTCCGAGGTGCGCACCCCGCGCGGCGTGATCGTCTC
GATCGGCGCAGACAACGTGTCGACCAGGTGCACGTTGTCCCGGTTGAACATTTCGTAGTA
GTCGATTTCCAGGATGAGGCGCTTGGTGCCGAACGGGTAGCCCTTGGGGACCAGGCGTTC
CGCCACCTCCGGGTCGCGCACGGTGTTGCGGATCTTGTTGCGGATGAATTCAGCGACCCG
TTCGTTGGCGTCCCGGTCGCGCAGGATGTCGCGGTAGGCGGCCAGAATGTCGGGGCCGCC
CTCCTGCCAGTAGCGTTCCAGGGTTTCCACCAGCTCTTCGTCGCTGACTTCCAGCGCGGA
CTTCGGCCCCTGGTAGCGGTGGGTTCCTCCGGGAGTGTTGCGGGACTCTTCCCGGAATTC
GGCGTAGCGCTTCTTCAGGTCGGCGAGGAACTCCGGGTCGAGCGGCGCGTTGCGGGCGGG
GACGGCAAAGTGGGGGGTGCGCTGGAACACGAACAGTTCCGCAGCCTGTTTCGCGATCTG
TGGGCTCACCTGGATTCCGGACGACCCGGTGCCGATCACGCCCACCCGCTGCCCGGAGAA
GTCCACGGGCTCGTGCGGCCAGTTCCCGGTGTGGTAGAGGTTGCCGGCGAAGTCTTTGAG
CCCTGGGAAGTTGGGGAGCTGCGGGACGGAGAGCTGGCCGCTGGCCATGATGAGGTAGCG
GGCGCGGATCCGGTCGCCGTGGTTGGTGTCGACCGTCCACGTGTTGGTGGCCTCGTCGAA
GGCTGCCGCGGTCACCGTGGTGTGGAAGGTGATTCCGCTCCGCAGGTCGAATTTGTCGGC
GACGAAGTTGATGTAGCGCAGGATCTCGGGCTGGGAAGCGTACCGCTCAGTCCAGTTCCA
CTCTTGGAGGACCTCCTCGGAGAACGAGTAGCAGTACTCGATGCTCTCGATGTCGCACCG
CGCCCCCGGGTAGCGGTTCCAGTACCACACACCGCCCACGTCGCCAGCGGTTTCGATGAC
GTGCACGCTACGCCCGAGTTCCCGCAGACGGTAGAGGGCGTACAGGCCGGAGAAGCCGGC
TCCCACGACCAGGACGTCCACTTCCTCTGGTGGTTGTCGGCGAGAGTCGACAGTCGTCTG
CCCGGCCAT

# Drug_Target_75_General_Function:
Involved in oxidoreductase activity

# Drug_Target_75_General_References:
Not Available

# Drug_Target_75_HGNC_ID:
Not Available

# Drug_Target_75_HPRD_ID:
Not Available

# Drug_Target_75_ID:
5111

# Drug_Target_75_Locus:
Not Available

# Drug_Target_75_Molecular_Weight:
61124

# Drug_Target_75_Name:
Phenylacetone monooxygenase

# Drug_Target_75_Number_of_Residues:
542

# Drug_Target_75_PDB_ID:
1W4X

# Drug_Target_75_Pathway:
Not Available

# Drug_Target_75_Pfam_Domain_Function:
PF01266	DAO

# Drug_Target_75_Protein_Sequence:
>Phenylacetone monooxygenase
MAGQTTVDSRRQPPEEVDVLVVGAGFSGLYALYRLRELGRSVHVIETAGDVGGVWYWNRY
PGARCDIESIEYCYSFSEEVLQEWNWTERYASQPEILRYINFVADKFDLRSGITFHTTVT
AAAFDEATNTWTVDTNHGDRIRARYLIMASGQLSVPQLPNFPGLKDFAGNLYHTGNWPHE
PVDFSGQRVGVIGTGSSGIQVSPQIAKQAAELFVFQRTPHFAVPARNAPLDPEFLADLKK
RYAEFREESRNTPGGTHRYQGPKSALEVSDEELVETLERYWQEGGPDILAAYRDILRDRD
ANERVAEFIRNKIRNTVRDPEVAERLVPKGYPFGTKRLILEIDYYEMFNRDNVHLVDTLS
APIETITPRGVRTSEREYELDSLVLATGFDALTGALFKIDIRGVGNVALKEKWAAGPRTY
LGLSTAGFPNLFFIAGPGSPSALSNMLVSIEQHVEWVTDHIAYMFKNGLTRSEAVLEKED
EWVEHVNEIADETLYPMTASWYTGANVPGKPRVFMLYVGGFHRYRQICDEVAAKGYEGFV
LT

# Drug_Target_75_Reaction:
Not Available

# Drug_Target_75_Signals:
None

# Drug_Target_75_Specific_Function:
Catalyzes a Baeyer-Villiger oxidation reaction, i.e., the insertion of an oxygen atom into a carbon-carbon bond adjacent to a carbonyl, which converts ketones to esters. Is most efficient with phenylacetone as substrate, leading to the formation of benzyl acetate. Can also oxidize other aromatic ketones (benzylacetone, alpha-methylphenylacetone and 4- hydroxyacetophenone), some alipatic ketones (dodecan-2-one and bicyclohept-2-en-6-one) and sulfides (e.g. methyl 4-tolylsulfide)

# Drug_Target_75_SwissProt_ID:
Q47PU3

# Drug_Target_75_SwissProt_Name:
PAMO_THEFY

# Drug_Target_75_Synonyms:
BVMO
Baeyer-Villiger monooxygenase
EC 1.14.13.92
PAMO

# Drug_Target_75_Theoretical_pI:
5.00

# Drug_Target_75_Transmembrane_Regions:
None

# Drug_Target_76_Cellular_Location:
Not Available

# Drug_Target_76_Chromosome_Location:
Not Available

# Drug_Target_76_Drug_References:
Not Available

# Drug_Target_76_Essentiality:
Non-Essential

# Drug_Target_76_GenAtlas_ID:
Not Available

# Drug_Target_76_GenBank_ID_Gene:
AF009224

# Drug_Target_76_GenBank_ID_Protein:
Not Available

# Drug_Target_76_GeneCard_ID:
Not Available

# Drug_Target_76_Gene_Name:
benC

# Drug_Target_76_Gene_Sequence:
>1017 bp
ATGTCAAACCATCAAGTAGCACTTCAATTTGAAGATGGCGTTACCCGTTTTATCTGCATC
GCTCAAGGTGAAACCTTATCCGATGCAGCATACCGTCAGCAAATCAATATTCCAATGGAC
TGCCGTGAAGGCGAGTGTGGTACCTGCCGTGCTTTTTGTGAATCGGGCAACTATGACATG
CCTGAAGACAATTACATTGAAGATGCACTCACCCCAGAAGAAGCGCAGCAGGGCTACGTT
TTGGCATGTCAATGCCGTCCAACTTCAGATGCTGTATTTCAAATTCAGGCGTCTTCTGAG
GTATGTAAAACCAAGATTCATCACTTTGAAGGCACGTTGGCGCGGGTTGAAAATCTATCG
GATTCGACCATCACCTTTGATATTCAGCTCGATGACGGTCAGCCCGATATTCATTTTCTG
GCAGGGCAGTATGTCAACGTGACGCTGCCGGGCACCACGGAAACACGCTCGTATTCGTTT
AGCTCACAACCAGGCAATCGCTTAACCGGGTTCGTGGTTCGTAATGTGCCGCAAGGTAAA
ATGAGCGAATATTTAAGTGTGCAGGCCAAAGCAGGCGACAAAATGAGCTTTACTGGACCA
TTTGGTAGTTTTTATCTGCGTGATGTCAAGCGTCCTGTGCTCATGCTGGCTGGCGGTACG
GGAATCGCACCGTTTTTATCGATGTTGCAAGTACTTGAGCAAAAAGGCAGTGAGCATCCA
GTACGACTGGTGTTTGGCGTAACCCAAGATTGTGATCTGGTGGCGCTTGAACAACTCGAT
GCACTTCAGCAGAAACTACCATGGTTTGAATATCGTACCGTGGTGGCACATGCAGAAAGT
CAACATGAACGTAAAGGTTACGTGACGGGTCATATCGAATATGACTGGCTAAATGGCGGT
GAAGTTGATGTGTATCTGTGCGGACCGGTTCCTATGGTGGAAGCGGTGCGGAGCTGGCTG
GATACGCAAGGTATTCAACCGGCGAACTTTTTATTTGAAAAATTCTCTGCCAACTAA

# Drug_Target_76_General_Function:
Involved in electron carrier activity

# Drug_Target_76_General_References:
1885518	Neidle EL, Hartnett C, Ornston LN, Bairoch A, Rekik M, Harayama S: Nucleotide sequences of the Acinetobacter calcoaceticus benABC genes for benzoate 1,2-dioxygenase reveal evolutionary relationships among multicomponent oxygenases. J Bacteriol. 1991 Sep;173(17):5385-95.

# Drug_Target_76_HGNC_ID:
Not Available

# Drug_Target_76_HPRD_ID:
Not Available

# Drug_Target_76_ID:
5112

# Drug_Target_76_Locus:
Not Available

# Drug_Target_76_Molecular_Weight:
38783

# Drug_Target_76_Name:
Benzoate 1,2-dioxygenase electron transfer component

# Drug_Target_76_Number_of_Residues:
348

# Drug_Target_76_PDB_ID:
1KRH

# Drug_Target_76_Pathway:
Not Available

# Drug_Target_76_Pfam_Domain_Function:
PF00111	Fer2
PF00175	NAD_binding_1
PF00970	FAD_binding_6

# Drug_Target_76_Protein_Sequence:
>Benzoate 1,2-dioxygenase electron transfer component
MSLYLNRIPAMSNHQVALQFEDGVTRFIRIAQGETLSDAAYRQQINIPMDCREGACGTCR
AFCESGNYDMPEDNYIEDALTPEEAQQGYVLACQCRPTSDAVFQIQASSEVCKTKIHHFE
GTLARVENLSDSTITFDIQLDDGQPDIHFLAGQYVNVTLPGTTETRSYSFSSQPGNRLTG
FVVRNVPQGKMSEYLSVQAKAGDKMSFTGPFGSFYLRDVKRPVLMLAGGTGIAPFLSMLQ
VLEQKGSEHPVRLVFGVTQDCDLVALEQLDALQQKLPWFEYRTVVAHAESQHERKGYVTG
HIEYDWLNGGEVDVYLCGPVPMVEAVRSWLDTQGIQPANFLFEKFSAN

# Drug_Target_76_Reaction:
Not Available

# Drug_Target_76_Signals:
None

# Drug_Target_76_Specific_Function:
Electron transfer component of benzoate 1,2-dioxygenase system

# Drug_Target_76_SwissProt_ID:
P07771

# Drug_Target_76_SwissProt_Name:
BENC_ACIAD

# Drug_Target_76_Synonyms:
Not Available

# Drug_Target_76_Theoretical_pI:
4.65

# Drug_Target_76_Transmembrane_Regions:
None

# Drug_Target_77_Cellular_Location:
Not Available

# Drug_Target_77_Chromosome_Location:
Not Available

# Drug_Target_77_Drug_References:
Not Available

# Drug_Target_77_Essentiality:
Non-Essential

# Drug_Target_77_GenAtlas_ID:
Not Available

# Drug_Target_77_GenBank_ID_Gene:
AE017221

# Drug_Target_77_GenBank_ID_Protein:
Not Available

# Drug_Target_77_GeneCard_ID:
Not Available

# Drug_Target_77_Gene_Name:
TT_C0779

# Drug_Target_77_Gene_Sequence:
>1146 bp
ATGCCCATAGACTTCAGCCTCACGGAGGAGCAAAGGCAGCTGCAGGCCCTGGCCCGGCGC
TTCGCCAAGGAGGTCATCCTCCCCGTGGCCCGGGAGTACGACGAGAAGGAGGAGGTCCCC
TGGCCCGTGATTGAGAAGCTCCACGAGGTGGGCCTCCTGAACGCCATCATCCCGGAGGAG
TACGGGGGGATGGGGCTCAAGATGCTGGACGAGGTCATCGTGGGGGAAGAGCTGGCCTAC
GCCTGCATGGGCATCTACACCATCCCCATGGCGAGCGACCTGGGCATCACCCCGGTGCTC
CTCGCAGGGACGGAGGAGCAGAAAGAGCGCTTCCTGAGGCCCCTCACCGAGAAGCCCGCC
CTCGCCGCCTTCGCCTTAAGCGAGCCCGGAAACGGCTCGGACGCCGCCGCCCTCAAGACC
AGGGCCATTCGCCAGGGCGACCACTACGTCCTGAACGGCACCAAGATGTGGATCTCTAAC
GGGGGAGAGGCGGAGTGGGTGGTGGTCTTCGCCACGGTGAACCCCGAACTCCGCCACAAG
GGGGTGGTGGCCCTGGTGGTGGAAAGGGGCACCCCCGGCTTCAAGGCCATCAAGATCCAC
GGGAAGATGGGCCAAAGGGCCAGCGGCACCTACGAGCTCGTCTTTGAGGACGTGAAGGTG
CCCGTGGAAAACCGCCTGGGCGAGGAGGGGGAGGGCTTTAAGATCGCCATGCAGACCCTA
AACAAGACCCGGATCCCCGTGGCCGCGGGAAGCGTAGGCGTGGCGAGGCGGGCCCTGGAC
GAGGCCAGGAAGTACGCCAAGGAGCGGCAGGCCTTCGGCCAGCCCATCGCCAACTTCCAG
GCCATCCAGTTCAAGCTCGCCGACATGCTCATCGGCATTGAGACCGCCCGCATGTACACC
TACTACGCCGCCTGGCTCGCGGACCAAGGCCTTCCCCACGCCCACGCCAGCGCCATCGCC
AAGGCCTACGCCTCGGAGATCGCCTTTGAGGCGGCCAACCAGGCCATCCAGATCCACGGC
GGCTACGGCTACGTGCGGGAGTTCCCCGTGGAAAAGCTCCTCAGGGACGTGAAGCTCAAC
CAGATCTACGAGGGGACCAACGAGATCCAGAGGCTCATCATCGCCAGGCACATCCTGGCG
GAGTGA

# Drug_Target_77_General_Function:
Involved in acyl-CoA dehydrogenase activity

# Drug_Target_77_General_References:
Not Available

# Drug_Target_77_HGNC_ID:
Not Available

# Drug_Target_77_HPRD_ID:
Not Available

# Drug_Target_77_ID:
5114

# Drug_Target_77_Locus:
Not Available

# Drug_Target_77_Molecular_Weight:
42160

# Drug_Target_77_Name:
Putative acyl-CoA dehydrogenase

# Drug_Target_77_Number_of_Residues:
381

# Drug_Target_77_PDB_ID:
1UKW

# Drug_Target_77_Pathway:
Not Available

# Drug_Target_77_Pfam_Domain_Function:
PF00441	Acyl-CoA_dh_1
PF02770	Acyl-CoA_dh_M
PF02771	Acyl-CoA_dh_N

# Drug_Target_77_Protein_Sequence:
>Putative acyl-CoA dehydrogenase
MPIDFSLTEEQRQLQALARRFAKEVILPVAREYDEKEEVPWPVIEKLHEVGLLNAIIPEE
YGGMGLKMLDEVIVGEELAYACMGIYTIPMASDLGITPVLLAGTEEQKERFLRPLTEKPA
LAAFALSEPGNGSDAAALKTRAIRQGDHYVLNGTKMWISNGGEAEWVVVFATVNPELRHK
GVVALVVERGTPGFKAIKIHGKMGQRASGTYELVFEDVKVPVENRLGEEGEGFKIAMQTL
NKTRIPVAAGSVGVARRALDEARKYAKERQAFGQPIANFQAIQFKLADMLIGIETARMYT
YYAAWLADQGLPHAHASAIAKAYASEIAFEAANQAIQIHGGYGYVREFPVEKLLRDVKLN
QIYEGTNEIQRLIIARHILAE

# Drug_Target_77_Reaction:
Not Available

# Drug_Target_77_Signals:
None

# Drug_Target_77_Specific_Function:
Not Available

# Drug_Target_77_SwissProt_ID:
Q72JJ3

# Drug_Target_77_SwissProt_Name:
Q72JJ3_THET2

# Drug_Target_77_Synonyms:
EC 1.3.99.-

# Drug_Target_77_Theoretical_pI:
5.93

# Drug_Target_77_Transmembrane_Regions:
None

# Drug_Target_78_Cellular_Location:
Not Available

# Drug_Target_78_Chromosome_Location:
Not Available

# Drug_Target_78_Drug_References:
Not Available

# Drug_Target_78_Essentiality:
Non-Essential

# Drug_Target_78_GenAtlas_ID:
Not Available

# Drug_Target_78_GenBank_ID_Gene:
AF235504

# Drug_Target_78_GenBank_ID_Protein:
Not Available

# Drug_Target_78_GeneCard_ID:
Not Available

# Drug_Target_78_Gene_Name:
fkbI

# Drug_Target_78_Gene_Sequence:
>1101 bp
TCAAGCCGGGAGCGCCAGCGCGTGCTGGGCCAGCATCACCCGGCACATCTCGCTGCTGCC
CTCGATGATCTCCATGAGCTTGGCGTCGCGGTACGCCCGTTCGACGACGTGTCCCTCTCT
CGCGCCTGCCGACGCGAGCACCTGTGCGGCGGTCGCGGCCCCGGCGGCGGCTCGTTCGGC
GGCGACGTGCTTGGCCAGGATCGTCGCGGGCACCATCTCGGGCGAGCCCTCGTCCCAGTG
GTCGCTGGCGTACTCGCACACGCGGGCCGCGATCTGCTCCGCGGTCCACAGGTCGGCGAT
GTGCCCGGCGACGAGTTGGTGGTCGCCGAGCGGCCGGCCGAACTGCTCCCGGGTCCGGGC
GTGGGCCACCGCGGCGGTGCGGCAGGCCCGCAGGATCCCGACGCAGCCCCAGGCGACCGA
CTTGCGCCCGTAGGCGAGTGACGCCGCGACCAGCATCGGCAGTGACGCGCCGGAGCCGGC
CAGGACCGCGCCGGCCGGCACACGCACCTGGTCCAGGTGCAGATCGGCGTGGCCGGCGGC
GCGGCAGCCGGACGGCTTCGGGACGCGCTCGACGCGTACGCCGGGGGTGTCGGCGGGCAC
GACCACCACCGCACCGGAACCATCCTCCTGGAGACCGAAGACGACCAGGTGGTCCGCGTA
GGCGGCGGCAGTCGTCCAGACCTTGTGGCCGTCGACGACAGCGGTGTCCCCGTCGAGCCG
AACCCGCGTCCGCATCGCCGACAGATCGCTGCCCGCCTGCCGCTCACTGAAGCCGACGGC
CGCGAGTTTCCCGCTGGTCAGCTCCTTCAGGAAGGTCGCCCGCTGACCGGCGTCGCCGAG
CCGCTGCACGGTCCACGCGGCCATGCCCTGCGACGTCATGACACTGCGCAGCGAACTGCA
GAGGCTGCCGACGTGTGCGGTGAACTCGCCGTTCTCCCGGCTGCCGAGTCCCAGACCGCC
GTGCTCGGCCGCCACTTCCGCGCAGAGCAGGCCGTCGGCGCCGAGCCGGACGAGCAGGTC
GCGCGGCAGTTCGCCGGACGTGTCCCACTCGGCGGCCCGGTCACCGACAAGGTCGGTCAG
CAGCGCGTCACGCTCAGGCAT

# Drug_Target_78_General_Function:
Involved in acyl-CoA dehydrogenase activity

# Drug_Target_78_General_References:
10863099	Wu K, Chung L, Revill WP, Katz L, Reeves CD: The FK520 gene cluster of Streptomyces hygroscopicus var. ascomyceticus (ATCC 14891) contains genes for biosynthesis of unusual polyketide extender units. Gene. 2000 Jun 13;251(1):81-90.

# Drug_Target_78_HGNC_ID:
Not Available

# Drug_Target_78_HPRD_ID:
Not Available

# Drug_Target_78_ID:
5115

# Drug_Target_78_Locus:
Not Available

# Drug_Target_78_Molecular_Weight:
38185

# Drug_Target_78_Name:
FkbI

# Drug_Target_78_Number_of_Residues:
366

# Drug_Target_78_PDB_ID:
1R2J

# Drug_Target_78_Pathway:
Not Available

# Drug_Target_78_Pfam_Domain_Function:
PF00441	Acyl-CoA_dh_1
PF02770	Acyl-CoA_dh_M

# Drug_Target_78_Protein_Sequence:
>FkbI
MPERDALLTDLVGDRAAEWDTSGELPRDLLVRLGADGLLCAEVAAEHGGLGLGSRENGEF
TAHVGSLCSSLRSVMTSQGMAAWTVQRLGDAGQRATFLKELTSGKLAAVGFSERQAGSDL
SAMRTRVRLDGDTAVVDGHKVWTTAAAYADHLVVFGLQEDGSGAVVVVPADTPGVRVERV
PKPSGCRAAGHADLHLDQVRVPAGAVLAGSGASLPMLVAASLAYGRKSVAWGCVGILRAC
RTAAVAHARTREQFGRPLGDHQLVAGHIADLWTAEQIAARVCEYASDHWDEGSPEMVPAT
ILAKHVAAERAAAGAATAAQVLASAGAREGHVVERAYRDAKLMEIIEGSSEMCRVMLAQH
ALALPA

# Drug_Target_78_Reaction:
Not Available

# Drug_Target_78_Signals:
None

# Drug_Target_78_Specific_Function:
Not Available

# Drug_Target_78_SwissProt_ID:
Q9KIE5

# Drug_Target_78_SwissProt_Name:
Q9KIE5_STRHY

# Drug_Target_78_Synonyms:
Not Available

# Drug_Target_78_Theoretical_pI:
6.32

# Drug_Target_78_Transmembrane_Regions:
None

# Drug_Target_79_Cellular_Location:
Cytoplasm

# Drug_Target_79_Chromosome_Location:
Not Available

# Drug_Target_79_Drug_References:
Not Available

# Drug_Target_79_Essentiality:
Non-Essential

# Drug_Target_79_GenAtlas_ID:
Not Available

# Drug_Target_79_GenBank_ID_Gene:
M57613

# Drug_Target_79_GenBank_ID_Protein:
Not Available

# Drug_Target_79_GeneCard_ID:
Not Available

# Drug_Target_79_Gene_Name:
lpdV

# Drug_Target_79_Gene_Sequence:
>1380 bp
ATGCAACAGACTATCCAGACAACCCTGTTGATCATCGGCGGCGGCCCTGGCGGCTATGTG
GCGGCCATCCGCGCCGGGCAACTGGGCATCCCTACCGTGCTGGTGGAAGGCCAGGCGCTG
GGCGGTACCTGCCTGAACATCGGCTGCATTCCGTCCAAGGCGCTGATCCATGTGGCCGAG
CAGTTCCACCAGGCCTCGCGCTTTACCGAACCCTCGCCGCTGGGCATCAGCGTGGCTTCG
CCACGCCTGGACATCGGCCAGAGCGTGGCCTGGAAAGACGGCATCGTCGATCGCCTGACC
ACTGGTGTCGCCGCCCTGCTGAAAAAGCACGGGGTGAAGGTGGTGCACGGCTGGGCCAAG
GTGCTTGATGGCAAGCAGGTCGAGGTGGATGGCCAGCGCATCCAGTGCGAGCACCTGTTG
CTGGCCACGGGCTCCAGCAGTGTCGAACTGCCGATGCTGCCGTTGGGTGGGCCGGTGATT
TCCTCGACCGAGGCCCTGGCACCGAAAGCCCTGCCGCAACACCTGGTGGTGGTGGGCGGT
GGCTACATCGGCCTGGAGCTGGGTATCGCCTACCGCAAGCTCGGCGCGCAGGTCAGCGTG
GTGGAAGCGCGCGAGCGCATCCTGCCGACTTACGACAGCGAACTGACCGCCCCGGTGGCC
GAGTCGCTGAAAAAGCTGGGTATCGCCCTGCACCTTGGCCACAGCGTCGAAGGTTACGAA
AATGGCTGCCTGCTGGCCAACGATGGCAAGGGCGGACAACTGCGCCTGGAAGCCGACCGG
GTGCTGGTGGCCGTGGGCCGCCGCCCACGCACCAAGGGCTTCAACCTGGAATGCCTGGAC
CTGAAGATGAATGGTGCCGCGATTGCCATCGACGAGCGCTGCCAGACCAGCATGCACAAC
GTCTGGGCCATCGGCGACGTGGCCGGCGAACCGATGCTGGCGCACCGGGCCATGGCCCAG
GGCGAGATGGTGGCCGAGATCATCGCCGGCAAGGCACGCCGCTTCGAACCCGCTGCGATA
GCCGCCGTGTGCTTCACCGACCCGGAAGTGGTCGTGGTCGGCAAGACGCCGGAACAGGCC
AGTCAGCAAGGCCTGGACTGCATCGTCGCGCAGTTCCCGTTCGCCGCCAACGGCCGGGCC
ATGAGCCTGGAGTCGAAAAGCGGTTTCGTGCGCGTGGTCGCGCGGCGTGACAACCACCTG
ATCCTGGGCTGGCAAGCGGTTGGCGTGGCGGTTTCCGAGCTGTCCACGGCGTTTGCCCAG
TCGCTGGAGATGGGTGCCTGCCTGGAGGATGTGGCCGGTACCATCCATGCCCACCCGACC
CTGGGTGAAGCGGTACAGGAAGCGGCACTGCGTGCCCTGGGCCACGCCCTGCATATCTGA

# Drug_Target_79_General_Function:
Involved in oxidoreductase activity

# Drug_Target_79_General_References:
1325638	Mattevi A, Obmolova G, Sokatch JR, Betzel C, Hol WG: The refined crystal structure of Pseudomonas putida lipoamide dehydrogenase complexed with NAD+ at 2.45 A resolution. Proteins. 1992 Aug;13(4):336-51.
2917566	Burns G, Brown T, Hatter K, Sokatch JR: Sequence analysis of the lpdV gene for lipoamide dehydrogenase of branched-chain-oxoacid dehydrogenase of Pseudomonas putida. Eur J Biochem. 1989 Jan 15;179(1):61-9.
3046941	Burns G, Brown T, Hatter K, Sokatch JR: Comparison of the amino acid sequences of the transacylase components of branched chain oxoacid dehydrogenase of Pseudomonas putida, and the pyruvate and 2-oxoglutarate dehydrogenases of Escherichia coli. Eur J Biochem. 1988 Sep 1;176(1):165-9.

# Drug_Target_79_HGNC_ID:
Not Available

# Drug_Target_79_HPRD_ID:
Not Available

# Drug_Target_79_ID:
4477

# Drug_Target_79_Locus:
Not Available

# Drug_Target_79_Molecular_Weight:
48159

# Drug_Target_79_Name:
Dihydrolipoyl dehydrogenase

# Drug_Target_79_Number_of_Residues:
459

# Drug_Target_79_PDB_ID:
1LVL

# Drug_Target_79_Pathway:
Not Available

# Drug_Target_79_Pfam_Domain_Function:
PF00070	Pyr_redox
PF02852	Pyr_redox_dim
PF07992	Pyr_redox_2

# Drug_Target_79_Protein_Sequence:
>Dihydrolipoyl dehydrogenase
MQQTIQTTLLIIGGGPGGYVAAIRAGQLGIPTVLVEGQALGGTCLNIGCIPSKALIHVAE
QFHQASRFTEPSPLGISVASPRLDIGQSVAWKDGIVDRLTTGVAALLKKHGVKVVHGWAK
VLDGKQVEVDGQRIQCEHLLLATGSSSVELPMLPLGGPVISSTEALAPKALPQHLVVVGG
GYIGLELGIAYRKLGAQVSVVEARERILPTYDSELTAPVAESLKKLGIALHLGHSVEGYE
NGCLLANDGKGGQLRLEADRVLVAVGRRPRTKGFNLECLDLKMNGAAIAIDERCQTSMHN
VWAIGDVAGEPMLAHRAMAQGEMVAEIIAGKARRFEPAAIAAVCFTDPEVVVVGKTPEQA
SQQGLDCIVAQFPFAANGRAMSLESKSGFVRVVARRDNHLILGWQAVGVAVSELSTAFAQ
SLEMGACLEDVAGTIHAHPTLGEAVQEAALRALGHALHI

# Drug_Target_79_Reaction:
Not Available

# Drug_Target_79_Signals:
None

# Drug_Target_79_Specific_Function:
The branched-chain alpha-keto dehydrogenase complex catalyzes the overall conversion of alpha-keto acids to acyl-CoA and CO(2). It contains multiple copies of 3 enzymatic components:branched-chain alpha-keto acid decarboxylase (E1), lipoamide acyltransferase (E2) and lipoamide dehydrogenase (E3)

# Drug_Target_79_SwissProt_ID:
P09063

# Drug_Target_79_SwissProt_Name:
DLDH1_PSEPU

# Drug_Target_79_Synonyms:
Dihydrolipoamide dehydrogenase
E3 component of branched- chain alpha-keto acid dehydrogenase complex
EC 1.8.1.4
LPD-Val

# Drug_Target_79_Theoretical_pI:
6.79

# Drug_Target_79_Transmembrane_Regions:
None

# Drug_Target_7_Cellular_Location:
Peroxisome

# Drug_Target_7_Chromosome_Location:
1

# Drug_Target_7_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_7_Essentiality:
Non-Essential

# Drug_Target_7_GenAtlas_ID:
Not Available

# Drug_Target_7_GenBank_ID_Gene:
X13227

# Drug_Target_7_GenBank_ID_Protein:
30446

# Drug_Target_7_GeneCard_ID:
DAO

# Drug_Target_7_Gene_Name:
DAO

# Drug_Target_7_Gene_Sequence:
>1044 bp
ATGCGTGTGGTGGTGATTGGAGCAGGAGTCATCGGGCTGTCCACCGCCCTCTGCATCCAT
GAGCGCTACCACTCAGTCCTGCAGCCACTGCACATAAAGGTCTACGCGGACCGCTTCACC
CCACTCACCACCACCGACGTGGCTGCCGGCCTCTGGCAGCCCTACCTTTCTGACCCCAAC
AACCCACAGGAGGCGGACTGGAGCCAACAGACCTTTGACTATCTCCTGAGCCATGTCCAT
TCTCCCAACGCTGAAAACCTGGGCCTGTTCCTAATCTCGGGCTACAACCTCTTCCATGAA
GCCATTCCGGACCCTTCCTGGAAGGACACAGTTCTGGGATTTCGGAAGCTGACCCCCAGA
GAGCTGGATATGTTCCCAGATTACGGCTATGGCTGGTTCCACACAAGCCTAATTCTGGAG
GGAAAGAACTATCTACAGTGGCTGACTGAAAGGTTAACTGAGAGGGGAGTGAAGTTCTTC
CAGCGGAAAGTGGAGTCTTTTGAGGAGGTGGCAAGAGAAGGCGCAGACGTGATTGTCAAC
TGCACTGGGGTATGGGCTGGGGCGCTACAACGAGACCCCCTGCTGCAGCCAGGCCGGGGG
CAGATCATGAAGGTGGACGCCCCTTGGATGAAGCACTTCATTCTCACCCATGACCCAGAG
AGAGGCATCTACAATTCCCCGTACATCATCCCAGGGACCCAGACAGTTACTCTTGGAGGC
ATCTTCCAGTTGGGAAACTGGAGTGAACTAAACAATATCCAGGACCACAACACCATTTGG
GAAGGCTGCTGCAGACTGGAGCCCACACTGAAGAATGCAAGAATTATTGGTGAAGCAACT
GGCTTCCGGCCAGTACGCCCCCAGATTCGGCTAGAAAGAGAACAGCTTCGCACTGGACCT
TCAAACACAGAGGTCATCCACAACTATGGCCATGGAGGCTACGGGCTCACCATCCACTGG
GGATGTGCCCTGGAGGCAGCCAAGCTCTTTGGGAGAATCCTGGAAGAAAAGAAATTGTCC
AGAATGCCACCATCCCACCTCTGA

# Drug_Target_7_General_Function:
Amino acid transport and metabolism

# Drug_Target_7_General_References:
1356107	Fukui K, Miyake Y: Molecular cloning and chromosomal localization of a human gene encoding D-amino-acid oxidase. J Biol Chem. 1992 Sep 15;267(26):18631-8.
15489334	Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7.
17088322	Kawazoe T, Tsuge H, Pilone MS, Fukui K: Crystal structure of human D-amino acid oxidase: context-dependent variability of the backbone conformation of the VAAGL hydrophobic stretch located at the si-face of the flavin ring. Protein Sci. 2006 Dec;15(12):2708-17. Epub 2006 Nov 6.
17303072	Kawazoe T, Tsuge H, Imagawa T, Aki K, Kuramitsu S, Fukui K: Structural basis of D-DOPA oxidation by D-amino acid oxidase: alternative pathway for dopamine biosynthesis. Biochem Biophys Res Commun. 2007 Apr 6;355(2):385-91. Epub 2007 Feb 8.
18455394	Sparey T, Abeywickrema P, Almond S, Brandon N, Byrne N, Campbell A, Hutson PH, Jacobson M, Jones B, Munshi S, Pascarella D, Pike A, Prasad GS, Sachs N, Sakatis M, Sardana V, Venkatraman S, Young MB: The discovery of fused pyrrole carboxylic acids as novel, potent D-amino acid oxidase (DAO) inhibitors. Bioorg Med Chem Lett. 2008 Jun 1;18(11):3386-91. Epub 2008 Apr 13.
2901986	Momoi K, Fukui K, Watanabe F, Miyake Y: Molecular cloning and sequence analysis of cDNA encoding human kidney D-amino acid oxidase. FEBS Lett. 1988 Sep 26;238(1):180-4.

# Drug_Target_7_HGNC_ID:
GNC:2671

# Drug_Target_7_HPRD_ID:
Not Available

# Drug_Target_7_ID:
6645

# Drug_Target_7_Locus:
12q24

# Drug_Target_7_Molecular_Weight:
39473.7

# Drug_Target_7_Name:
D-amino-acid oxidase

# Drug_Target_7_Number_of_Residues:
347

# Drug_Target_7_PDB_ID:
Not Available

# Drug_Target_7_Pathway:
Not Available

# Drug_Target_7_Pfam_Domain_Function:
PF01266	DAO

# Drug_Target_7_Protein_Sequence:
>D-amino-acid oxidase
MRVVVIGAGVIGLSTALCIHERYHSVLQPLDIKVYADRFTPLTTTDVAAGLWQPYLSDPN
NPQEADWSQQTFDYLLSHVHSPNAENLGLFLISGYNLFHEAIPDPSWKDTVLGFRKLTPR
ELDMFPDYGYGWFHTSLILEGKNYLQWLTERLTERGVKFFQRKVESFEEVAREGADVIVN
CTGVWAGALQRDPLLQPGRGQIMKVDAPWMKHFILTHDPERGIYNSPYIIPGTQTVTLGG
IFQLGNWSELNNIQDHNTIWEGCCRLEPTLKNARIIGERTGFRPVRPQIRLEREQLRTGP
SNTEVIHNYGHGGYGLTIHWGCALEAAKLFGRILEEKKLSRMPPSHL

# Drug_Target_7_Reaction:
Not Available

# Drug_Target_7_Signals:
None

# Drug_Target_7_Specific_Function:
Regulates the level of the neuromodulator D-serine in the brain. Has high activity towards D-DOPA and contributes to dopamine synthesis. Could act as a detoxifying agent which removes D-amino acids accumulated during aging. Acts on a variety of D- amino acids with a preference for those having small hydrophobic side chains followed by those bearing polar, aromatic, and basic groups. Does not act on acidic amino acids

# Drug_Target_7_SwissProt_ID:
P14920

# Drug_Target_7_SwissProt_Name:
OXDA_HUMAN

# Drug_Target_7_Synonyms:
DAAO
DAMOX
DAO

# Drug_Target_7_Theoretical_pI:
6.84

# Drug_Target_7_Transmembrane_Regions:
None

# Drug_Target_80_Cellular_Location:
Cytoplasm

# Drug_Target_80_Chromosome_Location:
Not Available

# Drug_Target_80_Drug_References:
Not Available

# Drug_Target_80_Essentiality:
Non-Essential

# Drug_Target_80_GenAtlas_ID:
Not Available

# Drug_Target_80_GenBank_ID_Gene:
M28356

# Drug_Target_80_GenBank_ID_Protein:
Not Available

# Drug_Target_80_GeneCard_ID:
Not Available

# Drug_Target_80_Gene_Name:
lpd

# Drug_Target_80_Gene_Sequence:
>1437 bp
ATGAGCCAGAAATTCGACGTGGTAGTGATTGGTGCCGGCCCCGGCGGTTACGTTGCCGCC
ATCCGCGCTGCCCAGCTGGGCCTGAAGACCGCCTGCATCGAGAAGTACATCGGCAAGGAA
GGCAAGGTGGCGCTCGGCGGTACCTGCCTGAACGTTGGCTGCATCCCGTCCAAGGCGCTG
CTGGACAGCTCCTACAAGTACCATGAGGCCAAAGAAGCCTTCAAAGTCCATGGTATCGAA
GCCAAGGGCGTCACCATCGACGTTCCGGCGATGGTTGCGCGCAAGGCCAACATCGTCAAG
AACCTGACCGGCGGCATCGCTACCCTGTTCAAGGCCAACGGCGTGACCTCCTTCGAAGGC
CACGGCAAGCTGCTGGCCAACAAGCAGGTGGAAGTGACCGGTCTGGACGGCAAGACCCAG
GTCCTGGAAGCCGAGAACGTGATCATCGCTTCCGGCTCCCGCCCGGTGGAGATCCCGCCG
GCCCCGCTGAGCGACGACATCATCGTCGACTCCACCGGCGCCCTGGAATTCCAGGCCGTG
CCGAAGAAGCTGGGTGTGATCGGCGCCGGCGTCATCGGCCTGGAGCTGGGTTCGGTATGG
GCCCGCCTGGGTGCCGAGGTGACCGTGCTGGAAGCCCTGGACAAGTTCCTCCCGGCTGCC
GACGAGCAGATCGCCAAGGAAGCCCTGAAGGTCCTGACCAAGCAAGGCCTGAACATTCGC
CTGGGCGCCCGCGTGACCGCCTCGGAAGTGAAGAAGAAGCAGGTCACCGTGACCTTCACC
GATGCCAACGGCGAGCAGAAGGAAACCTTCGACAAGCTGATCGTCGCGGTCGGCCGTCGC
CCGGTGACCACCGACCTGCTGGCCGCCGACAGCGGCGTGACCCTGGACGAGCGTGGCTTC
ATCTACGTCGACGACCACTGCAAGACCAGCGTTCCGGGCGTCTTCGCCATCGGTGACGTG
GTTCGCGGCGCGATGCTCGCGCACAAGGCCTCGGAAGAGGGCGTGATGGTCGCCGAGCGC
ATCGCCGGCCACAAGGCGCAGATGAACTACGACCTGATCCCGTCGGTCATCTACACCCAC
CCGGAAATCGCCTGGGTCGGCAAGACCGAGCAGACCCTCAAGGCCGAGGGCGTCGAAGTC
AACGTCGGCACCTTCCCGTTCGCCGCCAGCGGTCGTGCGATGGCTGCCAACGACACCACC
GGCCTGGTCAAGGTCATCGCCGATGCGAAGACCGACCGCGTCCTGGGCGTCCACGTGATC
GGCCCGAGCGCCGCCGAGCTGGTACAGCAAGGCGCGATCGGCATGGAATTCGGCACCAGC
GCCGAAGATCTGGGCATGATGGTCTTCTCCCACCCGACGCTGTCCGAAGCCCTGCACGAA
GCTGCCCTGGCGGTGAATGGCCATGCCATCCACATCGCCAACCGCAAGAAGCGCTGA

# Drug_Target_80_General_Function:
Involved in oxidoreductase activity

# Drug_Target_80_General_References:
2515251	Benen JA, Van Berkel WJ, Van Dongen WM, Muller F, De Kok A: Molecular cloning and sequence determination of the lpd gene encoding lipoamide dehydrogenase from Pseudomonas fluorescens. J Gen Microbiol. 1989 Jul;135(7):1787-97.
8487301	Mattevi A, Obmolova G, Kalk KH, van Berkel WJ, Hol WG: Three-dimensional structure of lipoamide dehydrogenase from Pseudomonas fluorescens at 2.8 A resolution. Analysis of redox and thermostability properties. J Mol Biol. 1993 Apr 20;230(4):1200-15.

# Drug_Target_80_HGNC_ID:
Not Available

# Drug_Target_80_HPRD_ID:
Not Available

# Drug_Target_80_ID:
5117

# Drug_Target_80_Locus:
Not Available

# Drug_Target_80_Molecular_Weight:
50151

# Drug_Target_80_Name:
Dihydrolipoyl dehydrogenase

# Drug_Target_80_Number_of_Residues:
478

# Drug_Target_80_PDB_ID:
1LPF

# Drug_Target_80_Pathway:
Not Available

# Drug_Target_80_Pfam_Domain_Function:
PF00070	Pyr_redox
PF02852	Pyr_redox_dim
PF07992	Pyr_redox_2

# Drug_Target_80_Protein_Sequence:
>Dihydrolipoyl dehydrogenase
MSQKFDVVVIGAGPGGYVAAIRAAQLGLKTACIEKYIGKEGKVALGGTCLNVGCIPSKAL
LDSSYKYHEAKEAFKVHGIEAKGVTIDVPAMVARKANIVKNLTGGIATLFKANGVTSFEG
HGKLLANKQVEVTGLDGKTQVLEAENVIIASGSRPVEIPPAPLSDDIIVDSTGALEFQAV
PKKLGVIGAGVIGLELGSVWARLGAEVTVLEALDKFLPAADEQIAKEALKVLTKQGLNIR
LGARVTASEVKKKQVTVTFTDANGEQKETFDKLIVAVGRRPVTTDLLAADSGVTLDERGF
IYVDDHCKTSVPGVFAIGDVVRGAMLAHKASEEGVMVAERIAGHKAQMNYDLIPSVIYTH
PEIAWVGKTEQTLKAEGVEVNVGTFPFAASGRAMAANDTTGLVKVIADAKTDRVLGVHVI
GPSAAELVQQGAIGMEFGTSAEDLGMMVFSHPTLSEALHEAALAVNGHAIHIANRKKR

# Drug_Target_80_Reaction:
Not Available

# Drug_Target_80_Signals:
None

# Drug_Target_80_Specific_Function:
The branched-chain alpha-keto dehydrogenase complex catalyzes the overall conversion of alpha-keto acids to acyl-CoA and CO(2). It contains multiple copies of 3 enzymatic components:branched-chain alpha-keto acid decarboxylase (E1), lipoamide acyltransferase (E2) and lipoamide dehydrogenase (E3)

# Drug_Target_80_SwissProt_ID:
P14218

# Drug_Target_80_SwissProt_Name:
DLDH_PSEFL

# Drug_Target_80_Synonyms:
Dihydrolipoamide dehydrogenase
E3 component of 2- oxoglutarate dehydrogenase complex
EC 1.8.1.4

# Drug_Target_80_Theoretical_pI:
6.96

# Drug_Target_80_Transmembrane_Regions:
None

# Drug_Target_81_Cellular_Location:
Not Available

# Drug_Target_81_Chromosome_Location:
Not Available

# Drug_Target_81_Drug_References:
Not Available

# Drug_Target_81_Essentiality:
Non-Essential

# Drug_Target_81_GenAtlas_ID:
Not Available

# Drug_Target_81_GenBank_ID_Gene:
D13187

# Drug_Target_81_GenBank_ID_Protein:
Not Available

# Drug_Target_81_GeneCard_ID:
Not Available

# Drug_Target_81_Gene_Name:
ahpF

# Drug_Target_81_Gene_Sequence:
Not Available

# Drug_Target_81_General_Function:
Involved in oxidoreductase activity, acting on NADH or NADPH

# Drug_Target_81_General_References:
1592833	Smillie DA, Hayward RS, Suzuki T, Fujita N, Ishihama A: Locations of genes encoding alkyl hydroperoxide reductase on the physical map of the Escherichia coli K-12 genome. J Bacteriol. 1992 Jun;174(11):3826-7.
8905232	Oshima T, Aiba H, Baba T, Fujita K, Hayashi K, Honjo A, Ikemoto K, Inada T, Itoh T, Kajihara M, Kanai K, Kashimoto K, Kimura S, Kitagawa M, Makino K, Masuda S, Miki T, Mizobuchi K, Mori H, Motomura K, Nakamura Y, Nashimoto H, Nishio Y, Saito N, Horiuchi T, et al.: A 718-kb DNA sequence of the Escherichia coli K-12 genome corresponding to the 12.7-28.0 min region on the linkage map. DNA Res. 1996 Jun 30;3(3):137-55.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.

# Drug_Target_81_HGNC_ID:
Not Available

# Drug_Target_81_HPRD_ID:
Not Available

# Drug_Target_81_ID:
5118

# Drug_Target_81_Locus:
Not Available

# Drug_Target_81_Molecular_Weight:
56178

# Drug_Target_81_Name:
Alkyl hydroperoxide reductase subunit F

# Drug_Target_81_Number_of_Residues:
521

# Drug_Target_81_PDB_ID:
1HYU

# Drug_Target_81_Pathway:
Not Available

# Drug_Target_81_Pfam_Domain_Function:
PF00070	Pyr_redox
PF07992	Pyr_redox_2

# Drug_Target_81_Protein_Sequence:
>Alkyl hydroperoxide reductase subunit F
MLDTNMKTQLKAYLEKLTKPVELIATLDDSAKSAEIKELLAEIAELSDKVTFKEDNSLPV
RKPSFLITNPGSNQGPRFAGSPLGHEFTSLVLALLWTGGHPSKEAQSLLEQIRHIDGDFE
FETYYSLSCHNCPDVVQALNLMSVLNPRIKHTAIDGGTFQNEITDRNVMGVPAVFVNGKE
FGQGRMTLTEIVAKIDTGAEKRAAEELNKRDAYDVLIVGSGPAGAAAAIYSARKGIRTGL
MGERFGGQILDTVDIENYISVPKTEGQKLAGALKVHVDEYDVDVIDSQSASKLIPAAVEG
GLHQIETASGAVLKARSIIVATGAKWRNMNVPGEDQYRTKGVTYCPHCDGPLFKGKRVAV
IGGGNSGVEAAIDLAGIVEHVTLLEFAPEMKADQVLQDKLRSLKNVDIILNAQTTEVKGD
GSKVVGLEYRDRVSGDIHNIELAGIFVQIGLLPNTNWLEGAVERNRMGEIIIDAKCETNV
KGVFAAGDCTTVPYKQIIIATGEGAKASLSAFDYLIRTKTA

# Drug_Target_81_Reaction:
Not Available

# Drug_Target_81_Signals:
None

# Drug_Target_81_Specific_Function:
Serves to protect the cell against DNA damage by alkyl hydroperoxides. It can use either NADH or NADPH as electron donor for direct reduction of redox dyes or of alkyl hydroperoxides when combined with the ahpC protein

# Drug_Target_81_SwissProt_ID:
P35340

# Drug_Target_81_SwissProt_Name:
AHPF_ECOLI

# Drug_Target_81_Synonyms:
Alkyl hydroperoxide reductase F52A protein
EC 1.6.4.-

# Drug_Target_81_Theoretical_pI:
5.40

# Drug_Target_81_Transmembrane_Regions:
None

# Drug_Target_82_Cellular_Location:
Cellular thylakoid membrane

# Drug_Target_82_Chromosome_Location:
Not Available

# Drug_Target_82_Drug_References:
Not Available

# Drug_Target_82_Essentiality:
Non-Essential

# Drug_Target_82_GenAtlas_ID:
Not Available

# Drug_Target_82_GenBank_ID_Gene:
BA000019

# Drug_Target_82_GenBank_ID_Protein:
Not Available

# Drug_Target_82_GeneCard_ID:
Not Available

# Drug_Target_82_Gene_Name:
petH

# Drug_Target_82_Gene_Sequence:
>1323 bp
TTAGTATGTTTCTACGTGCCAGCGACCAGCTTTCTTGAGGTCTTTTTGGTAATCACTCCA
GGTAACACCTTCTTTCGCAGCCGCAGCACTTAAAGCAGCATCAATGCCCTCTTCCATACC
GCGCAAACCACAGATGTAGGTGTGGGTTTTTTCATTCTTGATTAATTGCCACAGTTCATC
AGCGTGTTCTGCCACACGGTCTTGGATGTACATTCTGCCACCTTGGGGATTCTTTTGCTC
CCGGCTGATAGCGTAAGTTAGGCGGAAGTTATCGGGATATTTTTGTTGGATTTCTTCCAG
TTCTTCTTTATAAAGAATGTTAGGAGTTGTAGGAACACCAAAGACTAACCAAGAGAATCC
TTTGAATTGATATTCTGGGTTAGCAGCTCTTTCTGCATCCTTGAACATCCGCCACAGGTA
AGTCCGCATAGGCGCAATACCAGTACCTGTTGCCAACATGATGACATTAGCTTCAGGATC
ATCGGGTAACAGCATTTCTTTACCCACAGGCCCAGTGATTTTCACTTCTGAACCTGGTTC
AATGTGAGTCAAGTAAGTAGAACAAACACCGTAAACTGTTTCGCCGCTTTCTGGATGTTT
GTACTCTAATTGACGGACGCACAGTGAGATGGTTTTATCATCCACATCATCGCCGTGACG
GGTCGAGGCAATGGAGTAGAGTCTCAATTTTTCCGGCTTGCCGTTCTTGTCCACTCCTGG
TGGAATGATACCAATACTTTGACCTTCGATGTACTTTAAGTTACCACCAGTTAGATCAAA
TTTAATGTGCTGAACAATACCTATCCCGCCTTCTTTTACCAGTGGTTCATTAGAGATTAC
CTTACCAATAAATGGAGCATTGGGACGGTAAAGATTAACAGGAACATCAGCGTGTTTGGC
TTTCGCTTGAGTCATGGTGTTGCCTTTGTTGTCTTTTTTCTTAAGCTGTTCTTCAGCTGG
TGGTTTAGCGAAGCCTTTAGCTCCACTATCAGTTTTTACAGGTGTGGCTTTACCATTCCC
CTCAGACTTAGCAATCTCACTAGACGCATCTGTTACTGTTGCAATGGTAGTTCTACCATT
GAGTTGTTGTAGTGCGCTTACTGTTTGAATGCTAACAATCTTGCCGCCTAGTCGAGTGAT
ACGCTGCATTTCTTGATTCATGCGGTTGTAAGGCACTCTAATGAACACACTGCCACTTTT
ACGAATTGGGTAGTTCGTTTGATCAGTTTCTTCGTTCTGACGCATACCCACCACTTCGTA
AACGAAGACGCGGCTACCTGATTCTACGTTGGCAGCACCATCAAAAGCACCTTGATTAGA
CAT

# Drug_Target_82_General_Function:
Involved in oxidoreductase activity

# Drug_Target_82_General_References:
11759840	Kaneko T, Nakamura Y, Wolk CP, Kuritz T, Sasamoto S, Watanabe A, Iriguchi M, Ishikawa A, Kawashima K, Kimura T, Kishida Y, Kohara M, Matsumoto M, Matsuno A, Muraki A, Nakazaki N, Shimpo S, Sugimoto M, Takazawa M, Yamada M, Yasuda M, Tabata S: Complete genomic sequence of the filamentous nitrogen-fixing cyanobacterium Anabaena sp. strain PCC 7120. DNA Res. 2001 Oct 31;8(5):205-13; 227-53.

# Drug_Target_82_HGNC_ID:
Not Available

# Drug_Target_82_HPRD_ID:
Not Available

# Drug_Target_82_ID:
5119

# Drug_Target_82_Locus:
Not Available

# Drug_Target_82_Molecular_Weight:
48839

# Drug_Target_82_Name:
Ferredoxin--NADP reductase

# Drug_Target_82_Number_of_Residues:
440

# Drug_Target_82_PDB_ID:
1GJR

# Drug_Target_82_Pathway:
Not Available

# Drug_Target_82_Pfam_Domain_Function:
PF00175	NAD_binding_1
PF00667	FAD_binding_1
PF01383	CpcD

# Drug_Target_82_Protein_Sequence:
>Ferredoxin--NADP reductase
MSNQGAFDGAANVESGSRVFVYEVVGMRQNEETDQTNYPIRKSGSVFIRVPYNRMNQEMQ
RITRLGGKIVSIQTVSALQQLNGRTTIATVTDASSEIAKSEGNGKATPVKTDSGAKGFAK
PPAEEQLKKKDNKGNTMTQAKAKHADVPVNLYRPNAPFIGKVISNEPLVKEGGIGIVQHI
KFDLTGGNLKYIEGQSIGIIPPGVDKNGKPEKLRLYSIASTRHGDDVDDKTISLCVRQLE
YKHPESGETVYGVCSTYLTHIEPGSEVKITGPVGKEMLLPDDPEANVIMLATGTGIAPMR
TYLWRMFKDAERAANPEYQFKGFSWLVFGVPTTPNILYKEELEEIQQKYPDNFRLTYAIS
REQKNPQGGRMYIQDRVAEHADELWQLIKNEKTHTYICGLRGMEEGIDAALSAAAAKEGV
TWSDYQKDLKKAGRWHVETY

# Drug_Target_82_Reaction:
Not Available

# Drug_Target_82_Signals:
None

# Drug_Target_82_Specific_Function:
Reduced ferredoxin + NADP(+) = oxidized ferredoxin + NADPH

# Drug_Target_82_SwissProt_ID:
P58558

# Drug_Target_82_SwissProt_Name:
FENR_NOSS1

# Drug_Target_82_Synonyms:
EC 1.18.1.2
FNR

# Drug_Target_82_Theoretical_pI:
8.05

# Drug_Target_82_Transmembrane_Regions:
None

# Drug_Target_83_Cellular_Location:
Not Available

# Drug_Target_83_Chromosome_Location:
Not Available

# Drug_Target_83_Drug_References:
Not Available

# Drug_Target_83_Essentiality:
Non-Essential

# Drug_Target_83_GenAtlas_ID:
Not Available

# Drug_Target_83_GenBank_ID_Gene:
L04757

# Drug_Target_83_GenBank_ID_Protein:
Not Available

# Drug_Target_83_GeneCard_ID:
Not Available

# Drug_Target_83_Gene_Name:
fpr

# Drug_Target_83_Gene_Sequence:
>747 bp
ATGGCTGATTGGGTAACAGGCAAAGTCACTAAAGTGCAGAACTGGACCGACGCCCTGTTT
AGTCTCACCGTTCACGCCCCCGTGCTTCCGTTTACCGCCGGGCAATTTACCAAGCTTGGC
CTTGAAATCGACGGCGAACGCGTCCAGCGCGCCTACTCCTATGTAAACTCGCCCGATAAT
CCCGATCTGGAGTTTTACCTGGTCACCGTCCCCGATGGCAAATTAAGCCCACGACTGGCG
GCACTGAAACCAGGCGATGAAGTGCAGGTGGTTAGCGAAGCGGCAGGATTCTTTGTGCTC
GATGAAGTGCCGCACTGCGAAACGCTATGGATGCTGGCAACCGGTACAGCGATTGGCCCT
TATTTATCGATTCTGCAACTAGGTAAAGATTTAGATCGCTTCAAAAATCTGGTCCTGGTG
CACGCCGCACGTTATGCCGCCGACTTAAGCTATTTGCCACTGATGCAGGAACTGGAAAAA
CGCTACGAAGGAAAACTGCGCATTCAGACGGTGGTCAGTCGGGAAACGGCAGCGGGGTCG
CTCACCGGACGGATACCGGCATTAATTGAAAGTGGGGAACTGGAAAGCACGATTGGCCTG
CCGATGAATAAAGAAACCAGCCATGTGATGCTGTGCGGCAATCCACAGATGGTGCGCGAT
ACACAACAGTTGCTGAAAGAGACCCGGCAGATGACGAAACATTTACGTCGCCGACCGGGC
CATATGACAGCGGAGCATTACTGGTAA

# Drug_Target_83_General_Function:
Involved in oxidoreductase activity

# Drug_Target_83_General_References:
1400248	Truniger V, Boos W, Sweet G: Molecular analysis of the glpFKX regions of Escherichia coli and Shigella flexneri. J Bacteriol. 1992 Nov;174(21):6981-91.
2834327	Morimyo M: Isolation and characterization of methyl viologen-sensitive mutants of Escherichia coli K-12. J Bacteriol. 1988 May;170(5):2136-42.
7961651	Jenkins CM, Waterman MR: Flavodoxin and NADPH-flavodoxin reductase from Escherichia coli support bovine cytochrome P450c17 hydroxylase activities. J Biol Chem. 1994 Nov 4;269(44):27401-8.
8346018	Plunkett G 3rd, Burland V, Daniels DL, Blattner FR: Analysis of the Escherichia coli genome. III. DNA sequence of the region from 87.2 to 89.2 minutes. Nucleic Acids Res. 1993 Jul 25;21(15):3391-8.
8449868	Bianchi V, Reichard P, Eliasson R, Pontis E, Krook M, Jornvall H, Haggard-Ljungquist E: Escherichia coli ferredoxin NADP+ reductase: activation of E. coli anaerobic ribonucleotide reduction, cloning of the gene (fpr), and overexpression of the protein. J Bacteriol. 1993 Mar;175(6):1590-5.
9149148	Ingelman M, Bianchi V, Eklund H: The three-dimensional structure of flavodoxin reductase from Escherichia coli at 1.7 A resolution. J Mol Biol. 1997 Apr 25;268(1):147-57.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.

# Drug_Target_83_HGNC_ID:
Not Available

# Drug_Target_83_HPRD_ID:
Not Available

# Drug_Target_83_ID:
5121

# Drug_Target_83_Locus:
Not Available

# Drug_Target_83_Molecular_Weight:
27751

# Drug_Target_83_Name:
Ferredoxin--NADP reductase

# Drug_Target_83_Number_of_Residues:
248

# Drug_Target_83_PDB_ID:
1FDR

# Drug_Target_83_Pathway:
Not Available

# Drug_Target_83_Pfam_Domain_Function:
PF00175	NAD_binding_1
PF00970	FAD_binding_6

# Drug_Target_83_Protein_Sequence:
>Ferredoxin--NADP reductase
MADWVTGKVTKVQNWTDALFSLTVHAPVLPFTAGQFTKLGLEIDGERVQRAYSYVNSPDN
PDLEFYLVTVPDGKLSPRLAALKPGDEVQVVSEAAGFFVLDEVPHCETLWMLATGTAIGP
YLSILQLGKDLDRFKNLVLVHAARYAADLSYLPLMQELEKRYEGKLRIQTVVSRETAAGS
LTGRIPALIESGELESTIGLPMNKETSHVMLCGNPQMVRDTQQLLKETRQMTKHLRRRPG
HMTAEHYW

# Drug_Target_83_Reaction:
Not Available

# Drug_Target_83_Signals:
None

# Drug_Target_83_Specific_Function:
Transports electrons between flavodoxin or ferredoxin and NADPH. Involved in the reductive activation of cobalamin- independent methionine synthase, pyruvate formate lyase and anaerobic ribonucleotide reductase. Also protects against superoxide radicals due to methyl viologen in the presence of oxygen

# Drug_Target_83_SwissProt_ID:
P28861

# Drug_Target_83_SwissProt_Name:
FENR_ECOLI

# Drug_Target_83_Synonyms:
DA1
EC 1.18.1.2
FLDR
FLXR
FNR
Flavodoxin reductase
Methyl viologen resistance protein A

# Drug_Target_83_Theoretical_pI:
6.63

# Drug_Target_83_Transmembrane_Regions:
None

# Drug_Target_84_Cellular_Location:
Not Available

# Drug_Target_84_Chromosome_Location:
Not Available

# Drug_Target_84_Drug_References:
Not Available

# Drug_Target_84_Essentiality:
Non-Essential

# Drug_Target_84_GenAtlas_ID:
Not Available

# Drug_Target_84_GenBank_ID_Gene:
AJ250862

# Drug_Target_84_GenBank_ID_Protein:
Not Available

# Drug_Target_84_GeneCard_ID:
Not Available

# Drug_Target_84_Gene_Name:
mrsD

# Drug_Target_84_Gene_Sequence:
>585 bp
TTATGTTAGTGAGGGGTGTTTTGTTCTTTCTTTAAAACCTTTTTCTATTGCTAATAAAGC
TTTGTCGGGTGTAATTAGACCACGATTAGGTTTTCTTGTACCCGTCGCAATCTCAAACGC
CATAATTTCAACTGGTTCAATAACAATATGCCCATCTTTTCTTAATTGTTCAATATTCCT
GGAAACAACTGTTTTATTCCACATTAAATCGTTCATATTAGGAAAGAAAATAGTGTTATG
TGGATGAGCTAATACAGTAGTTGCAACTAAATTCATTGCTACACCATTAGCAGTTTGTCC
TAAGATGTTCGCTGTAGCTGGAATAATGCAATATATGTCCGCCCAGCGGCCAATTTCTAC
GTGGCTATGTCTTTTTCCGTTTTCCCCATGTTCTGAGTATACATGGTCACAAAAATAAGA
AACAGTATGAGCTGGAATAAGGTCTTCCGCTGTTTTTGTCATAACAACCCTTATTTCCTT
AAAGAAGCTTTTAAAATATAAGAGATACGAGGAGATGCCGACAGATGAGATTGATCCGCA
AATCCCGATCAATAACTTTTTATCTTTTAATATTGAAATACTCAT

# Drug_Target_84_General_Function:
Involved in catalytic activity

# Drug_Target_84_General_References:
10831439	Altena K, Guder A, Cramer C, Bierbaum G: Biosynthesis of the lantibiotic mersacidin: organization of a type B lantibiotic gene cluster. Appl Environ Microbiol. 2000 Jun;66(6):2565-71.
11844751	Majer F, Schmid DG, Altena K, Bierbaum G, Kupke T: The flavoprotein MrsD catalyzes the oxidative decarboxylation reaction involved in formation of the peptidoglycan biosynthesis inhibitor mersacidin. J Bacteriol. 2002 Mar;184(5):1234-43.
12876343	Blaesse M, Kupke T, Huber R, Steinbacher S: Structure of MrsD, an FAD-binding protein of the HFCD family. Acta Crystallogr D Biol Crystallogr. 2003 Aug;59(Pt 8):1414-21. Epub 2003 Jul 23.

# Drug_Target_84_HGNC_ID:
Not Available

# Drug_Target_84_HPRD_ID:
Not Available

# Drug_Target_84_ID:
5122

# Drug_Target_84_Locus:
Not Available

# Drug_Target_84_Molecular_Weight:
21678

# Drug_Target_84_Name:
Mersacidin decarboxylase

# Drug_Target_84_Number_of_Residues:
194

# Drug_Target_84_PDB_ID:
1P3Y

# Drug_Target_84_Pathway:
Not Available

# Drug_Target_84_Pfam_Domain_Function:
PF02441	Flavoprotein

# Drug_Target_84_Protein_Sequence:
>Mersacidin decarboxylase
MSISILKDKKLLIGICGSISSVGISSYLLYFKSFFKEIRVVMTKTAEDLIPAHTVSYFCD
HVYSEHGENGKRHSHVEIGRWADIYCIIPATANILGQTANGVAMNLVATTVLAHPHNTIF
FPNMNDLMWNKTVVSRNIEQLRKDGHIVIEPVEIMAFEIATGTRKPNRGLITPDKALLAI
EKGFKERTKHPSLT

# Drug_Target_84_Reaction:
Not Available

# Drug_Target_84_Signals:
None

# Drug_Target_84_Specific_Function:
Catalyzes the oxidative decarboxylation of the C- terminal cysteine residue of mersacidin to an aminoenethiol residue

# Drug_Target_84_SwissProt_ID:
Q9RC23

# Drug_Target_84_SwissProt_Name:
MRSD_BACSY

# Drug_Target_84_Synonyms:
EC 4.1.1.-
Mersacidin-modifying enzyme mrsD

# Drug_Target_84_Theoretical_pI:
9.14

# Drug_Target_84_Transmembrane_Regions:
None

# Drug_Target_85_Cellular_Location:
Periplasm

# Drug_Target_85_Chromosome_Location:
Not Available

# Drug_Target_85_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_85_Essentiality:
Non-Essential

# Drug_Target_85_GenAtlas_ID:
Not Available

# Drug_Target_85_GenBank_ID_Gene:
AJ132010

# Drug_Target_85_GenBank_ID_Protein:
4539587

# Drug_Target_85_GeneCard_ID:
Not Available

# Drug_Target_85_Gene_Name:
fccA

# Drug_Target_85_Gene_Sequence:
>1683 bp
AACCAAGAATGTGATAGCTGCCATACACCAGATGGTGAACTGTCAAATGACAGCTTAACT
TATGAAAATACACAATGTGTATCTTGCCATGGCACACTAGAGGAAGTCGCTGAAACGACA
AAACATGAACACTATAATGCTCATGCTTCTCATTTCCCTGGCGAAGTAGCTTGTACCTCA
TGCCACAGCGCACACGAAAAATCGATGGTGTATTGTGACTCTTGCCATAGCTTCGATTTC
AACATGCCTTATGCTAAAAAATGGCAACGTGACGAGCCTACTATTGCTGAACTGGCCAAA
GATAAATCAGAACGTCAGGCTGCTCTTGCTAGCGCACCTCACGATACTGTTGACGTAGTG
GTTGTCGGTTCTGGCGGCGCAGGTTTCTCAGCAGCAATATCTGCAACAGACAGTGGTGCT
AAAGTCATTCTTATTGAAAAAGAGCCTGTTATTGGTGGTAATGCTAAGTTAGCTGCGGGT
GGCATGAACGCTGCTTGGACTGATCAACAAAAAGCCAAAAAAATTACTGACAGCCCAGAG
TTAATGTTCGAAGACACCATGAAAGGTGGCCAAAACATAAATGATCCTGCATTAGTTAAA
GTATTAAGCTCACACTCTAAAGACTCTGTTGATTGGATGACCGCTATGGGTGCCGATTTA
ACTGATGTTGGCATGATGGGTGGCGCATCTGTTAATCGTGCGCATCGTCCAACCGGTGGT
GCTGGTGTAGGTGCTCATGTTGTTCAAGTACTTTATGATAATGCAGTGAAACGCAATATC
GACTTACGCATGAACACTCGCGGCATTGAAGTGCTTAAAGATGATAAAGGCACTGTTAAA
GGTATTCTGGTTAAGGGTATGTATAAAGGTTACTACTGGGTGAAAGCCGATGCGGTAATC
TTAGCAACGGGTGGTTTCGCTAAAAATAACGAGCGTGTCGCTAAGCTTGATCCTTCACTA
AAAGGCTTTATCTCTACTAACCAACCTGGTGCAGTAGGTGATGGACTGGATGTAGCGGAA
AATGCGGGCGGCGCATTGAAAGACATGCAGTATATCCAAGCTCACCCAACACTATCTGTT
AAAGGTGGCGTAATGGTCACTGAAGCGGTTCGTGGTAATGGTGCGATTTTGGTTAACCGT
GAAGGTAAGCGTTTCGTTAACGAAATTACTACTCGTGATAAAGCATCTGCCGCTATCTTA
GCGCAAACCGGTAAATCAGCTTATTTGATTTTTGATGATTCTGTGCGTAAGTCACTGTCA
AAAATTGATAAGTATATTGGTTTAGGTGTTGCACCAACCGCAGATAGCCTAGTTAAATTA
GGTAAAATGGAAGGTATTGACGGCAAAGCATTGACTGAAACTGTCGCGCGTTACAACAGC
TTAGTGAGTAGCGGTAAAGACACTGATTTTGAGCGTCCAAACCTACCGCGCGCACTTAAC
GAAGGTAACTACTATGCAATTGAAGTTACACCTGGTGTTCACCACACTATGGGTGGCGTG
ATGATCGACACTAAAGCTGAAGTCATGAATGCTAAGAAGCAGGTTATCCCTGGCTTGTAT
GGTGCTGGTGAGGTTACTGGCGGTGTTCATGGTGCTAACCGCTTAGGTGGTAATGCTATT
TCAGACATCATCACCTTCGGTCGCTTAGCGGGTGAAGAAGCTGCAAAATATTCTAAAAAG
AAC

# Drug_Target_85_General_Function:
Energy production and conversion

# Drug_Target_85_General_References:
10479620	Pealing SL, Lysek DA, Taylor P, Alexeev D, Reid GA, Chapman SK, Walkinshaw MD: Crystallization and preliminary X-ray analysis of flavocytochrome c(3), the fumarate reductase from Shewanella frigidimarina. J Struct Biol. 1999 Aug;127(1):76-8.
12093271	Pankhurst KL, Mowat CG, Miles CS, Leys D, Walkinshaw MD, Reid GA, Chapman SK: Role of His505 in the soluble fumarate reductase from Shewanella frigidimarina. Biochemistry. 2002 Jul 9;41(27):8551-6.
12356299	Mowat CG, Pankhurst KL, Miles CS, Leys D, Walkinshaw MD, Reid GA, Chapman SK: Engineering water to act as an active site acid catalyst in a soluble fumarate reductase. Biochemistry. 2002 Oct 8;41(40):11990-6.

# Drug_Target_85_HGNC_ID:
Not Available

# Drug_Target_85_HPRD_ID:
Not Available

# Drug_Target_85_ID:
3673

# Drug_Target_85_Locus:
Not Available

# Drug_Target_85_Molecular_Weight:
60622

# Drug_Target_85_Name:
Fumarate reductase flavoprotein subunit

# Drug_Target_85_Number_of_Residues:
571

# Drug_Target_85_PDB_ID:
1QJD

# Drug_Target_85_Pathway:
Not Available

# Drug_Target_85_Pfam_Domain_Function:
PF00890	FAD_binding_2

# Drug_Target_85_Protein_Sequence:
>Fumarate reductase flavoprotein subunit
ADNLAEFHVQNQECDSCHTPDGELSNDSLTYENTQCVSCHGTLEEVAETTKHEHYNAHAS
HFPGEVACTSCHSAHEKSMVYCDSCHSFDFNMPYAKKWQRDEPTIAELAKDKSERQAALA
SAPHDTVDVVVVGSGGAGFSAAISATDSGAKVILIEKEPVIGGNAKLAAGGMNAAWTDQQ
KAKKITDSPELMFEDTMKGGQNINDPALVKVLSSHSKDSVDWMTAMGADLTDVGMMGGAS
VNRAHRPTGGAGVGAHVVQVLYDNAVKRNIDLRMNTRGIEVLKDDKGTVKGILVKGMYKG
YYWVKADAVILATGGFAKNNERVAKLDPSLKGFISTNQPGAVGDGLDVAENAGGALKDMQ
YIQAHPTLSVKGGVMVTEAVRGNGAILVNREGKRFVNEITTRDKASAAILAQTGKSAYLI
FDDSVRKSLSKIDKYIGLGVAPTADSLVKLGKMEGIDGKALTETVARYNSLVSSGKDTDF
ERPNLPRALNEGNYYAIEVTPGVHHTMGGVMIDTKAEVMNAKKQVIPGLYGAGEVTGGVH
GANRLGGNAISDIITFGRLAGEEAAKYSKKN

# Drug_Target_85_Reaction:
succinate + acceptor = fumarate + reduced acceptor

# Drug_Target_85_Signals:
None

# Drug_Target_85_Specific_Function:
Catalyzes fumarate reduction using artificial electron donors such as methyl viologen. The physiological reductant is unknown, but evidence indicates that flavocytochrome c participates in electron transfer from formate to fumarate and possibly also to trimethylamine oxide (TMAO). This enzyme is essentially unidirectional

# Drug_Target_85_SwissProt_ID:
P0C278

# Drug_Target_85_SwissProt_Name:
FRDA_SHEFR

# Drug_Target_85_Synonyms:
EC 1.3.99.1
Fcc3
Flavocytochrome c
Flavocytochrome c3

# Drug_Target_85_Theoretical_pI:
6.51

# Drug_Target_85_Transmembrane_Regions:
None

# Drug_Target_8_Cellular_Location:
Cytoplasmic

# Drug_Target_8_Chromosome_Location:
Not Available

# Drug_Target_8_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_8_Essentiality:
Non-Essential

# Drug_Target_8_GenAtlas_ID:
Not Available

# Drug_Target_8_GenBank_ID_Gene:
U05212

# Drug_Target_8_GenBank_ID_Protein:
468875

# Drug_Target_8_GeneCard_ID:
Not Available

# Drug_Target_8_Gene_Name:
putA

# Drug_Target_8_Gene_Sequence:
>3963 bp
ATGGGAACCACCACCATGGGGGTTAAGCTGGACGACGCGACGCGTGAGCGTATTAAGTCT
GCCGCGACACGTATCGATCGCACACCACACTGGTTAATTAAGCAGGCGATTTTTTCTTAT
CTCGAACAACTGGAAAACAGCGATACTCTGCCGGAGCTACCTGCGCTGCTTTCTGGCGCG
GCCAATGAGAGCGATGAAGCACCGACTCCGGCAGAGGAACCACACCAGCCATTCCTCGAC
TTTGCCGAGCAAATATTGCCCCAGTCGGTTTCCCGCGCCGCGATCACCGCGGCCTATCGC
CGCCCGGAAACCGAAGCGGTTTCTATGCTGCTGGAACAAGCCCGCCTGCCGCAGCCAGTT
GCTGAACAGGCGCACAAACTGGCGTATCAGCTGGCCGATAAACTGCGTAATCAAAAAAAT
GCCAGTGGTCGCGCAGGTATGGTCCAGGGGTTATTGCAGGAGTTTTCGCTGTCATCGCAG
GAAGGCGTGGCGCTGATGTGTCTGGCGGAAGCGTTGTTGCGTATTCCCGACAAAGCCACC
CGCGACGCGTTAATTCGCGACAAAATCAGCAACGGTAACTGGCAGTCACACATTGGTCGT
AGCCCGTCACTGTTTGTTAATGCCGCCACCTGGGGGCTGCTGTTTACTGGCAAACTGGTT
TCCACCCATAACGAAGCCAGCCTCTCCCGCTCGCTGAACCGCATTATCGGTAAAAGCGGT
GAACCGCTGATCCGCAAAGGTGTGGATATGGCGATGCGCCTGATGGGTGAGCAGTTCGTC
ACTGGCGAAACCATCGCGGAAGCGTTAGCCAATGCCCGCAAGCTGGAAGAGAAAGGTTTC
CGTTACTCTTACGATATGCTGGGCGAAGCCGCGCTGACCGCCGCAGATGCACAGGCGTAT
ATGGTTTCCTATCAGCAGGCGATTCACGCCATCGGTAAAGCGTCTAACGGTCGTGGCATC
TATGAAGGGCCGGGCATTTCAATCAAACTGTCGGCGCTGCATCCGCGTTATAGCCGCGCC
CAGTATGACCGGGTAATGGAAGAGCTTTACCCGCGTCTGAAATCACTCACCCTGCTGGCG
CGTCAGTACGATATTGGTATCAACATTGACGCCGAAGAGTCCGATCGCCTGGAGATCTCC
CTCGATCTGCTGGAAAAACTCTGTTTCGAGCCGGAACTGGCAGGCTGGAACGGCATCGGT
TTTGTTATTCAGGCTTATCAAAAACGCTGCCCGTTGGTGATCGATTACCTGATTGATCTC
GCCACCCGCAGCCGTCGCCGTCTGATGATTCGCCTGGTGAAAGGCGCGTACTGGGATAGT
GAAATTAAGCGTGCGCAGATGGACGGCCTTGAAGGTTATCCGGTTTATACCCGCAAGGTG
TATACCGACGTTTCTTATCTCGCCTGTGCGAAAAAGCTGCTGGCGGTGCCGAATCTAATC
TACCCGCAGTTCGCGACGCACAACGCCCATACGCTGGCGGCGATTTATCAACTGGCGGGG
CAGAACTACTACCCGGGTCAGTACGAGTTCCAGTGCCTGCATGGTATGGGCGAGCCACTG
TATGAGCAGGTCACCGGGAAAGTTGCCGACGCAAAACTTAACCGTCCGTGTCGTATTTAT
GCTCCGGTTGGCACACATGAAACGCTGTTGGCGTATCTGGTGCGTCGCCTGCTGGAAAAC
GGTGCTAACACCTCGTTTGTTAACCGTATTGCCGACACCTCTTTGCCACTGGATGAACTG
GTCGCCGATCCGGTCACTGCTGTAGAAAAACTGGCGCAACAGGAAGGGCAAACTGGATTA
CCGCATCCGAAAATTCCCCTGCCGCGCGATCTTTACGGTCACGGGCGCGACAACTCGGCA
GGGCTGGATCTCGCTAACGAACACCGCCTGGCCTCGCTCTCCTCTGCCCTGCTCAATAGT
GCACTGCAAAAATGGCAGGCCTTGCCAATGCTGGAACAACCGGTAGCGGCAGGTGAGATG
TCGCCCGTTATTAACCCTGCGGAACCGAAAGATATTGTGGGCTATGTGCGTGAAGCCACG
CCGCGTGAAGTAGAACAGGCGCTGGAAAGTGCGGTTAATAACGCGCCAATCTGGTTTGCC
ACGCCTCCGGCTGAACGCGCAGCGATTTTGCACCGCGCTGCCGTGCTGATGGAAAGCCAG
ATGCAGCAACTGATTGGTATTCTGGTGCGTGAGGCCGGAAAAACCTTCAGTAACGCCATT
GCCGAAGTGCGCGAAGCGGTCGATTTTCTCCACTACTACGCCGGACAGGTGCGGGATGAT
TTCGCTAACGAAACCCACCGTCCATTAGGGCCTGTGGTGTGTATCAGTCCGTGGAACTTC
CCGCTGGCTATTTTCACCGGGCAGATCGCCGCCGCACTGGCGGCAGGTAACAGCGTGCTG
GCAAAACCGGCAGAACAAACGCCGCTGATTGCCGCGCAAGGGATCGCCATTTTGCTGGAA
GCGGGTGTACCGCCAGGCGTGGTGCAATTGCTGCCAGGTCGGGGTGAAACCGTGGGCGCG
CAACTGACGGGTGATGATCGCGTGCGCGGGGTGATGTTTACCGGTTCAACCGAAGTCGCT
ACGTTACTGCAGCGCAATATCGCCAGCCGCCTGGACGCTCAGGGTCGCCCTATTCCGCTC
ATCGCTGAAACCGGCGGCATGAACGCGATGATTGTCGATTCTTCAGCACTGACCGAACAG
GTCGTCGTGGATGTACTGGCCTCGGCGTTCGACAGTGCGGGTCAGCGTTGTTCGGCGCTG
CGCGTGCTGTGCCTGCAAGATGAGATTGCCGACCACACGTTGAAAATGCTGCGCGGCGCA
ATGGCCGAATGCCGGATGGGTAATCCGGGTCGCCTGACCACCGATATCGGTCCAGTGATT
GATAGCGAAGCGAAAGCCAATATTGAGCGCCATATTCAGACCATGCGTAGCAAAGGCCGT
CCGGTGTTCCAGGCGGTGCGGGAAAACAGCGAAGATGCCCGTGAATGGCAAAGCGGCACC
TTTGTCGCCCCGACGCTGATCGAACTGGATGACTTTGCCGAATTGCAAAAAGAGGTCTTT
GGTCCGGTGCTGCATGTGGTGCGTTACAACCGTAACCAGCTACCAGAGCTGATCGAGCAG
ATTAACGCTTCCGGTTATGGTCTGACGCTTGGCGTCCATACGCGCATTGATGAAACCATC
GCCCAGGTCACTGGCTCGGCCCATGTTGGTAACCTGTATGTTAACCGTAATATGGTGGGC
GCAGTGGTTGGTGTGCAGCCGTTCGGCGGCGAAGGGTTGTCCGGTACCGGGCCGAAAGCA
GGCGGTCCGCTCTATCTCTACCGTCTGCTGGCGAATCGCCCGGAAAGTGCGCTGGCAGTG
ACGCTCGCGCGTCAGGATGCAAAGTATCCGGTCGATGCGCAGTTGAAAGCCGCATTGACT
CAGCCGCTAAATGCACTGCGGGAATGGGCAGCAAATCGTCCAGAATTGCAGGCGTTATGT
ACGCAATATGGCGAGCTGGCGCAGGCAGGAACACAACGATTGCTGCCGGGGCCGACGGGT
GAACGCAACACCTGGACGCTGCTGCCGCGTGAGCGCGTGTTGTGTATTGCCGATGATGAG
CAGGATGCGCTGACTCAGCTCGCCGCCGTGCTGGCGGTGGGCAGCCAGGTACTGTGGCCG
GATGACGCGCTGCATCGTCAGTTAGTGAAGGCATTGCCATCGGCAGTCAGCGAACGTATT
CAACTGGCGAAAGCGGAAAATATAACCGCTCAACCGTTTGATGCGGTGATCTTCCACGGT
GATTCGGATCAGCTTCGCGCATTGTGTGAAGCAGTTGCCGCGCGGGATGGCACAATTGTT
TCGGTGCAGGGTTTTGCCCGTGGCGAAAGCAATATCCTTCTGGAACGGCTGTATATCGAG
CGTTCGCTGAGTGTGAATACCGCTGCCGCTGGCGGTAACGCCAGCTTAATGACTATAGGT
TAA

# Drug_Target_8_General_Function:
Energy production and conversion

# Drug_Target_8_General_References:
12514740	Lee YH, Nadaraia S, Gu D, Becker DF, Tanner JJ: Structure of the proline dehydrogenase domain of the multifunctional PutA flavoprotein. Nat Struct Biol. 2003 Feb;10(2):109-14.
3325781	Nakao T, Yamato I, Anraku Y: Nucleotide sequence of putC, the regulatory region for the put regulon of Escherichia coli K12. Mol Gen Genet. 1987 Dec;210(2):364-8.
7966312	Ling M, Allen SW, Wood JM: Sequence analysis identifies the proline dehydrogenase and delta 1-pyrroline-5-carboxylate dehydrogenase domains of the multifunctional Escherichia coli PutA protein. J Mol Biol. 1994 Nov 11;243(5):950-6.
8905232	Oshima T, Aiba H, Baba T, Fujita K, Hayashi K, Honjo A, Ikemoto K, Inada T, Itoh T, Kajihara M, Kanai K, Kashimoto K, Kimura S, Kitagawa M, Makino K, Masuda S, Miki T, Mizobuchi K, Mori H, Motomura K, Nakamura Y, Nashimoto H, Nishio Y, Saito N, Horiuchi T, et al.: A 718-kb DNA sequence of the Escherichia coli K-12 genome corresponding to the 12.7-28.0 min region on the linkage map. DNA Res. 1996 Jun 30;3(3):137-55.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.

# Drug_Target_8_HGNC_ID:
Not Available

# Drug_Target_8_HPRD_ID:
Not Available

# Drug_Target_8_ID:
3254

# Drug_Target_8_Locus:
Not Available

# Drug_Target_8_Molecular_Weight:
143817

# Drug_Target_8_Name:
Bifunctional protein putA [Includes: Proline dehydrogenase

# Drug_Target_8_Number_of_Residues:
1320

# Drug_Target_8_PDB_ID:
1K87

# Drug_Target_8_Pathway:
Not Available

# Drug_Target_8_Pfam_Domain_Function:
PF00171	Aldedh
PF01619	Pro_dh

# Drug_Target_8_Protein_Sequence:
>Bifunctional protein putA [Includes: Proline dehydrogenase
MGTTTMGVKLDDATRERIKSAATRIDRTPHWLIKQAIFSYLEQLENSDTLPELPALLSGA
ANESDEAPTPAEEPHQPFLDFAEQILPQSVSRAAITAAYRRPETEAVSMLLEQARLPQPV
AEQAHKLAYQLADKLRNQKNASGRAGMVQGLLQEFSLSSQEGVALMCLAEALLRIPDKAT
RDALIRDKISNGNWQSHIGRSPSLFVNAATWGLLFTGKLVSTHNEASLSRSLNRIIGKSG
EPLIRKGVDMAMRLMGEQFVTGETIAEALANARKLEEKGFRYSYDMLGEAALTAADAQAY
MVSYQQAIHAIGKASNGRGIYEGPGISIKLSALHPRYSRAQYDRVMEELYPRLKSLTLLA
RQYDIGINIDAEESDRLEISLDLLEKLCFEPELAGWNGIGFVIQAYQKRCPLVIDYLIDL
ATRSRRRLMIRLVKGAYWDSEIKRAQMDGLEGYPVYTRKVYTDVSYLACAKKLLAVPNLI
YPQFATHNAHTLAAIYQLAGQNYYPGQYEFQCLHGMGEPLYEQVTGKVADGKLNRPCRIY
APVGTHETLLAYLVRRLLENGANTSFVNRIADTSLPLDELVADPVTAVEKLAQQEGQTGL
PHPKIPLPRDLYGHGRDNSAGLDLANEHRLASLSSALLNSALQKWQALPMLEQPVAAGEM
SPVINPAEPKDIVGYVREATPREVEQALESAVNNAPIWFATPPAERAAILHRAAVLMESQ
MQQLIGILVREAGKTFSNAIAEVREAVDFLHYYAGQVRDDFANETHRPLGPVVCISPWNF
PLAIFTGQIAAALAAGNSVLAKPAEQTPLIAAQGIAILLEAGVPPGVVQLLPGRGETVGA
QLTGDDRVRGVMFTGSTEVATLLQRNIASRLDAQGRPIPLIAETGGMNAMIVDSSALTEQ
VVVDVLASAFDSAGQRCSALRVLCLQDEIADHTLKMLRGAMAECRMGNPGRLTTDIGPVI
DSEAKANIERHIQTMRSKGRPVFQAVRENSEDAREWQSGTFVAPTLIELDDFAELQKEVF
GPVLHVVRYNRNQLPELIEQINASGYGLTLGVHTRIDETIAQVTGSAHVGNLYVNRNMVG
AVVGVQPFGGEGLSGTGPKAGGPLYLYRLLANRPESALAVTLARQDAKYPVDAQLKAALT
QPLNALREWAANRPELQALCTQYGELAQAGTQRLLPGPTGERNTWTLLPRERVLCIADDE
QDALTQLAAVLAVGSQVLWPDDALHRQLVKALPSAVSERIQLAKAENITAQPFDAVIFHG
DSDQLRALCEAVAARDGTIVSVQGFARGESNILLERLYIERSLSVNTAAAGGNASLMTIG

# Drug_Target_8_Reaction:
(S)-1-pyrroline-5-carboxylate + NAD+ + 2 H2O = L-glutamate + NADH + H+

# Drug_Target_8_Signals:
None

# Drug_Target_8_Specific_Function:
Oxidizes proline to glutamate for use as a carbon and nitrogen source and also function as a transcriptional repressor of the put operon

# Drug_Target_8_SwissProt_ID:
P09546

# Drug_Target_8_SwissProt_Name:
PUTA_ECOLI

# Drug_Target_8_Synonyms:
Delta-1-pyrroline-5-carboxylate dehydrogenase
EC 1.5.1.12
EC 1.5.99.8
Proline oxidase

# Drug_Target_8_Theoretical_pI:
5.84

# Drug_Target_8_Transmembrane_Regions:
None

# Drug_Target_9_Cellular_Location:
Not Available

# Drug_Target_9_Chromosome_Location:
Not Available

# Drug_Target_9_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_9_Essentiality:
Non-Essential

# Drug_Target_9_GenAtlas_ID:
Not Available

# Drug_Target_9_GenBank_ID_Gene:
AB064548

# Drug_Target_9_GenBank_ID_Protein:
15080709

# Drug_Target_9_GeneCard_ID:
Not Available

# Drug_Target_9_Gene_Name:
phr

# Drug_Target_9_Gene_Sequence:
>1263 bp
ATGGGCCCCCTTCTCGTCTGGCACCGGGGCGACCTCCGCCTCCACGACCACCCGGCCCTC
CTGGAGGCCCTGGCCCGGGGGCCGGTGGTGGGCCTCGTGGTCCTGGACCCCAACAACCTG
AAGACCACCCCGAGGCGGCGGGCCTGGTTCCTGGAAAACGTCCGGGCCCTGCGGGAGGCC
TACCGGGCCCGGGGCGGGGCCCTTTGGGTCCTGGAGGGCCTCCCTTGGGAGAAGGTGCCC
GAGGCGGCGAGGCGGCTTAAGGCCAAGGCCGTCTACGCCCTCACGAGCCACACCCCTTAC
GGCCGCTACCGGGACGGGAGGGTGCGGGAGGCCCTCCCCGTGCCCCTCCACCTCCTCCCC
GCCCCCCACCTCCTCCCCCCCGACCTCCCCCGGGCCTACCGGGTTTACACCCCCTTTAGC
CGCCTCTACCGGGGGGCCGCCCCGCCCCTTCCCCCTCCCGAGGCCCTGCCCAAGGGGCCA
GAGGAGGGGGAAATCCCCCGGGAAGACCCGGGGCTTCCCCTCCCCGAGCCGGGGGAGGAG
GCGGCCCTCGCGGGGCTTCGGGCCTTCCTCGAGGCCAAGCTCCCCCGCTACGCCGAGGAG
CGGGACCGGCTGGACGGAGAGGGGGGCTCGAGGCTCTCCCCCTACTTCGCCCTAGGGGTC
CTCTCCCCCAGGCTCGCCGCCTGGGAGGCGGAAAGGCGGGGCGGGGAGGGAGCGAGGAAG
TGGGTGGCGGAGCTCCTCTGGCGGGACTTCTCCTACCACCTCCTCTACCACTTCCCCTGG
ATGGCGGAAAGGCCCCTGGACCCGAGGTTCCAGGCCTTCCCCTGGCAGGAGGACGAGGCC
CTCTTCCAAGCTTGGTACGAGGGGAAGACGGGCGTCCCCCTGGTGGACGCCGCCATGCGG
GAGCTCCACGCCACGGGCTTCCTCTCCAACCGGGCCCGGATGAACGCGGCCCAGTTCGCG
GTGAAGCACCTCCTCCTCCCCTGGAAAAGGTGCGAGGAGGCCTTCCGCCACCTCCTCCTG
GACGGGGACCGGGCGGTGAACCTCCAGGGCTGGCAGTGGGCGGGGGGCCTGGGGGTGGAC
GCCGCCCCCTACTTCCGGGTCTTCAACCCGGTGCTCCAGGGGGAAAGGCACGACCCCGAG
GGGAGGTGGCTTAAGCGCTGGGCCCCGGAATACCCCTCCTACGCCCCCAAGGACCCCGTG
GTGGACCTGGAGGAGGCGAGAAGGCGCTACCTGCGCCTGGCGAGGGATCTCGCCCGAGGG
TAG

# Drug_Target_9_General_Function:
Replication, recombination and repair

# Drug_Target_9_General_References:
Not Available

# Drug_Target_9_HGNC_ID:
Not Available

# Drug_Target_9_HPRD_ID:
Not Available

# Drug_Target_9_ID:
3594

# Drug_Target_9_Locus:
Not Available

# Drug_Target_9_Molecular_Weight:
47901

# Drug_Target_9_Name:
Deoxyribodipyrimidine photo-lyase

# Drug_Target_9_Number_of_Residues:
420

# Drug_Target_9_PDB_ID:
1IQU

# Drug_Target_9_Pathway:
Not Available

# Drug_Target_9_Pfam_Domain_Function:
PF00875	DNA_photolyase
PF03441	FAD_binding_7

# Drug_Target_9_Protein_Sequence:
>Deoxyribodipyrimidine photo-lyase
MGPLLVWHRGDLRLHDHPALLEALARGPVVGLVVLDPNNLKTTPRRRAWFLENVRALREA
YRARGGALWVLEGLPWEKVPEAARRLKAKAVYALTSHTPYGRYRDGRVREALPVPLHLLP
APHLLPPDLPRAYRVYTPFSRLYRGAAPPLPPPEALPKGPEEGEIPREDPGLPLPEPGEE
AALAGLRAFLEAKLPRYAEERDRLDGEGGSRLSPYFALGVLSPRLAAWEAERRGGEGARK
WVAELLWRDFSYHLLYHFPWMAERPLDPRFQAFPWQEDEALFQAWYEGKTGVPLVDAAMR
ELHATGFLSNRARMNAAQFAVKHLLLPWKRCEEAFRHLLLDGDRAVNLQGWQWAGGLGVD
AAPYFRVFNPVLQGERHDPEGRWLKRWAPEYPSYAPKDPVVDLEEARRRYLRLARDLARG

# Drug_Target_9_Reaction:
cyclobutadipyrimidine (in DNA) = 2 pyrimidine residues (in DNA) ALL_REAC (other) R00034

# Drug_Target_9_Signals:
None

# Drug_Target_9_Specific_Function:
Involved in repair of UV radiation-induced DNA damage. Catalyzes the light-dependent monomerization (300-600 nm) of cyclobutyl pyrimidine dimers (in cis-syn configuration), which are formed between adjacent bases on the same DNA strand upon exposure to ultraviolet radiation

# Drug_Target_9_SwissProt_ID:
P61497

# Drug_Target_9_SwissProt_Name:
PHR_THET8

# Drug_Target_9_Synonyms:
DNA photolyase
EC 4.1.99.3
Photoreactivating enzyme

# Drug_Target_9_Theoretical_pI:
9.66

# Drug_Target_9_Transmembrane_Regions:
None

#END_DRUGCARD DB03147
